{ "version": "2.2", "instance": { "zk2532892.htm": { "nsprefix": "evgn", "nsuri": "http://www.evogene.com/20241231", "dts": { "schema": { "local": [ "evgn-20241231.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/dimensions/rol_full_ifrs-dim_2024-03-27.xsd", "https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd", "https://xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/currency/2024/currency-2024.xsd", "https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd", "https://xbrl.sec.gov/cyd/2024/cyd-af-2024.xsd", "https://xbrl.sec.gov/cyd/2024/cyd-af-sub-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd", "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd", "https://xbrl.sec.gov/ecd/2024/ecd-sub-2024.xsd", "https://xbrl.sec.gov/exch/2024/exch-2024.xsd", "https://xbrl.sec.gov/naics/2024/naics-2024.xsd", "https://xbrl.sec.gov/sic/2024/sic-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd" ] }, "calculationLink": { "local": [ "evgn-20241231_cal.xml" ] }, "definitionLink": { "local": [ "evgn-20241231_def.xml" ], "remote": [ "https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/dimensions/dim_full_ifrs_2024-03-27_role-995000.xml" ] }, "labelLink": { "local": [ "evgn-20241231_lab.xml" ] }, "presentationLink": { "local": [ "evgn-20241231_pre.xml" ] }, "inline": { "local": [ "zk2532892.htm" ] } }, "keyStandard": 275, "keyCustom": 189, "axisStandard": 18, "axisCustom": 6, "memberStandard": 25, "memberCustom": 62, "hidden": { "total": 19, "http://www.evogene.com/20241231": 15, "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full": 1, "http://xbrl.sec.gov/dei/2024": 3 }, "contextCount": 376, "entityCount": 1, "segmentCount": 93, "elementCount": 880, "unitCount": 9, "baseTaxonomies": { "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full": 969, "http://xbrl.sec.gov/dei/2024": 44, "http://xbrl.sec.gov/cyd/2024": 16, "http://xbrl.sec.gov/ecd/2024": 1 }, "report": { "R1": { "role": "http://www.evogene.com/role/DocumentAndEntityInformation", "longName": "0001 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "C_20240101to20241231", "name": "dei:EntityRegistrantName", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "span", "span", "span", "span", "div", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532892.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20240101to20241231", "name": "dei:EntityRegistrantName", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "span", "span", "span", "span", "div", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532892.htm", "first": true, "unique": true } }, "R2": { "role": "http://www.evogene.com/role/ConsolidatedStatementsOfFinancialPosition", "longName": "0002 - Statement - CONSOLIDATED STATEMENTS OF FINANCIAL POSITION", "shortName": "CONSOLIDATED STATEMENTS OF FINANCIAL POSITION", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "C_20241231", "name": "ifrs-full:CashAndCashEquivalents", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532892.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_20241231", "name": "ifrs-full:ShorttermDepositsNotClassifiedAsCashEquivalents", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532892.htm", "unique": true } }, "R3": { "role": "http://www.evogene.com/role/ConsolidatedStatementsOfFinancialPositionParenthetical", "longName": "0003 - Statement - CONSOLIDATED STATEMENTS OF FINANCIAL POSITION (Parenthetical)", "shortName": "CONSOLIDATED STATEMENTS OF FINANCIAL POSITION (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "C_20241231", "name": "ifrs-full:ParValuePerShare", "unitRef": "NIS_per_share", "xsiNil": "false", "lang": null, "decimals": "1", "ancestors": [ "ifrs-full:ParValuePerShare", "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532892.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_20241231", "name": "ifrs-full:NumberOfSharesOutstanding", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532892.htm", "unique": true } }, "R4": { "role": "http://www.evogene.com/role/ConsolidatedStatementsOfProfitOrLoss", "longName": "0004 - Statement - CONSOLIDATED STATEMENTS OF PROFIT OR LOSS", "shortName": "CONSOLIDATED STATEMENTS OF PROFIT OR LOSS", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "C_20240101to20241231", "name": "ifrs-full:Revenue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532892.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_20240101to20241231", "name": "ifrs-full:GrossProfit", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532892.htm", "unique": true } }, "R5": { "role": "http://www.evogene.com/role/ConsolidatedStatementsOfChangesInEquity", "longName": "0005 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY", "shortName": "CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "C_20211231_ifrsfullComponentsOfEquityAxis_ifrsfullIssuedCapitalMember", "name": "ifrs-full:Equity", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "span", "span", "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532892.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20211231_ifrsfullComponentsOfEquityAxis_ifrsfullIssuedCapitalMember", "name": "ifrs-full:Equity", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "span", "span", "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532892.htm", "first": true, "unique": true } }, "R6": { "role": "http://www.evogene.com/role/ConsolidatedStatementsOfCashFlows", "longName": "0006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS", "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "C_20240101to20241231", "name": "ifrs-full:ProfitLoss", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532892.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_20240101to20241231", "name": "ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532892.htm", "unique": true } }, "R7": { "role": "http://www.evogene.com/role/General", "longName": "0007 - Disclosure - GENERAL", "shortName": "GENERAL", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "7", "firstAnchor": { "contextRef": "C_20240101to20241231", "name": "ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532892.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20240101to20241231", "name": "ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532892.htm", "first": true, "unique": true } }, "R8": { "role": "http://www.evogene.com/role/SignificantAccountingPolicies", "longName": "0008 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES", "shortName": "SIGNIFICANT ACCOUNTING POLICIES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "C_20240101to20241231", "name": "ifrs-full:DisclosureOfChangesInAccountingPoliciesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532892.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20240101to20241231", "name": "ifrs-full:DisclosureOfChangesInAccountingPoliciesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532892.htm", "first": true, "unique": true } }, "R9": { "role": "http://www.evogene.com/role/SignificantAccountingJudgmentsEstimatesAndAssupmtionsUsedInPreparationOfFinancialStatements", "longName": "0009 - Disclosure - SIGNIFICANT ACCOUNTING JUDGMENTS, ESTIMATES AND ASSUMPTIONS USED IN THE PREPARATION OF THE FINANCIAL STATEMENTS", "shortName": "SIGNIFICANT ACCOUNTING JUDGMENTS, ESTIMATES AND ASSUMPTIONS USED IN THE PREPARATION OF THE FINANCIAL STATEMENTS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "C_20240101to20241231", "name": "ifrs-full:DisclosureOfAccountingJudgementsAndEstimatesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532892.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20240101to20241231", "name": "ifrs-full:DisclosureOfAccountingJudgementsAndEstimatesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532892.htm", "first": true, "unique": true } }, "R10": { "role": "http://www.evogene.com/role/DisclosureOfNewStandardsInPeriodPriorToTheirAdoption", "longName": "0010 - Disclosure - DISCLOSURE OF NEW STANDARDS IN THE PERIOD PRIOR TO THEIR ADOPTION", "shortName": "DISCLOSURE OF NEW STANDARDS IN THE PERIOD PRIOR TO THEIR ADOPTION", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "C_20240101to20241231", "name": "evgn:DisclosureOfNewStandardsInPeriodPriorToTheirAdoptionExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532892.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20240101to20241231", "name": "evgn:DisclosureOfNewStandardsInPeriodPriorToTheirAdoptionExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532892.htm", "first": true, "unique": true } }, "R11": { "role": "http://www.evogene.com/role/CollaborationAndResearchAgreements", "longName": "0011 - Disclosure - COLLABORATION, RESEARCH AND DISTRIBUTION AND SALES AGREEMENTS", "shortName": "COLLABORATION, RESEARCH AND DISTRIBUTION AND SALES AGREEMENTS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "C_20240101to20241231", "name": "evgn:DisclosureOfCollaborationAgreementsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532892.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20240101to20241231", "name": "evgn:DisclosureOfCollaborationAgreementsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532892.htm", "first": true, "unique": true } }, "R12": { "role": "http://www.evogene.com/role/CashAndCashEquivalents", "longName": "0013 - Disclosure - CASH AND CASH EQUIVALENTS", "shortName": "CASH AND CASH EQUIVALENTS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "C_20240101to20241231", "name": "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532892.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20240101to20241231", "name": "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532892.htm", "first": true, "unique": true } }, "R13": { "role": "http://www.evogene.com/role/OtherReceivablesAndPrepaidExpenses", "longName": "0014 - Disclosure - OTHER RECEIVABLES AND PREPAID EXPENSES", "shortName": "OTHER RECEIVABLES AND PREPAID EXPENSES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "C_20240101to20241231", "name": "ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532892.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20240101to20241231", "name": "ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532892.htm", "first": true, "unique": true } }, "R14": { "role": "http://www.evogene.com/role/Leases", "longName": "0015 - Disclosure - LEASES", "shortName": "LEASES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "C_20240101to20241231", "name": "ifrs-full:DisclosureOfLeasesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532892.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20240101to20241231", "name": "ifrs-full:DisclosureOfLeasesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532892.htm", "first": true, "unique": true } }, "R15": { "role": "http://www.evogene.com/role/PropertyPlantAndEquipmentNet", "longName": "0016 - Disclosure - PROPERTY, PLANT AND EQUIPMENT, NET", "shortName": "PROPERTY, PLANT AND EQUIPMENT, NET", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "C_20240101to20241231", "name": "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532892.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20240101to20241231", "name": "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532892.htm", "first": true, "unique": true } }, "R16": { "role": "http://www.evogene.com/role/IntangibleAssetsNet", "longName": "0017 - Disclosure - INTANGIBLE ASSETS, NET", "shortName": "INTANGIBLE ASSETS, NET", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "C_20240101to20241231", "name": "ifrs-full:DisclosureOfIntangibleAssetsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532892.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20240101to20241231", "name": "ifrs-full:DisclosureOfIntangibleAssetsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532892.htm", "first": true, "unique": true } }, "R17": { "role": "http://www.evogene.com/role/LiabilitiesInRespectOfGovernmentGrants", "longName": "0018 - Disclosure - LIABILITIES IN RESPECT OF GOVERNMENT GRANTS", "shortName": "LIABILITIES IN RESPECT OF GOVERNMENT GRANTS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "C_20240101to20241231", "name": "ifrs-full:DisclosureOfGovernmentGrantsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532892.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20240101to20241231", "name": "ifrs-full:DisclosureOfGovernmentGrantsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532892.htm", "first": true, "unique": true } }, "R18": { "role": "http://www.evogene.com/role/ConvertibleSAFE", "longName": "0019 - Disclosure - CONVERTIBLE SAFE", "shortName": "CONVERTIBLE SAFE", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "C_20240101to20241231", "name": "ifrs-full:DisclosureOfDebtSecuritiesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532892.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20240101to20241231", "name": "ifrs-full:DisclosureOfDebtSecuritiesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532892.htm", "first": true, "unique": true } }, "R19": { "role": "http://www.evogene.com/role/FinancialInstruments", "longName": "0020 - Disclosure - FINANCIAL INSTRUMENTS", "shortName": "FINANCIAL INSTRUMENTS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "C_20240101to20241231", "name": "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532892.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20240101to20241231", "name": "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532892.htm", "first": true, "unique": true } }, "R20": { "role": "http://www.evogene.com/role/CommitmentsAndContingentLiabilities", "longName": "0021 - Disclosure - COMMITMENTS AND CONTINGENT LIABILITIES", "shortName": "COMMITMENTS AND CONTINGENT LIABILITIES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "C_20240101to20241231", "name": "ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532892.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20240101to20241231", "name": "ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532892.htm", "first": true, "unique": true } }, "R21": { "role": "http://www.evogene.com/role/SeverancePayLiabilityNet", "longName": "0022 - Disclosure - SEVERANCE PAY LIABILITY", "shortName": "SEVERANCE PAY LIABILITY", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "21", "firstAnchor": { "contextRef": "C_20240101to20241231", "name": "ifrs-full:DisclosureOfEmployeeBenefitsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532892.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20240101to20241231", "name": "ifrs-full:DisclosureOfEmployeeBenefitsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532892.htm", "first": true, "unique": true } }, "R22": { "role": "http://www.evogene.com/role/TaxesOnIncome", "longName": "0023 - Disclosure - TAXES ON INCOME", "shortName": "TAXES ON INCOME", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "22", "firstAnchor": { "contextRef": "C_20240101to20241231", "name": "ifrs-full:DisclosureOfIncomeTaxExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532892.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20240101to20241231", "name": "ifrs-full:DisclosureOfIncomeTaxExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532892.htm", "first": true, "unique": true } }, "R23": { "role": "http://www.evogene.com/role/ShareholdersEquity", "longName": "0024 - Disclosure - SHAREHOLDERS' EQUITY", "shortName": "SHAREHOLDERS' EQUITY", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "23", "firstAnchor": { "contextRef": "C_20240101to20241231", "name": "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532892.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20240101to20241231", "name": "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532892.htm", "first": true, "unique": true } }, "R24": { "role": "http://www.evogene.com/role/Share-BasedCompensation", "longName": "0025 - Disclosure - SHARE- BASED COMPENSATION", "shortName": "SHARE- BASED COMPENSATION", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "24", "firstAnchor": { "contextRef": "C_20240101to20241231", "name": "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532892.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20240101to20241231", "name": "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532892.htm", "first": true, "unique": true } }, "R25": { "role": "http://www.evogene.com/role/StatementsOfComprehensiveLoss-AdditionalInformation", "longName": "0026 - Disclosure - STATEMENTS OF PROFIT OR LOSS - ADDITIONAL INFORMATION", "shortName": "STATEMENTS OF PROFIT OR LOSS - ADDITIONAL INFORMATION", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "25", "firstAnchor": { "contextRef": "C_20240101to20241231", "name": "evgn:StatementsOfComprehensiveLossAdditionalInformationExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532892.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20240101to20241231", "name": "evgn:StatementsOfComprehensiveLossAdditionalInformationExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532892.htm", "first": true, "unique": true } }, "R26": { "role": "http://www.evogene.com/role/LossPerShare", "longName": "0027 - Disclosure - LOSS PER SHARE", "shortName": "LOSS PER SHARE", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "26", "firstAnchor": { "contextRef": "C_20240101to20241231", "name": "ifrs-full:DisclosureOfEarningsPerShareExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532892.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20240101to20241231", "name": "ifrs-full:DisclosureOfEarningsPerShareExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532892.htm", "first": true, "unique": true } }, "R27": { "role": "http://www.evogene.com/role/OperatingSegments", "longName": "0028 - Disclosure - OPERATING SEGMENTS", "shortName": "OPERATING SEGMENTS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "27", "firstAnchor": { "contextRef": "C_20240101to20241231", "name": "ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532892.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20240101to20241231", "name": "ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532892.htm", "first": true, "unique": true } }, "R28": { "role": "http://www.evogene.com/role/BalancesAndTransactionsWithExecutiveOfficersAndCertainShareholders", "longName": "0029 - Disclosure - BALANCES AND TRANSACTIONS WITH EXECUTIVE OFFICERS AND CERTAIN SHAREHOLDERS", "shortName": "BALANCES AND TRANSACTIONS WITH EXECUTIVE OFFICERS AND CERTAIN SHAREHOLDERS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "28", "firstAnchor": { "contextRef": "C_20240101to20241231", "name": "ifrs-full:DisclosureOfRelatedPartyExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532892.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20240101to20241231", "name": "ifrs-full:DisclosureOfRelatedPartyExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532892.htm", "first": true, "unique": true } }, "R29": { "role": "http://www.evogene.com/role/SUBSEQUENTEVENTS", "longName": "0030 - Disclosure - SUBSEQUENT EVENTS", "shortName": "SUBSEQUENT EVENTS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "29", "firstAnchor": { "contextRef": "C_20240101to20241231", "name": "ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532892.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20240101to20241231", "name": "ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532892.htm", "first": true, "unique": true } }, "R30": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc", "longName": "995447 - Disclosure - Insider Trading Policies and Procedures", "shortName": "Insider Trading Policies and Procedures", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "30", "firstAnchor": { "contextRef": "C_20240101to20241231", "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "span", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532892.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20240101to20241231", "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "span", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532892.htm", "first": true, "unique": true } }, "R31": { "role": "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure", "longName": "995550 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure", "shortName": "Cybersecurity Risk Management and Strategy Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "31", "firstAnchor": { "contextRef": "C_20240101to20241231", "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532892.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20240101to20241231", "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532892.htm", "first": true, "unique": true } }, "R32": { "role": "http://www.evogene.com/role/SignificantAccountingPoliciesPolicies", "longName": "9960701 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)", "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "32", "firstAnchor": { "contextRef": "C_20240101to20241231", "name": "evgn:DescriptionOfAccountingPolicyForBasisOfPresentationOfFinancialStatement", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ifrs-full:DisclosureOfChangesInAccountingPoliciesExplanatory", "div", "div", "div", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532892.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20240101to20241231", "name": "evgn:DescriptionOfAccountingPolicyForBasisOfPresentationOfFinancialStatement", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ifrs-full:DisclosureOfChangesInAccountingPoliciesExplanatory", "div", "div", "div", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532892.htm", "first": true, "unique": true } }, "R33": { "role": "http://www.evogene.com/role/SignificantAccountingPoliciesTables", "longName": "9960702 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Tables)", "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "33", "firstAnchor": { "contextRef": "C_20240101to20241231", "name": "ifrs-full:DisclosureOfInventoriesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "ifrs-full:DescriptionOfAccountingPolicyForMeasuringInventories", "div", "ifrs-full:DisclosureOfChangesInAccountingPoliciesExplanatory", "div", "div", "div", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532892.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20240101to20241231", "name": "ifrs-full:DisclosureOfInventoriesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "ifrs-full:DescriptionOfAccountingPolicyForMeasuringInventories", "div", "ifrs-full:DisclosureOfChangesInAccountingPoliciesExplanatory", "div", "div", "div", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532892.htm", "first": true, "unique": true } }, "R34": { "role": "http://www.evogene.com/role/CashAndCashEquivalentsTables", "longName": "9960703 - Disclosure - CASH AND CASH EQUIVALENTS (Tables)", "shortName": "CASH AND CASH EQUIVALENTS (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "34", "firstAnchor": { "contextRef": "C_20240101to20241231", "name": "evgn:DisclosureOfDetailedInformationAboutCashAndCashEquivalentsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "div", "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532892.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20240101to20241231", "name": "evgn:DisclosureOfDetailedInformationAboutCashAndCashEquivalentsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "div", "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532892.htm", "first": true, "unique": true } }, "R35": { "role": "http://www.evogene.com/role/OtherReceivablesAndPrepaidExpensesTables", "longName": "9960704 - Disclosure - OTHER RECEIVABLES AND PREPAID EXPENSES (Tables)", "shortName": "OTHER RECEIVABLES AND PREPAID EXPENSES (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "35", "firstAnchor": { "contextRef": "C_20240101to20241231", "name": "evgn:DisclosureOfDetailedInformationAboutOtherRecevablesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532892.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20240101to20241231", "name": "evgn:DisclosureOfDetailedInformationAboutOtherRecevablesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532892.htm", "first": true, "unique": true } }, "R36": { "role": "http://www.evogene.com/role/LeasesTables", "longName": "9960705 - Disclosure - LEASES (Tables)", "shortName": "LEASES (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "36", "firstAnchor": { "contextRef": "C_20240101to20241231", "name": "evgn:DisclosureOfLeaseExpensesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "ifrs-full:DisclosureOfLeasesExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532892.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20240101to20241231", "name": "evgn:DisclosureOfLeaseExpensesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "ifrs-full:DisclosureOfLeasesExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532892.htm", "first": true, "unique": true } }, "R37": { "role": "http://www.evogene.com/role/PropertyPlantAndEquipmentNetTables", "longName": "9960706 - Disclosure - PROPERTY, PLANT AND EQUIPMENT, NET (Tables)", "shortName": "PROPERTY, PLANT AND EQUIPMENT, NET (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "37", "firstAnchor": { "contextRef": "C_20240101to20241231", "name": "ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532892.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20240101to20241231", "name": "ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532892.htm", "first": true, "unique": true } }, "R38": { "role": "http://www.evogene.com/role/IntangibleAssetsNetTables", "longName": "9960707 - Disclosure - INTANGIBLE ASSETS, NET (Tables)", "shortName": "INTANGIBLE ASSETS, NET (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "38", "firstAnchor": { "contextRef": "C_20240101to20241231", "name": "ifrs-full:DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "div", "div", "div", "div", "ifrs-full:DisclosureOfIntangibleAssetsExplanatory", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532892.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20240101to20241231", "name": "ifrs-full:DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "div", "div", "div", "div", "ifrs-full:DisclosureOfIntangibleAssetsExplanatory", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532892.htm", "first": true, "unique": true } }, "R39": { "role": "http://www.evogene.com/role/LiabilitiesInRespectOfGovernmentGrantsTables", "longName": "9960708 - Disclosure - LIABILITIES IN RESPECT OF GOVERNMENT GRANTS (Tables)", "shortName": "LIABILITIES IN RESPECT OF GOVERNMENT GRANTS (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "39", "firstAnchor": { "contextRef": "C_20240101to20241231", "name": "evgn:DisclosureOfDetailedInformationAboutLiabilitiesInRespectOfGovernmentGrantsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "ifrs-full:DisclosureOfGovernmentGrantsExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532892.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20240101to20241231", "name": "evgn:DisclosureOfDetailedInformationAboutLiabilitiesInRespectOfGovernmentGrantsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "ifrs-full:DisclosureOfGovernmentGrantsExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532892.htm", "first": true, "unique": true } }, "R40": { "role": "http://www.evogene.com/role/FinancialInstrumentsTables", "longName": "9960709 - Disclosure - FINANCIAL INSTRUMENTS (Tables)", "shortName": "FINANCIAL INSTRUMENTS (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "40", "firstAnchor": { "contextRef": "C_20240101to20241231", "name": "ifrs-full:DisclosureOfFairValueMeasurementOfAssetsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532892.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20240101to20241231", "name": "ifrs-full:DisclosureOfFairValueMeasurementOfAssetsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532892.htm", "first": true, "unique": true } }, "R41": { "role": "http://www.evogene.com/role/SeverancePayLiabilityNetTables", "longName": "9960710 - Disclosure - SEVERANCE PAY LIABILITY (Tables)", "shortName": "SEVERANCE PAY LIABILITY (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "41", "firstAnchor": { "contextRef": "C_20240101to20241231", "name": "ifrs-full:DisclosureOfDefinedBenefitPlansExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ifrs-full:DisclosureOfEmployeeBenefitsExplanatory", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532892.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20240101to20241231", "name": "ifrs-full:DisclosureOfDefinedBenefitPlansExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ifrs-full:DisclosureOfEmployeeBenefitsExplanatory", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532892.htm", "first": true, "unique": true } }, "R42": { "role": "http://www.evogene.com/role/ShareholdersEquityTables", "longName": "9960711 - Disclosure - SHAREHOLDERS' EQUITY (Tables)", "shortName": "SHAREHOLDERS' EQUITY (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "42", "firstAnchor": { "contextRef": "C_20240101to20241231", "name": "ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "div", "div", "div", "div", "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532892.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20240101to20241231", "name": "ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "div", "div", "div", "div", "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532892.htm", "first": true, "unique": true } }, "R43": { "role": "http://www.evogene.com/role/Share-BasedCompensationTables", "longName": "9960712 - Disclosure - SHARE- BASED COMPENSATION (Tables)", "shortName": "SHARE- BASED COMPENSATION (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "43", "firstAnchor": { "contextRef": "C_20240101to20241231", "name": "ifrs-full:ExplanationOfEffectOfSharebasedPaymentsOnFinancialPositions", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "div", "div", "div", "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532892.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20240101to20241231", "name": "ifrs-full:ExplanationOfEffectOfSharebasedPaymentsOnFinancialPositions", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "div", "div", "div", "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532892.htm", "first": true, "unique": true } }, "R44": { "role": "http://www.evogene.com/role/StatementsOfComprehensiveLoss-AdditionalInformationTables", "longName": "9960713 - Disclosure - STATEMENTS OF PROFIT OR LOSS - ADDITIONAL INFORMATION (Tables)", "shortName": "STATEMENTS OF PROFIT OR LOSS - ADDITIONAL INFORMATION (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "44", "firstAnchor": { "contextRef": "C_20240101to20241231", "name": "evgn:DisclosureOfDetailedInformationAboutIncomeAndExpensesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "evgn:StatementsOfComprehensiveLossAdditionalInformationExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532892.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20240101to20241231", "name": "evgn:DisclosureOfDetailedInformationAboutIncomeAndExpensesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "evgn:StatementsOfComprehensiveLossAdditionalInformationExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532892.htm", "first": true, "unique": true } }, "R45": { "role": "http://www.evogene.com/role/LossPerShareTables", "longName": "9960714 - Disclosure - LOSS PER SHARE (Tables)", "shortName": "LOSS PER SHARE (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "45", "firstAnchor": { "contextRef": "C_20240101to20241231", "name": "ifrs-full:EarningsPerShareExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "ifrs-full:DisclosureOfEarningsPerShareExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532892.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20240101to20241231", "name": "ifrs-full:EarningsPerShareExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "ifrs-full:DisclosureOfEarningsPerShareExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532892.htm", "first": true, "unique": true } }, "R46": { "role": "http://www.evogene.com/role/OperatingSegmentsTables", "longName": "9960715 - Disclosure - OPERATING SEGMENTS (Tables)", "shortName": "OPERATING SEGMENTS (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "46", "firstAnchor": { "contextRef": "C_20240101to20241231", "name": "ifrs-full:DisclosureOfOperatingSegmentsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532892.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20240101to20241231", "name": "ifrs-full:DisclosureOfOperatingSegmentsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532892.htm", "first": true, "unique": true } }, "R47": { "role": "http://www.evogene.com/role/BalancesAndTransactionsWithExecutiveOfficersAndCertainShareholdersTables", "longName": "9960716 - Disclosure - BALANCES AND TRANSACTIONS WITH EXECUTIVE OFFICERS AND CERTAIN SHAREHOLDERS (Tables)", "shortName": "BALANCES AND TRANSACTIONS WITH EXECUTIVE OFFICERS AND CERTAIN SHAREHOLDERS (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "47", "firstAnchor": { "contextRef": "C_20240101to20241231", "name": "evgn:DisclosureOfDetailedInformationAboutBalancesWithRelatedPartiesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "ifrs-full:DisclosureOfRelatedPartyExplanatory", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532892.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20240101to20241231", "name": "evgn:DisclosureOfDetailedInformationAboutBalancesWithRelatedPartiesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "ifrs-full:DisclosureOfRelatedPartyExplanatory", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532892.htm", "first": true, "unique": true } }, "R48": { "role": "http://www.evogene.com/role/GeneralNarrativeDetails", "longName": "9960717 - Disclosure - GENERAL (Narrative) (Details)", "shortName": "GENERAL (Narrative) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "48", "firstAnchor": { "contextRef": "C_20240101to20241231", "name": "ifrs-full:ProfitLossFromOperatingActivities", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532892.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_20220801to20220831_ifrsfullCategoriesOfRelatedPartiesAxis_evgnIclGroupMember", "name": "evgn:AmountOfInvestmentUnderCollaborationAgreement", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532892.htm", "unique": true } }, "R49": { "role": "http://www.evogene.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails", "longName": "9960718 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Narrative) (Details)", "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Narrative) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "49", "firstAnchor": { "contextRef": "C_20240101to20241231", "name": "evgn:RevenueRecognisedOverTheNext12Months", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "div", "div", "div", "div", "ifrs-full:DescriptionOfAccountingPolicyForRecognitionOfRevenue", "div", "ifrs-full:DisclosureOfChangesInAccountingPoliciesExplanatory", "div", "div", "div", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532892.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20240101to20241231", "name": "evgn:RevenueRecognisedOverTheNext12Months", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "div", "div", "div", "div", "ifrs-full:DescriptionOfAccountingPolicyForRecognitionOfRevenue", "div", "ifrs-full:DisclosureOfChangesInAccountingPoliciesExplanatory", "div", "div", "div", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532892.htm", "first": true, "unique": true } }, "R50": { "role": "http://www.evogene.com/role/SIGNIFICANTACCOUNTINGPOLICIESScheduleOfSummarizesInformationAboutTheInventoryDetails", "longName": "9960719 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Schedule of summarizes information about the inventory) (Details)", "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Schedule of summarizes information about the inventory) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "50", "firstAnchor": { "contextRef": "C_20241231", "name": "ifrs-full:RawMaterials", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "span", "span", "div", "td", "tr", "table", "ifrs-full:DisclosureOfInventoriesExplanatory", "div", "div", "div", "ifrs-full:DescriptionOfAccountingPolicyForMeasuringInventories", "div", "ifrs-full:DisclosureOfChangesInAccountingPoliciesExplanatory", "div", "div", "div", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532892.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20241231", "name": "ifrs-full:RawMaterials", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "span", "span", "div", "td", "tr", "table", "ifrs-full:DisclosureOfInventoriesExplanatory", "div", "div", "div", "ifrs-full:DescriptionOfAccountingPolicyForMeasuringInventories", "div", "ifrs-full:DisclosureOfChangesInAccountingPoliciesExplanatory", "div", "div", "div", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532892.htm", "first": true, "unique": true } }, "R51": { "role": "http://www.evogene.com/role/SignificantAccountingPoliciesScheduleOfUsefulLifeOfRightOfUseAssetsDetails", "longName": "9960720 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Schedule of Useful Life of Right of Use Assets) (Details)", "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Schedule of Useful Life of Right of Use Assets) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "51", "firstAnchor": { "contextRef": "C_20240101to20241231_ifrsfullClassesOfPropertyPlantAndEquipmentAxis_evgnOfficeSpaceMember", "name": "evgn:DescriptionOfUsefulLifeOrLeasePeriodOfRightOfUseAssets", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "evgn:DisclosureOfDetailedInformationAboutUsefulLifeOfPropertyPlantAndEquipmentExplanatory", "div", "div", "ifrs-full:DescriptionOfAccountingPolicyForLeasesExplanatory", "div", "div", "ifrs-full:DisclosureOfChangesInAccountingPoliciesExplanatory", "div", "div", "div", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532892.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20240101to20241231_ifrsfullClassesOfPropertyPlantAndEquipmentAxis_evgnOfficeSpaceMember", "name": "evgn:DescriptionOfUsefulLifeOrLeasePeriodOfRightOfUseAssets", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "evgn:DisclosureOfDetailedInformationAboutUsefulLifeOfPropertyPlantAndEquipmentExplanatory", "div", "div", "ifrs-full:DescriptionOfAccountingPolicyForLeasesExplanatory", "div", "div", "ifrs-full:DisclosureOfChangesInAccountingPoliciesExplanatory", "div", "div", "div", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532892.htm", "first": true, "unique": true } }, "R52": { "role": "http://www.evogene.com/role/SignificantAccountingPoliciesScheduleOfDepreciationCalculatedUsingStraight-lineMethodDetails", "longName": "9960721 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Schedule of Depreciation Calculated Using Straight-Line Method) (Details)", "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Schedule of Depreciation Calculated Using Straight-Line Method) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "52", "firstAnchor": { "contextRef": "C_20240101to20241231_ifrsfullClassesOfPropertyPlantAndEquipmentAxis_evgnLaboratoryEquipmentMember", "name": "ifrs-full:DescriptionOfUsefulLifePropertyPlantAndEquipment", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "span", "span", "span", "div", "td", "tr", "table", "div", "evgn:DisclosureOfUsefulLifeOfRightOfUseAssetsExplanatory", "div", "div", "ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory", "div", "div", "ifrs-full:DisclosureOfChangesInAccountingPoliciesExplanatory", "div", "div", "div", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532892.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20240101to20241231_ifrsfullClassesOfPropertyPlantAndEquipmentAxis_evgnLaboratoryEquipmentMember", "name": "ifrs-full:DescriptionOfUsefulLifePropertyPlantAndEquipment", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "span", "span", "span", "div", "td", "tr", "table", "div", "evgn:DisclosureOfUsefulLifeOfRightOfUseAssetsExplanatory", "div", "div", "ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory", "div", "div", "ifrs-full:DisclosureOfChangesInAccountingPoliciesExplanatory", "div", "div", "div", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532892.htm", "first": true, "unique": true } }, "R53": { "role": "http://www.evogene.com/role/SignificantAccountingPoliciesScheduleOfIntangibleAssetsPurchasedDetails", "longName": "9960722 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Schedule of Intangible Assets Purchased) (Details)", "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Schedule of Intangible Assets Purchased) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "53", "firstAnchor": { "contextRef": "C_20240101to20241231_ifrsfullClassesOfPropertyPlantAndEquipmentAxis_evgnPipelineProductsMember", "name": "ifrs-full:DescriptionOfUsefulLifeIntangibleAssetsOtherThanGoodwill", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "span", "span", "span", "div", "td", "tr", "table", "div", "evgn:DisclosureOfScheduleOfIntangibleAssetsPurchasedExplanatory", "div", "div", "div", "ifrs-full:DisclosureOfIntangibleAssetsAndGoodwillExplanatory", "div", "ifrs-full:DisclosureOfChangesInAccountingPoliciesExplanatory", "div", "div", "div", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532892.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20240101to20241231_ifrsfullClassesOfPropertyPlantAndEquipmentAxis_evgnPipelineProductsMember", "name": "ifrs-full:DescriptionOfUsefulLifeIntangibleAssetsOtherThanGoodwill", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "span", "span", "span", "div", "td", "tr", "table", "div", "evgn:DisclosureOfScheduleOfIntangibleAssetsPurchasedExplanatory", "div", "div", "div", "ifrs-full:DisclosureOfIntangibleAssetsAndGoodwillExplanatory", "div", "ifrs-full:DisclosureOfChangesInAccountingPoliciesExplanatory", "div", "div", "div", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532892.htm", "first": true, "unique": true } }, "R54": { "role": "http://www.evogene.com/role/ScheduleOfTimingOfRevenuesByTimingOfRevenueRecognition", "longName": "9960723 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Schedule of timing of revenues by timing of revenue recognition) (Details)", "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Schedule of timing of revenues by timing of revenue recognition) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "54", "firstAnchor": { "contextRef": "C_20240101to20241231", "name": "ifrs-full:Revenue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532892.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_20240101to20241231_evgnTimingOfRevenueRecognitionAxis_evgnRevenueRecognizedAtAPointInTimeMember", "name": "ifrs-full:Revenue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "span", "span", "div", "td", "tr", "table", "evgn:DisclosureOfScheduleOfTimingOfRevenuesByTimingOfRevenueRecognitionExplanatory", "div", "div", "ifrs-full:DescriptionOfAccountingPolicyForRecognitionOfRevenue", "div", "ifrs-full:DisclosureOfChangesInAccountingPoliciesExplanatory", "div", "div", "div", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532892.htm", "unique": true } }, "R55": { "role": "http://www.evogene.com/role/SIGNIFICANTACCOUNTINGJUDGMENTSESTIMATESANDASSUMPTIONSUSEDINTHEPREPARATIONOFTHEFINANCIALSTATEMENTSNarrativeDetails", "longName": "9960724 - Disclosure - SIGNIFICANT ACCOUNTING JUDGMENTS, ESTIMATES AND ASSUMPTIONS USED IN THE PREPARATION OF THE FINANCIAL STATEMENTS (Narrative) (Details)", "shortName": "SIGNIFICANT ACCOUNTING JUDGMENTS, ESTIMATES AND ASSUMPTIONS USED IN THE PREPARATION OF THE FINANCIAL STATEMENTS (Narrative) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "55", "firstAnchor": { "contextRef": "C_20240101to20241231", "name": "ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted", "unitRef": "Percentage", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ifrs-full:DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory", "div", "div", "div", "div", "div", "div", "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532892.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_20240101to20241231_ifrsfullTypesOfSharebasedPaymentArrangementsAxis_evgnWarrantsAndPreFundedWarrantsLiabilityMember", "name": "ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted", "unitRef": "Percentage", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "span", "span", "span", "span", "div", "div", "ifrs-full:DisclosureOfAccountingJudgementsAndEstimatesExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532892.htm", "unique": true } }, "R56": { "role": "http://www.evogene.com/role/CollaborationAndResearchAgreementsNarrativeDetails", "longName": "9960725 - Disclosure - COLLABORATION, RESEARCH AND DISTRIBUTION AND SALES AGREEMENTS (Narrative) (Details)", "shortName": "COLLABORATION, RESEARCH AND DISTRIBUTION AND SALES AGREEMENTS (Narrative) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "56", "firstAnchor": { "contextRef": "C_20210801to20210831_ifrsfullCategoriesOfRelatedPartiesAxis_evgnCanonicLtdMember_srtMajorCustomersAxis_evgnCustomerCMember", "name": "evgn:TermOfAgreement", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "evgn:DisclosureOfCollaborationAgreementsExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532892.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20210801to20210831_ifrsfullCategoriesOfRelatedPartiesAxis_evgnCanonicLtdMember_srtMajorCustomersAxis_evgnCustomerCMember", "name": "evgn:TermOfAgreement", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "evgn:DisclosureOfCollaborationAgreementsExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532892.htm", "first": true, "unique": true } }, "R57": { "role": "http://www.evogene.com/role/CashAndCashEquivalentsScheduleOfCashAndEquivalentsDetails", "longName": "9960726 - Disclosure - CASH AND CASH EQUIVALENTS (Schedule of Cash and Equivalents) (Details)", "shortName": "CASH AND CASH EQUIVALENTS (Schedule of Cash and Equivalents) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "57", "firstAnchor": { "contextRef": "C_20241231", "name": "ifrs-full:Cash", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "div", "td", "tr", "table", "div", "evgn:DisclosureOfDetailedInformationAboutCashAndCashEquivalentsExplanatory", "div", "div", "div", "div", "div", "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532892.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20241231", "name": "ifrs-full:Cash", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "div", "td", "tr", "table", "div", "evgn:DisclosureOfDetailedInformationAboutCashAndCashEquivalentsExplanatory", "div", "div", "div", "div", "div", "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532892.htm", "first": true, "unique": true } }, "R58": { "role": "http://www.evogene.com/role/OtherReceivablesAndPrepaidExpensesScheduleOfOtherReceivablesAndPrepaidExpensesDetails", "longName": "9960727 - Disclosure - OTHER RECEIVABLES AND PREPAID EXPENSES (Schedule of Other Receivables and Prepaid Expenses) (Details)", "shortName": "OTHER RECEIVABLES AND PREPAID EXPENSES (Schedule of Other Receivables and Prepaid Expenses) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "58", "firstAnchor": { "contextRef": "C_20241231", "name": "evgn:GovernmentAuthoritiesCurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "div", "td", "tr", "table", "div", "evgn:DisclosureOfDetailedInformationAboutOtherRecevablesExplanatory", "div", "div", "div", "div", "ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532892.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20241231", "name": "evgn:GovernmentAuthoritiesCurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "div", "td", "tr", "table", "div", "evgn:DisclosureOfDetailedInformationAboutOtherRecevablesExplanatory", "div", "div", "div", "div", "ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532892.htm", "first": true, "unique": true } }, "R59": { "role": "http://www.evogene.com/role/LeasesNarrativeDetails", "longName": "9960728 - Disclosure - LEASES (Narrative) (Details)", "shortName": "LEASES (Narrative) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "59", "firstAnchor": { "contextRef": "C_20181201to20181231_ifrsfullClassesOfPropertyPlantAndEquipmentAxis_evgnOfficesAndCarLeasesMember", "name": "evgn:OriginalLeaseMaturityPeriods", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "span", "div", "div", "ifrs-full:DisclosureOfLeasesExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532892.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20181201to20181231_ifrsfullClassesOfPropertyPlantAndEquipmentAxis_evgnOfficesAndCarLeasesMember", "name": "evgn:OriginalLeaseMaturityPeriods", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "span", "div", "div", "ifrs-full:DisclosureOfLeasesExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532892.htm", "first": true, "unique": true } }, "R60": { "role": "http://www.evogene.com/role/LeasesScheduleOfLeaseExpensesDetails", "longName": "9960729 - Disclosure - LEASES (Schedule of Lease Expenses) (Details)", "shortName": "LEASES (Schedule of Lease Expenses) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "60", "firstAnchor": { "contextRef": "C_20240101to20241231", "name": "ifrs-full:InterestExpenseOnLeaseLiabilities", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "div", "td", "tr", "table", "evgn:DisclosureOfLeaseExpensesExplanatory", "div", "div", "ifrs-full:DisclosureOfLeasesExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532892.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_20240101to20241231", "name": "evgn:ExchangeDifferences", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "div", "td", "tr", "table", "evgn:DisclosureOfLeaseExpensesExplanatory", "div", "div", "ifrs-full:DisclosureOfLeasesExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532892.htm", "unique": true } }, "R61": { "role": "http://www.evogene.com/role/LeasesScheduleOfRight-of-useAssetsDetails", "longName": "9960730 - Disclosure - LEASES (Schedule of Right-of-Use Assets) (Details)", "shortName": "LEASES (Schedule of Right-of-Use Assets) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "61", "firstAnchor": { "contextRef": "C_20231231", "name": "ifrs-full:RightofuseAssets", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532892.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_20241231", "name": "evgn:RightofuseAssetsGrossCarryingAmountFullyDepreciated", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ifrs-full:DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory", "div", "div", "ifrs-full:DisclosureOfLeasesExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532892.htm", "unique": true } }, "R62": { "role": "http://www.evogene.com/role/LeasesScheduleOfLeaseLiabilityDetails", "longName": "9960731 - Disclosure - LEASES (Schedule of Lease Liability) (Details)", "shortName": "LEASES (Schedule of Lease Liability) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "62", "firstAnchor": { "contextRef": "C_20231231", "name": "ifrs-full:LeaseLiabilities", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "div", "td", "tr", "table", "ifrs-full:DisclosureOfNetDefinedBenefitLiabilityAssetExplanatory", "div", "div", "div", "ifrs-full:DisclosureOfLeasesExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532892.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_20221231", "name": "ifrs-full:LeaseLiabilities", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "div", "div", "div", "div", "ifrs-full:DisclosureOfLeasesExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532892.htm", "unique": true } }, "R63": { "role": "http://www.evogene.com/role/LeasesScheduleOfFutureMinimumLeasePaymentsUnderNon-cancelableLeasesDetails", "longName": "9960732 - Disclosure - LEASES (Schedule of Future Minimum Lease Payments Under Non-Cancelable Leases) (Details)", "shortName": "LEASES (Schedule of Future Minimum Lease Payments Under Non-Cancelable Leases) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "63", "firstAnchor": { "contextRef": "C_20241231", "name": "evgn:UndiscountedOperatingLeasePaymentsToBeReceivedOneYear", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "div", "td", "tr", "table", "ifrs-full:DisclosureOfMaturityAnalysisOfFinanceLeasePaymentsReceivableExplanatory", "div", "div", "ifrs-full:DisclosureOfLeasesExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532892.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20241231", "name": "evgn:UndiscountedOperatingLeasePaymentsToBeReceivedOneYear", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "div", "td", "tr", "table", "ifrs-full:DisclosureOfMaturityAnalysisOfFinanceLeasePaymentsReceivableExplanatory", "div", "div", "ifrs-full:DisclosureOfLeasesExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532892.htm", "first": true, "unique": true } }, "R64": { "role": "http://www.evogene.com/role/PROPERTYPLANTANDEQUIPMENTNETNarrativeDetails", "longName": "9960733 - Disclosure - PROPERTY, PLANT AND EQUIPMENT, NET (Narrative) (Details)", "shortName": "PROPERTY, PLANT AND EQUIPMENT, NET (Narrative) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "64", "firstAnchor": { "contextRef": "C_20240101to20241231", "name": "ifrs-full:DepreciationPropertyPlantAndEquipment", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "p", "div", "div", "div", "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532892.htm", "first": true }, "uniqueAnchor": null }, "R65": { "role": "http://www.evogene.com/role/PropertyPlantAndEquipmentNetScheduleOfPropertyPlantEquipmentToAccumulatedDepreciationDetails", "longName": "9960734 - Disclosure - PROPERTY, PLANT AND EQUIPMENT, NET (Schedule of Property Plant Equipment to Accumulated Depreciation) (Details)", "shortName": "PROPERTY, PLANT AND EQUIPMENT, NET (Schedule of Property Plant Equipment to Accumulated Depreciation) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "65", "firstAnchor": { "contextRef": "C_20231231", "name": "ifrs-full:PropertyPlantAndEquipment", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532892.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_20240101to20241231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullGrossCarryingAmountMember", "name": "ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory", "div", "div", "div", "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532892.htm", "unique": true } }, "R66": { "role": "http://www.evogene.com/role/IntangibleAssetsNetNarrativeDetails", "longName": "9960735 - Disclosure - INTANGIBLE ASSETS, NET (Narrative) (Details)", "shortName": "INTANGIBLE ASSETS, NET (Narrative) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "66", "firstAnchor": { "contextRef": "C_20190806_ifrsfullBusinessCombinationsAxis_evgnLavieBioLtdMember", "name": "ifrs-full:InvestmentsInSubsidiaries", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532892.htm", "first": true }, "uniqueAnchor": null }, "R67": { "role": "http://www.evogene.com/role/IntangibleAssetsNetScheduleOfIntangibleAssetsDetails", "longName": "9960736 - Disclosure - INTANGIBLE ASSETS, NET (Schedule of Intangible Assets) (Details)", "shortName": "INTANGIBLE ASSETS, NET (Schedule of Intangible Assets) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "67", "firstAnchor": { "contextRef": "C_20231231", "name": "ifrs-full:IntangibleAssetsOtherThanGoodwill", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532892.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_20241231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullGrossCarryingAmountMember", "name": "ifrs-full:IntangibleAssetsOtherThanGoodwill", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "ifrs-full:DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory", "div", "div", "div", "div", "div", "div", "div", "div", "ifrs-full:DisclosureOfIntangibleAssetsExplanatory", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532892.htm", "unique": true } }, "R68": { "role": "http://www.evogene.com/role/LiabilitiesInRespectOfGovernmentGrantsNarrativeDetails", "longName": "9960737 - Disclosure - LIABILITIES IN RESPECT OF GOVERNMENT GRANTS (Narrative) (Details)", "shortName": "LIABILITIES IN RESPECT OF GOVERNMENT GRANTS (Narrative) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "68", "firstAnchor": { "contextRef": "C_20240101to20241231", "name": "ifrs-full:Revenue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532892.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_20240101to20241231_ifrsfullCategoriesOfRelatedPartiesAxis_evgnOfficeOfChiefScientistMember", "name": "evgn:PercentageOfRoyaltiesCompanyUndertookToPayDescription", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "span", "div", "div", "ifrs-full:DisclosureOfGovernmentGrantsExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532892.htm", "unique": true } }, "R69": { "role": "http://www.evogene.com/role/LiabilitiesInRespectOfGovernmentGrantsScheduleOfLiabilitiesInRespectOfGovernmentGrantsDetails", "longName": "9960738 - Disclosure - LIABILITIES IN RESPECT OF GOVERNMENT GRANTS (Schedule of Liabilities in Respect of Government Grants) (Details)", "shortName": "LIABILITIES IN RESPECT OF GOVERNMENT GRANTS (Schedule of Liabilities in Respect of Government Grants) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "69", "firstAnchor": { "contextRef": "C_20231231", "name": "evgn:GovernmentGrant", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "evgn:DisclosureOfDetailedInformationAboutLiabilitiesInRespectOfGovernmentGrantsExplanatory", "div", "div", "ifrs-full:DisclosureOfGovernmentGrantsExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532892.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_20221231", "name": "evgn:GovernmentGrant", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "evgn:DisclosureOfDetailedInformationAboutLiabilitiesInRespectOfGovernmentGrantsExplanatory", "div", "div", "ifrs-full:DisclosureOfGovernmentGrantsExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532892.htm", "unique": true } }, "R70": { "role": "http://www.evogene.com/role/ConvertibleSAFENarrativeDetails", "longName": "9960739 - Disclosure - CONVERTIBLE SAFE (Narrative) (Details)", "shortName": "CONVERTIBLE SAFE (Narrative) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "70", "firstAnchor": { "contextRef": "C_20220801to20220831_ifrsfullCategoriesOfRelatedPartiesAxis_evgnIclGroupMember", "name": "evgn:AmountOfSafeAgreement", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "evgn:DisclosureOfCollaborationAgreementsExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532892.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_20220801to20220831_evgnAgreementAxis_evgnMultiYearCollaborationAgreementMember_ifrsfullBusinessCombinationsAxis_evgnLavieBioLtdMember_ifrsfullCategoriesOfRelatedPartiesAxis_evgnIclGroupMember_ifrsfullComponentsOfEquityAxis_ifrsfullReserveOfEquityComponentOfConvertibleInstruments", "name": "evgn:DiscountPercentageForConversionOfDebtToEquity", "unitRef": "Percentage", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "ifrs-full:DescriptionOfConversionOfDebtToEquity", "span", "span", "div", "div", "div", "div", "div", "div", "div", "div", "div", "div", "ifrs-full:DisclosureOfDebtSecuritiesExplanatory", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532892.htm", "unique": true } }, "R71": { "role": "http://www.evogene.com/role/FinancialInstrumentsNarrativeDetails", "longName": "9960740 - Disclosure - FINANCIAL INSTRUMENTS (Narrative) (Details)", "shortName": "FINANCIAL INSTRUMENTS (Narrative) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "71", "firstAnchor": { "contextRef": "C_20241231", "name": "evgn:PercentageOfWeightedAverageCostOfCapitalMeasurement", "unitRef": "Percentage", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": [ "span", "span", "span", "span", "div", "div", "div", "div", "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532892.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20241231", "name": "evgn:PercentageOfWeightedAverageCostOfCapitalMeasurement", "unitRef": "Percentage", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": [ "span", "span", "span", "span", "div", "div", "div", "div", "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532892.htm", "first": true, "unique": true } }, "R72": { "role": "http://www.evogene.com/role/FinancialInstrumentsScheduleOfCompanysFinancialLiabilitiesDetails", "longName": "9960741 - Disclosure - FINANCIAL INSTRUMENTS (Schedule of Company's Financial Liabilities) (Details)", "shortName": "FINANCIAL INSTRUMENTS (Schedule of Company's Financial Liabilities) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "72", "firstAnchor": { "contextRef": "C_20241231", "name": "ifrs-full:TradeAndOtherCurrentPayables", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532892.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_20241231", "name": "ifrs-full:ShorttermEmployeeBenefitsAccruals", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "span", "span", "div", "td", "tr", "table", "div", "div", "div", "ifrs-full:DisclosureOfFairValueMeasurementOfAssetsExplanatory", "div", "div", "div", "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532892.htm", "unique": true } }, "R73": { "role": "http://www.evogene.com/role/FinancialInstrumentsScheduleOfSensitivityTestsRelatingToChangesInMarketFactorsDetails", "longName": "9960742 - Disclosure - FINANCIAL INSTRUMENTS (Schedule of Sensitivity Tests Relating to Changes in Market Factors) (Details)", "shortName": "FINANCIAL INSTRUMENTS (Schedule of Sensitivity Tests Relating to Changes in Market Factors) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "73", "firstAnchor": { "contextRef": "C_20240101to20241231_evgnSensitivityAnalysisAxis_evgnFivePercentDecreaseInExchangeRateMember", "name": "evgn:SensitivityTestToChangesInNisExchangeRateGainLossFromChange", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "span", "span", "span", "span", "div", "td", "tr", "table", "ifrs-full:SensitivityAnalysisForEachTypeOfMarketRisk", "div", "div", "div", "div", "div", "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532892.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20240101to20241231_evgnSensitivityAnalysisAxis_evgnFivePercentDecreaseInExchangeRateMember", "name": "evgn:SensitivityTestToChangesInNisExchangeRateGainLossFromChange", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "span", "span", "span", "span", "div", "td", "tr", "table", "ifrs-full:SensitivityAnalysisForEachTypeOfMarketRisk", "div", "div", "div", "div", "div", "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532892.htm", "first": true, "unique": true } }, "R74": { "role": "http://www.evogene.com/role/COMMITMENTSANDCONTINGENTLIABILITIESNarrativeDetails", "longName": "9960743 - Disclosure - COMMITMENTS AND CONTINGENT LIABILITIES (Narrative) (Details)", "shortName": "COMMITMENTS AND CONTINGENT LIABILITIES (Narrative) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "74", "firstAnchor": { "contextRef": "C_20240131_ifrsfullClassesOfContingentLiabilitiesAxis_ifrsfullLegalProceedingsContingentLiabilityMember", "name": "evgn:PrePaymentForServices", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "div", "div", "div", "div", "ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532892.htm", "first": true }, "uniqueAnchor": null }, "R75": { "role": "http://www.evogene.com/role/SeverancePayLiabilityNetScheduleOfDefinedContributionPlansDetails", "longName": "9960744 - Disclosure - SEVERANCE PAY LIABILITY (Schedule of Defined Contribution Plans) (Details)", "shortName": "SEVERANCE PAY LIABILITY (Schedule of Defined Contribution Plans) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "75", "firstAnchor": { "contextRef": "C_20240101to20241231", "name": "ifrs-full:PostemploymentBenefitExpenseDefinedContributionPlans", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ifrs-full:DisclosureOfDefinedBenefitPlansExplanatory", "div", "ifrs-full:DisclosureOfEmployeeBenefitsExplanatory", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532892.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20240101to20241231", "name": "ifrs-full:PostemploymentBenefitExpenseDefinedContributionPlans", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ifrs-full:DisclosureOfDefinedBenefitPlansExplanatory", "div", "ifrs-full:DisclosureOfEmployeeBenefitsExplanatory", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532892.htm", "first": true, "unique": true } }, "R76": { "role": "http://www.evogene.com/role/TaxesOnIncomeDetails", "longName": "9960745 - Disclosure - TAXES ON INCOME (Narrative) (Details)", "shortName": "TAXES ON INCOME (Narrative) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "76", "firstAnchor": { "contextRef": "C_20241231", "name": "evgn:OperatingTaxLossCarryforwardOfParent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "div", "div", "td", "tr", "table", "div", "div", "div", "div", "div", "ifrs-full:DisclosureOfIncomeTaxExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532892.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20241231", "name": "evgn:OperatingTaxLossCarryforwardOfParent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "div", "div", "td", "tr", "table", "div", "div", "div", "div", "div", "ifrs-full:DisclosureOfIncomeTaxExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532892.htm", "first": true, "unique": true } }, "R77": { "role": "http://www.evogene.com/role/ShareholdersEquityNarrativeDetails", "longName": "9960746 - Disclosure - SHAREHOLDERS' EQUITY (Narrative) (Details)", "shortName": "SHAREHOLDERS' EQUITY (Narrative) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "77", "firstAnchor": { "contextRef": "C_20240701to20240723", "name": "evgn:StockholdersEquityReverseShareSplit", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532892.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_20210101to20210114", "name": "evgn:ProceedsFromIssueOfOrdinarySharesAndPreFundedWarrants", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "div", "td", "tr", "table", "div", "div", "div", "div", "div", "div", "div", "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532892.htm", "unique": true } }, "R78": { "role": "http://www.evogene.com/role/ShareholdersEquityScheduleOfShareCapitalDetails", "longName": "9960747 - Disclosure - SHAREHOLDERS' EQUITY (Schedule of Share Capital) (Details)", "shortName": "SHAREHOLDERS' EQUITY (Schedule of Share Capital) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "78", "firstAnchor": { "contextRef": "C_20241231", "name": "ifrs-full:NumberOfSharesAuthorised", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "ifrs-full:NumberOfSharesAuthorised", "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532892.htm", "first": true }, "uniqueAnchor": null }, "R79": { "role": "http://www.evogene.com/role/ShareholdersEquityScheduleOfChangesInShareCapitalDetails", "longName": "9960748 - Disclosure - SHAREHOLDERS' EQUITY (Schedule of Changes in Share Capital) (Details)", "shortName": "SHAREHOLDERS' EQUITY (Schedule of Changes in Share Capital) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "79", "firstAnchor": { "contextRef": "C_20231231", "name": "evgn:OrdinarySharesIssuedAndOutstandingReducedByTreasurySharesHeld", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "span", "span", "div", "td", "tr", "table", "ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory", "div", "div", "div", "div", "div", "div", "div", "div", "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532892.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_20221231_ifrsfullComponentsOfEquityAxis_evgnStockOptionsMember", "name": "evgn:OrdinarySharesIssuedAndOutstandingReducedByTreasurySharesHeld", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "div", "div", "div", "div", "evgn:DisclosureOfDetailedInformationAboutChangesInShareCapitalExplanatory", "div", "div", "div", "div", "div", "div", "div", "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532892.htm", "unique": true } }, "R80": { "role": "http://www.evogene.com/role/ShareholdersEquityScheduleOfCompositionNon-controllingInterestsDetails", "longName": "9960749 - Disclosure - SHAREHOLDERS' EQUITY (Schedule of Composition Non-Controlling Interests) (Details)", "shortName": "SHAREHOLDERS' EQUITY (Schedule of Composition Non-Controlling Interests) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "80", "firstAnchor": { "contextRef": "C_20231231", "name": "ifrs-full:NoncontrollingInterests", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532892.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_20240101to20241231_evgnNoncontrollingInterestAxis_ifrsfullNoncontrollingInterestsMember", "name": "evgn:ForfeitureOfNonControllingInterestsRegardingShareBasedCompensation", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "div", "td", "tr", "table", "ifrs-full:DisclosureOfNoncontrollingInterestsExplanatory", "div", "div", "div", "div", "div", "div", "div", "div", "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532892.htm", "unique": true } }, "R81": { "role": "http://www.evogene.com/role/Share-BasedCompensationNarrativeDetails", "longName": "9960750 - Disclosure - SHARE- BASED COMPENSATION (Narrative) (Details)", "shortName": "SHARE- BASED COMPENSATION (Narrative) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "81", "firstAnchor": { "contextRef": "C_20240101to20241231", "name": "evgn:ShareOptionAndIncentivePlansDescription", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "div", "div", "div", "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532892.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20240101to20241231", "name": "evgn:ShareOptionAndIncentivePlansDescription", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "div", "div", "div", "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532892.htm", "first": true, "unique": true } }, "R82": { "role": "http://www.evogene.com/role/Share-BasedCompensationScheduleOfCompanysFinancialStatementsDetails", "longName": "9960751 - Disclosure - SHARE- BASED COMPENSATION (Schedule of Company's Financial Statements) (Details)", "shortName": "SHARE- BASED COMPENSATION (Schedule of Company's Financial Statements) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "82", "firstAnchor": { "contextRef": "C_20240101to20241231", "name": "evgn:IncreaseDecreaseThroughShareBasedPaymentTransactionsEquityHoldersOfCompany", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "td", "tr", "table", "ifrs-full:ExplanationOfEffectOfSharebasedPaymentsOnFinancialPositions", "div", "div", "div", "div", "div", "div", "div", "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532892.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20240101to20241231", "name": "evgn:IncreaseDecreaseThroughShareBasedPaymentTransactionsEquityHoldersOfCompany", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "td", "tr", "table", "ifrs-full:ExplanationOfEffectOfSharebasedPaymentsOnFinancialPositions", "div", "div", "div", "div", "div", "div", "div", "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532892.htm", "first": true, "unique": true } }, "R83": { "role": "http://www.evogene.com/role/Share-BasedCompensationScheduleOfSummarizedNumberOfShareOptionsDetails", "longName": "9960752 - Disclosure - SHARE- BASED COMPENSATION (Schedule of Summarized Number of Share Options) (Details)", "shortName": "SHARE- BASED COMPENSATION (Schedule of Summarized Number of Share Options) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "83", "firstAnchor": { "contextRef": "C_20231231_ifrsfullTypesOfSharebasedPaymentArrangementsAxis_evgnEmployeesConsultantsDirectorsMember", "name": "ifrs-full:NumberOfOutstandingShareOptions", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory", "div", "div", "div", "div", "div", "div", "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532892.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_20211231_ifrsfullTypesOfSharebasedPaymentArrangementsAxis_evgnEmployeesConsultantsDirectorsMember", "name": "ifrs-full:NumberOfOutstandingShareOptions", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory", "div", "div", "div", "div", "div", "div", "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532892.htm", "unique": true } }, "R84": { "role": "http://www.evogene.com/role/Share-BasedCompensationScheduleOfShareOptionsOutstandingDetails", "longName": "9960753 - Disclosure - SHARE- BASED COMPENSATION (Schedule of Share Options Outstanding) (Details)", "shortName": "SHARE- BASED COMPENSATION (Schedule of Share Options Outstanding) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "84", "firstAnchor": { "contextRef": "C_20241231_ifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis_evgnExercisePriceRangeMember", "name": "ifrs-full:NumberOfOutstandingShareOptions", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ifrs-full:DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory", "div", "div", "div", "div", "div", "div", "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532892.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20241231_ifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis_evgnExercisePriceRangeMember", "name": "ifrs-full:NumberOfOutstandingShareOptions", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ifrs-full:DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory", "div", "div", "div", "div", "div", "div", "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532892.htm", "first": true, "unique": true } }, "R85": { "role": "http://www.evogene.com/role/Share-BasedCompensationScheduleOfAssumptionsUsedToValueOptionsDetails", "longName": "9960754 - Disclosure - SHARE- BASED COMPENSATION (Schedule of Assumptions Used to Value Options) (Details)", "shortName": "SHARE- BASED COMPENSATION (Schedule of Assumptions Used to Value Options) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "85", "firstAnchor": { "contextRef": "C_20240101to20241231", "name": "ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted", "unitRef": "Percentage", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ifrs-full:DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory", "div", "div", "div", "div", "div", "div", "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532892.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_20240101to20241231_ifrsfullRangeAxis_ifrsfullBottomOfRangeMember", "name": "evgn:SuboptimalFactor", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "1", "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ifrs-full:DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory", "div", "div", "div", "div", "div", "div", "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532892.htm", "unique": true } }, "R86": { "role": "http://www.evogene.com/role/SHAREBASEDCOMPENSATIONScheduleOfRestrictedStockUnitsActivityDetails", "longName": "9960755 - Disclosure - SHARE- BASED COMPENSATION (Schedule of Restricted Stock Units activity) (Details)", "shortName": "SHARE- BASED COMPENSATION (Schedule of Restricted Stock Units activity) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "86", "firstAnchor": { "contextRef": "C_20231231_ifrsfullTypesOfSharebasedPaymentArrangementsAxis_evgnRestrictedStockUnitsMember", "name": "ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory", "div", "div", "div", "div", "div", "div", "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532892.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_20221231_ifrsfullTypesOfSharebasedPaymentArrangementsAxis_evgnRestrictedStockUnitsMember", "name": "ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory", "div", "div", "div", "div", "div", "div", "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532892.htm", "unique": true } }, "R87": { "role": "http://www.evogene.com/role/STATEMENTSOFPROFITORLOSSADDITIONALINFORMATIONNarrativeDetails", "longName": "9960756 - Disclosure - STATEMENTS OF PROFIT OR LOSS - ADDITIONAL INFORMATION (Narrative) (Details)", "shortName": "STATEMENTS OF PROFIT OR LOSS - ADDITIONAL INFORMATION (Narrative) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "87", "firstAnchor": { "contextRef": "C_20240101to20241231", "name": "ifrs-full:OtherIncome", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532892.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_20240101to20241231", "name": "evgn:OtherExpensesDueToImpairmentOfFixedAssets", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "evgn:StatementsOfComprehensiveLossAdditionalInformationExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532892.htm", "unique": true } }, "R88": { "role": "http://www.evogene.com/role/StatementsOfComprehensiveLoss-AdditionalInformationScheduleOfIncomeAndExpensesDetails", "longName": "9960757 - Disclosure - STATEMENTS OF PROFIT OR LOSS - ADDITIONAL INFORMATION (Schedule of Income and Expenses) (Details)", "shortName": "STATEMENTS OF PROFIT OR LOSS - ADDITIONAL INFORMATION (Schedule of Income and Expenses) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "88", "firstAnchor": { "contextRef": "C_20240101to20241231", "name": "ifrs-full:WagesAndSalaries", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "evgn:DisclosureOfDetailedInformationAboutIncomeAndExpensesExplanatory", "div", "evgn:StatementsOfComprehensiveLossAdditionalInformationExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532892.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20240101to20241231", "name": "ifrs-full:WagesAndSalaries", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "evgn:DisclosureOfDetailedInformationAboutIncomeAndExpensesExplanatory", "div", "evgn:StatementsOfComprehensiveLossAdditionalInformationExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532892.htm", "first": true, "unique": true } }, "R89": { "role": "http://www.evogene.com/role/LossPerShareScheduleOfBasicLossPerShareDetails", "longName": "9960758 - Disclosure - LOSS PER SHARE (Schedule of Basic Loss Per Share) (Details)", "shortName": "LOSS PER SHARE (Schedule of Basic Loss Per Share) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "89", "firstAnchor": { "contextRef": "C_20240101to20241231", "name": "ifrs-full:WeightedAverageShares", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "ifrs-full:AdjustedWeightedAverageShares", "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532892.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_20240101to20241231", "name": "ifrs-full:ProfitLossFromContinuingOperationsAttributableToOrdinaryEquityHoldersOfParentEntity", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "span", "span", "div", "td", "tr", "table", "div", "div", "ifrs-full:EarningsPerShareExplanatory", "div", "div", "div", "ifrs-full:DisclosureOfEarningsPerShareExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532892.htm", "unique": true } }, "R90": { "role": "http://www.evogene.com/role/OperatingSegmentsScheduleOfRevenuesAndOperatingLossBySegmentsDetails", "longName": "9960759 - Disclosure - OPERATING SEGMENTS (Schedule of Revenues and Operating Loss by Segments) (Details)", "shortName": "OPERATING SEGMENTS (Schedule of Revenues and Operating Loss by Segments) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "90", "firstAnchor": { "contextRef": "C_20240101to20241231", "name": "ifrs-full:Revenue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532892.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_20240101to20241231", "name": "evgn:FinancingIncomeExpensesBySegment", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ifrs-full:DisclosureOfOperatingSegmentsExplanatory", "div", "div", "ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532892.htm", "unique": true } }, "R91": { "role": "http://www.evogene.com/role/OperatingSegmentsScheduleOfRevenuesFromMajorCustomersDetails", "longName": "9960760 - Disclosure - OPERATING SEGMENTS (Schedule of Revenues from Major Customers) (Details)", "shortName": "OPERATING SEGMENTS (Schedule of Revenues from Major Customers) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "91", "firstAnchor": { "contextRef": "C_20240101to20241231", "name": "ifrs-full:PercentageOfEntitysRevenue", "unitRef": "Percentage", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "span", "span", "div", "td", "tr", "table", "ifrs-full:DisclosureOfGeographicalAreasExplanatory", "div", "div", "div", "ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532892.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_20240101to20241231_srtMajorCustomersAxis_evgnCustomerShareholderMember", "name": "ifrs-full:PercentageOfEntitysRevenue", "unitRef": "Percentage", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "span", "span", "div", "td", "tr", "table", "ifrs-full:DisclosureOfSegmentsMajorCustomersExplanatory", "div", "div", "div", "ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532892.htm", "unique": true } }, "R92": { "role": "http://www.evogene.com/role/OperatingSegmentsScheduleOfRevenuesBasedOnCustomersDetails", "longName": "9960761 - Disclosure - OPERATING SEGMENTS (Schedule of Revenues Based on Customers) (Details)", "shortName": "OPERATING SEGMENTS (Schedule of Revenues Based on Customers) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "92", "firstAnchor": { "contextRef": "C_20240101to20241231", "name": "ifrs-full:PercentageOfEntitysRevenue", "unitRef": "Percentage", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "span", "span", "div", "td", "tr", "table", "ifrs-full:DisclosureOfGeographicalAreasExplanatory", "div", "div", "div", "ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532892.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_20240101to20241231_ifrsfullGeographicalAreasAxis_countryUS", "name": "ifrs-full:PercentageOfEntitysRevenue", "unitRef": "Percentage", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "span", "span", "div", "td", "tr", "table", "ifrs-full:DisclosureOfGeographicalAreasExplanatory", "div", "div", "div", "ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532892.htm", "unique": true } }, "R93": { "role": "http://www.evogene.com/role/OperatingSegmentsScheduleOfPercentageOfNon-currentAssetsDetails", "longName": "9960762 - Disclosure - OPERATING SEGMENTS (Schedule of Percentage of Non-Current Assets) (Details)", "shortName": "OPERATING SEGMENTS (Schedule of Percentage of Non-Current Assets) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "93", "firstAnchor": { "contextRef": "C_20240101to20241231", "name": "evgn:PercentageOfEntityAccordingToLocation", "unitRef": "Percentage", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "span", "span", "div", "td", "tr", "table", "ifrs-full:DisclosureOfNoncurrentAssetsHeldForSaleAndDiscontinuedOperationsExplanatory", "div", "div", "div", "ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532892.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20240101to20241231", "name": "evgn:PercentageOfEntityAccordingToLocation", "unitRef": "Percentage", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "span", "span", "div", "td", "tr", "table", "ifrs-full:DisclosureOfNoncurrentAssetsHeldForSaleAndDiscontinuedOperationsExplanatory", "div", "div", "div", "ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532892.htm", "first": true, "unique": true } }, "R94": { "role": "http://www.evogene.com/role/BalancesAndTransactionsWithExecutiveOfficersAndCertainShareholdersNarrativeDetails", "longName": "9960763 - Disclosure - BALANCES AND TRANSACTIONS WITH EXECUTIVE OFFICERS AND CERTAIN SHAREHOLDERS (Narrative) (Details)", "shortName": "BALANCES AND TRANSACTIONS WITH EXECUTIVE OFFICERS AND CERTAIN SHAREHOLDERS (Narrative) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "94", "firstAnchor": { "contextRef": "C_20240101to20241231_srtMajorCustomersAxis_evgnCortevaMember", "name": "ifrs-full:ProportionOfOwnershipInterestInSubsidiary", "unitRef": "Percentage", "xsiNil": "false", "lang": null, "decimals": "4", "ancestors": [ "p", "td", "tr", "table", "div", "div", "div", "div", "div", "ifrs-full:DisclosureOfRelatedPartyExplanatory", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532892.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20240101to20241231_srtMajorCustomersAxis_evgnCortevaMember", "name": "ifrs-full:ProportionOfOwnershipInterestInSubsidiary", "unitRef": "Percentage", "xsiNil": "false", "lang": null, "decimals": "4", "ancestors": [ "p", "td", "tr", "table", "div", "div", "div", "div", "div", "ifrs-full:DisclosureOfRelatedPartyExplanatory", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532892.htm", "first": true, "unique": true } }, "R95": { "role": "http://www.evogene.com/role/BalancesAndTransactionsWithExecutiveOfficersAndCertainShareholdersScheduleOfBalancesDetails", "longName": "9960764 - Disclosure - BALANCES AND TRANSACTIONS WITH EXECUTIVE OFFICERS AND CERTAIN SHAREHOLDERS (Schedule of Balances) (Details)", "shortName": "BALANCES AND TRANSACTIONS WITH EXECUTIVE OFFICERS AND CERTAIN SHAREHOLDERS (Schedule of Balances) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "95", "firstAnchor": { "contextRef": "C_20241231_ifrsfullCategoriesOfRelatedPartiesAxis_evgnExecutiveOfficersMember", "name": "ifrs-full:AmountsReceivableRelatedPartyTransactions", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "evgn:DisclosureOfDetailedInformationAboutBalancesWithRelatedPartiesExplanatory", "div", "div", "div", "div", "ifrs-full:DisclosureOfRelatedPartyExplanatory", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532892.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20241231_ifrsfullCategoriesOfRelatedPartiesAxis_evgnExecutiveOfficersMember", "name": "ifrs-full:AmountsReceivableRelatedPartyTransactions", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "evgn:DisclosureOfDetailedInformationAboutBalancesWithRelatedPartiesExplanatory", "div", "div", "div", "div", "ifrs-full:DisclosureOfRelatedPartyExplanatory", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532892.htm", "first": true, "unique": true } }, "R96": { "role": "http://www.evogene.com/role/BalancesAndTransactionsWithKeyOfficersAndCertainShareholdersScheduleOfBenefitsToDirectorsDetails", "longName": "9960765 - Disclosure - BALANCES AND TRANSACTIONS WITH EXECUTIVE OFFICERS AND CERTAIN SHAREHOLDERS (Schedule of Benefits to Directors) (Details)", "shortName": "BALANCES AND TRANSACTIONS WITH EXECUTIVE OFFICERS AND CERTAIN SHAREHOLDERS (Schedule of Benefits to Directors) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "96", "firstAnchor": { "contextRef": "C_20240101to20241231_ifrsfullCategoriesOfRelatedPartiesAxis_evgnDirectorsMember", "name": "ifrs-full:DirectorsRemunerationExpense", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "div", "td", "tr", "table", "evgn:DisclosureOfDetailedInformationAboutBenefitsToRelatedPartiesExplanatory", "div", "div", "div", "div", "div", "ifrs-full:DisclosureOfRelatedPartyExplanatory", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532892.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20240101to20241231_ifrsfullCategoriesOfRelatedPartiesAxis_evgnDirectorsMember", "name": "ifrs-full:DirectorsRemunerationExpense", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "div", "td", "tr", "table", "evgn:DisclosureOfDetailedInformationAboutBenefitsToRelatedPartiesExplanatory", "div", "div", "div", "div", "div", "ifrs-full:DisclosureOfRelatedPartyExplanatory", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532892.htm", "first": true, "unique": true } }, "R97": { "role": "http://www.evogene.com/role/BalancesAndTransactionsWithExecutiveOfficersAndCertainShareholdersScheduleOfBenefitsToKeyOfficersDetails", "longName": "9960766 - Disclosure - BALANCES AND TRANSACTIONS WITH EXECUTIVE OFFICERS AND CERTAIN SHAREHOLDERS (Schedule of Benefits to Key Officers) (Details)", "shortName": "BALANCES AND TRANSACTIONS WITH EXECUTIVE OFFICERS AND CERTAIN SHAREHOLDERS (Schedule of Benefits to Key Officers) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "97", "firstAnchor": { "contextRef": "C_20240101to20241231_ifrsfullCategoriesOfRelatedPartiesAxis_evgnKeyOfficersMember", "name": "ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "div", "td", "tr", "table", "ifrs-full:DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesExplanatory", "div", "div", "div", "div", "div", "ifrs-full:DisclosureOfRelatedPartyExplanatory", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532892.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20240101to20241231_ifrsfullCategoriesOfRelatedPartiesAxis_evgnKeyOfficersMember", "name": "ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "div", "td", "tr", "table", "ifrs-full:DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesExplanatory", "div", "div", "div", "div", "div", "ifrs-full:DisclosureOfRelatedPartyExplanatory", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532892.htm", "first": true, "unique": true } }, "R98": { "role": "http://www.evogene.com/role/BalancesAndTransactionsWithKeyOfficersAndCertainShareholdersScheduleOfTransactionsWithRelatedPartiesDetails", "longName": "9960767 - Disclosure - BALANCES AND TRANSACTIONS WITH EXECUTIVE OFFICERS AND CERTAIN SHAREHOLDERS (Schedule of Transactions Related Parties) (Details)", "shortName": "BALANCES AND TRANSACTIONS WITH EXECUTIVE OFFICERS AND CERTAIN SHAREHOLDERS (Schedule of Transactions Related Parties) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "98", "firstAnchor": { "contextRef": "C_20240101to20241231_ifrsfullCategoriesOfRelatedPartiesAxis_evgnExecutiveOfficersMember", "name": "evgn:RevenuesForTransactionsWithKeyOfficersAndCertainShareholders", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory", "div", "div", "div", "div", "ifrs-full:DisclosureOfRelatedPartyExplanatory", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532892.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20240101to20241231_ifrsfullCategoriesOfRelatedPartiesAxis_evgnExecutiveOfficersMember", "name": "evgn:RevenuesForTransactionsWithKeyOfficersAndCertainShareholders", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory", "div", "div", "div", "div", "ifrs-full:DisclosureOfRelatedPartyExplanatory", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532892.htm", "first": true, "unique": true } }, "R99": { "role": "http://www.evogene.com/role/SUBSEQUENTEVENTSNarrativeDetails", "longName": "9960768 - Disclosure - SUBSEQUENT EVENTS (Narrative) (Details)", "shortName": "SUBSEQUENT EVENTS (Narrative) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "99", "firstAnchor": { "contextRef": "C_20240131_ifrsfullClassesOfContingentLiabilitiesAxis_ifrsfullLegalProceedingsContingentLiabilityMember", "name": "evgn:PrePaymentForServices", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "div", "div", "div", "div", "ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532892.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_20250301to20250306_ifrsfullClassesOfContingentLiabilitiesAxis_ifrsfullLegalProceedingsContingentLiabilityMember_ifrsfullNonadjustingEventsAfterReportingPeriodAxis_evgnSubsequentEventsMember", "name": "evgn:ConsentJudgementPaid", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532892.htm", "unique": true } }, "R100": { "role": "http://www.evogene.com/role/FINANCIALINSTRUMENTSScheduleOfFairValueOfFinancialLiabilitiesDetails", "longName": "9960769 - Disclosure - FINANCIAL INSTRUMENTS (Schedule of fair value of financial liabilities) (Details)", "shortName": "FINANCIAL INSTRUMENTS (Schedule of fair value of financial liabilities) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "100", "firstAnchor": { "contextRef": "C_20241231", "name": "ifrs-full:FinancialLiabilities", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "span", "span", "div", "td", "tr", "table", "div", "div", "div", "ifrs-full:DisclosureOfFairValueMeasurementOfAssetsExplanatory", "div", "div", "div", "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532892.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_20241231_ifrsfullClassesOfFinancialInstrumentsAxis_evgnConvertibleSafeMember", "name": "ifrs-full:FinancialLiabilities", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "div", "td", "tr", "table", "ifrs-full:MaturityAnalysisForNonderivativeFinancialLiabilities", "div", "div", "div", "div", "div", "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532892.htm", "unique": true } } }, "tag": { "ifrs-full_AccumulatedDepreciationAndAmortisationMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "AccumulatedDepreciationAndAmortisationMember", "presentation": [ "http://www.evogene.com/role/IntangibleAssetsNetScheduleOfIntangibleAssetsDetails", "http://www.evogene.com/role/LeasesScheduleOfRight-of-useAssetsDetails", "http://www.evogene.com/role/PropertyPlantAndEquipmentNetScheduleOfPropertyPlantEquipmentToAccumulatedDepreciationDetails" ], "lang": { "en-us": { "role": { "label": "Accumulated depreciation [Member]" } }, "en": { "role": { "documentation": "This member stands for accumulated depreciation and amortisation. [Refer: Depreciation and amortisation expense]" } } }, "auth_ref": [ "r54", "r371", "r378", "r379", "r380" ] }, "evgn_AccumulatedLossAttributedToNoncontrollingInterests": { "xbrltype": "monetaryItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "AccumulatedLossAttributedToNoncontrollingInterests", "crdr": "debit", "presentation": [ "http://www.evogene.com/role/LiabilitiesInRespectOfGovernmentGrantsNarrativeDetails", "http://www.evogene.com/role/ShareholdersEquityNarrativeDetails", "http://www.evogene.com/role/ShareholdersEquityScheduleOfCompositionNon-controllingInterestsDetails" ], "lang": { "en-us": { "role": { "documentation": "Accumulated loss attributed to non-controlling interests.", "negatedLabel": "Accumulated loss attributed to non-controlling interests", "label": "Accumulated Loss Attributed To Noncontrolling Interests" } } }, "auth_ref": [] }, "evgn_AcquisitionOfIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "AcquisitionOfIntangibleAssets", "crdr": "credit", "presentation": [ "http://www.evogene.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Acquisition of intangible assets.", "label": "Acquisition Of Intangible Assets", "verboseLabel": "Acquisition of intangible assets" } } }, "auth_ref": [] }, "evgn_AcquisitionOfPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "AcquisitionOfPropertyPlantAndEquipment", "crdr": "credit", "presentation": [ "http://www.evogene.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Acquisition of property, plant and equipment through non-cash activities.", "label": "Acquisition Of Property Plant And Equipment", "verboseLabel": "Purchase of property, plant and equipment" } } }, "auth_ref": [] }, "ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill", "crdr": "debit", "presentation": [ "http://www.evogene.com/role/IntangibleAssetsNetScheduleOfIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Additions (Acquisition on August 6, 2019)", "terseLabel": "Additions" } }, "en": { "role": { "documentation": "The increase in intangible assets other than goodwill resulting from acquisitions through business combinations. [Refer: Total for all business combinations [member]; Intangible assets other than goodwill]" } } }, "auth_ref": [ "r94" ] }, "ecd_Additional402vDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Additional402vDisclosureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Additional 402(v) Disclosure [Text Block]", "terseLabel": "Additional 402(v) Disclosure" } } }, "auth_ref": [ "r300" ] }, "evgn_AdditionalExpectedPaymentForFirstBatchGrowingServices": { "xbrltype": "monetaryItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "AdditionalExpectedPaymentForFirstBatchGrowingServices", "crdr": "credit", "presentation": [ "http://www.evogene.com/role/COMMITMENTSANDCONTINGENTLIABILITIESNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Additional expected payment for first batch growing services.", "label": "Additional Expected Payment For First Batch Growing Services", "verboseLabel": "Additional expected payment for first batch growing services" } } }, "auth_ref": [] }, "evgn_AdditionalOrderAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "AdditionalOrderAmount", "crdr": "credit", "presentation": [ "http://www.evogene.com/role/CollaborationAndResearchAgreementsNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of additional order during the period.", "label": "Additional Order Amount", "terseLabel": "Additional order amount" } } }, "auth_ref": [] }, "evgn_AdditionsInRightofuseAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "AdditionsInRightofuseAssetsAbstract", "presentation": [ "http://www.evogene.com/role/LeasesScheduleOfRight-of-useAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Additions In Rightofuse Assets Abstract", "verboseLabel": "Additions during the year:" } } }, "auth_ref": [] }, "ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment", "crdr": "debit", "presentation": [ "http://www.evogene.com/role/PropertyPlantAndEquipmentNetScheduleOfPropertyPlantEquipmentToAccumulatedDepreciationDetails" ], "lang": { "en-us": { "role": { "label": "Additions" } }, "en": { "role": { "documentation": "The amount of additions to property, plant and equipment other than those acquired through business combinations. [Refer: Total for all business combinations [member]; Property, plant and equipment]" } } }, "auth_ref": [ "r49" ] }, "evgn_AdditionsToLeaseLiabilityForNewLeasesInPeriod": { "xbrltype": "monetaryItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "AdditionsToLeaseLiabilityForNewLeasesInPeriod", "crdr": "debit", "presentation": [ "http://www.evogene.com/role/LeasesScheduleOfLeaseLiabilityDetails" ], "lang": { "en-us": { "role": { "documentation": "Additions to lease liability for new leases in the period.", "label": "Additions To Lease Liability For New Leases In Period", "terseLabel": "Additions to lease liability for new leases in the period" } } }, "auth_ref": [] }, "ifrs-full_AdditionsToRightofuseAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "AdditionsToRightofuseAssets", "crdr": "debit", "presentation": [ "http://www.evogene.com/role/LeasesScheduleOfRight-of-useAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Additions to right-of-use assets for new leases in the period" } }, "en": { "role": { "documentation": "The amount of additions to right-of-use assets. [Refer: Right-of-use assets]" } } }, "auth_ref": [ "r150" ] }, "dei_AddressTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AddressTypeDomain", "presentation": [ "http://www.evogene.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Address Type [Domain]", "documentation": "An entity may have several addresses for different purposes and this domain represents all such types." } } }, "auth_ref": [] }, "ecd_AdjToCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation Amount", "terseLabel": "Adjustment to Compensation, Amount" } } }, "auth_ref": [ "r313" ] }, "ecd_AdjToCompAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation [Axis]", "terseLabel": "Adjustment to Compensation:" } } }, "auth_ref": [ "r313" ] }, "ecd_AdjToNonPeoNeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToNonPeoNeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]", "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote" } } }, "auth_ref": [ "r313" ] }, "ecd_AdjToPeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToPeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment To PEO Compensation, Footnote [Text Block]", "terseLabel": "Adjustment To PEO Compensation, Footnote" } } }, "auth_ref": [ "r313" ] }, "ifrs-full_AdjustedWeightedAverageShares": { "xbrltype": "sharesItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "AdjustedWeightedAverageShares", "presentation": [ "http://www.evogene.com/role/ConsolidatedStatementsOfProfitOrLoss" ], "lang": { "en-us": { "role": { "label": "Weighted average number of ordinary shares used in calculating diluted earnings per share", "terseLabel": "Weighted average number of shares used in computing diluted loss per share" } }, "en": { "role": { "documentation": "The weighted average number of ordinary shares outstanding plus the weighted average number of ordinary shares that would be issued on the conversion of all the dilutive potential ordinary shares into ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]" } } }, "auth_ref": [ "r85" ] }, "evgn_AdjustmentForIncreaseDecreaseInChangesInAssetAndLiabilityItems": { "xbrltype": "monetaryItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "AdjustmentForIncreaseDecreaseInChangesInAssetAndLiabilityItems", "crdr": "debit", "calculation": { "http://www.evogene.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://www.evogene.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Adjustments for increase (decrease) in change in assets and liability items to reconcile profit (loss) to net cash flow from (used in) operating activities.", "label": "Adjustment For Increase Decrease In Changes In Asset And Liability Items", "totalLabel": "Changes in asset and liability" } } }, "auth_ref": [] }, "evgn_AdjustmentForRemeasurementOfPrefundedWarrantsAndWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "AdjustmentForRemeasurementOfPrefundedWarrantsAndWarrants", "crdr": "debit", "calculation": { "http://www.evogene.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "ifrs-full_AdjustmentsForReconcileProfitLoss", "weight": 1.0, "order": 100.0 } }, "presentation": [ "http://www.evogene.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Represents the amount of remeasurement of pre-funded warrants and warrants.", "label": "Adjustment For Remeasurement Of Pre-funded Warrants And Warrants", "terseLabel": "Remeasurement of pre-funded warrants and warrants" } } }, "auth_ref": [] }, "evgn_AdjustmentForRevaluationOfConvertibleSafe": { "xbrltype": "monetaryItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "AdjustmentForRevaluationOfConvertibleSafe", "crdr": "debit", "calculation": { "http://www.evogene.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "ifrs-full_AdjustmentsForReconcileProfitLoss", "weight": 1.0, "order": 30.0 } }, "presentation": [ "http://www.evogene.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Represents the amount of adjustment for revaluation of convertible SAFE.", "label": "Adjustment For Revaluation Of Convertible Safe", "terseLabel": "Remeasurement of Convertible SAFE" } } }, "auth_ref": [] }, "evgn_AdjustmentsForAmortizationOfDeferredExpensesRelatedToIssuanceOfWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "AdjustmentsForAmortizationOfDeferredExpensesRelatedToIssuanceOfWarrants", "crdr": "debit", "calculation": { "http://www.evogene.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "ifrs-full_AdjustmentsForReconcileProfitLoss", "weight": 1.0, "order": 90.0 } }, "presentation": [ "http://www.evogene.com/role/ConsolidatedStatementsOfCashFlows", "http://www.evogene.com/role/ShareholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the amount of amortization of deferred expenses related to issuance of warrants", "label": "Adjustments For Amortization Of Deferred Expenses Related To Issuance Of Warrants", "terseLabel": "Amortization of deferred expenses related to issuance of warrants" } } }, "auth_ref": [] }, "ifrs-full_AdjustmentsForDecreaseIncreaseInInventories": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "AdjustmentsForDecreaseIncreaseInInventories", "crdr": "debit", "calculation": { "http://www.evogene.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "evgn_AdjustmentForIncreaseDecreaseInChangesInAssetAndLiabilityItems", "weight": 1.0, "order": 20.0 } }, "presentation": [ "http://www.evogene.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Adjustments for decrease (increase) in inventories", "terseLabel": "Decrease (increase) in inventories" } }, "en": { "role": { "documentation": "Adjustments for decrease (increase) in inventories to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Inventories; Profit (loss)]" } } }, "auth_ref": [ "r383" ] }, "ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables", "crdr": "debit", "calculation": { "http://www.evogene.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "evgn_AdjustmentForIncreaseDecreaseInChangesInAssetAndLiabilityItems", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://www.evogene.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Decrease (increase) in other receivables", "terseLabel": "Decrease (increase) in other receivables and prepaid expenses" } }, "en": { "role": { "documentation": "Adjustments for decrease (increase) in other operating receivables to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]" } } }, "auth_ref": [ "r383" ] }, "ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "AdjustmentsForDecreaseIncreaseInTradeAccountReceivable", "crdr": "debit", "calculation": { "http://www.evogene.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "evgn_AdjustmentForIncreaseDecreaseInChangesInAssetAndLiabilityItems", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.evogene.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Decrease (increase) in trade receivables", "terseLabel": "Increase in trade receivables" } }, "en": { "role": { "documentation": "Adjustments for decrease (increase) in trade accounts receivable to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]" } } }, "auth_ref": [ "r383" ] }, "ifrs-full_AdjustmentsForDeferredTaxExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "AdjustmentsForDeferredTaxExpense", "crdr": "debit", "calculation": { "http://www.evogene.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "evgn_AdjustmentForIncreaseDecreaseInChangesInAssetAndLiabilityItems", "weight": 1.0, "order": 30.0 } }, "presentation": [ "http://www.evogene.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Adjustments for deferred tax expense", "terseLabel": "Decrease (increase) in deferred taxes" } }, "en": { "role": { "documentation": "Adjustments for deferred tax expense to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Deferred tax expense (income); Profit (loss)]" } } }, "auth_ref": [ "r385" ] }, "ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "AdjustmentsForDepreciationAndAmortisationExpense", "crdr": "debit", "calculation": { "http://www.evogene.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "ifrs-full_AdjustmentsForReconcileProfitLoss", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.evogene.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Depreciation", "terseLabel": "Depreciation and amortization of property, plant and equipment and right-of-use-assets" } }, "en": { "role": { "documentation": "Adjustments for depreciation and amortisation expense to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Depreciation and amortisation expense; Profit (loss)]" } } }, "auth_ref": [ "r384" ] }, "evgn_AdjustmentsForExcessOfInitialFairValueOfPrefundedWarrantsOverTransactionProceeds": { "xbrltype": "monetaryItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "AdjustmentsForExcessOfInitialFairValueOfPrefundedWarrantsOverTransactionProceeds", "crdr": "credit", "calculation": { "http://www.evogene.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "ifrs-full_AdjustmentsForReconcileProfitLoss", "weight": -1.0, "order": 80.0 } }, "presentation": [ "http://www.evogene.com/role/ConsolidatedStatementsOfCashFlows", "http://www.evogene.com/role/ShareholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the amount of excess of initial fair value of pre-funded warrants over transaction proceeds.", "negatedLabel": "Excess of initial fair value of pre-funded warrants over transaction proceeds", "label": "Adjustments For Excess Of Initial Fair Value Of Pre-funded Warrants Over Transaction Proceeds", "terseLabel": "Excess of initial fair value of pre-funded warrants over transaction proceeds" } } }, "auth_ref": [] }, "ifrs-full_AdjustmentsForFinanceIncomeCost": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "AdjustmentsForFinanceIncomeCost", "crdr": "credit", "calculation": { "http://www.evogene.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "ifrs-full_AdjustmentsForReconcileProfitLoss", "weight": -1.0, "order": 50.0 } }, "presentation": [ "http://www.evogene.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Net financing income", "label": "Adjustments for finance income (cost)" } }, "en": { "role": { "documentation": "Adjustments for net finance income or cost to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Finance income (cost); Profit (loss)]" } } }, "auth_ref": [ "r385" ] }, "ifrs-full_AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://www.evogene.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "ifrs-full_AdjustmentsForReconcileProfitLoss", "weight": -1.0, "order": 40.0 } }, "presentation": [ "http://www.evogene.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Loss (gain) from sale of property, plant and equipment", "label": "Adjustments for gain (loss) on disposals, property, plant and equipment" } }, "en": { "role": { "documentation": "Adjustments for gain (loss) on disposals of property, plant and equipment to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss); Property, plant and equipment; Disposals, property, plant and equipment]" } } }, "auth_ref": [ "r385" ] }, "ifrs-full_AdjustmentsForIncomeTaxExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "AdjustmentsForIncomeTaxExpense", "crdr": "debit", "calculation": { "http://www.evogene.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "ifrs-full_AdjustmentsForReconcileProfitLoss", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://www.evogene.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Adjustments for income tax expense", "verboseLabel": "Taxes on income (tax benefit)" } }, "en": { "role": { "documentation": "Adjustments for income tax expense to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]" } } }, "auth_ref": [ "r112" ] }, "ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncomeOtherThanContractLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "AdjustmentsForIncreaseDecreaseInDeferredIncomeOtherThanContractLiabilities", "crdr": "debit", "calculation": { "http://www.evogene.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "evgn_AdjustmentForIncreaseDecreaseInChangesInAssetAndLiabilityItems", "weight": 1.0, "order": 80.0 } }, "presentation": [ "http://www.evogene.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase (decrease) in deferred revenues and other advances", "terseLabel": "Decrease in deferred revenues and other advances" } }, "en": { "role": { "documentation": "Adjustments for the increase (decrease) in deferred income other than contract liabilities to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Deferred income other than contract liabilities; Profit (loss)]" } } }, "auth_ref": [ "r383" ] }, "ifrs-full_AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities", "crdr": "debit", "calculation": { "http://www.evogene.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "evgn_AdjustmentForIncreaseDecreaseInChangesInAssetAndLiabilityItems", "weight": 1.0, "order": 60.0 } }, "presentation": [ "http://www.evogene.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase (decrease) in employees and payroll accruals" } }, "en": { "role": { "documentation": "Adjustments for increase (decrease) in employee benefit liabilities to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]" } } }, "auth_ref": [ "r385" ] }, "evgn_AdjustmentsForIncreaseDecreaseInLongTermDeposits": { "xbrltype": "monetaryItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "AdjustmentsForIncreaseDecreaseInLongTermDeposits", "crdr": "debit", "calculation": { "http://www.evogene.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "evgn_AdjustmentForIncreaseDecreaseInChangesInAssetAndLiabilityItems", "weight": 1.0, "order": 40.0 } }, "presentation": [ "http://www.evogene.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Adjustments for increase (decrease) in long term deposits to reconcile profit (loss) to net cash flow from (used in) operating activities.", "label": "Adjustments For Increase Decrease In Long Term Deposits", "verboseLabel": "Increase in long term deposits" } } }, "auth_ref": [] }, "ifrs-full_AdjustmentsForIncreaseDecreaseInOtherOperatingPayables": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "AdjustmentsForIncreaseDecreaseInOtherOperatingPayables", "crdr": "debit", "calculation": { "http://www.evogene.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "evgn_AdjustmentForIncreaseDecreaseInChangesInAssetAndLiabilityItems", "weight": 1.0, "order": 70.0 } }, "presentation": [ "http://www.evogene.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase (decrease) in other payables" } }, "en": { "role": { "documentation": "Adjustments for increase (decrease) in other operating payables to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]" } } }, "auth_ref": [ "r383" ] }, "ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "AdjustmentsForIncreaseDecreaseInTradeAccountPayable", "crdr": "debit", "calculation": { "http://www.evogene.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "evgn_AdjustmentForIncreaseDecreaseInChangesInAssetAndLiabilityItems", "weight": 1.0, "order": 50.0 } }, "presentation": [ "http://www.evogene.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase (decrease) in trade payables", "terseLabel": "Increase (decrease) in trade payables" } }, "en": { "role": { "documentation": "Adjustments for increase (decrease) in trade accounts payable to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]" } } }, "auth_ref": [ "r383" ] }, "evgn_AdjustmentsForIndexation": { "xbrltype": "monetaryItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "AdjustmentsForIndexation", "crdr": "credit", "presentation": [ "http://www.evogene.com/role/LeasesScheduleOfLeaseLiabilityDetails", "http://www.evogene.com/role/LeasesScheduleOfRight-of-useAssetsDetails" ], "lang": { "en-us": { "role": { "documentation": "Adjustments for indexation.", "label": "Adjustments For Indexation", "terseLabel": "Adjustments for indexation" } } }, "auth_ref": [] }, "ifrs-full_AdjustmentsForReconcileProfitLoss": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "AdjustmentsForReconcileProfitLoss", "crdr": "debit", "calculation": { "http://www.evogene.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.evogene.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile profit (loss)", "totalLabel": "Adjustments to the profit or loss items" } }, "en": { "role": { "documentation": "Adjustments to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]" } } }, "auth_ref": [ "r108" ] }, "ifrs-full_AdjustmentsForReconcileProfitLossAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "AdjustmentsForReconcileProfitLossAbstract", "presentation": [ "http://www.evogene.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Adjustments to the profit or loss items:" } } }, "auth_ref": [] }, "ifrs-full_AdjustmentsForSharebasedPayments": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "AdjustmentsForSharebasedPayments", "crdr": "debit", "calculation": { "http://www.evogene.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "ifrs-full_AdjustmentsForReconcileProfitLoss", "weight": 1.0, "order": 20.0 }, "http://www.evogene.com/role/Share-BasedCompensationScheduleOfCompanysFinancialStatementsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.evogene.com/role/ConsolidatedStatementsOfCashFlows", "http://www.evogene.com/role/Share-BasedCompensationScheduleOfCompanysFinancialStatementsDetails" ], "lang": { "en-us": { "role": { "label": "Adjustments for share-based payments", "totalLabel": "Total share-based compensation", "verboseLabel": "Share-based compensation" } }, "en": { "role": { "documentation": "Adjustments for share-based payments to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]" } } }, "auth_ref": [ "r384" ] }, "evgn_AdjustmentsToReconcileNetLossToNetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "AdjustmentsToReconcileNetLossToNetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.evogene.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Adjustments To Reconcile Net Loss To Net Cash Provided By Used In Operating Activities Abstract", "verboseLabel": "Adjustments to reconcile loss to net cash used in operating activities:" } } }, "auth_ref": [] }, "ifrs-full_Advances": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "Advances", "crdr": "credit", "calculation": { "http://www.evogene.com/role/ConsolidatedStatementsOfFinancialPosition": { "parentTag": "ifrs-full_NoncurrentLiabilities", "weight": 1.0, "order": 20.0 } }, "presentation": [ "http://www.evogene.com/role/ConsolidatedStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Advances received, representing contract liabilities for performance obligations satisfied at point in time", "verboseLabel": "Deferred revenues and other advances" } }, "en": { "role": { "documentation": "The amount of advances received representing contract liabilities for performance obligations satisfied at a point in time. [Refer: Contract liabilities; Performance obligations satisfied at point in time [member]]" } } }, "auth_ref": [ "r367", "r368" ] }, "evgn_AgPlenusLtdMember": { "xbrltype": "domainItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "AgPlenusLtdMember", "presentation": [ "http://www.evogene.com/role/GeneralNarrativeDetails", "http://www.evogene.com/role/ShareholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "AgPlenus Ltd [Member]", "label": "Ag Plenus Ltd Member", "verboseLabel": "AgPlenus Ltd [Member]" } } }, "auth_ref": [] }, "evgn_AggregateGrantPaid": { "xbrltype": "monetaryItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "AggregateGrantPaid", "crdr": "debit", "presentation": [ "http://www.evogene.com/role/LiabilitiesInRespectOfGovernmentGrantsNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Aggregate grant paid.", "label": "Aggregate grant paid", "verboseLabel": "Aggregate grant paid" } } }, "auth_ref": [] }, "evgn_AggregateGrantReceivedIncludingAccruedInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "AggregateGrantReceivedIncludingAccruedInterest", "crdr": "credit", "presentation": [ "http://www.evogene.com/role/LiabilitiesInRespectOfGovernmentGrantsNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Aggregate grant received including accrued interest.", "label": "Aggregate Grant Received Including Accrued Interest", "verboseLabel": "Aggregate grant received including accrued interest" } } }, "auth_ref": [] }, "evgn_AggregateGrantReceivedLinkedToUsCpi": { "xbrltype": "monetaryItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "AggregateGrantReceivedLinkedToUsCpi", "crdr": "credit", "presentation": [ "http://www.evogene.com/role/LiabilitiesInRespectOfGovernmentGrantsNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Aggregate grant received linked to the US CPI.", "label": "Aggregate Grant Received Linked To Us Cpi", "verboseLabel": "Aggregate grant received linked to the US CPI" } } }, "auth_ref": [] }, "evgn_AggregateOfferingPrice": { "xbrltype": "monetaryItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "AggregateOfferingPrice", "crdr": "credit", "presentation": [ "http://www.evogene.com/role/GeneralNarrativeDetails", "http://www.evogene.com/role/ShareholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents aggregate offering price.", "label": "Aggregate Offering Price", "verboseLabel": "Aggregate offering price" } } }, "auth_ref": [] }, "evgn_AggregateOfferingPriceSubsequentlyReduced": { "xbrltype": "monetaryItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "AggregateOfferingPriceSubsequentlyReduced", "crdr": "credit", "presentation": [ "http://www.evogene.com/role/GeneralNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents aggregate offering price subsequently reduced.", "label": "Aggregate Offering Price Subsequently Reduced", "verboseLabel": "Aggregate offering price subsequently reduced" } } }, "auth_ref": [] }, "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]", "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table" } } }, "auth_ref": [ "r358" ] }, "ecd_AggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Amount", "terseLabel": "Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r271", "r282", "r292", "r325" ] }, "ecd_AggtErrCompNotYetDeterminedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompNotYetDeterminedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]", "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined" } } }, "auth_ref": [ "r274", "r285", "r295", "r328" ] }, "ecd_AggtPnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtPnsnAdjsSvcCstMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Pension Adjustments Service Cost [Member]", "terseLabel": "Aggregate Pension Adjustments Service Cost" } } }, "auth_ref": [ "r359" ] }, "evgn_AgreementAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "AgreementAxis", "presentation": [ "http://www.evogene.com/role/ConvertibleSAFENarrativeDetails", "http://www.evogene.com/role/GeneralNarrativeDetails", "http://www.evogene.com/role/ShareholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table.", "label": "Agreement [Axis]" } } }, "auth_ref": [] }, "evgn_AgreementDomain": { "xbrltype": "domainItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "AgreementDomain", "presentation": [ "http://www.evogene.com/role/ConvertibleSAFENarrativeDetails", "http://www.evogene.com/role/GeneralNarrativeDetails", "http://www.evogene.com/role/ShareholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for all segments of an entity. It also represents the standard value for the 'Agreement ' axis if no other member is used.", "label": "Agreement [Domain]" } } }, "auth_ref": [] }, "evgn_AgricultureMember": { "xbrltype": "domainItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "AgricultureMember", "presentation": [ "http://www.evogene.com/role/OperatingSegmentsScheduleOfRevenuesAndOperatingLossBySegmentsDetails" ], "lang": { "en-us": { "role": { "documentation": "Agriculture [Member]", "label": "Agriculture [Member]" } } }, "auth_ref": [] }, "ecd_AllAdjToCompMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllAdjToCompMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "All Adjustments to Compensation [Member]", "terseLabel": "All Adjustments to Compensation" } } }, "auth_ref": [ "r313" ] }, "ecd_AllExecutiveCategoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllExecutiveCategoriesMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "All Executive Categories [Member]", "terseLabel": "All Executive Categories" } } }, "auth_ref": [ "r320" ] }, "ecd_AllIndividualsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllIndividualsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "All Individuals [Member]", "terseLabel": "All Individuals" } } }, "auth_ref": [ "r275", "r286", "r296", "r320", "r329", "r333", "r341" ] }, "ecd_AllTradingArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllTradingArrangementsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "All Trading Arrangements [Member]", "terseLabel": "All Trading Arrangements" } } }, "auth_ref": [ "r339" ] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": [ "http://www.evogene.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "ifrs-full_AmortisationExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "AmortisationExpense", "crdr": "debit", "presentation": [ "http://www.evogene.com/role/SignificantAccountingPoliciesScheduleOfDepreciationCalculatedUsingStraight-lineMethodDetails" ], "lang": { "en-us": { "role": { "label": "Amortization expenses" } }, "en": { "role": { "documentation": "The amount of amortisation expense. Amortisation is the systematic allocation of depreciable amounts of intangible assets over their useful lives." } } }, "auth_ref": [ "r365" ] }, "ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "AmortisationIntangibleAssetsOtherThanGoodwill", "calculation": { "http://www.evogene.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "ifrs-full_AdjustmentsForReconcileProfitLoss", "weight": 1.0, "order": 60.0 } }, "presentation": [ "http://www.evogene.com/role/ConsolidatedStatementsOfCashFlows", "http://www.evogene.com/role/IntangibleAssetsNetScheduleOfIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Amortisation, intangible assets other than goodwill", "terseLabel": "Amortization", "verboseLabel": "Amortization of intangible assets" } }, "en": { "role": { "documentation": "The amount of amortisation of intangible assets other than goodwill. [Refer: Depreciation and amortisation expense; Intangible assets other than goodwill]" } } }, "auth_ref": [ "r95" ] }, "evgn_AmortizationOfDeferredExpensesRelatedToIssuanceOfWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "AmortizationOfDeferredExpensesRelatedToIssuanceOfWarrants", "crdr": "debit", "calculation": { "http://www.evogene.com/role/StatementsOfComprehensiveLoss-AdditionalInformationScheduleOfIncomeAndExpensesDetails": { "parentTag": "ifrs-full_FinanceCosts", "weight": 1.0, "order": 110.0 } }, "presentation": [ "http://www.evogene.com/role/StatementsOfComprehensiveLoss-AdditionalInformationScheduleOfIncomeAndExpensesDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of amortization of deferred expenses related to issuance of warrants.", "label": "Amortization Of Deferred Expenses Related To Issuance Of Warrants", "terseLabel": "Amortization of deferred expenses related to issuance of warrants" } } }, "auth_ref": [] }, "evgn_AmountOfBenefitsToDirectors": { "xbrltype": "monetaryItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "AmountOfBenefitsToDirectors", "crdr": "debit", "calculation": { "http://www.evogene.com/role/BalancesAndTransactionsWithKeyOfficersAndCertainShareholdersScheduleOfBenefitsToDirectorsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.evogene.com/role/BalancesAndTransactionsWithKeyOfficersAndCertainShareholdersScheduleOfBenefitsToDirectorsDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of benefits to directors.", "label": "Amount Of Benefits To Directors", "terseLabel": "Benefits to directors", "totalLabel": "Total" } } }, "auth_ref": [] }, "evgn_AmountOfConvertibleLoansToOrdinaryShares": { "xbrltype": "monetaryItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "AmountOfConvertibleLoansToOrdinaryShares", "crdr": "credit", "presentation": [ "http://www.evogene.com/role/ShareholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "It represents amount of convertible loans to ordinary shares.", "label": "Amount Of Convertible Loans To Ordinary Shares", "terseLabel": "Amount of convertible loans to ordinary shares" } } }, "auth_ref": [] }, "evgn_AmountOfInvestmentInFinancingRound": { "xbrltype": "monetaryItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "AmountOfInvestmentInFinancingRound", "crdr": "credit", "presentation": [ "http://www.evogene.com/role/GeneralNarrativeDetails", "http://www.evogene.com/role/ShareholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of investment in financing round.", "label": "Amount Of Investment In Financing Round", "terseLabel": "Amount of investment in financing round" } } }, "auth_ref": [] }, "evgn_AmountOfInvestmentUnderCollaborationAgreement": { "xbrltype": "monetaryItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "AmountOfInvestmentUnderCollaborationAgreement", "crdr": "credit", "presentation": [ "http://www.evogene.com/role/GeneralNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "It represents amount of investment under collaboration agreement.", "label": "Amount Of Investment Under Collaboration Agreement", "verboseLabel": "Amount of investment under collaboration agreement" } } }, "auth_ref": [] }, "evgn_AmountOfOrdersReceived": { "xbrltype": "monetaryItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "AmountOfOrdersReceived", "crdr": "credit", "presentation": [ "http://www.evogene.com/role/CollaborationAndResearchAgreementsNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of orders received.", "label": "Amount Of Orders Received", "verboseLabel": "Amount of orders received" } } }, "auth_ref": [] }, "evgn_AmountOfSafeAgreement": { "xbrltype": "monetaryItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "AmountOfSafeAgreement", "crdr": "credit", "presentation": [ "http://www.evogene.com/role/CollaborationAndResearchAgreementsNarrativeDetails", "http://www.evogene.com/role/ConvertibleSAFENarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "It represents amount of SAFE agreement.", "label": "Amount Of Safe Agreement", "verboseLabel": "Amount of SAFE agreement" } } }, "auth_ref": [] }, "ifrs-full_AmountsPayableRelatedPartyTransactions": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "AmountsPayableRelatedPartyTransactions", "crdr": "credit", "presentation": [ "http://www.evogene.com/role/BalancesAndTransactionsWithExecutiveOfficersAndCertainShareholdersScheduleOfBalancesDetails" ], "lang": { "en-us": { "role": { "label": "Amounts payable, related party transactions", "verboseLabel": "Other payables" } }, "en": { "role": { "documentation": "The amounts payable resulting from related party transactions. [Refer: Total for all related parties [member]]" } } }, "auth_ref": [ "r68", "r72" ] }, "ifrs-full_AmountsReceivableRelatedPartyTransactions": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "AmountsReceivableRelatedPartyTransactions", "crdr": "debit", "presentation": [ "http://www.evogene.com/role/BalancesAndTransactionsWithExecutiveOfficersAndCertainShareholdersScheduleOfBalancesDetails" ], "lang": { "en-us": { "role": { "label": "Receivables" } }, "en": { "role": { "documentation": "The amounts receivable resulting from related party transactions. [Refer: Total for all related parties [member]]" } } }, "auth_ref": [ "r68", "r72" ] }, "evgn_AmountsRecordedInProfitOrLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "AmountsRecordedInProfitOrLoss", "crdr": "credit", "presentation": [ "http://www.evogene.com/role/LiabilitiesInRespectOfGovernmentGrantsScheduleOfLiabilitiesInRespectOfGovernmentGrantsDetails" ], "lang": { "en-us": { "role": { "documentation": "The amounts recorded in profit or loss.", "label": "Amounts Recorded In Profit Or Loss", "verboseLabel": "Amounts recorded in profit or loss" } } }, "auth_ref": [] }, "ifrs-full_ApplicableTaxRate": { "xbrltype": "percentItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "ApplicableTaxRate", "presentation": [ "http://www.evogene.com/role/TaxesOnIncomeDetails" ], "lang": { "en-us": { "role": { "label": "Israeli corporate income tax rate" } }, "en": { "role": { "documentation": "The applicable income tax rate." } } }, "auth_ref": [ "r43" ] }, "ifrs-full_Assets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "Assets", "crdr": "debit", "calculation": { "http://www.evogene.com/role/ConsolidatedStatementsOfFinancialPosition": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.evogene.com/role/ConsolidatedStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Assets", "totalLabel": "TOTAL ASSETS" } }, "en": { "role": { "documentation": "The amount of a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits." } } }, "auth_ref": [ "r16", "r137", "r138", "r139", "r200", "r204" ] }, "evgn_AtmOfferingMember": { "xbrltype": "domainItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "AtmOfferingMember", "presentation": [ "http://www.evogene.com/role/GeneralNarrativeDetails", "http://www.evogene.com/role/ShareholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "ATM offering.", "label": "Atm Offering [Member]", "terseLabel": "ATM offering [Member]" } } }, "auth_ref": [] }, "dei_AuditorFirmId": { "xbrltype": "nonemptySequenceNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AuditorFirmId", "presentation": [ "http://www.evogene.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Auditor Firm ID", "documentation": "PCAOB issued Audit Firm Identifier" } } }, "auth_ref": [ "r254", "r255", "r278" ] }, "dei_AuditorLocation": { "xbrltype": "internationalNameItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AuditorLocation", "presentation": [ "http://www.evogene.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Auditor Location" } } }, "auth_ref": [ "r254", "r255", "r278" ] }, "dei_AuditorName": { "xbrltype": "internationalNameItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AuditorName", "presentation": [ "http://www.evogene.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Auditor Name" } } }, "auth_ref": [ "r254", "r255", "r278" ] }, "ecd_AwardExrcPrice": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardExrcPrice", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Exercise Price", "terseLabel": "Exercise Price" } } }, "auth_ref": [ "r336" ] }, "ecd_AwardGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardGrantDateFairValue", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Grant Date Fair Value", "terseLabel": "Fair Value as of Grant Date" } } }, "auth_ref": [ "r337" ] }, "ecd_AwardTmgDiscLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgDiscLineItems", "lang": { "en-us": { "role": { "label": "Award Timing Disclosures [Line Items]", "terseLabel": "Award Timing Disclosures" } } }, "auth_ref": [ "r332" ] }, "ecd_AwardTmgHowMnpiCnsdrdTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgHowMnpiCnsdrdTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing, How MNPI Considered [Text Block]", "terseLabel": "Award Timing, How MNPI Considered" } } }, "auth_ref": [ "r332" ] }, "ecd_AwardTmgMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing Method [Text Block]", "terseLabel": "Award Timing Method" } } }, "auth_ref": [ "r332" ] }, "ecd_AwardTmgMnpiCnsdrdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiCnsdrdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Considered [Flag]", "terseLabel": "Award Timing MNPI Considered" } } }, "auth_ref": [ "r332" ] }, "ecd_AwardTmgMnpiDiscTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiDiscTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Disclosure [Text Block]", "terseLabel": "Award Timing MNPI Disclosure" } } }, "auth_ref": [ "r332" ] }, "ecd_AwardTmgPredtrmndFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgPredtrmndFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing Predetermined [Flag]", "terseLabel": "Award Timing Predetermined" } } }, "auth_ref": [ "r332" ] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AwardTypeAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Type [Axis]", "terseLabel": "Award Type" } } }, "auth_ref": [] }, "ecd_AwardUndrlygSecuritiesAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardUndrlygSecuritiesAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Underlying Securities Amount", "terseLabel": "Underlying Securities" } } }, "auth_ref": [ "r335" ] }, "ecd_AwardsCloseToMnpiDiscIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures, Individual Name", "terseLabel": "Name" } } }, "auth_ref": [ "r334" ] }, "ecd_AwardsCloseToMnpiDiscTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table]", "terseLabel": "Awards Close in Time to MNPI Disclosures" } } }, "auth_ref": [ "r333" ] }, "ecd_AwardsCloseToMnpiDiscTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]", "terseLabel": "Awards Close in Time to MNPI Disclosures, Table" } } }, "auth_ref": [ "r333" ] }, "country_BR": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2024", "localname": "BR", "presentation": [ "http://www.evogene.com/role/OperatingSegmentsScheduleOfRevenuesBasedOnCustomersDetails" ], "lang": { "en-us": { "role": { "label": "BRAZIL", "terseLabel": "Brazil [Member]" } } }, "auth_ref": [] }, "ifrs-full_BalancesWithBanks": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "BalancesWithBanks", "crdr": "debit", "calculation": { "http://www.evogene.com/role/CashAndCashEquivalentsScheduleOfCashAndEquivalentsDetails": { "parentTag": "ifrs-full_CashAndCashEquivalents", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://www.evogene.com/role/CashAndCashEquivalentsScheduleOfCashAndEquivalentsDetails" ], "lang": { "en-us": { "role": { "label": "Cash equivalents in NIS bank deposit" } }, "en": { "role": { "documentation": "The amount of cash balances held at banks." } } }, "auth_ref": [ "r387" ] }, "evgn_BaseForRoyaltyPayments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "BaseForRoyaltyPayments", "crdr": "debit", "presentation": [ "http://www.evogene.com/role/LiabilitiesInRespectOfGovernmentGrantsNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents about base for royalty payments amount.", "label": "Base For Royalty Payments", "terseLabel": "Base for royalty payments" } } }, "auth_ref": [] }, "ifrs-full_BasicEarningsLossPerShare": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "BasicEarningsLossPerShare", "presentation": [ "http://www.evogene.com/role/ConsolidatedStatementsOfProfitOrLoss" ], "lang": { "en-us": { "role": { "commentaryGuidance": "The reported value should be tagged twice, with both this element and the element \u2018Diluted earnings (loss) per share\u2019 when: (a) basic and diluted earnings per share are equal; and (b) an entity presents one line item to accomplish the dual presentation requirement of paragraph 67 of IAS 33.", "label": "Basic earnings (loss) per share", "terseLabel": "Basic loss per share, attributable to equity holders of the Company", "totalLabel": "Total basic earnings (loss) per share" } }, "en": { "role": { "documentation": "The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator) divided by the weighted average number of ordinary shares outstanding during the period (the denominator)." } } }, "auth_ref": [ "r82", "r83" ] }, "evgn_BenefitToNoncontrollingInterestsRegardingSharebasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "BenefitToNoncontrollingInterestsRegardingSharebasedCompensation", "crdr": "credit", "presentation": [ "http://www.evogene.com/role/ConsolidatedStatementsOfChangesInEquity", "http://www.evogene.com/role/ShareholdersEquityScheduleOfCompositionNon-controllingInterestsDetails" ], "lang": { "en-us": { "role": { "documentation": "Benefit to non-controlling interests regarding Share-based compensation.", "label": "Benefit To Noncontrolling Interests Regarding Sharebased Compensation", "verboseLabel": "Benefit to non-controlling interests regarding share-based compensation" } } }, "auth_ref": [] }, "evgn_BinationalIndustrialResearchAndDevelopmentFoundationMember": { "xbrltype": "domainItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "BinationalIndustrialResearchAndDevelopmentFoundationMember", "presentation": [ "http://www.evogene.com/role/LiabilitiesInRespectOfGovernmentGrantsNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "BIRD [Member]", "label": "Binational Industrial Research And Development Foundation Member", "verboseLabel": "BIRD [Member]" } } }, "auth_ref": [] }, "evgn_BiomicaMember": { "xbrltype": "domainItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "BiomicaMember", "presentation": [ "http://www.evogene.com/role/GeneralNarrativeDetails", "http://www.evogene.com/role/ShareholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Biomica [Member]", "label": "Biomica [Member]", "verboseLabel": "Biomica [Member]" } } }, "auth_ref": [] }, "ifrs-full_BottomOfRangeMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "BottomOfRangeMember", "presentation": [ "http://www.evogene.com/role/LeasesNarrativeDetails", "http://www.evogene.com/role/SIGNIFICANTACCOUNTINGJUDGMENTSESTIMATESANDASSUMPTIONSUSEDINTHEPREPARATIONOFTHEFINANCIALSTATEMENTSNarrativeDetails", "http://www.evogene.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails", "http://www.evogene.com/role/Share-BasedCompensationScheduleOfAssumptionsUsedToValueOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Bottom of range [member]" } }, "en": { "role": { "documentation": "This member stands for the bottom of a range." } } }, "auth_ref": [ "r113", "r141", "r160", "r171", "r235", "r236", "r389" ] }, "ifrs-full_BusinessCombinationsAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "BusinessCombinationsAxis", "presentation": [ "http://www.evogene.com/role/ConvertibleSAFENarrativeDetails", "http://www.evogene.com/role/GeneralNarrativeDetails", "http://www.evogene.com/role/IntangibleAssetsNetNarrativeDetails", "http://www.evogene.com/role/ShareholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Business combinations [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r178" ] }, "ifrs-full_BusinessCombinationsDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "BusinessCombinationsDomain", "presentation": [ "http://www.evogene.com/role/ConvertibleSAFENarrativeDetails", "http://www.evogene.com/role/GeneralNarrativeDetails", "http://www.evogene.com/role/IntangibleAssetsNetNarrativeDetails", "http://www.evogene.com/role/ShareholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Business combinations [domain]" } }, "en": { "role": { "documentation": "This member stands for the standard value for the 'Business combinations' axis if no other member is used." } } }, "auth_ref": [ "r178", "r181" ] }, "dei_BusinessContactMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "BusinessContactMember", "presentation": [ "http://www.evogene.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Business Contact [Member]", "documentation": "Business contact for the entity" } } }, "auth_ref": [ "r255", "r278" ] }, "evgn_CPIExpensesOnLeaseLiabilitiesAndRightOfUseAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "CPIExpensesOnLeaseLiabilitiesAndRightOfUseAssets", "crdr": "debit", "presentation": [ "http://www.evogene.com/role/LeasesScheduleOfLeaseExpensesDetails" ], "lang": { "en-us": { "role": { "documentation": "CPI expenses on lease liabilities and right-of-use assets.", "label": "C P I Expenses On Lease Liabilities And Right Of Use Assets", "terseLabel": "CPI recognized on lease liabilities and right-of-use assets" } } }, "auth_ref": [] }, "evgn_CancelledAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "CancelledAmount", "crdr": "credit", "presentation": [ "http://www.evogene.com/role/LiabilitiesInRespectOfGovernmentGrantsNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Cancelled amount.", "label": "Cancelled Amount", "verboseLabel": "Cancelled amount" } } }, "auth_ref": [] }, "evgn_CanonicLtdMember": { "xbrltype": "domainItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "CanonicLtdMember", "presentation": [ "http://www.evogene.com/role/CollaborationAndResearchAgreementsNarrativeDetails", "http://www.evogene.com/role/LiabilitiesInRespectOfGovernmentGrantsNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "This member is stand for Canonic Ltd.", "label": "Canonic Ltd [Member]" } } }, "auth_ref": [] }, "ifrs-full_CapitalReserve": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "CapitalReserve", "crdr": "credit", "calculation": { "http://www.evogene.com/role/ConsolidatedStatementsOfFinancialPosition": { "parentTag": "ifrs-full_EquityAttributableToOwnersOfParent", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://www.evogene.com/role/ConsolidatedStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Share premium and other capital reserves" } }, "en": { "role": { "documentation": "A component of equity representing the capital reserves." } } }, "auth_ref": [ "r367" ] }, "ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis", "presentation": [ "http://www.evogene.com/role/IntangibleAssetsNetScheduleOfIntangibleAssetsDetails", "http://www.evogene.com/role/LeasesScheduleOfRight-of-useAssetsDetails", "http://www.evogene.com/role/PropertyPlantAndEquipmentNetScheduleOfPropertyPlantEquipmentToAccumulatedDepreciationDetails" ], "lang": { "en-us": { "role": { "label": "Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount [Axis]", "verboseLabel": "Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r48", "r51", "r93", "r96", "r100", "r101", "r102", "r104", "r105", "r180", "r187", "r188" ] }, "ifrs-full_CarryingAmountMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "CarryingAmountMember", "presentation": [ "http://www.evogene.com/role/IntangibleAssetsNetScheduleOfIntangibleAssetsDetails", "http://www.evogene.com/role/LeasesScheduleOfRight-of-useAssetsDetails", "http://www.evogene.com/role/PropertyPlantAndEquipmentNetScheduleOfPropertyPlantEquipmentToAccumulatedDepreciationDetails" ], "lang": { "en-us": { "role": { "label": "Carrying amount [member]" } }, "en": { "role": { "documentation": "This member stands for the amount at which an asset is recognised in the statement of financial position (after deducting any accumulated depreciation or amortisation and accumulated impairment losses). It also represents the standard value for the 'Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount' axis if no other member is used. [Refer: Depreciation and amortisation expense; Impairment loss]" } } }, "auth_ref": [ "r51", "r96", "r100", "r102", "r104", "r180", "r187", "r188" ] }, "ifrs-full_Cash": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "Cash", "crdr": "debit", "calculation": { "http://www.evogene.com/role/CashAndCashEquivalentsScheduleOfCashAndEquivalentsDetails": { "parentTag": "ifrs-full_CashAndCashEquivalents", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.evogene.com/role/CashAndCashEquivalentsScheduleOfCashAndEquivalentsDetails" ], "lang": { "en-us": { "role": { "label": "Cash for immediate withdrawal in USD" } }, "en": { "role": { "documentation": "The amount of cash on hand and demand deposits. [Refer: Cash on hand]" } } }, "auth_ref": [ "r387" ] }, "ifrs-full_CashAndCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "CashAndCashEquivalents", "crdr": "debit", "calculation": { "http://www.evogene.com/role/ConsolidatedStatementsOfFinancialPosition": { "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0, "order": 0.0 }, "http://www.evogene.com/role/CashAndCashEquivalentsScheduleOfCashAndEquivalentsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.evogene.com/role/CashAndCashEquivalentsScheduleOfCashAndEquivalentsDetails", "http://www.evogene.com/role/ConsolidatedStatementsOfCashFlows", "http://www.evogene.com/role/ConsolidatedStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "periodEndLabel": "Cash and cash equivalents end of the year", "periodStartLabel": "Cash and cash equivalents beginning of the year", "label": "Cash and cash equivalents", "totalLabel": "Cash and cash equivalents" } }, "en": { "role": { "documentation": "The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]" } } }, "auth_ref": [ "r10", "r114", "r132" ] }, "ifrs-full_CashAndCashEquivalentsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "CashAndCashEquivalentsAbstract", "lang": { "en-us": { "role": { "label": "Cash and cash equivalents [Abstract]" } } }, "auth_ref": [] }, "ifrs-full_CashFlowsFromUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "CashFlowsFromUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://www.evogene.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents", "weight": 1.0, "order": 20.0 } }, "presentation": [ "http://www.evogene.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Net cash provided by financing activities", "totalLabel": "Net cash provided by financing activities" } }, "en": { "role": { "documentation": "The cash flows from (used in) financing activities, which are activities that result in changes in the size and composition of the contributed equity and borrowings of the entity, from continuing and discontinued operations." } } }, "auth_ref": [ "r106", "r116" ] }, "ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "CashFlowsFromUsedInFinancingActivitiesAbstract", "presentation": [ "http://www.evogene.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash flows from financing activities:" } } }, "auth_ref": [] }, "ifrs-full_CashFlowsFromUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "CashFlowsFromUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://www.evogene.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://www.evogene.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash flows from (used in) investing activities", "totalLabel": "Net cash provided by (used in) investing activities" } }, "en": { "role": { "documentation": "The cash flows from (used in) investing activities, which are the acquisition and disposal of long-term assets and other investments not included in cash equivalents, from continuing and discontinued operations." } } }, "auth_ref": [ "r106", "r116" ] }, "ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "CashFlowsFromUsedInInvestingActivitiesAbstract", "presentation": [ "http://www.evogene.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash flows from investing activities:", "verboseLabel": "Cash flows from investing activities:" } } }, "auth_ref": [] }, "ifrs-full_CashFlowsFromUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "CashFlowsFromUsedInOperatingActivities", "calculation": { "http://www.evogene.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.evogene.com/role/ConsolidatedStatementsOfCashFlows", "http://www.evogene.com/role/GeneralNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Cash flows from (used in) operating activities", "terseLabel": "Net operating cash outflows", "totalLabel": "Net cash used in operating activities" } }, "en": { "role": { "documentation": "The cash flows from (used in) operating activities, which are the principal revenue-producing activities of the entity and other activities that are not investing or financing activities, from continuing and discontinued operations. [Refer: Revenue]" } } }, "auth_ref": [ "r106", "r116" ] }, "ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "CashFlowsFromUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.evogene.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash flows from operating activities:" } } }, "auth_ref": [] }, "evgn_CashForImmediateWithdrawlInEuroAndOtherCurrencies": { "xbrltype": "monetaryItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "CashForImmediateWithdrawlInEuroAndOtherCurrencies", "crdr": "debit", "calculation": { "http://www.evogene.com/role/CashAndCashEquivalentsScheduleOfCashAndEquivalentsDetails": { "parentTag": "ifrs-full_CashAndCashEquivalents", "weight": 1.0, "order": 30.0 } }, "presentation": [ "http://www.evogene.com/role/CashAndCashEquivalentsScheduleOfCashAndEquivalentsDetails" ], "lang": { "en-us": { "role": { "documentation": "Cash for immediate withdrawal in Euro and other currencies.", "label": "Cash For Immediate Withdrawl In Euro And Other Currencies", "verboseLabel": "Cash for immediate withdrawal in Euro and other currencies" } } }, "auth_ref": [] }, "evgn_CashForImmediateWithdrawlInIsraelShekels": { "xbrltype": "monetaryItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "CashForImmediateWithdrawlInIsraelShekels", "crdr": "debit", "calculation": { "http://www.evogene.com/role/CashAndCashEquivalentsScheduleOfCashAndEquivalentsDetails": { "parentTag": "ifrs-full_CashAndCashEquivalents", "weight": 1.0, "order": 20.0 } }, "presentation": [ "http://www.evogene.com/role/CashAndCashEquivalentsScheduleOfCashAndEquivalentsDetails" ], "lang": { "en-us": { "role": { "documentation": "Cash for immediate withdrawal in NIS.", "label": "Cash For Immediate Withdrawl In Israel Shekels", "verboseLabel": "Cash for immediate withdrawal in New Israeli Shekels (\"NIS\")" } } }, "auth_ref": [] }, "evgn_CashInflowFromIssuingShares": { "xbrltype": "monetaryItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "CashInflowFromIssuingShares", "crdr": "debit", "presentation": [ "http://www.evogene.com/role/GeneralNarrativeDetails", "http://www.evogene.com/role/ShareholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the amount of cash inflow from issuing shares.", "label": "Cash Inflow From Issuing Shares", "verboseLabel": "Cash inflow from issuing shares" } } }, "auth_ref": [] }, "ifrs-full_CashOutflowForLeases": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "CashOutflowForLeases", "crdr": "credit", "presentation": [ "http://www.evogene.com/role/LeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Cash outflow for leases" } }, "en": { "role": { "documentation": "The cash outflow for leases." } } }, "auth_ref": [ "r149" ] }, "evgn_CashReceivedPaidDuringYearAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "CashReceivedPaidDuringYearAbstract", "presentation": [ "http://www.evogene.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash Received Paid During Year Abstract", "verboseLabel": "Cash received (paid) during the year for:" } } }, "auth_ref": [] }, "evgn_CasterraAgLimitedMember": { "xbrltype": "domainItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "CasterraAgLimitedMember", "presentation": [ "http://www.evogene.com/role/CollaborationAndResearchAgreementsNarrativeDetails", "http://www.evogene.com/role/FinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Information about the Casterra Ag Ltd.", "label": "Casterra Ag Limited [Member]", "terseLabel": "Casterra Ag Ltd. [Member]" } } }, "auth_ref": [] }, "ifrs-full_CategoriesOfRelatedPartiesAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "CategoriesOfRelatedPartiesAxis", "presentation": [ "http://www.evogene.com/role/BalancesAndTransactionsWithExecutiveOfficersAndCertainShareholdersScheduleOfBalancesDetails", "http://www.evogene.com/role/BalancesAndTransactionsWithExecutiveOfficersAndCertainShareholdersScheduleOfBenefitsToKeyOfficersDetails", "http://www.evogene.com/role/BalancesAndTransactionsWithKeyOfficersAndCertainShareholdersScheduleOfBenefitsToDirectorsDetails", "http://www.evogene.com/role/BalancesAndTransactionsWithKeyOfficersAndCertainShareholdersScheduleOfTransactionsWithRelatedPartiesDetails", "http://www.evogene.com/role/CollaborationAndResearchAgreementsNarrativeDetails", "http://www.evogene.com/role/ConvertibleSAFENarrativeDetails", "http://www.evogene.com/role/GeneralNarrativeDetails", "http://www.evogene.com/role/LiabilitiesInRespectOfGovernmentGrantsNarrativeDetails", "http://www.evogene.com/role/ShareholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Categories of related parties [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r71" ] }, "ifrs-full_CategoriesOfRelatedPartiesDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "CategoriesOfRelatedPartiesDomain", "presentation": [ "http://www.evogene.com/role/BalancesAndTransactionsWithExecutiveOfficersAndCertainShareholdersScheduleOfBalancesDetails", "http://www.evogene.com/role/BalancesAndTransactionsWithExecutiveOfficersAndCertainShareholdersScheduleOfBenefitsToKeyOfficersDetails", "http://www.evogene.com/role/BalancesAndTransactionsWithKeyOfficersAndCertainShareholdersScheduleOfBenefitsToDirectorsDetails", "http://www.evogene.com/role/BalancesAndTransactionsWithKeyOfficersAndCertainShareholdersScheduleOfTransactionsWithRelatedPartiesDetails", "http://www.evogene.com/role/CollaborationAndResearchAgreementsNarrativeDetails", "http://www.evogene.com/role/ConvertibleSAFENarrativeDetails", "http://www.evogene.com/role/GeneralNarrativeDetails", "http://www.evogene.com/role/LiabilitiesInRespectOfGovernmentGrantsNarrativeDetails", "http://www.evogene.com/role/ShareholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Categories of related parties [domain]" } }, "en": { "role": { "documentation": "This member stands for the standard value for the 'Categories of related parties' axis if no other member is used." } } }, "auth_ref": [ "r71" ] }, "evgn_CertainShareholderMember": { "xbrltype": "domainItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "CertainShareholderMember", "presentation": [ "http://www.evogene.com/role/BalancesAndTransactionsWithExecutiveOfficersAndCertainShareholdersScheduleOfBalancesDetails", "http://www.evogene.com/role/BalancesAndTransactionsWithKeyOfficersAndCertainShareholdersScheduleOfTransactionsWithRelatedPartiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Certain shareholder [Member]", "label": "Certain shareholder [Member]", "terseLabel": "Certain shareholders [Member]" } } }, "auth_ref": [] }, "evgn_ChangeInFairValueOfMarketableSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "ChangeInFairValueOfMarketableSecurities", "crdr": "debit", "calculation": { "http://www.evogene.com/role/StatementsOfComprehensiveLoss-AdditionalInformationScheduleOfIncomeAndExpensesDetails": { "parentTag": "ifrs-full_FinanceCosts", "weight": 1.0, "order": 20.0 } }, "presentation": [ "http://www.evogene.com/role/StatementsOfComprehensiveLoss-AdditionalInformationScheduleOfIncomeAndExpensesDetails" ], "lang": { "en-us": { "role": { "documentation": "Change in the fair value of marketable securities.", "label": "Change In Fair Value Of Marketable Securities", "verboseLabel": "Change in the fair value of marketable securities" } } }, "auth_ref": [] }, "ecd_ChangedPeerGroupFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChangedPeerGroupFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Changed Peer Group, Footnote [Text Block]", "terseLabel": "Changed Peer Group, Footnote" } } }, "auth_ref": [ "r311" ] }, "evgn_ChangesInAssetAndLiabilityItemsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "ChangesInAssetAndLiabilityItemsAbstract", "presentation": [ "http://www.evogene.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Changes In Asset And Liability Items Abstract", "verboseLabel": "Changes in asset and liability items:" } } }, "auth_ref": [] }, "ifrs-full_ChangesInInvestmentProperty": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "ChangesInInvestmentProperty", "crdr": "debit", "calculation": { "http://www.evogene.com/role/StatementsOfComprehensiveLoss-AdditionalInformationScheduleOfIncomeAndExpensesDetails": { "parentTag": "ifrs-full_FinanceCosts", "weight": 1.0, "order": 40.0 } }, "presentation": [ "http://www.evogene.com/role/StatementsOfComprehensiveLoss-AdditionalInformationScheduleOfIncomeAndExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Devaluation of investment" } }, "en": { "role": { "documentation": "The increase (decrease) in investment property. [Refer: Investment property]" } } }, "auth_ref": [ "r100", "r102" ] }, "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]", "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year" } } }, "auth_ref": [ "r308" ] }, "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]", "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested" } } }, "auth_ref": [ "r306" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": [ "http://www.evogene.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "ifrs-full_ClassesOfContingentLiabilitiesAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "ClassesOfContingentLiabilitiesAxis", "presentation": [ "http://www.evogene.com/role/COMMITMENTSANDCONTINGENTLIABILITIESNarrativeDetails", "http://www.evogene.com/role/SUBSEQUENTEVENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Classes of contingent liabilities [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r90", "r179" ] }, "ifrs-full_ClassesOfContingentLiabilitiesDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "ClassesOfContingentLiabilitiesDomain", "presentation": [ "http://www.evogene.com/role/COMMITMENTSANDCONTINGENTLIABILITIESNarrativeDetails", "http://www.evogene.com/role/SUBSEQUENTEVENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Classes of contingent liabilities [domain]" } }, "en": { "role": { "documentation": "This member stands for possible obligations that arise from past events and whose existence will be confirmed only by the occurrence or non-occurrence of one or more uncertain future events not wholly within the control of the entity; or, present obligations that arise from past events but are not recognised because (a) it is probable that an outflow of resources embodying economic benefits will be required to settle the obligations; or (b) the amount of the obligations cannot be measured with sufficient reliability. It also represents the standard value for the 'Classes of contingent liabilities' axis if no other member is used." } } }, "auth_ref": [ "r91", "r179" ] }, "ifrs-full_ClassesOfFinancialInstrumentsAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "ClassesOfFinancialInstrumentsAxis", "presentation": [ "http://www.evogene.com/role/FINANCIALINSTRUMENTSScheduleOfFairValueOfFinancialLiabilitiesDetails", "http://www.evogene.com/role/FinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Classes of financial instruments [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r187", "r189", "r190", "r191" ] }, "ifrs-full_ClassesOfFinancialInstrumentsDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "ClassesOfFinancialInstrumentsDomain", "presentation": [ "http://www.evogene.com/role/FINANCIALINSTRUMENTSScheduleOfFairValueOfFinancialLiabilitiesDetails", "http://www.evogene.com/role/FinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Classes of financial instruments [domain]" } }, "en": { "role": { "documentation": "This member stands for aggregated classes of financial instruments. Financial instruments are contracts that give rise to a financial asset of one entity and a financial liability or equity instrument of another entity. It also represents the standard value for the 'Classes of financial instruments' axis if no other member is used. [Refer: Financial assets; Financial liabilities]" } } }, "auth_ref": [ "r187", "r189", "r190", "r191" ] }, "ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "ClassesOfIntangibleAssetsOtherThanGoodwillAxis", "presentation": [ "http://www.evogene.com/role/IntangibleAssetsNetScheduleOfIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Classes of intangible assets other than goodwill [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r97" ] }, "ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "ClassesOfPropertyPlantAndEquipmentAxis", "presentation": [ "http://www.evogene.com/role/LeasesNarrativeDetails", "http://www.evogene.com/role/LeasesScheduleOfFutureMinimumLeasePaymentsUnderNon-cancelableLeasesDetails", "http://www.evogene.com/role/LeasesScheduleOfLeaseLiabilityDetails", "http://www.evogene.com/role/LeasesScheduleOfRight-of-useAssetsDetails", "http://www.evogene.com/role/PropertyPlantAndEquipmentNetScheduleOfPropertyPlantEquipmentToAccumulatedDepreciationDetails", "http://www.evogene.com/role/SignificantAccountingPoliciesScheduleOfDepreciationCalculatedUsingStraight-lineMethodDetails", "http://www.evogene.com/role/SignificantAccountingPoliciesScheduleOfIntangibleAssetsPurchasedDetails", "http://www.evogene.com/role/SignificantAccountingPoliciesScheduleOfUsefulLifeOfRightOfUseAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Classes of property, plant and equipment [Axis]", "verboseLabel": "Classes of property, plant and equipment [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r52" ] }, "ecd_CoSelectedMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Company Selected Measure Amount", "terseLabel": "Company Selected Measure Amount" } } }, "auth_ref": [ "r312" ] }, "ecd_CoSelectedMeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Company Selected Measure Name", "terseLabel": "Company Selected Measure Name" } } }, "auth_ref": [ "r312" ] }, "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]", "terseLabel": "Compensation Actually Paid vs. Company Selected Measure" } } }, "auth_ref": [ "r317" ] }, "ecd_CompActuallyPaidVsNetIncomeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsNetIncomeTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Net Income [Text Block]", "terseLabel": "Compensation Actually Paid vs. Net Income" } } }, "auth_ref": [ "r316" ] }, "ecd_CompActuallyPaidVsOtherMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Other Measure [Text Block]", "terseLabel": "Compensation Actually Paid vs. Other Measure" } } }, "auth_ref": [ "r318" ] }, "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]", "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return" } } }, "auth_ref": [ "r315" ] }, "ifrs-full_ComponentsOfEquityAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "ComponentsOfEquityAxis", "presentation": [ "http://www.evogene.com/role/ConsolidatedStatementsOfChangesInEquity", "http://www.evogene.com/role/ConvertibleSAFENarrativeDetails", "http://www.evogene.com/role/GeneralNarrativeDetails", "http://www.evogene.com/role/ShareholdersEquityNarrativeDetails", "http://www.evogene.com/role/ShareholdersEquityScheduleOfChangesInShareCapitalDetails" ], "lang": { "en-us": { "role": { "label": "Components of equity [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r4" ] }, "ifrs-full_ComponentsOfEquityDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "ComponentsOfEquityDomain", "presentation": [ "http://www.evogene.com/role/ConsolidatedStatementsOfChangesInEquity", "http://www.evogene.com/role/ConvertibleSAFENarrativeDetails", "http://www.evogene.com/role/GeneralNarrativeDetails", "http://www.evogene.com/role/ShareholdersEquityNarrativeDetails", "http://www.evogene.com/role/ShareholdersEquityScheduleOfChangesInShareCapitalDetails" ], "lang": { "en-us": { "role": { "label": "Equity [Member]" } }, "en": { "role": { "documentation": "This member stands for the residual interest in the assets of the entity after deducting all its liabilities. It also represents the standard value for the 'Components of equity' axis if no other member is used." } } }, "auth_ref": [ "r4" ] }, "ifrs-full_ComputerEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "ComputerEquipmentMember", "presentation": [ "http://www.evogene.com/role/PropertyPlantAndEquipmentNetScheduleOfPropertyPlantEquipmentToAccumulatedDepreciationDetails", "http://www.evogene.com/role/SignificantAccountingPoliciesScheduleOfDepreciationCalculatedUsingStraight-lineMethodDetails" ], "lang": { "en-us": { "role": { "label": "Computers and peripheral equipment [Member]" } }, "en": { "role": { "documentation": "This member stands for a class of property, plant and equipment representing computer equipment. [Refer: Property, plant and equipment]" } } }, "auth_ref": [ "r370" ] }, "evgn_ConsentJudgementPaid": { "xbrltype": "monetaryItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "ConsentJudgementPaid", "crdr": "debit", "presentation": [ "http://www.evogene.com/role/SUBSEQUENTEVENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the amount of consent judgement paid.", "label": "Consent Judgement Paid", "verboseLabel": "Consent judgement paid" } } }, "auth_ref": [] }, "evgn_ConsiderationFromOptionExercises": { "xbrltype": "monetaryItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "ConsiderationFromOptionExercises", "crdr": "credit", "presentation": [ "http://www.evogene.com/role/GeneralNarrativeDetails", "http://www.evogene.com/role/ShareholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents amount of total consideration.", "label": "Consideration From Option Exercises", "verboseLabel": "Total consideration" } } }, "auth_ref": [] }, "dei_ContactPersonnelName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "ContactPersonnelName", "presentation": [ "http://www.evogene.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Contact Personnel Name", "documentation": "Name of contact personnel" } } }, "auth_ref": [] }, "ifrs-full_ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis", "presentation": [ "http://www.evogene.com/role/LossPerShareScheduleOfBasicLossPerShareDetails" ], "lang": { "en-us": { "role": { "label": "Continuing involvement in derecognised financial assets by type of instrument [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r244" ] }, "ifrs-full_ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentDomain", "presentation": [ "http://www.evogene.com/role/LossPerShareScheduleOfBasicLossPerShareDetails" ], "lang": { "en": { "role": { "documentation": "This member stands for all types of financial instruments. It also represents the standard value for the 'Continuing involvement in derecognised financial assets by type of instrument' axis if no other member is used." } } }, "auth_ref": [ "r244" ] }, "evgn_ConversionValuation": { "xbrltype": "monetaryItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "ConversionValuation", "crdr": "debit", "presentation": [ "http://www.evogene.com/role/ConvertibleSAFENarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the amount of conversion valuation prior to relevant event.", "label": "Conversion Valuation", "terseLabel": "Conversion valuation" } } }, "auth_ref": [] }, "evgn_ConvertibleDebtLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "ConvertibleDebtLineItems", "presentation": [ "http://www.evogene.com/role/ConvertibleSAFENarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.", "label": "Convertible Debt [Line Items]" } } }, "auth_ref": [] }, "evgn_ConvertibleDebtTable": { "xbrltype": "stringItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "ConvertibleDebtTable", "presentation": [ "http://www.evogene.com/role/ConvertibleSAFENarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Schedule of convertible debt.", "label": "Convertible Debt [Table]" } } }, "auth_ref": [] }, "evgn_ConvertibleSafe": { "xbrltype": "monetaryItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "ConvertibleSafe", "crdr": "credit", "calculation": { "http://www.evogene.com/role/ConsolidatedStatementsOfFinancialPosition": { "parentTag": "ifrs-full_NoncurrentLiabilities", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.evogene.com/role/ConsolidatedStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "documentation": "Represents the amount of convertible safe.", "label": "Convertible Safe", "terseLabel": "Convertible SAFE" } } }, "auth_ref": [] }, "evgn_ConvertibleSafeAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "ConvertibleSafeAmount", "crdr": "debit", "presentation": [ "http://www.evogene.com/role/ConvertibleSAFENarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Convertible SAFE amount.", "label": "Convertible Safe Amount", "terseLabel": "Convertible SAFE amount" } } }, "auth_ref": [] }, "evgn_ConvertibleSafeMember": { "xbrltype": "domainItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "ConvertibleSafeMember", "presentation": [ "http://www.evogene.com/role/FINANCIALINSTRUMENTSScheduleOfFairValueOfFinancialLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Convertible SAFE [Member].", "label": "Convertible Safe [Member]", "verboseLabel": "Convertible SAFE [Member]" } } }, "auth_ref": [] }, "evgn_CortevaMember": { "xbrltype": "domainItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "CortevaMember", "presentation": [ "http://www.evogene.com/role/BalancesAndTransactionsWithExecutiveOfficersAndCertainShareholdersNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Corteva [Member]", "label": "Corteva [Member]" } } }, "auth_ref": [] }, "evgn_CostOfRevenuesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "CostOfRevenuesAbstract", "presentation": [ "http://www.evogene.com/role/StatementsOfComprehensiveLoss-AdditionalInformationScheduleOfIncomeAndExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Cost Of Revenues Abstract", "verboseLabel": "Cost of revenues:" } } }, "auth_ref": [] }, "evgn_CostOfRevenuesForTransactions": { "xbrltype": "monetaryItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "CostOfRevenuesForTransactions", "crdr": "debit", "presentation": [ "http://www.evogene.com/role/BalancesAndTransactionsWithKeyOfficersAndCertainShareholdersScheduleOfTransactionsWithRelatedPartiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of cost of revenues for transactions with key officers and shareholders.", "label": "Cost Of Revenues For Transactions", "verboseLabel": "Cost of revenues" } } }, "auth_ref": [] }, "ifrs-full_CostOfSales": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "CostOfSales", "crdr": "debit", "calculation": { "http://www.evogene.com/role/ConsolidatedStatementsOfProfitOrLoss": { "parentTag": "ifrs-full_GrossProfit", "weight": -1.0, "order": 10.0 }, "http://www.evogene.com/role/StatementsOfComprehensiveLoss-AdditionalInformationScheduleOfIncomeAndExpensesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.evogene.com/role/ConsolidatedStatementsOfProfitOrLoss", "http://www.evogene.com/role/StatementsOfComprehensiveLoss-AdditionalInformationScheduleOfIncomeAndExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Cost of revenues", "totalLabel": "Total cost of revenues" } }, "en": { "role": { "documentation": "The amount of all expenses directly or indirectly attributed to the goods or services sold. Attributed expenses include, but are not limited to, costs previously included in the measurement of inventory that has now been sold, such as depreciation and maintenance of factory buildings and equipment used in the production process, unallocated production overheads, and abnormal amounts of production costs of inventories." } } }, "auth_ref": [ "r0", "r38" ] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "verboseLabel": "Document And Entity Information", "documentation": "Cover page." } } }, "auth_ref": [] }, "ifrs-full_CurrentAdvancesToSuppliers": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "CurrentAdvancesToSuppliers", "crdr": "debit", "calculation": { "http://www.evogene.com/role/OtherReceivablesAndPrepaidExpensesScheduleOfOtherReceivablesAndPrepaidExpensesDetails": { "parentTag": "ifrs-full_OtherCurrentReceivables", "weight": 1.0, "order": 60.0 } }, "presentation": [ "http://www.evogene.com/role/OtherReceivablesAndPrepaidExpensesScheduleOfOtherReceivablesAndPrepaidExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Current advances to suppliers", "verboseLabel": "Suppliers' advances" } }, "en": { "role": { "documentation": "The amount of current advances made to suppliers before goods or services are received." } } }, "auth_ref": [ "r365" ] }, "ifrs-full_CurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "CurrentAssets", "crdr": "debit", "calculation": { "http://www.evogene.com/role/ConsolidatedStatementsOfFinancialPosition": { "parentTag": "ifrs-full_Assets", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.evogene.com/role/ConsolidatedStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Current assets", "totalLabel": "Total current assets" } }, "en": { "role": { "documentation": "The amount of assets that the entity (a) expects to realise or intends to sell or consume in its normal operating cycle; (b) holds primarily for the purpose of trading; (c) expects to realise within twelve months after the reporting period; or (d) classifies as cash or cash equivalents (as defined in IAS 7) unless the asset is restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period. [Refer: Assets]" } } }, "auth_ref": [ "r20", "r126", "r234" ] }, "ifrs-full_CurrentAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "CurrentAssetsAbstract", "presentation": [ "http://www.evogene.com/role/ConsolidatedStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "CURRENT ASSETS:" } } }, "auth_ref": [] }, "evgn_CurrentConvertibleSafe": { "xbrltype": "monetaryItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "CurrentConvertibleSafe", "crdr": "credit", "calculation": { "http://www.evogene.com/role/ConsolidatedStatementsOfFinancialPosition": { "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0, "order": 60.0 } }, "lang": { "en-us": { "role": { "documentation": "Represents the amount of Current Convertible Safe", "label": "Current Convertible Safe" } } }, "auth_ref": [] }, "evgn_CurrentDeferredExpensesRelatedToIssuanceOfWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "CurrentDeferredExpensesRelatedToIssuanceOfWarrants", "crdr": "debit", "calculation": { "http://www.evogene.com/role/ConsolidatedStatementsOfFinancialPosition": { "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0, "order": 30.0 } }, "presentation": [ "http://www.evogene.com/role/ConsolidatedStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "documentation": "Represents the amount of current deferred expenses related to issuance of warrants.", "label": "Current Deferred Expenses Related To Issuance Of Warrants", "terseLabel": "Deferred expenses related to issuance of warrants" } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://www.evogene.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "ifrs-full_CurrentGovernmentGrants": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "CurrentGovernmentGrants", "crdr": "credit", "calculation": { "http://www.evogene.com/role/ConsolidatedStatementsOfFinancialPosition": { "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0, "order": 20.0 } }, "presentation": [ "http://www.evogene.com/role/ConsolidatedStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Liabilities in respect of government grants" } }, "en": { "role": { "documentation": "The amount of current government grants recognised in the statement of financial position as deferred income. [Refer: Government [member]; Government grants]" } } }, "auth_ref": [ "r367" ] }, "ifrs-full_CurrentInterestReceivable": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "CurrentInterestReceivable", "crdr": "debit", "calculation": { "http://www.evogene.com/role/OtherReceivablesAndPrepaidExpensesScheduleOfOtherReceivablesAndPrepaidExpensesDetails": { "parentTag": "ifrs-full_OtherCurrentReceivables", "weight": 1.0, "order": 30.0 } }, "presentation": [ "http://www.evogene.com/role/OtherReceivablesAndPrepaidExpensesScheduleOfOtherReceivablesAndPrepaidExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Accrued bank interests" } }, "en": { "role": { "documentation": "The amount of current interest receivable. [Refer: Interest receivable]" } } }, "auth_ref": [ "r365" ] }, "ifrs-full_CurrentLeaseLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "CurrentLeaseLiabilities", "crdr": "credit", "calculation": { "http://www.evogene.com/role/ConsolidatedStatementsOfFinancialPosition": { "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0, "order": 80.0 } }, "presentation": [ "http://www.evogene.com/role/ConsolidatedStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Current maturities of lease liabilities", "terseLabel": "Lease liabilities" } }, "en": { "role": { "documentation": "The amount of current lease liabilities. [Refer: Lease liabilities]" } } }, "auth_ref": [ "r146" ] }, "ifrs-full_CurrentLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "CurrentLiabilities", "crdr": "credit", "calculation": { "http://www.evogene.com/role/ConsolidatedStatementsOfFinancialPosition": { "parentTag": "ifrs-full_Liabilities", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.evogene.com/role/ConsolidatedStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Current liabilities", "totalLabel": "Total current liabilities" } }, "en": { "role": { "documentation": "The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have the right at the end of the reporting period to defer settlement for at least twelve months after the reporting period." } } }, "auth_ref": [ "r21", "r128", "r234" ] }, "ifrs-full_CurrentLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "CurrentLiabilitiesAbstract", "presentation": [ "http://www.evogene.com/role/ConsolidatedStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "CURRENT LIABILITIES:" } } }, "auth_ref": [] }, "ifrs-full_CurrentNotesAndDebenturesIssuedAndCurrentPortionOfNoncurrentNotesAndDebenturesIssued": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "CurrentNotesAndDebenturesIssuedAndCurrentPortionOfNoncurrentNotesAndDebenturesIssued", "crdr": "credit", "calculation": { "http://www.evogene.com/role/ConsolidatedStatementsOfFinancialPosition": { "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0, "order": 70.0 } }, "presentation": [ "http://www.evogene.com/role/ConsolidatedStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Current notes and debentures issued and current portion of non-current notes and debentures issued", "verboseLabel": "Convertible SAFE" } }, "en": { "role": { "documentation": "The amount of current notes and debentures issued and the current portion of non-current notes and debentures issued. [Refer: Notes and debentures issued]" } } }, "auth_ref": [ "r365" ] }, "ifrs-full_CurrentPrepaidExpenses": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "CurrentPrepaidExpenses", "crdr": "debit", "calculation": { "http://www.evogene.com/role/OtherReceivablesAndPrepaidExpensesScheduleOfOtherReceivablesAndPrepaidExpensesDetails": { "parentTag": "ifrs-full_OtherCurrentReceivables", "weight": 1.0, "order": 40.0 } }, "presentation": [ "http://www.evogene.com/role/OtherReceivablesAndPrepaidExpensesScheduleOfOtherReceivablesAndPrepaidExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Prepaid expenses" } }, "en": { "role": { "documentation": "The amount recognised as a current asset for expenditures made prior to the period when the economic benefit will be realised." } } }, "auth_ref": [ "r365" ] }, "ifrs-full_CurrentProvisionsForEmployeeBenefits": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "CurrentProvisionsForEmployeeBenefits", "crdr": "credit", "calculation": { "http://www.evogene.com/role/ConsolidatedStatementsOfFinancialPosition": { "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0, "order": 40.0 } }, "presentation": [ "http://www.evogene.com/role/ConsolidatedStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Employees and payroll accruals" } }, "en": { "role": { "documentation": "The amount of current provisions for employee benefits. [Refer: Provisions for employee benefits]" } } }, "auth_ref": [ "r22" ] }, "ifrs-full_CurrentTaxLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "CurrentTaxLiabilities", "crdr": "credit", "presentation": [ "http://www.evogene.com/role/TaxesOnIncomeDetails" ], "lang": { "en-us": { "role": { "label": "Current tax liabilities" } }, "en": { "role": { "documentation": "The amount of current tax for current and prior periods to the extent unpaid. Current tax is the amount of income taxes payable (recoverable) in respect of the taxable profit (tax loss) for a period." } } }, "auth_ref": [ "r12" ] }, "ifrs-full_CurrentTradeReceivables": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "CurrentTradeReceivables", "crdr": "debit", "calculation": { "http://www.evogene.com/role/ConsolidatedStatementsOfFinancialPosition": { "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0, "order": 20.0 } }, "presentation": [ "http://www.evogene.com/role/ConsolidatedStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Trade receivables", "terseLabel": "Trade receivables" } }, "en": { "role": { "documentation": "The amount of current trade receivables. [Refer: Trade receivables]" } } }, "auth_ref": [ "r216", "r217" ] }, "ifrs-full_CurrentWarrantLiability": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "CurrentWarrantLiability", "crdr": "credit", "calculation": { "http://www.evogene.com/role/ConsolidatedStatementsOfFinancialPosition": { "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0, "order": 50.0 } }, "presentation": [ "http://www.evogene.com/role/ConsolidatedStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Current warrant liability", "verboseLabel": "Warrants and pre-funded warrants liability" } }, "en": { "role": { "documentation": "The amount of current warrant liabilities. [Refer: Warrant liability]" } } }, "auth_ref": [ "r367" ] }, "evgn_CustomerBMember": { "xbrltype": "domainItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "CustomerBMember", "presentation": [ "http://www.evogene.com/role/OperatingSegmentsScheduleOfRevenuesFromMajorCustomersDetails" ], "lang": { "en-us": { "role": { "documentation": "Customer B [Member]", "label": "Customer B Member", "verboseLabel": "Customer B [Member]" } } }, "auth_ref": [] }, "evgn_CustomerCMember": { "xbrltype": "domainItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "CustomerCMember", "presentation": [ "http://www.evogene.com/role/CollaborationAndResearchAgreementsNarrativeDetails", "http://www.evogene.com/role/OperatingSegmentsScheduleOfRevenuesFromMajorCustomersDetails" ], "lang": { "en-us": { "role": { "documentation": "Customer C [Member]", "label": "Customer C Member", "verboseLabel": "Customer C [Member]" } } }, "auth_ref": [] }, "evgn_CustomerDMember": { "xbrltype": "domainItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "CustomerDMember", "presentation": [ "http://www.evogene.com/role/CollaborationAndResearchAgreementsNarrativeDetails", "http://www.evogene.com/role/OperatingSegmentsScheduleOfRevenuesFromMajorCustomersDetails" ], "lang": { "en-us": { "role": { "documentation": "Customer D [Member]", "label": "Customer D [Member]" } } }, "auth_ref": [] }, "evgn_CustomerShareholderMember": { "xbrltype": "domainItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "CustomerShareholderMember", "presentation": [ "http://www.evogene.com/role/OperatingSegmentsScheduleOfRevenuesFromMajorCustomersDetails" ], "lang": { "en-us": { "role": { "documentation": "Customer A shareholder [Member]", "label": "Customer Shareholder Member", "verboseLabel": "Customer A (subsidiary shareholder) [Member]" } } }, "auth_ref": [] }, "cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]" } } }, "auth_ref": [ "r263", "r352" ] }, "cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskBoardOfDirectorsOversightTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Board of Directors Oversight [Text Block]" } } }, "auth_ref": [ "r263", "r352" ] }, "cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Expertise of Management Responsible [Text Block]" } } }, "auth_ref": [ "r265", "r354" ] }, "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Positions or Committees Responsible [Flag]" } } }, "auth_ref": [ "r265", "r354" ] }, "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]" } } }, "auth_ref": [ "r267", "r356" ] }, "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Positions or Committees Responsible [Text Block]" } } }, "auth_ref": [ "r265", "r354" ] }, "cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]" } } }, "auth_ref": [ "r258", "r347" ] }, "cyd_CybersecurityRiskManagementProcessesIntegratedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskManagementProcessesIntegratedFlag", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Processes Integrated [Flag]" } } }, "auth_ref": [ "r259", "r348" ] }, "cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskManagementProcessesIntegratedTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Processes Integrated [Text Block]" } } }, "auth_ref": [ "r259", "r348" ] }, "cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskManagementStrategyAndGovernanceAbstract", "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management, Strategy, and Governance [Abstract]" } } }, "auth_ref": [ "r257", "r346" ] }, "cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskManagementStrategyAndGovernanceLineItems", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management, Strategy, and Governance [Line Items]" } } }, "auth_ref": [ "r257", "r346" ] }, "cyd_CybersecurityRiskManagementStrategyAndGovernanceTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskManagementStrategyAndGovernanceTable", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management, Strategy, and Governance [Table]" } } }, "auth_ref": [ "r257", "r346" ] }, "cyd_CybersecurityRiskManagementThirdPartyEngagedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskManagementThirdPartyEngagedFlag", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Third Party Engaged [Flag]" } } }, "auth_ref": [ "r260", "r349" ] }, "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]" } } }, "auth_ref": [ "r262", "r351" ] }, "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]" } } }, "auth_ref": [ "r262", "r351" ] }, "cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]" } } }, "auth_ref": [ "r263", "r352" ] }, "cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]" } } }, "auth_ref": [ "r266", "r355" ] }, "cyd_CybersecurityRiskRoleOfManagementTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskRoleOfManagementTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Role of Management [Text Block]" } } }, "auth_ref": [ "r264", "r353" ] }, "cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]" } } }, "auth_ref": [ "r261", "r350" ] }, "country_DE": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2024", "localname": "DE", "presentation": [ "http://www.evogene.com/role/OperatingSegmentsScheduleOfRevenuesBasedOnCustomersDetails" ], "lang": { "en-us": { "role": { "label": "GERMANY" } } }, "auth_ref": [] }, "ifrs-full_DebtInstrumentsHeldAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DebtInstrumentsHeldAbstract", "lang": { "en-us": { "role": { "label": "Debt instruments held [Abstract]" } } }, "auth_ref": [] }, "evgn_DecreaseInAccruedBankInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "DecreaseInAccruedBankInterest", "crdr": "credit", "calculation": { "http://www.evogene.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "ifrs-full_AdjustmentsForReconcileProfitLoss", "weight": -1.0, "order": 110.0 } }, "presentation": [ "http://www.evogene.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Decrease in accrued bank interest.", "negatedLabel": "Decrease in accrued bank interest", "label": "Decrease In Accrued Bank Interest" } } }, "auth_ref": [] }, "ifrs-full_DeferredTaxAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DeferredTaxAssets", "crdr": "debit", "presentation": [ "http://www.evogene.com/role/TaxesOnIncomeDetails" ], "lang": { "en-us": { "role": { "label": "Deferred tax assets", "terseLabel": "Deferred taxes" } }, "en": { "role": { "documentation": "The amounts of income taxes recoverable in future periods in respect of: (a) deductible temporary differences; (b) the carryforward of unused tax losses; and (c) the carryforward of unused tax credits. [Refer: Temporary differences [member]; Unused tax credits [member]; Unused tax losses [member]]" } } }, "auth_ref": [ "r13", "r17", "r44" ] }, "evgn_DefinitiveAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "DefinitiveAgreementMember", "presentation": [ "http://www.evogene.com/role/GeneralNarrativeDetails", "http://www.evogene.com/role/ShareholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stand for definitive agreement.", "label": "Definitive Agreement [Member]", "verboseLabel": "Definitive Agreement [Member]" } } }, "auth_ref": [] }, "ifrs-full_DepreciationExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DepreciationExpense", "crdr": "debit", "calculation": { "http://www.evogene.com/role/StatementsOfComprehensiveLoss-AdditionalInformationScheduleOfIncomeAndExpensesDetails": { "parentTag": "ifrs-full_CostOfSales", "weight": 1.0, "order": 30.0 } }, "presentation": [ "http://www.evogene.com/role/StatementsOfComprehensiveLoss-AdditionalInformationScheduleOfIncomeAndExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Depreciation expense", "verboseLabel": "Depreciation" } }, "en": { "role": { "documentation": "The amount of depreciation expense. Depreciation is the systematic allocation of depreciable amounts of tangible assets over their useful lives." } } }, "auth_ref": [ "r365" ] }, "evgn_DepreciationForResearchAndDevelopment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "DepreciationForResearchAndDevelopment", "crdr": "debit", "calculation": { "http://www.evogene.com/role/StatementsOfComprehensiveLoss-AdditionalInformationScheduleOfIncomeAndExpensesDetails": { "parentTag": "ifrs-full_ResearchAndDevelopmentExpense", "weight": 1.0, "order": 50.0 } }, "presentation": [ "http://www.evogene.com/role/StatementsOfComprehensiveLoss-AdditionalInformationScheduleOfIncomeAndExpensesDetails" ], "lang": { "en-us": { "role": { "documentation": "Depreciation for research and development.", "label": "Depreciation For Research And Development", "verboseLabel": "Depreciation and amortization" } } }, "auth_ref": [] }, "ifrs-full_DepreciationPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DepreciationPropertyPlantAndEquipment", "presentation": [ "http://www.evogene.com/role/PROPERTYPLANTANDEQUIPMENTNETNarrativeDetails", "http://www.evogene.com/role/PropertyPlantAndEquipmentNetScheduleOfPropertyPlantEquipmentToAccumulatedDepreciationDetails" ], "lang": { "en-us": { "role": { "label": "Depreciation, property, plant and equipment", "terseLabel": "Depreciation" } }, "en": { "role": { "documentation": "The amount of depreciation of property, plant and equipment. [Refer: Depreciation and amortisation expense; Property, plant and equipment]" } } }, "auth_ref": [ "r50", "r53" ] }, "ifrs-full_DepreciationRightofuseAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DepreciationRightofuseAssets", "presentation": [ "http://www.evogene.com/role/LeasesScheduleOfLeaseExpensesDetails", "http://www.evogene.com/role/LeasesScheduleOfRight-of-useAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Depreciation expenses on right-of-use assets", "verboseLabel": "Depreciation" } }, "en": { "role": { "documentation": "The amount of depreciation of right-of-use assets. [Refer: Depreciation and amortisation expense; Right-of-use assets]" } } }, "auth_ref": [ "r147" ] }, "evgn_DescriptionOfAccountingPolicyForBasisOfPresentationOfFinancialStatement": { "xbrltype": "textBlockItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "DescriptionOfAccountingPolicyForBasisOfPresentationOfFinancialStatement", "presentation": [ "http://www.evogene.com/role/SignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "documentation": "The description of the entity's material accounting policy information for Basis Of Presentation Of The Financial Statement", "label": "Description Of Accounting Policy For Basis Of Presentation Of Financial Statement", "terseLabel": "Basis of presentation of the financial statements" } } }, "auth_ref": [] }, "evgn_DescriptionOfAccountingPolicyForConsolidatedFinancialStatementsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "DescriptionOfAccountingPolicyForConsolidatedFinancialStatementsExplanatory", "presentation": [ "http://www.evogene.com/role/SignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "documentation": "The description of the entity's accounting policy for consolidated financial statements.", "label": "Description Of Accounting Policy For Consolidated Financial Statements Explanatory", "verboseLabel": "Consolidated financial statements" } } }, "auth_ref": [] }, "ifrs-full_DescriptionOfAccountingPolicyForDerivativeFinancialInstrumentsAndHedgingExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DescriptionOfAccountingPolicyForDerivativeFinancialInstrumentsAndHedgingExplanatory", "presentation": [ "http://www.evogene.com/role/SignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Derivative financial instruments designated as hedges" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for derivative financial instruments and hedging. [Refer: Classes of financial instruments [domain]; Derivatives [member]]" } } }, "auth_ref": [ "r366" ] }, "ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DescriptionOfAccountingPolicyForEarningsPerShareExplanatory", "presentation": [ "http://www.evogene.com/role/SignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Loss per share" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for earnings per share." } } }, "auth_ref": [ "r366" ] }, "ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory", "presentation": [ "http://www.evogene.com/role/SignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Employee benefit liabilities" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for employee benefits. Employee benefits are all forms of consideration given by an entity in exchange for services rendered by employees or for the termination of employment." } } }, "auth_ref": [ "r366" ] }, "ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory", "presentation": [ "http://www.evogene.com/role/SignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Fair value measurement" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for fair value measurement. [Refer: At fair value [member]]" } } }, "auth_ref": [ "r366" ] }, "ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsAtFairValueThroughProfitOrLossExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DescriptionOfAccountingPolicyForFinancialInstrumentsAtFairValueThroughProfitOrLossExplanatory", "presentation": [ "http://www.evogene.com/role/SignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Other comprehensive loss" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for financial instruments at fair value through profit or loss. [Refer: At fair value [member]; Classes of financial instruments [domain]]" } } }, "auth_ref": [ "r366" ] }, "ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory", "presentation": [ "http://www.evogene.com/role/SignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Description of accounting policy for financial instruments [text block]", "terseLabel": "Financial instruments" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for financial instruments. [Refer: Classes of financial instruments [domain]]" } } }, "auth_ref": [ "r366" ] }, "ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory", "presentation": [ "http://www.evogene.com/role/SignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Functional currency, presentation currency and foreign currency" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for foreign currency translation." } } }, "auth_ref": [ "r366" ] }, "ifrs-full_DescriptionOfAccountingPolicyForGovernmentGrants": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DescriptionOfAccountingPolicyForGovernmentGrants", "presentation": [ "http://www.evogene.com/role/SignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Government grants" } }, "en": { "role": { "documentation": "The description of the entity's accounting policy for government grants, including the methods of presentation adopted in the financial statements. [Refer: Government [member]; Government grants]" } } }, "auth_ref": [ "r63" ] }, "evgn_DescriptionOfAccountingPolicyForIFRSThreeBusinessCombinationsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "DescriptionOfAccountingPolicyForIFRSThreeBusinessCombinationsExplanatory", "presentation": [ "http://www.evogene.com/role/SignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "documentation": "IFRS 3, \"Business Combinations\".", "label": "Description Of Accounting Policy For I F R S Three Business Combinations Explanatory", "verboseLabel": "IFRS 3, \"Business Combinations\"" } } }, "auth_ref": [] }, "ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory", "presentation": [ "http://www.evogene.com/role/SignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Impairment of non-financial assets" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for the impairment of non-financial assets. [Refer: Financial assets]" } } }, "auth_ref": [ "r366" ] }, "ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DescriptionOfAccountingPolicyForIncomeTaxExplanatory", "presentation": [ "http://www.evogene.com/role/SignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Description of accounting policy for income tax [text block]", "verboseLabel": "Taxes on income" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for income tax." } } }, "auth_ref": [ "r366" ] }, "ifrs-full_DescriptionOfAccountingPolicyForInvestmentInAssociates": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DescriptionOfAccountingPolicyForInvestmentInAssociates", "presentation": [ "http://www.evogene.com/role/SignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Description of accounting policy for investment in associates [text block]", "terseLabel": "Investment in an associate" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for investments in associates. [Refer: Total for all associates [member]]" } } }, "auth_ref": [ "r366" ] }, "ifrs-full_DescriptionOfAccountingPolicyForInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethodExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DescriptionOfAccountingPolicyForInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethodExplanatory", "presentation": [ "http://www.evogene.com/role/SignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Short-term deposits" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for investments other than investments accounted for using the equity method. [Refer: Investments accounted for using equity method; Investments other than investments accounted for using equity method]" } } }, "auth_ref": [ "r366" ] }, "ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DescriptionOfAccountingPolicyForLeasesExplanatory", "presentation": [ "http://www.evogene.com/role/SignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Leases" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for leases. A lease is an agreement whereby the lessor conveys to the lessee in return for a payment or series of payments the right to use an asset for an agreed period of time." } } }, "auth_ref": [ "r366" ] }, "ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DescriptionOfAccountingPolicyForMeasuringInventories", "presentation": [ "http://www.evogene.com/role/SignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Description of accounting policy for measuring inventories [text block]", "terseLabel": "Inventories" } }, "en": { "role": { "documentation": "The description of the entity's accounting policy for measuring inventories. [Refer: Inventories]" } } }, "auth_ref": [ "r60" ] }, "ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory", "presentation": [ "http://www.evogene.com/role/SignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Description of accounting policy for property, plant and equipment [text block]", "terseLabel": "Property, plant and equipment" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for property, plant and equipment. [Refer: Property, plant and equipment]" } } }, "auth_ref": [ "r366" ] }, "ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DescriptionOfAccountingPolicyForProvisionsExplanatory", "presentation": [ "http://www.evogene.com/role/SignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Provisions" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for provisions. [Refer: Provisions]" } } }, "auth_ref": [ "r366" ] }, "ifrs-full_DescriptionOfAccountingPolicyForReclassificationOfFinancialInstrumentsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DescriptionOfAccountingPolicyForReclassificationOfFinancialInstrumentsExplanatory", "presentation": [ "http://www.evogene.com/role/SignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Reclassification" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for the reclassification of financial instruments. [Refer: Classes of financial instruments [domain]]" } } }, "auth_ref": [ "r366" ] }, "ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DescriptionOfAccountingPolicyForRecognitionOfRevenue", "presentation": [ "http://www.evogene.com/role/SignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Revenue recognition" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for recognising revenue. [Refer: Revenue]" } } }, "auth_ref": [ "r366" ] }, "ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory", "presentation": [ "http://www.evogene.com/role/SignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Share-based payment transactions" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for transactions in which the entity: (a) receives goods or services from the supplier of those goods or services (including an employee) in a share-based payment arrangement; or (b) incurs an obligation to settle the transaction with the supplier in a share-based payment arrangement when another group entity receives those goods or services. [Refer: Types of share-based payment arrangements [domain]]" } } }, "auth_ref": [ "r366" ] }, "ifrs-full_DescriptionOfAccountingPolicyForTransactionsWithNoncontrollingInterestsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DescriptionOfAccountingPolicyForTransactionsWithNoncontrollingInterestsExplanatory", "presentation": [ "http://www.evogene.com/role/SignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Description of accounting policy for transactions with non-controlling interests [text block]", "terseLabel": "Non-controlling interests measurement" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for transactions with non-controlling interests. [Refer: Non-controlling interests]" } } }, "auth_ref": [ "r366" ] }, "ifrs-full_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents", "presentation": [ "http://www.evogene.com/role/SignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Description of accounting policy for determining components of cash and cash equivalents [text block]", "terseLabel": "Cash equivalents" } }, "en": { "role": { "documentation": "The description of the entity's accounting policy used to determine the components of cash and cash equivalents. [Refer: Cash and cash equivalents]" } } }, "auth_ref": [ "r115" ] }, "ifrs-full_DescriptionOfConversionOfDebtToEquity": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DescriptionOfConversionOfDebtToEquity", "presentation": [ "http://www.evogene.com/role/ConvertibleSAFENarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Description of conversion of debt to equity" } }, "en": { "role": { "documentation": "The description of the non-cash conversion of debt to equity." } } }, "auth_ref": [ "r233" ] }, "ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted": { "xbrltype": "percentItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DescriptionOfExpectedVolatilityShareOptionsGranted", "presentation": [ "http://www.evogene.com/role/SIGNIFICANTACCOUNTINGJUDGMENTSESTIMATESANDASSUMPTIONSUSEDINTHEPREPARATIONOFTHEFINANCIALSTATEMENTSNarrativeDetails", "http://www.evogene.com/role/Share-BasedCompensationScheduleOfAssumptionsUsedToValueOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Expected volatility, share options granted", "terseLabel": "Expected volatility of the share prices" } }, "en": { "role": { "documentation": "The expected volatility of the share price used to calculate the fair value of the share options granted. Expected volatility is a measure of the amount by which a price is expected to fluctuate during a period. The measure of volatility used in option pricing models is the annualised standard deviation of the continuously compounded rates of return on the share over a period of time." } } }, "auth_ref": [ "r173" ] }, "ifrs-full_DescriptionOfGrowthRateUsedToExtrapolateCashFlowProjections": { "xbrltype": "percentItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DescriptionOfGrowthRateUsedToExtrapolateCashFlowProjections", "presentation": [ "http://www.evogene.com/role/FinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Growth rate used to extrapolate cash flow projections", "verboseLabel": "Cash flow projections of long-term growth rates" } }, "en": { "role": { "documentation": "The growth rate used to extrapolate cash flow projections beyond the period covered by the most recent budgets/forecasts for a cash-generating unit (group of units). [Refer: Total for all cash-generating units [member]]" } } }, "auth_ref": [ "r88", "r89" ] }, "ifrs-full_DescriptionOfOptionLifeShareOptionsGranted": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DescriptionOfOptionLifeShareOptionsGranted", "presentation": [ "http://www.evogene.com/role/Share-BasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Maturity for share option and incentive plans" } }, "en": { "role": { "documentation": "The option life of share options granted." } } }, "auth_ref": [ "r173" ] }, "ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted": { "xbrltype": "percentItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DescriptionOfRiskFreeInterestRateShareOptionsGranted", "presentation": [ "http://www.evogene.com/role/SIGNIFICANTACCOUNTINGJUDGMENTSESTIMATESANDASSUMPTIONSUSEDINTHEPREPARATIONOFTHEFINANCIALSTATEMENTSNarrativeDetails", "http://www.evogene.com/role/Share-BasedCompensationScheduleOfAssumptionsUsedToValueOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Risk free interest rate, share options granted", "terseLabel": "Risk-free interest rate" } }, "en": { "role": { "documentation": "The implied yield currently available on zero-coupon government issues of the country in whose currency the exercise price for share options granted is expressed, with a remaining term equal to the expected term of the option being valued (based on the option's remaining contractual life and taking into account the effects of expected early exercise). [Refer: Government [member]]" } } }, "auth_ref": [ "r173" ] }, "ifrs-full_DescriptionOfUsefulLifeIntangibleAssetsOtherThanGoodwill": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DescriptionOfUsefulLifeIntangibleAssetsOtherThanGoodwill", "presentation": [ "http://www.evogene.com/role/SignificantAccountingPoliciesScheduleOfIntangibleAssetsPurchasedDetails" ], "lang": { "en-us": { "role": { "label": "Description of useful life, intangible assets other than goodwill", "verboseLabel": "Intangible assets" } }, "en": { "role": { "documentation": "Description of useful life used for intangible assets other than goodwill. [Refer: Intangible assets other than goodwill]" } } }, "auth_ref": [ "r92" ] }, "evgn_DescriptionOfUsefulLifeOrLeasePeriodOfRightOfUseAssets": { "xbrltype": "stringItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "DescriptionOfUsefulLifeOrLeasePeriodOfRightOfUseAssets", "presentation": [ "http://www.evogene.com/role/SignificantAccountingPoliciesScheduleOfUsefulLifeOfRightOfUseAssetsDetails" ], "lang": { "en-us": { "role": { "documentation": "Description of useful life or lease period of right of use assets.", "label": "Description Of Useful Life Or Lease Period Of Right Of Use Assets", "verboseLabel": "Years" } } }, "auth_ref": [] }, "ifrs-full_DescriptionOfUsefulLifePropertyPlantAndEquipment": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DescriptionOfUsefulLifePropertyPlantAndEquipment", "presentation": [ "http://www.evogene.com/role/SignificantAccountingPoliciesScheduleOfDepreciationCalculatedUsingStraight-lineMethodDetails" ], "lang": { "en-us": { "role": { "label": "Depreciation percentage on straight-line basis over the useful life of the assets (in %)" } }, "en": { "role": { "documentation": "Description of useful life used for property, plant and equipment. [Refer: Property, plant and equipment]" } } }, "auth_ref": [ "r47" ] }, "ifrs-full_DilutedEarningsLossPerShare": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DilutedEarningsLossPerShare", "presentation": [ "http://www.evogene.com/role/ConsolidatedStatementsOfProfitOrLoss" ], "lang": { "en-us": { "role": { "label": "Diluted earnings (loss) per share", "terseLabel": "Diluted loss per share, attributable to equity holders of the Company" } }, "en": { "role": { "documentation": "The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator), divided by the weighted average number of ordinary shares outstanding during the period (the denominator), both adjusted for the effects of all dilutive potential ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]" } } }, "auth_ref": [ "r82", "r83" ] }, "ifrs-full_DilutiveEffectOfConvertibleInstrumentsOnNumberOfOrdinaryShares": { "xbrltype": "sharesItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DilutiveEffectOfConvertibleInstrumentsOnNumberOfOrdinaryShares", "presentation": [ "http://www.evogene.com/role/LossPerShareScheduleOfBasicLossPerShareDetails" ], "lang": { "en-us": { "role": { "label": "Convertible instruments of number of ordinary shares" } }, "en": { "role": { "documentation": "The potential dilutive effect on the weighted average number of ordinary shares that relate to the assumed conversion of the entity's convertible instruments." } } }, "auth_ref": [ "r376" ] }, "ifrs-full_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares": { "xbrltype": "sharesItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares", "presentation": [ "http://www.evogene.com/role/LossPerShareScheduleOfBasicLossPerShareDetails" ], "lang": { "en-us": { "role": { "label": "Number of ordinary shares" } }, "en": { "role": { "documentation": "The potential dilutive effect on the weighted average number of ordinary shares that relate to the assumed exercise of the entity's share options." } } }, "auth_ref": [ "r376" ] }, "evgn_DirectorsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "DirectorsMember", "presentation": [ "http://www.evogene.com/role/BalancesAndTransactionsWithKeyOfficersAndCertainShareholdersScheduleOfBenefitsToDirectorsDetails" ], "lang": { "en-us": { "role": { "documentation": "Directors [Member]", "label": "Directors Member", "verboseLabel": "Director [Member]" } } }, "auth_ref": [] }, "ifrs-full_DirectorsRemunerationExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DirectorsRemunerationExpense", "crdr": "debit", "calculation": { "http://www.evogene.com/role/BalancesAndTransactionsWithKeyOfficersAndCertainShareholdersScheduleOfBenefitsToDirectorsDetails": { "parentTag": "evgn_AmountOfBenefitsToDirectors", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://www.evogene.com/role/BalancesAndTransactionsWithKeyOfficersAndCertainShareholdersScheduleOfBenefitsToDirectorsDetails" ], "lang": { "en-us": { "role": { "label": "Compensation to directors not employed by the Company or on its behalf" } }, "en": { "role": { "documentation": "The amount of remuneration paid or payable to the entity's directors." } } }, "auth_ref": [ "r365" ] }, "ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DisclosureOfAccountingJudgementsAndEstimatesExplanatory", "presentation": [ "http://www.evogene.com/role/SignificantAccountingJudgmentsEstimatesAndAssupmtionsUsedInPreparationOfFinancialStatements" ], "lang": { "en-us": { "role": { "label": "SIGNIFICANT ACCOUNTING JUDGMENTS, ESTIMATES AND ASSUMPTIONS USED IN THE PREPARATION OF THE FINANCIAL STATEMENTS", "verboseLabel": "SIGNIFICANT ACCOUNTING JUDGMENTS, ESTIMATES AND ASSUMPTIONS USED IN THE PREPARATION OF THE FINANCIAL STATEMENTS" } }, "en": { "role": { "documentation": "The disclosure of judgements that management has made in the process of applying the entity's accounting policies that have the most significant effect on amounts recognised in the financial statements along with information about the assumptions that the entity makes about the future, and other major sources of estimation uncertainty at the end of the reporting period, that have a significant risk of resulting in a material adjustment to the carrying amounts of assets and liabilities within the next year. [Refer: Carrying amount [member]]" } } }, "auth_ref": [ "r363" ] }, "ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesExplanatory", "presentation": [ "http://www.evogene.com/role/BalancesAndTransactionsWithExecutiveOfficersAndCertainShareholdersTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Benefits to Key Executive Personnel" } }, "en": { "role": { "documentation": "The disclosure of amounts incurred by the entity for provision of key management personnel services that are provided by separate management entities. [Refer: Key management personnel of entity or parent [member]; Separate management entities [domain]]" } } }, "auth_ref": [ "r70" ] }, "ifrs-full_DisclosureOfBusinessCombinationsLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DisclosureOfBusinessCombinationsLineItems", "presentation": [ "http://www.evogene.com/role/GeneralNarrativeDetails", "http://www.evogene.com/role/ShareholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of detailed information about business combination [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfBusinessCombinationsTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DisclosureOfBusinessCombinationsTable", "presentation": [ "http://www.evogene.com/role/GeneralNarrativeDetails", "http://www.evogene.com/role/ShareholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of detailed information about business combination [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to details of business combinations." } } }, "auth_ref": [ "r178" ] }, "ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DisclosureOfCashAndCashEquivalentsExplanatory", "presentation": [ "http://www.evogene.com/role/CashAndCashEquivalents" ], "lang": { "en-us": { "role": { "label": "CASH AND CASH EQUIVALENTS" } }, "en": { "role": { "documentation": "The disclosure of cash and cash equivalents. [Refer: Cash and cash equivalents]" } } }, "auth_ref": [ "r363" ] }, "ifrs-full_DisclosureOfChangesInAccountingPoliciesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DisclosureOfChangesInAccountingPoliciesExplanatory", "presentation": [ "http://www.evogene.com/role/SignificantAccountingPolicies" ], "lang": { "en-us": { "role": { "label": "Changes in accounting policies", "terseLabel": "SIGNIFICANT ACCOUNTING POLICIES" } }, "en": { "role": { "documentation": "The disclosure of changes made to accounting policies by the entity." } } }, "auth_ref": [ "r363" ] }, "ifrs-full_DisclosureOfClassesOfShareCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DisclosureOfClassesOfShareCapitalAbstract", "lang": { "en-us": { "role": { "label": "Disclosure of classes of share capital [Abstract]" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DisclosureOfClassesOfShareCapitalExplanatory", "presentation": [ "http://www.evogene.com/role/ShareholdersEquityTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Share Capital" } }, "en": { "role": { "documentation": "The disclosure of classes of share capital. [Refer: Classes of share capital [domain]]" } } }, "auth_ref": [ "r28" ] }, "ifrs-full_DisclosureOfClassesOfShareCapitalLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DisclosureOfClassesOfShareCapitalLineItems", "presentation": [ "http://www.evogene.com/role/ShareholdersEquityScheduleOfChangesInShareCapitalDetails", "http://www.evogene.com/role/ShareholdersEquityScheduleOfCompositionNon-controllingInterestsDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of classes of share capital [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfClassesOfShareCapitalTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DisclosureOfClassesOfShareCapitalTable", "presentation": [ "http://www.evogene.com/role/ShareholdersEquityScheduleOfChangesInShareCapitalDetails", "http://www.evogene.com/role/ShareholdersEquityScheduleOfCompositionNon-controllingInterestsDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of classes of share capital [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to classes of share capital." } } }, "auth_ref": [ "r28" ] }, "evgn_DisclosureOfCollaborationAgreementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "DisclosureOfCollaborationAgreementAbstract", "lang": { "en-us": { "role": { "documentation": "Disclosure of collaboration agreement [Abstract]", "label": "Disclosure Of Collaboration Agreement [Abstract]", "verboseLabel": "Collaboration And Research Agreements Narrative" } } }, "auth_ref": [] }, "evgn_DisclosureOfCollaborationAgreementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "DisclosureOfCollaborationAgreementLineItems", "presentation": [ "http://www.evogene.com/role/CollaborationAndResearchAgreementsNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.", "label": "Disclosure Of Collaboration Agreement [Line Items]" } } }, "auth_ref": [] }, "evgn_DisclosureOfCollaborationAgreementTable": { "xbrltype": "stringItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "DisclosureOfCollaborationAgreementTable", "presentation": [ "http://www.evogene.com/role/CollaborationAndResearchAgreementsNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Schedule of collaboration agreement.", "label": "Disclosure Of Collaboration Agreement [Table]" } } }, "auth_ref": [] }, "evgn_DisclosureOfCollaborationAgreementsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "DisclosureOfCollaborationAgreementsExplanatory", "presentation": [ "http://www.evogene.com/role/CollaborationAndResearchAgreements" ], "lang": { "en-us": { "role": { "documentation": "The disclosure provides information regarding major collaboration agreements of the entity.", "label": "Disclosure Of Collaboration Agreements Explanatory", "verboseLabel": "COLLABORATION, RESEARCH AND DISTRIBUTION AND SALES AGREEMENTS" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory", "presentation": [ "http://www.evogene.com/role/CommitmentsAndContingentLiabilities" ], "lang": { "en-us": { "role": { "label": "COMMITMENTS AND CONTINGENT LIABILITIES" } }, "en": { "role": { "documentation": "The disclosure of commitments and contingent liabilities. [Refer: Classes of contingent liabilities [domain]]" } } }, "auth_ref": [ "r363" ] }, "ifrs-full_DisclosureOfContingentLiabilitiesLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DisclosureOfContingentLiabilitiesLineItems", "presentation": [ "http://www.evogene.com/role/COMMITMENTSANDCONTINGENTLIABILITIESNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of contingent liabilities [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfContingentLiabilitiesTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DisclosureOfContingentLiabilitiesTable", "presentation": [ "http://www.evogene.com/role/COMMITMENTSANDCONTINGENTLIABILITIESNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of contingent liabilities [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to contingent liabilities." } } }, "auth_ref": [ "r90" ] }, "ifrs-full_DisclosureOfDebtSecuritiesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DisclosureOfDebtSecuritiesExplanatory", "presentation": [ "http://www.evogene.com/role/ConvertibleSAFE" ], "lang": { "en-us": { "role": { "label": "Disclosure of debt instruments [text block]", "terseLabel": "CONVERTIBLE SAFE", "verboseLabel": "Convertible SAFE" } }, "en": { "role": { "documentation": "The disclosure of debt instruments. [Refer: Debt instruments issued; Debt instruments held]" } } }, "auth_ref": [ "r363" ] }, "ifrs-full_DisclosureOfDefinedBenefitPlansAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DisclosureOfDefinedBenefitPlansAbstract", "lang": { "en-us": { "role": { "label": "Disclosure of defined benefit plans [Abstract]" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfDefinedBenefitPlansExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DisclosureOfDefinedBenefitPlansExplanatory", "presentation": [ "http://www.evogene.com/role/SeverancePayLiabilityNetTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Defined Contribution Plans" } }, "en": { "role": { "documentation": "The disclosure of defined benefit plans. [Refer: Defined benefit plans [domain]]" } } }, "auth_ref": [ "r56" ] }, "evgn_DisclosureOfDetailedInformationAboutBalancesWithRelatedPartiesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "DisclosureOfDetailedInformationAboutBalancesWithRelatedPartiesExplanatory", "presentation": [ "http://www.evogene.com/role/BalancesAndTransactionsWithExecutiveOfficersAndCertainShareholdersTables" ], "lang": { "en-us": { "role": { "documentation": "The disclosure of detailed information about balances with related parties.", "label": "Disclosure Of Detailed Information About Balances With Related Parties Explanatory", "verboseLabel": "Schedule of Balances with Related Parties" } } }, "auth_ref": [] }, "evgn_DisclosureOfDetailedInformationAboutBenefitsToRelatedPartiesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "DisclosureOfDetailedInformationAboutBenefitsToRelatedPartiesExplanatory", "presentation": [ "http://www.evogene.com/role/BalancesAndTransactionsWithExecutiveOfficersAndCertainShareholdersTables" ], "lang": { "en-us": { "role": { "documentation": "The disclosure of detailed information about benefits to related parties.", "label": "Disclosure Of Detailed Information About Benefits To Related Parties Explanatory", "verboseLabel": "Schedule of Benefits to Related Parties" } } }, "auth_ref": [] }, "evgn_DisclosureOfDetailedInformationAboutCashAndCashEquivalentsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "DisclosureOfDetailedInformationAboutCashAndCashEquivalentsExplanatory", "presentation": [ "http://www.evogene.com/role/CashAndCashEquivalentsTables" ], "lang": { "en-us": { "role": { "documentation": "The disclosure of detailed information about cash and cash equivalents.", "label": "Disclosure Of Detailed Information About Cash And Cash Equivalents Explanatory", "verboseLabel": "Schedule of Cash and Cash Equivalents" } } }, "auth_ref": [] }, "evgn_DisclosureOfDetailedInformationAboutChangesInShareCapitalExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "DisclosureOfDetailedInformationAboutChangesInShareCapitalExplanatory", "presentation": [ "http://www.evogene.com/role/ShareholdersEquityTables" ], "lang": { "en-us": { "role": { "documentation": "The disclosure of detailed information about changes in share capital.", "label": "Disclosure Of Detailed Information About Changes In Share Capital Explanatory", "verboseLabel": "Schedule of Changes in Share Capital" } } }, "auth_ref": [] }, "evgn_DisclosureOfDetailedInformationAboutIncomeAndExpensesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "DisclosureOfDetailedInformationAboutIncomeAndExpensesExplanatory", "presentation": [ "http://www.evogene.com/role/StatementsOfComprehensiveLoss-AdditionalInformationTables" ], "lang": { "en-us": { "role": { "documentation": "The disclosure of detailed information about income and expense.", "label": "Disclosure Of Detailed Information About Income And Expenses Explanatory", "verboseLabel": "Schedule of Income and Expenses" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory", "presentation": [ "http://www.evogene.com/role/IntangibleAssetsNetTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Intangible Assets" } }, "en": { "role": { "documentation": "The disclosure of detailed information about intangible assets. [Refer: Intangible assets other than goodwill]" } } }, "auth_ref": [ "r97" ] }, "evgn_DisclosureOfDetailedInformationAboutLiabilitiesInRespectOfGovernmentGrantsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "DisclosureOfDetailedInformationAboutLiabilitiesInRespectOfGovernmentGrantsExplanatory", "presentation": [ "http://www.evogene.com/role/LiabilitiesInRespectOfGovernmentGrantsTables" ], "lang": { "en-us": { "role": { "documentation": "The disclosure of detailed information about liabilities in respect of Government grants.", "label": "Disclosure Of Detailed Information About Liabilities In Respect Of Government Grants Explanatory", "verboseLabel": "Schedule of Liabilities in Respect of Government Grants" } } }, "auth_ref": [] }, "evgn_DisclosureOfDetailedInformationAboutOtherRecevablesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "DisclosureOfDetailedInformationAboutOtherRecevablesExplanatory", "presentation": [ "http://www.evogene.com/role/OtherReceivablesAndPrepaidExpensesTables" ], "lang": { "en-us": { "role": { "documentation": "The disclosure of detailed information about other recevables and prepaid expenses.", "label": "Disclosure Of Detailed Information About Other Recevables Explanatory", "verboseLabel": "Schedule of Other Receivables and Prepaid Expenses" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory", "presentation": [ "http://www.evogene.com/role/PropertyPlantAndEquipmentNetTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Property, Plant and Equipment, Net" } }, "en": { "role": { "documentation": "The disclosure of detailed information about property, plant and equipment. [Refer: Property, plant and equipment]" } } }, "auth_ref": [ "r52" ] }, "evgn_DisclosureOfDetailedInformationAboutUsefulLifeOfPropertyPlantAndEquipmentExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "DisclosureOfDetailedInformationAboutUsefulLifeOfPropertyPlantAndEquipmentExplanatory", "presentation": [ "http://www.evogene.com/role/SignificantAccountingPoliciesTables" ], "lang": { "en-us": { "role": { "documentation": "The disclosure of detailed information about useful lives for property, plant and equipment.", "label": "Disclosure Of Detailed Information About Useful Life Of Property Plant And Equipment Explanatory", "verboseLabel": "Schedule of Depreciation Calculated Using Straight-Line Method" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems", "presentation": [ "http://www.evogene.com/role/OperatingSegmentsScheduleOfPercentageOfNon-currentAssetsDetails", "http://www.evogene.com/role/OperatingSegmentsScheduleOfRevenuesAndOperatingLossBySegmentsDetails", "http://www.evogene.com/role/OperatingSegmentsScheduleOfRevenuesBasedOnCustomersDetails", "http://www.evogene.com/role/ScheduleOfTimingOfRevenuesByTimingOfRevenueRecognition" ], "lang": { "en-us": { "role": { "label": "Disclosure of disaggregation of revenue from contracts with customers [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable", "presentation": [ "http://www.evogene.com/role/OperatingSegmentsScheduleOfPercentageOfNon-currentAssetsDetails", "http://www.evogene.com/role/OperatingSegmentsScheduleOfRevenuesAndOperatingLossBySegmentsDetails", "http://www.evogene.com/role/OperatingSegmentsScheduleOfRevenuesBasedOnCustomersDetails", "http://www.evogene.com/role/ScheduleOfTimingOfRevenuesByTimingOfRevenueRecognition" ], "lang": { "en-us": { "role": { "label": "Disclosure of disaggregation of revenue from contracts with customers [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to the disaggregation of revenue from contracts with customers." } } }, "auth_ref": [ "r142" ] }, "ifrs-full_DisclosureOfEarningsPerShareExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DisclosureOfEarningsPerShareExplanatory", "presentation": [ "http://www.evogene.com/role/LossPerShare" ], "lang": { "en-us": { "role": { "label": "LOSS PER SHARE" } }, "en": { "role": { "documentation": "The entire disclosure for earnings per share." } } }, "auth_ref": [ "r86" ] }, "ifrs-full_DisclosureOfEmployeeBenefitsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DisclosureOfEmployeeBenefitsExplanatory", "presentation": [ "http://www.evogene.com/role/SeverancePayLiabilityNet" ], "lang": { "en-us": { "role": { "label": "SEVERANCE PAY LIABILITY, NET", "terseLabel": "SEVERANCE PAY LIABILITY" } }, "en": { "role": { "documentation": "The entire disclosure for employee benefits." } } }, "auth_ref": [ "r59" ] }, "ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DisclosureOfEntitysReportableSegmentsExplanatory", "presentation": [ "http://www.evogene.com/role/OperatingSegments" ], "lang": { "en-us": { "role": { "label": "OPERATING SEGMENTS" } }, "en": { "role": { "documentation": "The entire disclosure for operating segments." } } }, "auth_ref": [ "r212" ] }, "ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DisclosureOfEventsAfterReportingPeriodExplanatory", "presentation": [ "http://www.evogene.com/role/SUBSEQUENTEVENTS" ], "lang": { "en-us": { "role": { "label": "Disclosure of events after reporting period [text block]", "verboseLabel": "SUBSEQUENT EVENTS" } }, "en": { "role": { "documentation": "The entire disclosure for events after the reporting period." } } }, "auth_ref": [ "r40" ] }, "ifrs-full_DisclosureOfFairValueMeasurementOfAssetsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DisclosureOfFairValueMeasurementOfAssetsExplanatory", "presentation": [ "http://www.evogene.com/role/FinancialInstrumentsTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Classification of Financial Instruments by Fair Value Hierarchy" } }, "en": { "role": { "documentation": "The disclosure of the fair value measurement of assets." } } }, "auth_ref": [ "r140" ] }, "ifrs-full_DisclosureOfFinancialInstrumentsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DisclosureOfFinancialInstrumentsAbstract", "lang": { "en-us": { "role": { "label": "Disclosure of detailed information about financial instruments [abstract]" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfFinancialInstrumentsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DisclosureOfFinancialInstrumentsExplanatory", "presentation": [ "http://www.evogene.com/role/FinancialInstruments" ], "lang": { "en-us": { "role": { "label": "FINANCIAL INSTRUMENTS" } }, "en": { "role": { "documentation": "The entire disclosure for financial instruments." } } }, "auth_ref": [ "r196" ] }, "ifrs-full_DisclosureOfFinancialInstrumentsLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DisclosureOfFinancialInstrumentsLineItems", "presentation": [ "http://www.evogene.com/role/FINANCIALINSTRUMENTSScheduleOfFairValueOfFinancialLiabilitiesDetails", "http://www.evogene.com/role/FinancialInstrumentsNarrativeDetails", "http://www.evogene.com/role/FinancialInstrumentsScheduleOfCompanysFinancialLiabilitiesDetails", "http://www.evogene.com/role/FinancialInstrumentsScheduleOfSensitivityTestsRelatingToChangesInMarketFactorsDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of detailed information about financial instruments [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfFinancialInstrumentsTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DisclosureOfFinancialInstrumentsTable", "presentation": [ "http://www.evogene.com/role/FINANCIALINSTRUMENTSScheduleOfFairValueOfFinancialLiabilitiesDetails", "http://www.evogene.com/role/FinancialInstrumentsNarrativeDetails", "http://www.evogene.com/role/FinancialInstrumentsScheduleOfCompanysFinancialLiabilitiesDetails", "http://www.evogene.com/role/FinancialInstrumentsScheduleOfSensitivityTestsRelatingToChangesInMarketFactorsDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of detailed information about financial instruments [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to details of financial instruments." } } }, "auth_ref": [ "r186", "r189", "r195" ] }, "ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory", "presentation": [ "http://www.evogene.com/role/General" ], "lang": { "en-us": { "role": { "label": "GENERAL" } }, "en": { "role": { "documentation": "The entire disclosure for general information about financial statements." } } }, "auth_ref": [ "r5" ] }, "evgn_DisclosureOfGeneralInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "DisclosureOfGeneralInformationAbstract", "lang": { "en-us": { "role": { "label": "Disclosure Of General Information [Abstract]", "verboseLabel": "Disclosure of general [Abstract]" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfGeographicalAreasExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DisclosureOfGeographicalAreasExplanatory", "presentation": [ "http://www.evogene.com/role/OperatingSegmentsTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Geographical Information" } }, "en": { "role": { "documentation": "The disclosure of geographical information." } } }, "auth_ref": [ "r210" ] }, "ifrs-full_DisclosureOfGovernmentGrantsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DisclosureOfGovernmentGrantsExplanatory", "presentation": [ "http://www.evogene.com/role/LiabilitiesInRespectOfGovernmentGrants" ], "lang": { "en-us": { "role": { "label": "LIABILITIES IN RESPECT OF GOVERNMENT GRANTS" } }, "en": { "role": { "documentation": "The entire disclosure for government grants." } } }, "auth_ref": [ "r64" ] }, "ifrs-full_DisclosureOfIncomeTaxExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DisclosureOfIncomeTaxExplanatory", "presentation": [ "http://www.evogene.com/role/TaxesOnIncome" ], "lang": { "en-us": { "role": { "label": "TAXES ON INCOME" } }, "en": { "role": { "documentation": "The entire disclosure for income taxes." } } }, "auth_ref": [ "r46" ] }, "evgn_DisclosureOfIncomeTaxesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "DisclosureOfIncomeTaxesAbstract", "lang": { "en-us": { "role": { "documentation": "Disclosure of taxes on income [Abstract].", "label": "Disclosure Of Income Taxes [Abstract]", "verboseLabel": "Disclosure of taxes on income [Abstract]" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory", "presentation": [ "http://www.evogene.com/role/Share-BasedCompensationTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Assumptions Used to Value Options" } }, "en": { "role": { "documentation": "The disclosure of information about indirect, by reference to the fair value of the equity instruments granted, measurement of the fair value of goods or services received as consideration for the entity's share options." } } }, "auth_ref": [ "r174" ] }, "ifrs-full_DisclosureOfIntangibleAssetsAndGoodwillExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DisclosureOfIntangibleAssetsAndGoodwillExplanatory", "presentation": [ "http://www.evogene.com/role/SignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Intangible assets" } }, "en": { "role": { "documentation": "The disclosure of intangible assets and goodwill. [Refer: Intangible assets and goodwill]" } } }, "auth_ref": [ "r363" ] }, "ifrs-full_DisclosureOfIntangibleAssetsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DisclosureOfIntangibleAssetsExplanatory", "presentation": [ "http://www.evogene.com/role/IntangibleAssetsNet" ], "lang": { "en-us": { "role": { "label": "INTANGIBLE ASSETS, NET" } }, "en": { "role": { "documentation": "The entire disclosure for intangible assets." } } }, "auth_ref": [ "r99" ] }, "ifrs-full_DisclosureOfIntangibleAssetsLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DisclosureOfIntangibleAssetsLineItems", "presentation": [ "http://www.evogene.com/role/IntangibleAssetsNetScheduleOfIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of detailed information about intangible assets [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfIntangibleAssetsTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DisclosureOfIntangibleAssetsTable", "presentation": [ "http://www.evogene.com/role/IntangibleAssetsNetScheduleOfIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of detailed information about intangible assets [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to details of intangible assets." } } }, "auth_ref": [ "r97" ] }, "ifrs-full_DisclosureOfInventoriesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DisclosureOfInventoriesExplanatory", "presentation": [ "http://www.evogene.com/role/SignificantAccountingPoliciesTables" ], "lang": { "en-us": { "role": { "label": "Disclosure of inventories [text block]", "terseLabel": "Schedule of summarizes information about the inventory" } }, "en": { "role": { "documentation": "The entire disclosure for inventories." } } }, "auth_ref": [ "r62" ] }, "ifrs-full_DisclosureOfInvestmentPropertyExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DisclosureOfInvestmentPropertyExplanatory", "presentation": [ "http://www.evogene.com/role/Long-termInvestment" ], "lang": { "en-us": { "role": { "label": "LONG-TERM INVESTMENT" } }, "en": { "role": { "documentation": "The entire disclosure for investment property." } } }, "auth_ref": [ "r103" ] }, "evgn_DisclosureOfLeaseExpensesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "DisclosureOfLeaseExpensesExplanatory", "presentation": [ "http://www.evogene.com/role/LeasesTables" ], "lang": { "en-us": { "role": { "documentation": "The disclosure of quantitative information about lease expenses.", "label": "Disclosure Of Lease Expenses Explanatory", "verboseLabel": "Schedule of Lease Expenses" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfLeasesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DisclosureOfLeasesExplanatory", "presentation": [ "http://www.evogene.com/role/Leases" ], "lang": { "en-us": { "role": { "label": "LEASES" } }, "en": { "role": { "documentation": "The entire disclosure for leases." } } }, "auth_ref": [ "r156", "r157" ] }, "evgn_DisclosureOfLiabilitiesInRespectOfGovernmentGrantAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "DisclosureOfLiabilitiesInRespectOfGovernmentGrantAbstract", "lang": { "en-us": { "role": { "documentation": "Disclosure of Liabilities in Respect of Government Grant [Abstract]", "label": "Disclosure Of Liabilities In Respect Of Government Grant [Abstract]", "terseLabel": "Liabilities In Respect Of Government Grants Schedule Of Liabilities In Respect Of Government Grants", "verboseLabel": "Liabilities In Respect Of Government Grants" } } }, "auth_ref": [] }, "evgn_DisclosureOfLongTermInvestmentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "DisclosureOfLongTermInvestmentsAbstract", "lang": { "en-us": { "role": { "label": "Disclosure Of Long Term Investments [Abstract]", "verboseLabel": "Disclosure of long term investment [Abstract]" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfMajorCustomersLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DisclosureOfMajorCustomersLineItems", "presentation": [ "http://www.evogene.com/role/OperatingSegmentsScheduleOfRevenuesFromMajorCustomersDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of major customers [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfMajorCustomersTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DisclosureOfMajorCustomersTable", "presentation": [ "http://www.evogene.com/role/OperatingSegmentsScheduleOfRevenuesFromMajorCustomersDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of major customers [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to the entity's major customers." } } }, "auth_ref": [ "r211" ] }, "ifrs-full_DisclosureOfMaturityAnalysisOfFinanceLeasePaymentsReceivableExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DisclosureOfMaturityAnalysisOfFinanceLeasePaymentsReceivableExplanatory", "presentation": [ "http://www.evogene.com/role/LeasesTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Future Minimum Lease Payments Under Non-Cancelable Leases" } }, "en": { "role": { "documentation": "The disclosure of a maturity analysis of finance lease payments receivable. Finance lease is a lease that transfers substantially all the risks and rewards incidental to ownership of an underlying asset." } } }, "auth_ref": [ "r153" ] }, "ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DisclosureOfNetDefinedBenefitLiabilityAssetExplanatory", "presentation": [ "http://www.evogene.com/role/LeasesTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Lease Liability" } }, "en": { "role": { "documentation": "The disclosure of a net defined benefit liability (asset). [Refer: Net defined benefit liability (asset)]" } } }, "auth_ref": [ "r57" ] }, "evgn_DisclosureOfNewStandardsInPeriodPriorToTheirAdoptionExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "DisclosureOfNewStandardsInPeriodPriorToTheirAdoptionExplanatory", "presentation": [ "http://www.evogene.com/role/DisclosureOfNewStandardsInPeriodPriorToTheirAdoption" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of all the IFRS standards that have been issued but are not yet effective up to the date of issuance of an entity's financial statements. An entity will adopt these standards if applicable, when they become effective. This disclosure includes also known or reasonably estimable information to enable users to assess the possible impact of the application of such IFRSs on an entity’s financial statements.", "label": "Disclosure Of New Standards In Period Prior To Their Adoption Explanatory", "verboseLabel": "DISCLOSURE OF NEW STANDARDS IN THE PERIOD PRIOR TO THEIR ADOPTION" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract", "lang": { "en-us": { "role": { "label": "Disclosure of non-adjusting events after reporting period [abstract]" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems", "presentation": [ "http://www.evogene.com/role/SUBSEQUENTEVENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of non-adjusting events after reporting period [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DisclosureOfNonadjustingEventsAfterReportingPeriodTable", "presentation": [ "http://www.evogene.com/role/SUBSEQUENTEVENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of non-adjusting events after reporting period [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to non-adjusting events after the reporting period." } } }, "auth_ref": [ "r39" ] }, "ifrs-full_DisclosureOfNoncontrollingInterestsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DisclosureOfNoncontrollingInterestsExplanatory", "presentation": [ "http://www.evogene.com/role/ShareholdersEquityTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Composition Non-Controlling Interests" } }, "en": { "role": { "documentation": "The disclosure of non-controlling interests. [Refer: Non-controlling interests]" } } }, "auth_ref": [ "r363" ] }, "ifrs-full_DisclosureOfNoncurrentAssetsHeldForSaleAndDiscontinuedOperationsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DisclosureOfNoncurrentAssetsHeldForSaleAndDiscontinuedOperationsExplanatory", "presentation": [ "http://www.evogene.com/role/OperatingSegmentsTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Percentage of Non-Current Assets" } }, "en": { "role": { "documentation": "The entire disclosure for non-current assets held for sale and discontinued operations." } } }, "auth_ref": [ "r183" ] }, "ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory", "presentation": [ "http://www.evogene.com/role/Share-BasedCompensationTables" ], "lang": { "en-us": { "role": { "label": "Disclosure of number and weighted average exercise prices of other equity instruments [text block]", "verboseLabel": "Schedule of Number of Restricted Stock Units (RSU)" } }, "en": { "role": { "documentation": "The disclosure of the number and weighted average exercise prices of other equity instruments (ie other than share options)." } } }, "auth_ref": [ "r388" ] }, "ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory", "presentation": [ "http://www.evogene.com/role/Share-BasedCompensationTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Number of Share Options" } }, "en": { "role": { "documentation": "The disclosure of the number and weighted average exercise prices of share options. [Refer: Weighted average [member]]" } } }, "auth_ref": [ "r169" ] }, "ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory", "presentation": [ "http://www.evogene.com/role/Share-BasedCompensationTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Share Options Outstanding" } }, "en": { "role": { "documentation": "The disclosure of the number and weighted average remaining contractual life of outstanding share options. [Refer: Weighted average [member]]" } } }, "auth_ref": [ "r171" ] }, "ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems", "presentation": [ "http://www.evogene.com/role/Share-BasedCompensationScheduleOfShareOptionsOutstandingDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable", "presentation": [ "http://www.evogene.com/role/Share-BasedCompensationScheduleOfShareOptionsOutstandingDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of number and weighted average remaining contractual life of outstanding share options [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to the number and weighted average remaining contractual life of outstanding share options." } } }, "auth_ref": [ "r171" ] }, "ifrs-full_DisclosureOfOperatingSegmentsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DisclosureOfOperatingSegmentsAbstract", "lang": { "en-us": { "role": { "label": "Disclosure of operating segments [Abstract]" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfOperatingSegmentsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DisclosureOfOperatingSegmentsExplanatory", "presentation": [ "http://www.evogene.com/role/OperatingSegmentsTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Revenues and Operating Loss by Segments" } }, "en": { "role": { "documentation": "The disclosure of operating segments. [Refer: Operating segments [member]]" } } }, "auth_ref": [ "r200" ] }, "evgn_DisclosureOfOtherAccountsReceivablesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "DisclosureOfOtherAccountsReceivablesAbstract", "lang": { "en-us": { "role": { "documentation": "Disclosure of other receivables [Abstract]", "label": "Disclosure Of Other Accounts Receivables [Abstract]", "terseLabel": "Other Receivables And Prepaid Expenses Schedule Of Other Receivables And Prepaid Expenses", "verboseLabel": "Other Receivables And Prepaid Expenses" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DisclosureOfPropertyPlantAndEquipmentAbstract", "lang": { "en-us": { "role": { "label": "Disclosure of detailed information about property, plant and equipment [abstract]" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DisclosureOfPropertyPlantAndEquipmentExplanatory", "presentation": [ "http://www.evogene.com/role/PropertyPlantAndEquipmentNet" ], "lang": { "en-us": { "role": { "label": "PROPERTY, PLANT AND EQUIPMENT, NET" } }, "en": { "role": { "documentation": "The entire disclosure for property, plant and equipment." } } }, "auth_ref": [ "r55" ] }, "ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DisclosureOfPropertyPlantAndEquipmentLineItems", "presentation": [ "http://www.evogene.com/role/PropertyPlantAndEquipmentNetScheduleOfPropertyPlantEquipmentToAccumulatedDepreciationDetails", "http://www.evogene.com/role/SignificantAccountingPoliciesScheduleOfDepreciationCalculatedUsingStraight-lineMethodDetails", "http://www.evogene.com/role/SignificantAccountingPoliciesScheduleOfIntangibleAssetsPurchasedDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of detailed information about property, plant and equipment [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DisclosureOfPropertyPlantAndEquipmentTable", "presentation": [ "http://www.evogene.com/role/PropertyPlantAndEquipmentNetScheduleOfPropertyPlantEquipmentToAccumulatedDepreciationDetails", "http://www.evogene.com/role/SignificantAccountingPoliciesScheduleOfDepreciationCalculatedUsingStraight-lineMethodDetails", "http://www.evogene.com/role/SignificantAccountingPoliciesScheduleOfIntangibleAssetsPurchasedDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of detailed information about property, plant and equipment [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to details of property, plant and equipment." } } }, "auth_ref": [ "r52" ] }, "ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory", "presentation": [ "http://www.evogene.com/role/LeasesTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Right-of-Use Assets" } }, "en": { "role": { "documentation": "The disclosure of quantitative information about right-of-use assets. [Refer: Right-of-use assets]" } } }, "auth_ref": [ "r152" ] }, "ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems", "presentation": [ "http://www.evogene.com/role/SignificantAccountingPoliciesScheduleOfUsefulLifeOfRightOfUseAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of quantitative information about right-of-use assets [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable", "presentation": [ "http://www.evogene.com/role/SignificantAccountingPoliciesScheduleOfUsefulLifeOfRightOfUseAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of quantitative information about right-of-use assets [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to right-of-use assets." } } }, "auth_ref": [ "r152" ] }, "ifrs-full_DisclosureOfRelatedPartyExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DisclosureOfRelatedPartyExplanatory", "presentation": [ "http://www.evogene.com/role/BalancesAndTransactionsWithExecutiveOfficersAndCertainShareholders" ], "lang": { "en-us": { "role": { "label": "BALANCES AND TRANSACTIONS WITH EXECUTIVE OFFICERS AND CERTAIN SHAREHOLDERS" } }, "en": { "role": { "documentation": "The entire disclosure for related parties." } } }, "auth_ref": [ "r73" ] }, "evgn_DisclosureOfScheduleOfIntangibleAssetsPurchasedExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "DisclosureOfScheduleOfIntangibleAssetsPurchasedExplanatory", "presentation": [ "http://www.evogene.com/role/SignificantAccountingPoliciesTables" ], "lang": { "en-us": { "role": { "documentation": "The disclosure of Intangible Assets Purchased.", "label": "Disclosure Of Schedule Of Intangible Assets Purchased Explanatory", "verboseLabel": "Schedule of Intangible Assets Purchased" } } }, "auth_ref": [] }, "evgn_DisclosureOfScheduleOfTimingOfRevenuesByTimingOfRevenueRecognitionExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "DisclosureOfScheduleOfTimingOfRevenuesByTimingOfRevenueRecognitionExplanatory", "presentation": [ "http://www.evogene.com/role/SignificantAccountingPoliciesTables" ], "lang": { "en-us": { "role": { "documentation": "The disclosure of timing of revenues by timing of revenue recognition.", "label": "Disclosure Of Schedule Of Timing Of Revenues By Timing Of Revenue Recognition Explanatory", "verboseLabel": "Schedule of timing of revenues by timing of revenue recognition" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfSegmentsMajorCustomersExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DisclosureOfSegmentsMajorCustomersExplanatory", "presentation": [ "http://www.evogene.com/role/OperatingSegmentsTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Major Customers" } }, "en": { "role": { "documentation": "The disclosure of major customers." } } }, "auth_ref": [ "r211" ] }, "ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "presentation": [ "http://www.evogene.com/role/ShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "SHAREHOLDERS' EQUITY" } }, "en": { "role": { "documentation": "The entire disclosure for share capital, reserves and other equity interest." } } }, "auth_ref": [ "r29" ] }, "ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DisclosureOfSharebasedPaymentArrangementsExplanatory", "presentation": [ "http://www.evogene.com/role/Share-BasedCompensation" ], "lang": { "en-us": { "role": { "label": "SHARE- BASED COMPENSATION" } }, "en": { "role": { "documentation": "The entire disclosure for share-based payment arrangements." } } }, "auth_ref": [ "r162" ] }, "evgn_DisclosureOfSignificantAccountingJudgmentsEstimatesAndAssumptionsUsedInPreparationOfFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "DisclosureOfSignificantAccountingJudgmentsEstimatesAndAssumptionsUsedInPreparationOfFinancialStatementsAbstract", "lang": { "en-us": { "role": { "label": "Disclosure of significant accounting judgments, estimates and assumptions used in preparation of financial statements [Abstract]" } } }, "auth_ref": [] }, "evgn_DisclosureOfSignificantAccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "DisclosureOfSignificantAccountingPoliciesAbstract", "lang": { "en-us": { "role": { "label": "Disclosure Of Significant Accounting Policies [Abstract]", "verboseLabel": "Disclosure of significant accounting policies [Abstract]" } } }, "auth_ref": [] }, "evgn_DisclosureOfStatementsOfComprehensiveLossAdditionalInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "DisclosureOfStatementsOfComprehensiveLossAdditionalInformationAbstract", "lang": { "en-us": { "role": { "documentation": "Disclosure of Statements of Comprehensive Loss Additional Information [Abstract]", "label": "Disclosure Of Statements Of Comprehensive Loss Additional Information [Abstract]", "terseLabel": "Statements Of Comprehensive Loss - Additional Information Schedule Of Income And Expenses", "verboseLabel": "Statements Of Comprehensive Loss - Additional Information" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems", "presentation": [ "http://www.evogene.com/role/TaxesOnIncomeDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of temporary difference, unused tax losses and unused tax credits [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable", "presentation": [ "http://www.evogene.com/role/TaxesOnIncomeDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of temporary difference, unused tax losses and unused tax credits [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to temporary differences, unused tax losses and unused tax credits." } } }, "auth_ref": [ "r45" ] }, "ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract", "lang": { "en-us": { "role": { "label": "Disclosure of terms and conditions of share-based payment arrangement [Abstract]" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems", "presentation": [ "http://www.evogene.com/role/SHAREBASEDCOMPENSATIONScheduleOfRestrictedStockUnitsActivityDetails", "http://www.evogene.com/role/SIGNIFICANTACCOUNTINGJUDGMENTSESTIMATESANDASSUMPTIONSUSEDINTHEPREPARATIONOFTHEFINANCIALSTATEMENTSNarrativeDetails", "http://www.evogene.com/role/Share-BasedCompensationNarrativeDetails", "http://www.evogene.com/role/Share-BasedCompensationScheduleOfAssumptionsUsedToValueOptionsDetails", "http://www.evogene.com/role/Share-BasedCompensationScheduleOfSummarizedNumberOfShareOptionsDetails", "http://www.evogene.com/role/Share-BasedCompensationTables" ], "lang": { "en-us": { "role": { "label": "Disclosure of terms and conditions of share-based payment arrangement [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable", "presentation": [ "http://www.evogene.com/role/SHAREBASEDCOMPENSATIONScheduleOfRestrictedStockUnitsActivityDetails", "http://www.evogene.com/role/SIGNIFICANTACCOUNTINGJUDGMENTSESTIMATESANDASSUMPTIONSUSEDINTHEPREPARATIONOFTHEFINANCIALSTATEMENTSNarrativeDetails", "http://www.evogene.com/role/Share-BasedCompensationNarrativeDetails", "http://www.evogene.com/role/Share-BasedCompensationScheduleOfAssumptionsUsedToValueOptionsDetails", "http://www.evogene.com/role/Share-BasedCompensationScheduleOfSummarizedNumberOfShareOptionsDetails", "http://www.evogene.com/role/Share-BasedCompensationTables" ], "lang": { "en-us": { "role": { "label": "Disclosure of terms and conditions of share-based payment arrangement [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to terms and conditions of share-based payment arrangements." } } }, "auth_ref": [ "r172" ] }, "ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DisclosureOfTradeAndOtherReceivablesExplanatory", "presentation": [ "http://www.evogene.com/role/OtherReceivablesAndPrepaidExpenses" ], "lang": { "en-us": { "role": { "label": "OTHER RECEIVABLES AND PREPAID EXPENSES" } }, "en": { "role": { "documentation": "The disclosure of trade and other receivables. [Refer: Trade and other receivables]" } } }, "auth_ref": [ "r363" ] }, "ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DisclosureOfTransactionsBetweenRelatedPartiesAbstract", "lang": { "en-us": { "role": { "label": "Disclosure of transactions between related parties [Abstract]" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DisclosureOfTransactionsBetweenRelatedPartiesExplanatory", "presentation": [ "http://www.evogene.com/role/BalancesAndTransactionsWithExecutiveOfficersAndCertainShareholdersTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Transactions Related Party" } }, "en": { "role": { "documentation": "The disclosure of transactions between the entity and its related parties. [Refer: Total for all related parties [member]]" } } }, "auth_ref": [ "r69" ] }, "ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DisclosureOfTransactionsBetweenRelatedPartiesLineItems", "presentation": [ "http://www.evogene.com/role/BalancesAndTransactionsWithExecutiveOfficersAndCertainShareholdersNarrativeDetails", "http://www.evogene.com/role/BalancesAndTransactionsWithExecutiveOfficersAndCertainShareholdersScheduleOfBalancesDetails", "http://www.evogene.com/role/BalancesAndTransactionsWithExecutiveOfficersAndCertainShareholdersScheduleOfBenefitsToKeyOfficersDetails", "http://www.evogene.com/role/BalancesAndTransactionsWithKeyOfficersAndCertainShareholdersScheduleOfBenefitsToDirectorsDetails", "http://www.evogene.com/role/BalancesAndTransactionsWithKeyOfficersAndCertainShareholdersScheduleOfTransactionsWithRelatedPartiesDetails", "http://www.evogene.com/role/LiabilitiesInRespectOfGovernmentGrantsNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of transactions between related parties [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DisclosureOfTransactionsBetweenRelatedPartiesTable", "presentation": [ "http://www.evogene.com/role/BalancesAndTransactionsWithExecutiveOfficersAndCertainShareholdersNarrativeDetails", "http://www.evogene.com/role/BalancesAndTransactionsWithExecutiveOfficersAndCertainShareholdersScheduleOfBalancesDetails", "http://www.evogene.com/role/BalancesAndTransactionsWithExecutiveOfficersAndCertainShareholdersScheduleOfBenefitsToKeyOfficersDetails", "http://www.evogene.com/role/BalancesAndTransactionsWithKeyOfficersAndCertainShareholdersScheduleOfBenefitsToDirectorsDetails", "http://www.evogene.com/role/BalancesAndTransactionsWithKeyOfficersAndCertainShareholdersScheduleOfTransactionsWithRelatedPartiesDetails", "http://www.evogene.com/role/LiabilitiesInRespectOfGovernmentGrantsNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of transactions between related parties [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to transactions between related parties." } } }, "auth_ref": [ "r71" ] }, "evgn_DisclosureOfUsefulLifeOfRightOfUseAssetsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "DisclosureOfUsefulLifeOfRightOfUseAssetsExplanatory", "presentation": [ "http://www.evogene.com/role/SignificantAccountingPoliciesTables" ], "lang": { "en-us": { "role": { "documentation": "The disclosure of detailed information of useful life of right of use assets.", "label": "Disclosure Of Useful Life Of Right Of Use Assets Explanatory", "verboseLabel": "Schedule of Useful Life of Right of Use Assets" } } }, "auth_ref": [] }, "evgn_DisclusureOfNewStandardsInPeriodPriorToTheirAdoptionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "DisclusureOfNewStandardsInPeriodPriorToTheirAdoptionAbstract", "lang": { "en-us": { "role": { "documentation": "Disclosure of new standards in the period prior to their adoption [Abstract]", "label": "Disclusure Of New Standards In Period Prior To Their Adoption [Abstract]", "verboseLabel": "Disclosure of new standards in the period prior to their adoption [Abstract]" } } }, "auth_ref": [] }, "evgn_DiscountPercentageForConversionOfDebtToEquity": { "xbrltype": "percentItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "DiscountPercentageForConversionOfDebtToEquity", "presentation": [ "http://www.evogene.com/role/ConvertibleSAFENarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "The discount percentage for the non-cash conversion of debt to equity.", "label": "Discount Percentage For Conversion Of Debt To Equity", "terseLabel": "Discount percentage for conversion", "verboseLabel": "Discount percentage for conversion" } } }, "auth_ref": [] }, "ifrs-full_DisposalsAndRetirementsPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DisposalsAndRetirementsPropertyPlantAndEquipment", "crdr": "credit", "presentation": [ "http://www.evogene.com/role/PropertyPlantAndEquipmentNetScheduleOfPropertyPlantEquipmentToAccumulatedDepreciationDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Deductions", "label": "Deductions", "terseLabel": "Deductions" } }, "en": { "role": { "documentation": "The decrease in property, plant and equipment resulting from disposals and retirements. [Refer: Property, plant and equipment]" } } }, "auth_ref": [ "r372" ] }, "evgn_DisposalsInRightofuseAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "DisposalsInRightofuseAssetsAbstract", "presentation": [ "http://www.evogene.com/role/LeasesScheduleOfRight-of-useAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Disposals In Rightofuse Assets [Abstract]", "verboseLabel": "Disposals during the year:" } } }, "auth_ref": [] }, "evgn_DisposalsOfRightofuseAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "DisposalsOfRightofuseAssets", "crdr": "debit", "presentation": [ "http://www.evogene.com/role/LeasesScheduleOfRight-of-useAssetsDetails" ], "lang": { "en-us": { "role": { "documentation": "Decrease (increase) in acculumated depreciation due to disposal of right-of-use assets.", "label": "Disposals Of Rightofuse Assets", "verboseLabel": "Disposals of right-of-use assets" } } }, "auth_ref": [] }, "evgn_DisposalsOfRightofuseAssetsForLeasesTerminatedInPeriod": { "xbrltype": "monetaryItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "DisposalsOfRightofuseAssetsForLeasesTerminatedInPeriod", "crdr": "credit", "presentation": [ "http://www.evogene.com/role/LeasesScheduleOfRight-of-useAssetsDetails" ], "lang": { "en-us": { "role": { "documentation": "Disposals of right-of-use assets for leases terminated in the period.", "label": "Disposals Of Rightofuse Assets For Leases Terminated In Period", "verboseLabel": "Disposals of right-of-use assets for leases terminated in the period" } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentAccountingStandard", "presentation": [ "http://www.evogene.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r255" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentAnnualReport", "presentation": [ "http://www.evogene.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r254", "r255", "r278" ] }, "dei_DocumentFinStmtErrorCorrectionFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFinStmtErrorCorrectionFlag", "presentation": [ "http://www.evogene.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Financial Statement Error Correction [Flag]", "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction." } } }, "auth_ref": [ "r254", "r255", "r278", "r321" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://www.evogene.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://www.evogene.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.evogene.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentRegistrationStatement", "presentation": [ "http://www.evogene.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r250" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentShellCompanyReport", "presentation": [ "http://www.evogene.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r255" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentTransitionReport", "presentation": [ "http://www.evogene.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r299" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": [ "http://www.evogene.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]", "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year" } } }, "auth_ref": [ "r310" ] }, "evgn_EUHorizonMember": { "xbrltype": "domainItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "EUHorizonMember", "presentation": [ "http://www.evogene.com/role/CollaborationAndResearchAgreementsNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "E U Horizon [Member]", "label": "E U Horizon [Member]", "terseLabel": "EU Horizon [Member]" } } }, "auth_ref": [] }, "ifrs-full_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "EarningsPerShareAbstract", "lang": { "en-us": { "role": { "label": "Earnings per share [Abstract]" } } }, "auth_ref": [] }, "ifrs-full_EarningsPerShareExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "EarningsPerShareExplanatory", "presentation": [ "http://www.evogene.com/role/LossPerShareTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Loss Per Share" } }, "en": { "role": { "documentation": "The disclosure of earnings per share." } } }, "auth_ref": [ "r82" ] }, "ifrs-full_EarningsPerShareLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "EarningsPerShareLineItems", "presentation": [ "http://www.evogene.com/role/LossPerShareScheduleOfBasicLossPerShareDetails" ], "lang": { "en-us": { "role": { "label": "Earnings per share [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_EarningsPerShareTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "EarningsPerShareTable", "presentation": [ "http://www.evogene.com/role/LossPerShareScheduleOfBasicLossPerShareDetails" ], "lang": { "en-us": { "role": { "label": "Earnings per share [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to earnings per share." } } }, "auth_ref": [ "r82" ] }, "ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "EffectOfExchangeRateChangesOnCashAndCashEquivalents", "crdr": "debit", "calculation": { "http://www.evogene.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents", "weight": 1.0, "order": 30.0 } }, "presentation": [ "http://www.evogene.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Exchange rate differences on cash and cash equivalent balances", "terseLabel": "Exchange rate differences on balances of cash and cash equivalent balances" } }, "en": { "role": { "documentation": "The effect of exchange rate changes on cash and cash equivalents held or due in a foreign currency. [Refer: Cash and cash equivalents]" } } }, "auth_ref": [ "r109", "r110" ] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeStockOptionMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Employee Stock Option [Member]", "terseLabel": "Employee Stock Option" } } }, "auth_ref": [] }, "evgn_EmployeesAndConsultantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "EmployeesAndConsultantsMember", "presentation": [ "http://www.evogene.com/role/Share-BasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Employees and consultants {Member]", "label": "Employees And Consultants [Member]", "verboseLabel": "Employees, Directors and Consultants [Member]" } } }, "auth_ref": [] }, "evgn_EmployeesConsultantsDirectorsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "EmployeesConsultantsDirectorsMember", "presentation": [ "http://www.evogene.com/role/Share-BasedCompensationScheduleOfSummarizedNumberOfShareOptionsDetails", "http://www.evogene.com/role/Share-BasedCompensationTables" ], "lang": { "en-us": { "role": { "documentation": "Employees Consultants and Directors [Member]", "label": "Employees Consultants Directors Member", "verboseLabel": "Employees Consultants and Directors [Member]" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.evogene.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine2", "presentation": [ "http://www.evogene.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine3", "presentation": [ "http://www.evogene.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.evogene.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCountry", "presentation": [ "http://www.evogene.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.evogene.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressesAddressTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressesAddressTypeAxis", "presentation": [ "http://www.evogene.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Addresses, Address Type [Axis]", "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table." } } }, "auth_ref": [] }, "dei_EntityAddressesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressesLineItems", "presentation": [ "http://www.evogene.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Addresses [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_EntityAddressesTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressesTable", "presentation": [ "http://www.evogene.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Addresses [Table]", "documentation": "Container of address information for the entity" } } }, "auth_ref": [ "r252" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.evogene.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r252" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://www.evogene.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://www.evogene.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity's Reporting Status Current", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.evogene.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r252" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": [ "http://www.evogene.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilerCategory", "presentation": [ "http://www.evogene.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r252" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.evogene.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation State Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://www.evogene.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r361" ] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": [ "http://www.evogene.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r252" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityShellCompany", "presentation": [ "http://www.evogene.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r252" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityVoluntaryFilers", "presentation": [ "http://www.evogene.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity a Voluntary Filer", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://www.evogene.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity a Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r362" ] }, "ecd_EqtyAwrdsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments, Footnote [Text Block]", "terseLabel": "Equity Awards Adjustments, Footnote" } } }, "auth_ref": [ "r304" ] }, "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]", "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table" } } }, "auth_ref": [ "r357" ] }, "ecd_EqtyAwrdsAdjsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments [Member]", "terseLabel": "Equity Awards Adjustments" } } }, "auth_ref": [ "r357" ] }, "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]", "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table" } } }, "auth_ref": [ "r357" ] }, "ifrs-full_Equity": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "Equity", "crdr": "credit", "calculation": { "http://www.evogene.com/role/ConsolidatedStatementsOfFinancialPosition": { "parentTag": "ifrs-full_EquityAndLiabilities", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://www.evogene.com/role/ConsolidatedStatementsOfChangesInEquity", "http://www.evogene.com/role/ConsolidatedStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "periodEndLabel": "Balance", "periodStartLabel": "Balance", "label": "Equity", "totalLabel": "TOTAL\u00a0EQUITY" } }, "en": { "role": { "documentation": "The amount of residual interest in the assets of the entity after deducting all its liabilities." } } }, "auth_ref": [ "r16", "r23", "r117", "r119", "r137", "r138", "r139" ] }, "ifrs-full_EquityAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "EquityAbstract", "presentation": [ "http://www.evogene.com/role/ConsolidatedStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "SHAREHOLDERS' EQUITY:" } } }, "auth_ref": [] }, "ifrs-full_EquityAndLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "EquityAndLiabilities", "crdr": "credit", "calculation": { "http://www.evogene.com/role/ConsolidatedStatementsOfFinancialPosition": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.evogene.com/role/ConsolidatedStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Equity and liabilities", "totalLabel": "TOTAL LIABILITIES AND EQUITY" } }, "en": { "role": { "documentation": "The amount of the entity's equity and liabilities. [Refer: Equity; Liabilities]" } } }, "auth_ref": [ "r16" ] }, "ifrs-full_EquityAndLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "EquityAndLiabilitiesAbstract", "presentation": [ "http://www.evogene.com/role/ConsolidatedStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Equity and liabilities [abstract]", "terseLabel": "LIABILITIES AND EQUITY" } } }, "auth_ref": [] }, "ifrs-full_EquityAttributableToOwnersOfParent": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "EquityAttributableToOwnersOfParent", "crdr": "credit", "calculation": { "http://www.evogene.com/role/ConsolidatedStatementsOfFinancialPosition": { "parentTag": "ifrs-full_Equity", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.evogene.com/role/ConsolidatedStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "periodEndLabel": "Balance", "periodStartLabel": "Balance", "label": "Equity attributable to owners of parent", "totalLabel": "Equity attributable to equity holders of the Company" } }, "en": { "role": { "documentation": "The amount of equity attributable to the owners of the parent. This specifically excludes non-controlling interest." } } }, "auth_ref": [ "r15" ] }, "ifrs-full_EquityAttributableToOwnersOfParentMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "EquityAttributableToOwnersOfParentMember", "presentation": [ "http://www.evogene.com/role/ConsolidatedStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "label": "Total equity" } }, "en": { "role": { "documentation": "This member stands for equity attributable to the owners of the parent." } } }, "auth_ref": [ "r4" ] }, "ecd_EquityValuationAssumptionDifferenceFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EquityValuationAssumptionDifferenceFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Equity Valuation Assumption Difference, Footnote [Text Block]", "terseLabel": "Equity Valuation Assumption Difference, Footnote" } } }, "auth_ref": [ "r314" ] }, "ecd_ErrCompAnalysisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompAnalysisTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Erroneous Compensation Analysis [Text Block]", "terseLabel": "Erroneous Compensation Analysis" } } }, "auth_ref": [ "r271", "r282", "r292", "r325" ] }, "ecd_ErrCompRecoveryTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompRecoveryTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Erroneously Awarded Compensation Recovery [Table]", "terseLabel": "Erroneously Awarded Compensation Recovery" } } }, "auth_ref": [ "r268", "r279", "r289", "r322" ] }, "evgn_ExcessOfInitialFairValueOfPrefundedWarrantsOverTransactionProceeds": { "xbrltype": "monetaryItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "ExcessOfInitialFairValueOfPrefundedWarrantsOverTransactionProceeds", "crdr": "debit", "calculation": { "http://www.evogene.com/role/StatementsOfComprehensiveLoss-AdditionalInformationScheduleOfIncomeAndExpensesDetails": { "parentTag": "ifrs-full_FinanceCosts", "weight": 1.0, "order": 100.0 } }, "presentation": [ "http://www.evogene.com/role/StatementsOfComprehensiveLoss-AdditionalInformationScheduleOfIncomeAndExpensesDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of Excess of initial fair value of pre-funded warrants over transaction proceeds.", "label": "Excess Of Initial Fair Value Of Pre-funded Warrants Over Transaction Proceeds", "terseLabel": "Excess of initial fair value of pre-funded warrants over transaction proceeds" } } }, "auth_ref": [] }, "evgn_ExchangeDifferences": { "xbrltype": "monetaryItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "ExchangeDifferences", "crdr": "debit", "presentation": [ "http://www.evogene.com/role/LeasesScheduleOfLeaseExpensesDetails" ], "lang": { "en-us": { "role": { "documentation": "Exchange differences.", "label": "Exchange Differences", "verboseLabel": "Exchange rate differences" } } }, "auth_ref": [] }, "evgn_ExchangeRateDifferences": { "xbrltype": "monetaryItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "ExchangeRateDifferences", "crdr": "debit", "presentation": [ "http://www.evogene.com/role/LeasesScheduleOfLeaseLiabilityDetails" ], "lang": { "en-us": { "role": { "documentation": "Exchange rate differences.", "label": "Exchange Rate Differences", "verboseLabel": "Exchange rate differences" } } }, "auth_ref": [] }, "evgn_ExchangeRateExpensesOnLeaseLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "ExchangeRateExpensesOnLeaseLiabilities", "crdr": "debit", "calculation": { "http://www.evogene.com/role/StatementsOfComprehensiveLoss-AdditionalInformationScheduleOfIncomeAndExpensesDetails": { "parentTag": "ifrs-full_FinanceCosts", "weight": 1.0, "order": 30.0 } }, "presentation": [ "http://www.evogene.com/role/StatementsOfComprehensiveLoss-AdditionalInformationScheduleOfIncomeAndExpensesDetails" ], "lang": { "en-us": { "role": { "documentation": "Exchange rate expenses on lease liabilities.", "label": "Exchange Rate Expenses On Lease Liabilities", "verboseLabel": "Operating lease liability exchange differences" } } }, "auth_ref": [] }, "ecd_ExecutiveCategoryAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ExecutiveCategoryAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Executive Category [Axis]", "terseLabel": "Executive Category:" } } }, "auth_ref": [ "r320" ] }, "evgn_ExecutiveOfficersMember": { "xbrltype": "domainItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "ExecutiveOfficersMember", "presentation": [ "http://www.evogene.com/role/BalancesAndTransactionsWithExecutiveOfficersAndCertainShareholdersScheduleOfBalancesDetails", "http://www.evogene.com/role/BalancesAndTransactionsWithKeyOfficersAndCertainShareholdersScheduleOfTransactionsWithRelatedPartiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Executive officers [Member]", "label": "Executive officers [Member]" } } }, "auth_ref": [] }, "evgn_ExerciseOfOptions": { "xbrltype": "monetaryItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "ExerciseOfOptions", "crdr": "debit", "presentation": [ "http://www.evogene.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Exercise of options", "label": "Exercise Of Options", "verboseLabel": "Exercise of options" } } }, "auth_ref": [] }, "evgn_ExerciseOfOptionsParValue": { "xbrltype": "perShareItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "ExerciseOfOptionsParValue", "presentation": [ "http://www.evogene.com/role/ShareholdersEquityNarrativeDetails", "http://www.evogene.com/role/ShareholdersEquityScheduleOfChangesInShareCapitalDetails" ], "lang": { "en-us": { "role": { "documentation": "The number of share options par value in a share-based payment arrangement.", "label": "Exercise Of Options Par Value", "terseLabel": "Exercise of options par value", "verboseLabel": "Exercise of options and vesting of restricted share units (\u201cRSUs\u201d)" } } }, "auth_ref": [] }, "evgn_ExerciseOfPreFundedWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "ExerciseOfPreFundedWarrants", "crdr": "debit", "presentation": [ "http://www.evogene.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Amount of exercise of pre-funded warrants.", "label": "Exercise Of Pre Funded Warrants", "terseLabel": "Exercise of pre-funded warrants" } } }, "auth_ref": [] }, "evgn_ExerciseOfPreFundedWarrantsParValue": { "xbrltype": "perShareItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "ExerciseOfPreFundedWarrantsParValue", "presentation": [ "http://www.evogene.com/role/ShareholdersEquityScheduleOfChangesInShareCapitalDetails" ], "lang": { "en-us": { "role": { "documentation": "The number of warrants par value in share-based payment arrangement.", "label": "Exercise Of Pre Funded Warrants Par Value", "verboseLabel": "Exercise of pre-funded warrants" } } }, "auth_ref": [] }, "evgn_ExerciseOfSubsidiaryOptions": { "xbrltype": "monetaryItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "ExerciseOfSubsidiaryOptions", "crdr": "credit", "presentation": [ "http://www.evogene.com/role/ConsolidatedStatementsOfChangesInEquity", "http://www.evogene.com/role/ShareholdersEquityScheduleOfCompositionNon-controllingInterestsDetails" ], "lang": { "en-us": { "role": { "documentation": "Exercise of subsidiary options.", "label": "Exercise Of Subsidiary Options", "verboseLabel": "Exercise of subsidiary options" } } }, "auth_ref": [] }, "evgn_ExercisePriceRangeFourMember": { "xbrltype": "domainItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "ExercisePriceRangeFourMember", "presentation": [ "http://www.evogene.com/role/Share-BasedCompensationScheduleOfShareOptionsOutstandingDetails" ], "lang": { "en-us": { "role": { "documentation": "Over 40.00 [Member]", "label": "Exercise Price Range Four [Member]", "verboseLabel": "103.40 \u2013 108.60 [Member]" } } }, "auth_ref": [] }, "evgn_ExercisePriceRangeMember": { "xbrltype": "domainItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "ExercisePriceRangeMember", "presentation": [ "http://www.evogene.com/role/Share-BasedCompensationScheduleOfShareOptionsOutstandingDetails" ], "lang": { "en-us": { "role": { "documentation": "Up to 10.00 [Member]", "label": "Exercise Price Range [Member]", "verboseLabel": "2.36 - 10 [Member]" } } }, "auth_ref": [] }, "evgn_ExercisePriceRangeNetMember": { "xbrltype": "domainItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "ExercisePriceRangeNetMember", "presentation": [ "http://www.evogene.com/role/Share-BasedCompensationScheduleOfShareOptionsOutstandingDetails" ], "lang": { "en-us": { "role": { "documentation": "Exercise price range [Member]", "label": "Exercise Price Range Net Member" } } }, "auth_ref": [] }, "evgn_ExercisePriceRangeOneMember": { "xbrltype": "domainItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "ExercisePriceRangeOneMember", "presentation": [ "http://www.evogene.com/role/Share-BasedCompensationScheduleOfShareOptionsOutstandingDetails" ], "lang": { "en-us": { "role": { "documentation": "10.01-20.00 [Member]", "label": "Exercise Price Range One [Member]", "verboseLabel": "10.20 - 20 [Member]" } } }, "auth_ref": [] }, "evgn_ExercisePriceRangeThreeMember": { "xbrltype": "domainItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "ExercisePriceRangeThreeMember", "presentation": [ "http://www.evogene.com/role/Share-BasedCompensationScheduleOfShareOptionsOutstandingDetails" ], "lang": { "en-us": { "role": { "documentation": "30.01-40.00 [Member]", "label": "Exercise Price Range Three [Member]", "verboseLabel": "48.80 \u2013 76.19 [Member]" } } }, "auth_ref": [] }, "evgn_ExercisePriceRangeTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "ExercisePriceRangeTwoMember", "presentation": [ "http://www.evogene.com/role/Share-BasedCompensationScheduleOfShareOptionsOutstandingDetails" ], "lang": { "en-us": { "role": { "documentation": "20.01-30.00 [Member]", "label": "Exercise Price Range Two [Member]", "verboseLabel": "22.26 - 40.22 [Member]" } } }, "auth_ref": [] }, "ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted": { "xbrltype": "percentItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "ExpectedDividendAsPercentageShareOptionsGranted", "presentation": [ "http://www.evogene.com/role/SIGNIFICANTACCOUNTINGJUDGMENTSESTIMATESANDASSUMPTIONSUSEDINTHEPREPARATIONOFTHEFINANCIALSTATEMENTSNarrativeDetails", "http://www.evogene.com/role/Share-BasedCompensationScheduleOfAssumptionsUsedToValueOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Expected dividend as percentage, share options granted", "terseLabel": "Dividend yield" } }, "en": { "role": { "documentation": "The percentage of an expected dividend used to calculate the fair value of share options granted." } } }, "auth_ref": [ "r173" ] }, "evgn_ExpensesDueToRemovalOfLeaseLiabilitiesAndRightOfUseAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "ExpensesDueToRemovalOfLeaseLiabilitiesAndRightOfUseAssets", "crdr": "debit", "presentation": [ "http://www.evogene.com/role/LeasesScheduleOfLeaseExpensesDetails" ], "lang": { "en-us": { "role": { "documentation": "Expenses (income) due to removal of lease liabilities and right-of-use assets.", "negatedLabel": "Expense due to removal of lease liabilities and right-of-use assets", "label": "Expenses Due To Removal Of Lease Liabilities And Right Of Use Assets" } } }, "auth_ref": [] }, "ifrs-full_ExplanationOfEffectOfSharebasedPaymentsOnFinancialPositions": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "ExplanationOfEffectOfSharebasedPaymentsOnFinancialPositions", "presentation": [ "http://www.evogene.com/role/Share-BasedCompensationTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Expense Recognized in Financial Statements" } }, "en": { "role": { "documentation": "The explanation that enables users of financial statements to understand the effect of share-based payment transactions on the entity's financial position." } } }, "auth_ref": [ "r176" ] }, "evgn_FairValueOfConvertibleSafe": { "xbrltype": "monetaryItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "FairValueOfConvertibleSafe", "crdr": "credit", "presentation": [ "http://www.evogene.com/role/ConvertibleSAFENarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of fair value of convertible SAFE.", "label": "Fair Value Of Convertible Safe", "terseLabel": "Fair value of convertible SAFE" } } }, "auth_ref": [] }, "evgn_FairValueOfConvertibleSafeAtInitialRecognition": { "xbrltype": "monetaryItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "FairValueOfConvertibleSafeAtInitialRecognition", "crdr": "credit", "presentation": [ "http://www.evogene.com/role/ConvertibleSAFENarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Fair value of convertible SAFE at initial recognition.", "label": "Fair Value Of Convertible Safe At Initial Recognition", "terseLabel": "Fair value of convertible SAFE at initial recognition", "verboseLabel": "Fair value of convertible SAFE at initial recognition" } } }, "auth_ref": [] }, "evgn_FairValueOfRestrictedShareUnitsGranted": { "xbrltype": "monetaryItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "FairValueOfRestrictedShareUnitsGranted", "crdr": "credit", "presentation": [ "http://www.evogene.com/role/Share-BasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Fair value of Restricted Share Units granted.", "label": "Fair Value Of Restricted Share Units Granted", "terseLabel": "Fair value of Restricted Share Units granted" } } }, "auth_ref": [] }, "evgn_FairValueOfRsuGranted": { "xbrltype": "monetaryItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "FairValueOfRsuGranted", "crdr": "debit", "presentation": [ "http://www.evogene.com/role/Share-BasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Fair value of RSU granted.", "label": "Fair Value Of Rsu Granted", "verboseLabel": "Fair value of options granted" } } }, "auth_ref": [] }, "evgn_FederalStatutoryTaxRateBeginningTwentyEighteen": { "xbrltype": "percentItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "FederalStatutoryTaxRateBeginningTwentyEighteen", "presentation": [ "http://www.evogene.com/role/TaxesOnIncomeDetails" ], "lang": { "en-us": { "role": { "documentation": "Corporate tax rate beginning 2018.", "label": "Federal Statutory Tax Rate Beginning Twenty Eighteen", "verboseLabel": "Corporate tax rate beginning 2018" } } }, "auth_ref": [] }, "evgn_FederalTaxAuthorityMember": { "xbrltype": "domainItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "FederalTaxAuthorityMember", "presentation": [ "http://www.evogene.com/role/TaxesOnIncomeDetails" ], "lang": { "en-us": { "role": { "documentation": "Federal tax authority.", "label": "Federal Tax Authority [Member]", "terseLabel": "Federal tax [Member]" } } }, "auth_ref": [] }, "ifrs-full_FeeAndCommissionExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "FeeAndCommissionExpense", "crdr": "debit", "calculation": { "http://www.evogene.com/role/StatementsOfComprehensiveLoss-AdditionalInformationScheduleOfIncomeAndExpensesDetails": { "parentTag": "ifrs-full_FinanceCosts", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.evogene.com/role/StatementsOfComprehensiveLoss-AdditionalInformationScheduleOfIncomeAndExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Bank expenses and commissions" } }, "en": { "role": { "documentation": "The amount of expense relating to fees and commissions." } } }, "auth_ref": [ "r369" ] }, "ifrs-full_FinanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "FinanceCosts", "crdr": "debit", "calculation": { "http://www.evogene.com/role/ConsolidatedStatementsOfProfitOrLoss": { "parentTag": "evgn_FinanceIncomeExpensesNet", "weight": -1.0, "order": 10.0 }, "http://www.evogene.com/role/StatementsOfComprehensiveLoss-AdditionalInformationScheduleOfIncomeAndExpensesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.evogene.com/role/ConsolidatedStatementsOfProfitOrLoss", "http://www.evogene.com/role/StatementsOfComprehensiveLoss-AdditionalInformationScheduleOfIncomeAndExpensesDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Financing expenses", "label": "Finance costs", "totalLabel": "Total financing expenses", "verboseLabel": "Finance expenses" } }, "en": { "role": { "documentation": "The amount of costs associated with financing activities of the entity." } } }, "auth_ref": [ "r35" ] }, "ifrs-full_FinanceIncome": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "FinanceIncome", "crdr": "credit", "calculation": { "http://www.evogene.com/role/ConsolidatedStatementsOfProfitOrLoss": { "parentTag": "evgn_FinanceIncomeExpensesNet", "weight": 1.0, "order": 0.0 }, "http://www.evogene.com/role/StatementsOfComprehensiveLoss-AdditionalInformationScheduleOfIncomeAndExpensesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.evogene.com/role/ConsolidatedStatementsOfProfitOrLoss", "http://www.evogene.com/role/StatementsOfComprehensiveLoss-AdditionalInformationScheduleOfIncomeAndExpensesDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Financing income", "label": "Finance income", "terseLabel": "Financing income", "totalLabel": "Financing income", "verboseLabel": "Financing income" } }, "en": { "role": { "documentation": "The amount of income associated with interest and other financing activities of the entity." } } }, "auth_ref": [ "r369" ] }, "evgn_FinanceIncomeDueToChangeInFairValueOfMarketableSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "FinanceIncomeDueToChangeInFairValueOfMarketableSecurities", "crdr": "credit", "calculation": { "http://www.evogene.com/role/StatementsOfComprehensiveLoss-AdditionalInformationScheduleOfIncomeAndExpensesDetails": { "parentTag": "ifrs-full_FinanceIncome", "weight": 1.0, "order": 40.0 } }, "presentation": [ "http://www.evogene.com/role/StatementsOfComprehensiveLoss-AdditionalInformationScheduleOfIncomeAndExpensesDetails" ], "lang": { "en-us": { "role": { "documentation": "Finance income due to change in the fair value of marketable securities.", "label": "Finance Income Due To Change In Fair Value Of Marketable Securities", "verboseLabel": "Change in the fair value of marketable securities" } } }, "auth_ref": [] }, "evgn_FinanceIncomeExpensesNet": { "xbrltype": "monetaryItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "FinanceIncomeExpensesNet", "crdr": "credit", "calculation": { "http://www.evogene.com/role/ConsolidatedStatementsOfProfitOrLoss": { "parentTag": "ifrs-full_ProfitLossBeforeTax", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://www.evogene.com/role/ConsolidatedStatementsOfProfitOrLoss" ], "lang": { "en-us": { "role": { "documentation": "Finance Income Expense Net.", "label": "Finance Income Expenses Net", "totalLabel": "Financing income (expenses), net" } } }, "auth_ref": [] }, "evgn_FinancialIncomeDueToTheRemeasurement": { "xbrltype": "monetaryItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "FinancialIncomeDueToTheRemeasurement", "crdr": "credit", "presentation": [ "http://www.evogene.com/role/ShareholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Financial income due to the remeasurement", "label": "Financial Income Due To The Remeasurement", "verboseLabel": "Financial income due to the remeasurement" } } }, "auth_ref": [] }, "evgn_FinancialIncomeNetRelatedToPreFundedWarrantsAndWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "FinancialIncomeNetRelatedToPreFundedWarrantsAndWarrants", "crdr": "credit", "presentation": [ "http://www.evogene.com/role/ShareholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the amount of financial income, net related to pre-funded warrants and warrants.", "label": "Financial Income, Net Related To Pre Funded Warrants And Warrants" } } }, "auth_ref": [] }, "ifrs-full_FinancialLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "FinancialLiabilities", "crdr": "credit", "calculation": { "http://www.evogene.com/role/FinancialInstrumentsScheduleOfCompanysFinancialLiabilitiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.evogene.com/role/FINANCIALINSTRUMENTSScheduleOfFairValueOfFinancialLiabilitiesDetails", "http://www.evogene.com/role/FinancialInstrumentsScheduleOfCompanysFinancialLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Financial liabilities", "totalLabel": "Total Financial Liabilities", "verboseLabel": "Financial liabilities" } }, "en": { "role": { "documentation": "The amount of liabilities that are: (a) a contractual obligation: (i) to deliver cash or another financial asset to another entity; or (ii) to exchange financial assets or financial liabilities with another entity under conditions that are potentially unfavourable to the entity; or (b) a contract that will, or may be, settled in the entity\u2019s own equity instruments and is: (i) a non-derivative for which the entity is, or may be, obliged to deliver a variable number of the entity\u2019s own equity instruments; or (ii) a derivative that will, or may be, settled other than by the exchange of a fixed amount of cash or another financial asset for a fixed number of the entity\u2019s own equity instruments. For this purpose, rights, options or warrants to acquire a fixed number of the entity\u2019s own equity instruments for a fixed amount of any currency are equity instruments if the entity offers the rights, options or warrants pro rata to all of its existing owners of the same class of its own non-derivative equity instruments. Also, for those purposes the entity\u2019s own equity instruments do not include puttable financial instruments that are classified as equity instruments in accordance with paragraphs 16A-16B of IAS 32, instruments that impose on the entity an obligation to deliver to another party a pro rata share of the net assets of the entity only on liquidation and are classified as equity instruments in accordance with paragraphs 16C-16D of IAS 32, or instruments that are contracts for the future receipt or delivery of the entity\u2019s own equity instruments. As an exception, an instrument that meets the definition of a financial liability is classified as an equity instrument if it has all the features and meets the conditions in paragraphs 16A-16B or paragraphs 16C-16D of IAS 32. [Refer: Classes of financial instruments [domain]; Financial assets; Derivatives [member]]" } } }, "auth_ref": [ "r185" ] }, "evgn_FinancingExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "FinancingExpensesAbstract", "presentation": [ "http://www.evogene.com/role/StatementsOfComprehensiveLoss-AdditionalInformationScheduleOfIncomeAndExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Financing Expenses Abstract", "verboseLabel": "Financing expenses:" } } }, "auth_ref": [] }, "evgn_FinancingExpensesForTransactions": { "xbrltype": "monetaryItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "FinancingExpensesForTransactions", "crdr": "debit", "presentation": [ "http://www.evogene.com/role/BalancesAndTransactionsWithKeyOfficersAndCertainShareholdersScheduleOfTransactionsWithRelatedPartiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of financing expenses for transactions.", "label": "Financing Expenses For Transactions", "verboseLabel": "Financing expenses" } } }, "auth_ref": [] }, "evgn_FinancingIncomeAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "FinancingIncomeAbstract", "presentation": [ "http://www.evogene.com/role/StatementsOfComprehensiveLoss-AdditionalInformationScheduleOfIncomeAndExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Financing Income Abstract", "verboseLabel": "Financing income:" } } }, "auth_ref": [] }, "evgn_FinancingIncomeAndExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "FinancingIncomeAndExpensesAbstract", "presentation": [ "http://www.evogene.com/role/StatementsOfComprehensiveLoss-AdditionalInformationScheduleOfIncomeAndExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Financing Income And Expenses Abstract", "verboseLabel": "Financing income and expenses" } } }, "auth_ref": [] }, "evgn_FinancingIncomeExpensesBySegment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "FinancingIncomeExpensesBySegment", "crdr": "credit", "presentation": [ "http://www.evogene.com/role/OperatingSegmentsScheduleOfRevenuesAndOperatingLossBySegmentsDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of financing income (expenses) by operating segment.", "label": "Financing Income Expenses By Segment", "terseLabel": "Net financing income (expenses)" } } }, "auth_ref": [] }, "evgn_FinancingIncomeHedgAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "FinancingIncomeHedgAmount", "crdr": "credit", "presentation": [ "http://www.evogene.com/role/FinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Financing income hedg amount.", "label": "Financing income hedg amount" } } }, "auth_ref": [] }, "ifrs-full_FinishedGoods": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "FinishedGoods", "crdr": "debit", "calculation": { "http://www.evogene.com/role/SIGNIFICANTACCOUNTINGPOLICIESScheduleOfSummarizesInformationAboutTheInventoryDetails": { "parentTag": "ifrs-full_Inventories", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://www.evogene.com/role/SIGNIFICANTACCOUNTINGPOLICIESScheduleOfSummarizesInformationAboutTheInventoryDetails" ], "lang": { "en-us": { "role": { "label": "Current finished goods", "terseLabel": "Finished goods" } }, "en": { "role": { "documentation": "A classification of current inventory representing the amount of goods that have completed the production process and are held for sale in the ordinary course of business. [Refer: Inventories]" } } }, "auth_ref": [ "r218", "r374" ] }, "evgn_FirstPaymentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "FirstPaymentMember", "presentation": [ "http://www.evogene.com/role/CollaborationAndResearchAgreementsNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "First Payment [Member]", "label": "First Payment [Member]" } } }, "auth_ref": [] }, "evgn_FivePercentDecreaseInExchangeRateMember": { "xbrltype": "domainItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "FivePercentDecreaseInExchangeRateMember", "presentation": [ "http://www.evogene.com/role/FinancialInstrumentsScheduleOfSensitivityTestsRelatingToChangesInMarketFactorsDetails" ], "lang": { "en-us": { "role": { "documentation": "Decrease of 5% in exchange rate [Member]", "label": "Five Percent Decrease In Exchange Rate Member", "verboseLabel": "Decrease of 5% in exchange rate [Member]" } } }, "auth_ref": [] }, "evgn_FivePercentDecreaseInMarketPriceMember": { "xbrltype": "domainItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "FivePercentDecreaseInMarketPriceMember", "presentation": [ "http://www.evogene.com/role/FinancialInstrumentsScheduleOfSensitivityTestsRelatingToChangesInMarketFactorsDetails" ], "lang": { "en-us": { "role": { "documentation": "Decrease of 5% in market price [Member]", "label": "Five Percent Decrease In Market Price Member" } } }, "auth_ref": [] }, "evgn_FivePercentIncreaseInExchangeRateMember": { "xbrltype": "domainItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "FivePercentIncreaseInExchangeRateMember", "presentation": [ "http://www.evogene.com/role/FinancialInstrumentsScheduleOfSensitivityTestsRelatingToChangesInMarketFactorsDetails" ], "lang": { "en-us": { "role": { "documentation": "Increase of 5% in exchange rate [Member]", "label": "Five Percent Increase In Exchange Rate Member", "verboseLabel": "Increase of 5% in exchange rate [Member]" } } }, "auth_ref": [] }, "evgn_FivePercentIncreaseInMarketPriceMember": { "xbrltype": "domainItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "FivePercentIncreaseInMarketPriceMember", "presentation": [ "http://www.evogene.com/role/FinancialInstrumentsScheduleOfSensitivityTestsRelatingToChangesInMarketFactorsDetails" ], "lang": { "en-us": { "role": { "documentation": "Increase of 5% in market price [Member]", "label": "Five Percent Increase In Market Price Member", "verboseLabel": "Increase of 5% in market price [Member]" } } }, "auth_ref": [] }, "evgn_ForfeitureOfNonControllingInterestsRegardingShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "ForfeitureOfNonControllingInterestsRegardingShareBasedCompensation", "crdr": "credit", "presentation": [ "http://www.evogene.com/role/ConsolidatedStatementsOfChangesInEquity", "http://www.evogene.com/role/ShareholdersEquityScheduleOfCompositionNon-controllingInterestsDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents amount of forfeiture of non-controlling interests regarding share based compensation.", "negatedLabel": "Forfeiture of non-controlling interests regarding share-based compensation", "label": "Forfeiture Of Non Controlling Interests Regarding Share Based Compensation", "terseLabel": "Forfeiture of non-controlling interests regarding share-based compensation" } } }, "auth_ref": [] }, "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount", "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount" } } }, "auth_ref": [ "r275", "r286", "r296", "r329" ] }, "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Expense of Enforcement, Amount", "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount" } } }, "auth_ref": [ "r275", "r286", "r296", "r329" ] }, "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Violation of Home Country Law, Amount", "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount" } } }, "auth_ref": [ "r275", "r286", "r296", "r329" ] }, "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery, Explanation of Impracticability [Text Block]", "terseLabel": "Forgone Recovery, Explanation of Impracticability" } } }, "auth_ref": [ "r275", "r286", "r296", "r329" ] }, "ecd_ForgoneRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery, Individual Name", "terseLabel": "Name" } } }, "auth_ref": [ "r275", "r286", "r296", "r329" ] }, "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]", "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year" } } }, "auth_ref": [ "r309" ] }, "evgn_GainAndLossFromDerecognitionOfPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "GainAndLossFromDerecognitionOfPropertyPlantAndEquipment", "crdr": "debit", "calculation": { "http://www.evogene.com/role/StatementsOfComprehensiveLoss-AdditionalInformationScheduleOfIncomeAndExpensesDetails": { "parentTag": "ifrs-full_ResearchAndDevelopmentExpense", "weight": 1.0, "order": 60.0 } }, "presentation": [ "http://www.evogene.com/role/StatementsOfComprehensiveLoss-AdditionalInformationScheduleOfIncomeAndExpensesDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents amount of gain or Loss from derecognition of property, plant and equipment.", "label": "Gain And Loss From Derecognition Of Property, Plant And Equipment", "verboseLabel": "Gain from derecognition of property, plant and equipment" } } }, "auth_ref": [] }, "evgn_GainsOnExchangeDifferencesOnTranslationNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "GainsOnExchangeDifferencesOnTranslationNetOfTax", "crdr": "credit", "calculation": { "http://www.evogene.com/role/StatementsOfComprehensiveLoss-AdditionalInformationScheduleOfIncomeAndExpensesDetails": { "parentTag": "ifrs-full_FinanceIncome", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://www.evogene.com/role/StatementsOfComprehensiveLoss-AdditionalInformationScheduleOfIncomeAndExpensesDetails" ], "lang": { "en-us": { "role": { "documentation": "The gains recognized in financing income on exchange differences on the translation of foreign currency monetary amounts.", "label": "Gains On Exchange Differences On Translation Net Of Tax", "verboseLabel": "Exchange differences" } } }, "auth_ref": [] }, "evgn_GeneralAndAdministrativeAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "GeneralAndAdministrativeAbstract", "presentation": [ "http://www.evogene.com/role/StatementsOfComprehensiveLoss-AdditionalInformationScheduleOfIncomeAndExpensesDetails" ], "lang": { "en-us": { "role": { "label": "General And Administrative Abstract", "verboseLabel": "General and administrative:" } } }, "auth_ref": [] }, "evgn_GeneralAndAdministrativeExpensesForTransactions": { "xbrltype": "monetaryItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "GeneralAndAdministrativeExpensesForTransactions", "crdr": "debit", "presentation": [ "http://www.evogene.com/role/BalancesAndTransactionsWithKeyOfficersAndCertainShareholdersScheduleOfTransactionsWithRelatedPartiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of general and administrative expenses for transactions.", "label": "General And Administrative Expenses For Transactions", "verboseLabel": "General and administrative expenses" } } }, "auth_ref": [] }, "evgn_GeneralAndAdministrativeSalaryAndRelatedExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "GeneralAndAdministrativeSalaryAndRelatedExpenses", "crdr": "debit", "calculation": { "http://www.evogene.com/role/StatementsOfComprehensiveLoss-AdditionalInformationScheduleOfIncomeAndExpensesDetails": { "parentTag": "ifrs-full_SellingGeneralAndAdministrativeExpense", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.evogene.com/role/StatementsOfComprehensiveLoss-AdditionalInformationScheduleOfIncomeAndExpensesDetails" ], "lang": { "en-us": { "role": { "documentation": "General and administrative salary and related expenses.", "label": "General And Administrative Salary And Related Expenses", "verboseLabel": "Salaries and benefits" } } }, "auth_ref": [] }, "evgn_GeneralAndAdministrativeShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "GeneralAndAdministrativeShareBasedCompensation", "crdr": "debit", "calculation": { "http://www.evogene.com/role/StatementsOfComprehensiveLoss-AdditionalInformationScheduleOfIncomeAndExpensesDetails": { "parentTag": "ifrs-full_SellingGeneralAndAdministrativeExpense", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://www.evogene.com/role/StatementsOfComprehensiveLoss-AdditionalInformationScheduleOfIncomeAndExpensesDetails" ], "lang": { "en-us": { "role": { "documentation": "General and administrative share based compensation.", "label": "General And Administrative Share Based Compensation", "verboseLabel": "Share-based compensation" } } }, "auth_ref": [] }, "ifrs-full_GeographicalAreasAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "GeographicalAreasAxis", "presentation": [ "http://www.evogene.com/role/OperatingSegmentsScheduleOfPercentageOfNon-currentAssetsDetails", "http://www.evogene.com/role/OperatingSegmentsScheduleOfRevenuesBasedOnCustomersDetails" ], "lang": { "en-us": { "role": { "label": "Geographical areas [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r210", "r224", "r237", "r240" ] }, "ifrs-full_GeographicalAreasDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "GeographicalAreasDomain", "presentation": [ "http://www.evogene.com/role/OperatingSegmentsScheduleOfPercentageOfNon-currentAssetsDetails", "http://www.evogene.com/role/OperatingSegmentsScheduleOfRevenuesBasedOnCustomersDetails" ], "lang": { "en": { "role": { "documentation": "This member stands for aggregated geographical areas. It also represents the standard value for the 'Geographical areas' axis if no other member is used." } } }, "auth_ref": [ "r210", "r224", "r237", "r240" ] }, "evgn_GovernmentAuthoritiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "GovernmentAuthoritiesCurrent", "crdr": "debit", "calculation": { "http://www.evogene.com/role/OtherReceivablesAndPrepaidExpensesScheduleOfOtherReceivablesAndPrepaidExpensesDetails": { "parentTag": "ifrs-full_OtherCurrentReceivables", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.evogene.com/role/OtherReceivablesAndPrepaidExpensesScheduleOfOtherReceivablesAndPrepaidExpensesDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount represent receivables from current governmental units.", "label": "Government Authorities Current", "verboseLabel": "Government authorities" } } }, "auth_ref": [] }, "evgn_GovernmentGrant": { "xbrltype": "monetaryItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "GovernmentGrant", "crdr": "credit", "presentation": [ "http://www.evogene.com/role/LiabilitiesInRespectOfGovernmentGrantsScheduleOfLiabilitiesInRespectOfGovernmentGrantsDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of assistance by government in the form of transfers of resources to an entity in return for past or future compliance with certain conditions relating to the operating activities of the entity, recognised as deferred income. They exclude those forms of government assistance that cannot reasonably have a value placed upon them and transactions with government that cannot be distinguished from the normal trading transactions of the entity.", "periodEndLabel": "Balance on December 31,", "periodStartLabel": "Balance on January 1,", "label": "Government Grant" } } }, "auth_ref": [] }, "evgn_GrantAmountForProject": { "xbrltype": "monetaryItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "GrantAmountForProject", "crdr": "debit", "presentation": [ "http://www.evogene.com/role/CollaborationAndResearchAgreementsNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount grant for project.", "label": "Grant Amount For Project", "terseLabel": "Grant amount" } } }, "auth_ref": [] }, "evgn_GrantReceivablesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "GrantReceivablesCurrent", "crdr": "debit", "calculation": { "http://www.evogene.com/role/OtherReceivablesAndPrepaidExpensesScheduleOfOtherReceivablesAndPrepaidExpensesDetails": { "parentTag": "ifrs-full_OtherCurrentReceivables", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://www.evogene.com/role/OtherReceivablesAndPrepaidExpensesScheduleOfOtherReceivablesAndPrepaidExpensesDetails" ], "lang": { "en-us": { "role": { "documentation": "Grant receivables current.", "label": "Grant Receivables Current", "verboseLabel": "Grant receivables" } } }, "auth_ref": [] }, "evgn_GrantsReceived": { "xbrltype": "monetaryItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "GrantsReceived", "crdr": "credit", "presentation": [ "http://www.evogene.com/role/LiabilitiesInRespectOfGovernmentGrantsScheduleOfLiabilitiesInRespectOfGovernmentGrantsDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of cash received in relation to royalty-bearing R and D government grants.", "label": "Grants received", "verboseLabel": "Grants received" } } }, "auth_ref": [] }, "evgn_GrantsToBeReceived": { "xbrltype": "monetaryItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "GrantsToBeReceived", "crdr": "credit", "presentation": [ "http://www.evogene.com/role/LiabilitiesInRespectOfGovernmentGrantsScheduleOfLiabilitiesInRespectOfGovernmentGrantsDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the amount of grants to be received.", "label": "Grants To Be Received", "verboseLabel": "Grants to be received" } } }, "auth_ref": [] }, "ifrs-full_GrossCarryingAmountMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "GrossCarryingAmountMember", "presentation": [ "http://www.evogene.com/role/IntangibleAssetsNetScheduleOfIntangibleAssetsDetails", "http://www.evogene.com/role/LeasesScheduleOfRight-of-useAssetsDetails", "http://www.evogene.com/role/PropertyPlantAndEquipmentNetScheduleOfPropertyPlantEquipmentToAccumulatedDepreciationDetails" ], "lang": { "en-us": { "role": { "label": "Cost [Member]" } }, "en": { "role": { "documentation": "This member stands for the amount at which an asset is recognised before deducting any accumulated depreciation (amortisation) and accumulated impairment losses thereon. [Refer: Depreciation and amortisation expense; Impairment loss]" } } }, "auth_ref": [ "r48", "r93", "r101", "r105", "r180", "r188", "r190", "r242" ] }, "ifrs-full_GrossProfit": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "GrossProfit", "crdr": "credit", "calculation": { "http://www.evogene.com/role/ConsolidatedStatementsOfProfitOrLoss": { "parentTag": "ifrs-full_ProfitLossFromOperatingActivities", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.evogene.com/role/ConsolidatedStatementsOfProfitOrLoss" ], "lang": { "en-us": { "role": { "label": "Gross profit", "totalLabel": "Gross profit" } }, "en": { "role": { "documentation": "The amount of revenue less cost of sales. [Refer: Cost of sales; Revenue]" } } }, "auth_ref": [ "r214" ] }, "evgn_HumanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "HumanMember", "presentation": [ "http://www.evogene.com/role/OperatingSegmentsScheduleOfRevenuesAndOperatingLossBySegmentsDetails" ], "lang": { "en-us": { "role": { "documentation": "Human [Member]", "label": "Human [Member]", "terseLabel": "Human health [Member]" } } }, "auth_ref": [] }, "country_IL": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2024", "localname": "IL", "presentation": [ "http://www.evogene.com/role/OperatingSegmentsScheduleOfPercentageOfNon-currentAssetsDetails", "http://www.evogene.com/role/OperatingSegmentsScheduleOfRevenuesBasedOnCustomersDetails" ], "lang": { "en-us": { "role": { "label": "ISRAEL", "verboseLabel": "Israel [Member]" } } }, "auth_ref": [] }, "dei_IcfrAuditorAttestationFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "IcfrAuditorAttestationFlag", "presentation": [ "http://www.evogene.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "ICFR Auditor Attestation Flag" } } }, "auth_ref": [ "r254", "r255", "r278" ] }, "evgn_IclGroupMember": { "xbrltype": "domainItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "IclGroupMember", "presentation": [ "http://www.evogene.com/role/CollaborationAndResearchAgreementsNarrativeDetails", "http://www.evogene.com/role/ConvertibleSAFENarrativeDetails", "http://www.evogene.com/role/GeneralNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "It represents Icl Group.", "label": "Icl Group [Member]", "terseLabel": "ICL Group [Member]", "verboseLabel": "ICL Group" } } }, "auth_ref": [] }, "evgn_IfrsStatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "IfrsStatementLineItems", "presentation": [ "http://www.evogene.com/role/IntangibleAssetsNetNarrativeDetails", "http://www.evogene.com/role/LeasesNarrativeDetails", "http://www.evogene.com/role/LeasesScheduleOfFutureMinimumLeasePaymentsUnderNon-cancelableLeasesDetails", "http://www.evogene.com/role/LeasesScheduleOfLeaseLiabilityDetails", "http://www.evogene.com/role/LeasesScheduleOfRight-of-useAssetsDetails" ], "lang": { "en-us": { "role": { "documentation": "Ifrs Statement [Line Items]", "label": "Ifrs Statement [Line Items]" } } }, "auth_ref": [] }, "evgn_IfrsStatementTableTable": { "xbrltype": "stringItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "IfrsStatementTableTable", "presentation": [ "http://www.evogene.com/role/IntangibleAssetsNetNarrativeDetails", "http://www.evogene.com/role/LeasesNarrativeDetails", "http://www.evogene.com/role/LeasesScheduleOfFutureMinimumLeasePaymentsUnderNon-cancelableLeasesDetails", "http://www.evogene.com/role/LeasesScheduleOfLeaseLiabilityDetails", "http://www.evogene.com/role/LeasesScheduleOfRight-of-useAssetsDetails" ], "lang": { "en-us": { "role": { "documentation": "Ifrs Statement [Table]", "label": "Ifrs Statement Table [Table]" } } }, "auth_ref": [] }, "ifrs-full_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "label": "Profit or loss [abstract]" } } }, "auth_ref": [] }, "ifrs-full_IncomeTaxExpenseContinuingOperations": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "IncomeTaxExpenseContinuingOperations", "crdr": "debit", "calculation": { "http://www.evogene.com/role/ConsolidatedStatementsOfProfitOrLoss": { "parentTag": "ifrs-full_ProfitLoss", "weight": -1.0, "order": 10.0 } }, "presentation": [ "http://www.evogene.com/role/ConsolidatedStatementsOfProfitOrLoss" ], "lang": { "en-us": { "role": { "negatedLabel": "Taxes on income (tax benefit)", "label": "Taxes on income", "verboseLabel": "Taxes on income (tax benefit)" } }, "en": { "role": { "documentation": "The aggregate amount included in the determination of profit (loss) for the period in respect of current tax and deferred tax. [Refer: Current tax expense (income); Deferred tax expense (income)]" } } }, "auth_ref": [ "r36", "r41", "r42", "r43", "r76", "r134", "r199" ] }, "ifrs-full_IncomeTaxesPaidClassifiedAsOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "IncomeTaxesPaidClassifiedAsOperatingActivities", "crdr": "credit", "calculation": { "http://www.evogene.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": -1.0, "order": 30.0 } }, "presentation": [ "http://www.evogene.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Taxes paid", "label": "Income taxes paid, classified as operating activities" } }, "en": { "role": { "documentation": "The cash outflow for income taxes paid, classified as operating activities." } } }, "auth_ref": [ "r386" ] }, "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "IncreaseDecreaseInCashAndCashEquivalents", "crdr": "debit", "calculation": { "http://www.evogene.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.evogene.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase (decrease) in cash and cash equivalents", "totalLabel": "Decrease in cash and cash equivalents" } }, "en": { "role": { "documentation": "The increase (decrease) in cash and cash equivalents after the effect of exchange rate changes on cash and cash equivalents held in foreign currencies. [Refer: Cash and cash equivalents; Effect of exchange rate changes on cash and cash equivalents]" } } }, "auth_ref": [ "r114" ] }, "evgn_IncreaseDecreaseInEquityResultingFromShareBasedPaymentTransactionsAndRestrictedStockUnit": { "xbrltype": "monetaryItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "IncreaseDecreaseInEquityResultingFromShareBasedPaymentTransactionsAndRestrictedStockUnit", "crdr": "debit", "presentation": [ "http://www.evogene.com/role/ConsolidatedStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "documentation": "Represents amount of increase (decrease) in equity resulting from share-based payment transactions and RSUs.", "label": "Increase Decrease In Equity Resulting From Share Based Payment Transactions And Restricted Stock Unit", "terseLabel": "Share-based compensation" } } }, "auth_ref": [] }, "ifrs-full_IncreaseDecreaseThroughExerciseOfOptions": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "IncreaseDecreaseThroughExerciseOfOptions", "crdr": "credit", "presentation": [ "http://www.evogene.com/role/ConsolidatedStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "label": "Exercise of options" } }, "en": { "role": { "documentation": "The increase (decrease) in equity resulting from the exercise of options." } } }, "auth_ref": [ "r364" ] }, "ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "IncreaseDecreaseThroughExerciseOfWarrantsEquity", "crdr": "credit", "presentation": [ "http://www.evogene.com/role/ConsolidatedStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "label": "Increase (decrease) through exercise of warrants, equity", "terseLabel": "Exercise of pre-funded warrants" } }, "en": { "role": { "documentation": "The increase (decrease) in equity resulting from the exercise of warrants." } } }, "auth_ref": [ "r364" ] }, "evgn_IncreaseDecreaseThroughShareBasedPaymentTransactionsEquityHoldersOfCompany": { "xbrltype": "monetaryItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "IncreaseDecreaseThroughShareBasedPaymentTransactionsEquityHoldersOfCompany", "crdr": "debit", "calculation": { "http://www.evogene.com/role/Share-BasedCompensationScheduleOfCompanysFinancialStatementsDetails": { "parentTag": "ifrs-full_AdjustmentsForSharebasedPayments", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.evogene.com/role/Share-BasedCompensationScheduleOfCompanysFinancialStatementsDetails" ], "lang": { "en-us": { "role": { "documentation": "Adjustments for share-based payments from equity holders of the Company to reconcile profit (loss) to net cash flow from (used in) operating activities.", "label": "Increase Decrease Through Share Based Payment Transactions Equity Holders Of Company", "verboseLabel": "Share-based compensation \u2013 Attributable to equity holders of the Company" } } }, "auth_ref": [] }, "evgn_IncreaseDecreaseThroughShareBasedPaymentTransactionsNonControllingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "IncreaseDecreaseThroughShareBasedPaymentTransactionsNonControllingInterest", "crdr": "debit", "calculation": { "http://www.evogene.com/role/Share-BasedCompensationScheduleOfCompanysFinancialStatementsDetails": { "parentTag": "ifrs-full_AdjustmentsForSharebasedPayments", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://www.evogene.com/role/Share-BasedCompensationScheduleOfCompanysFinancialStatementsDetails" ], "lang": { "en-us": { "role": { "documentation": "Adjustments for share-based payments from non-controlling interests to reconcile profit (loss) to net cash flow from (used in) operating activities.", "label": "Increase Decrease Through Share Based Payment Transactions Non Controlling Interest", "terseLabel": "Share-based compensation \u2013 Attributable to non-controlling interests" } } }, "auth_ref": [] }, "ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "IncreaseDecreaseThroughSharebasedPaymentTransactions", "crdr": "credit", "presentation": [ "http://www.evogene.com/role/ConsolidatedStatementsOfChangesInEquity", "http://www.evogene.com/role/ShareholdersEquityScheduleOfCompositionNon-controllingInterestsDetails" ], "lang": { "en-us": { "role": { "label": "Share-based compensation" } }, "en": { "role": { "documentation": "The increase (decrease) in equity resulting from share-based payment transactions. [Refer: Equity]" } } }, "auth_ref": [ "r3" ] }, "evgn_IncreaseInNonControllingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "IncreaseInNonControllingInterest", "crdr": "debit", "presentation": [ "http://www.evogene.com/role/ShareholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the amount of increase in non controlling interest.", "label": "Increase In Non Controlling Interest", "terseLabel": "Increase in non controlling interest" } } }, "auth_ref": [] }, "evgn_IncreaseOfOperatingLeaseRightofuseassets": { "xbrltype": "monetaryItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "IncreaseOfOperatingLeaseRightofuseassets", "crdr": "credit", "presentation": [ "http://www.evogene.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Increase of operating lease right-of-use-assets.", "label": "Increase Of Operating Lease Rightofuseassets", "verboseLabel": "Right-of-use asset recognized with corresponding lease liability" } } }, "auth_ref": [] }, "ecd_IndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "IndividualAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Individual [Axis]", "terseLabel": "Individual:" } } }, "auth_ref": [ "r275", "r286", "r296", "r320", "r329", "r333", "r341" ] }, "evgn_IndustryMember": { "xbrltype": "domainItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "IndustryMember", "presentation": [ "http://www.evogene.com/role/OperatingSegmentsScheduleOfRevenuesAndOperatingLossBySegmentsDetails" ], "lang": { "en-us": { "role": { "documentation": "Industry [Member]", "label": "Industry [Member]", "terseLabel": "Industrial application [Member]" } } }, "auth_ref": [] }, "evgn_InitialPayment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "InitialPayment", "crdr": "credit", "presentation": [ "http://www.evogene.com/role/CollaborationAndResearchAgreementsNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of initial payment.", "label": "Initial Payment", "terseLabel": "Initial payment" } } }, "auth_ref": [] }, "ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingArrLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Arrangements [Line Items]", "terseLabel": "Insider Trading Arrangements:" } } }, "auth_ref": [ "r339" ] }, "ecd_InsiderTradingPoliciesProcLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingPoliciesProcLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures [Line Items]", "terseLabel": "Insider Trading Policies and Procedures:" } } }, "auth_ref": [ "r256", "r345" ] }, "ecd_InsiderTrdPoliciesProcAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Adopted [Flag]", "terseLabel": "Insider Trading Policies and Procedures Adopted" } } }, "auth_ref": [ "r256", "r345" ] }, "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]", "terseLabel": "Insider Trading Policies and Procedures Not Adopted" } } }, "auth_ref": [ "r256", "r345" ] }, "evgn_IntangibleAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "IntangibleAssetsAbstract", "lang": { "en-us": { "role": { "label": "Intangible Assets [Abstract]" } } }, "auth_ref": [] }, "evgn_IntangibleAssetsGrossCarryingAmountFullyAmortized": { "xbrltype": "monetaryItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "IntangibleAssetsGrossCarryingAmountFullyAmortized", "crdr": "debit", "presentation": [ "http://www.evogene.com/role/IntangibleAssetsNetScheduleOfIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "documentation": "The gross carrying amount of fully amortized intangible assets that is still in use.", "periodEndLabel": "Amortized cost on end of year", "label": "Intangible Assets Gross Carrying Amount Fully Amortized" } } }, "auth_ref": [] }, "ifrs-full_IntangibleAssetsOtherThanGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "IntangibleAssetsOtherThanGoodwill", "crdr": "debit", "calculation": { "http://www.evogene.com/role/ConsolidatedStatementsOfFinancialPosition": { "parentTag": "ifrs-full_NoncurrentAssets", "weight": 1.0, "order": 30.0 } }, "presentation": [ "http://www.evogene.com/role/ConsolidatedStatementsOfFinancialPosition", "http://www.evogene.com/role/IntangibleAssetsNetScheduleOfIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "periodEndLabel": "Balance on end of year", "periodStartLabel": "Balance on beginning year", "label": "Intangible assets, net" } }, "en": { "role": { "documentation": "The amount of identifiable non-monetary assets without physical substance. This amount does not include goodwill. [Refer: Goodwill]" } } }, "auth_ref": [ "r7", "r96" ] }, "ifrs-full_IntangibleAssetsOtherThanGoodwillMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "IntangibleAssetsOtherThanGoodwillMember", "presentation": [ "http://www.evogene.com/role/IntangibleAssetsNetScheduleOfIntangibleAssetsDetails" ], "lang": { "en": { "role": { "documentation": "This member stands for intangible assets other than goodwill. [Refer: Intangible assets other than goodwill]" } } }, "auth_ref": [ "r228", "r238" ] }, "ifrs-full_InterestExpenseOnLeaseLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "InterestExpenseOnLeaseLiabilities", "crdr": "debit", "presentation": [ "http://www.evogene.com/role/LeasesScheduleOfLeaseExpensesDetails", "http://www.evogene.com/role/LeasesScheduleOfLeaseLiabilityDetails" ], "lang": { "en-us": { "role": { "label": "Interest expense on lease liabilities", "verboseLabel": "Interest expense" } }, "en": { "role": { "documentation": "The amount of interest expense on lease liabilities. [Refer: Lease liabilities]" } } }, "auth_ref": [ "r148" ] }, "ifrs-full_InterestPaidClassifiedAsOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "InterestPaidClassifiedAsOperatingActivities", "crdr": "credit", "calculation": { "http://www.evogene.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": -1.0, "order": 50.0 } }, "presentation": [ "http://www.evogene.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Interest paid", "label": "Interest paid, classified as operating activities" } }, "en": { "role": { "documentation": "The cash outflow for interest paid, classified as operating activities." } } }, "auth_ref": [ "r111" ] }, "ifrs-full_InterestReceivedClassifiedAsOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "InterestReceivedClassifiedAsOperatingActivities", "crdr": "debit", "calculation": { "http://www.evogene.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0, "order": 20.0 } }, "presentation": [ "http://www.evogene.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Interest received" } }, "en": { "role": { "documentation": "The cash inflow from interest received, classified as operating activities." } } }, "auth_ref": [ "r111" ] }, "ifrs-full_Inventories": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "Inventories", "crdr": "debit", "calculation": { "http://www.evogene.com/role/ConsolidatedStatementsOfFinancialPosition": { "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0, "order": 50.0 }, "http://www.evogene.com/role/SIGNIFICANTACCOUNTINGPOLICIESScheduleOfSummarizesInformationAboutTheInventoryDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.evogene.com/role/ConsolidatedStatementsOfFinancialPosition", "http://www.evogene.com/role/SIGNIFICANTACCOUNTINGPOLICIESScheduleOfSummarizesInformationAboutTheInventoryDetails" ], "lang": { "en-us": { "role": { "label": "Current inventories", "terseLabel": "Inventories", "totalLabel": "Inventories" } }, "en": { "role": { "documentation": "The amount of current inventories. [Refer: Inventories]" } } }, "auth_ref": [ "r9", "r61", "r216" ] }, "ifrs-full_InvestmentAccountedForUsingEquityMethod": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "InvestmentAccountedForUsingEquityMethod", "crdr": "debit", "calculation": { "http://www.evogene.com/role/ConsolidatedStatementsOfFinancialPosition": { "parentTag": "ifrs-full_NoncurrentAssets", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://www.evogene.com/role/ConsolidatedStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Investments accounted for using equity method", "terseLabel": "Investment in an associate" } }, "en": { "role": { "documentation": "The amount of investments accounted for using the equity method. The equity method is a method of accounting whereby the investment is initially recognised at cost and adjusted thereafter for the post-acquisition change in the investor's share of net assets of the investee. The investor's profit or loss includes its share of the profit or loss of the investee. The investor's other comprehensive income includes its share of the other comprehensive income of the investee. [Refer: At cost [member]]" } } }, "auth_ref": [ "r8", "r135", "r201" ] }, "evgn_InvestmentInAffiliatedCompanyWithCorrespondingDeferredRevenues": { "xbrltype": "monetaryItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "InvestmentInAffiliatedCompanyWithCorrespondingDeferredRevenues", "crdr": "credit", "presentation": [ "http://www.evogene.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Represents the amount of investment in affiliated company with corresponding deferred revenues.", "label": "Investment In Affiliated Company With Corresponding Deferred Revenues", "terseLabel": "Investment in affiliated company with corresponding deferred revenues" } } }, "auth_ref": [] }, "ifrs-full_InvestmentsInSubsidiaries": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "InvestmentsInSubsidiaries", "crdr": "debit", "presentation": [ "http://www.evogene.com/role/GeneralNarrativeDetails", "http://www.evogene.com/role/IntangibleAssetsNetNarrativeDetails", "http://www.evogene.com/role/ShareholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Investments in subsidiaries reported in separate financial statements", "terseLabel": "Equity Investment", "verboseLabel": "Investments in subsidiaries" } }, "en": { "role": { "documentation": "The amount of investments in subsidiaries in an entity's separate financial statements. [Refer: Total for all subsidiaries [member]]" } } }, "auth_ref": [ "r77" ] }, "evgn_IsraeliCorporateIncomeTaxAuthorityMember": { "xbrltype": "domainItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "IsraeliCorporateIncomeTaxAuthorityMember", "presentation": [ "http://www.evogene.com/role/TaxesOnIncomeDetails" ], "lang": { "en-us": { "role": { "documentation": "Israeli corporate income tax authority.", "label": "Israeli Corporate Income Tax Authority [Member]", "verboseLabel": "Israeli corporate income tax [Member]" } } }, "auth_ref": [] }, "evgn_IsraeliSubsidiariesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "IsraeliSubsidiariesMember", "presentation": [ "http://www.evogene.com/role/TaxesOnIncomeDetails" ], "lang": { "en-us": { "role": { "documentation": "Israeli subsidiaries.", "label": "Israeli Subsidiaries [Member]", "terseLabel": "Israeli subsidiaries [Member]" } } }, "auth_ref": [] }, "evgn_IssuanceOfOrdinarySharesNet": { "xbrltype": "monetaryItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "IssuanceOfOrdinarySharesNet", "crdr": "credit", "presentation": [ "http://www.evogene.com/role/ConsolidatedStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "documentation": "Represents Issuance of ordinary shares, net.", "label": "Issuance Of Ordinary Shares, Net", "terseLabel": "Issuance of ordinary shares, net" } } }, "auth_ref": [] }, "evgn_IssuanceOfOrdinarySharesParValue": { "xbrltype": "perShareItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "IssuanceOfOrdinarySharesParValue", "presentation": [ "http://www.evogene.com/role/ShareholdersEquityScheduleOfChangesInShareCapitalDetails" ], "lang": { "en-us": { "role": { "documentation": "Issuance of ordinary shares, par value.", "label": "Issuance of ordinary shares, par value" } } }, "auth_ref": [] }, "evgn_IssuanceOfSubsidiaryOrdinarySharesToCompany": { "xbrltype": "monetaryItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "IssuanceOfSubsidiaryOrdinarySharesToCompany", "crdr": "debit", "presentation": [ "http://www.evogene.com/role/ConsolidatedStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "documentation": "Represent the amount of Issuance of a subsidiary ordinary shares to the company", "label": "Issuance Of Subsidiary Ordinary Shares To Company", "verboseLabel": "Issuance of a subsidiary's ordinary shares to the Company" } } }, "auth_ref": [] }, "evgn_IssuanceOfSubsidiaryPreferredSharesToNonControllingInterests": { "xbrltype": "monetaryItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "IssuanceOfSubsidiaryPreferredSharesToNonControllingInterests", "crdr": "credit", "presentation": [ "http://www.evogene.com/role/ConsolidatedStatementsOfChangesInEquity", "http://www.evogene.com/role/ShareholdersEquityNarrativeDetails", "http://www.evogene.com/role/ShareholdersEquityScheduleOfCompositionNon-controllingInterestsDetails" ], "lang": { "en-us": { "role": { "documentation": "Represent the amount of Issuance of a subsidiary preferred shares to non-controlling interests", "label": "Issuance Of Subsidiary Preferred Shares To Non Controlling Interests", "terseLabel": "Shares issuance by a subsidiary to a non-controlling interest", "verboseLabel": "Issuance of a subsidiary's preferred shares to non-controlling interests" } } }, "auth_ref": [] }, "evgn_IssuanceOfSubsidiarySharesToCompany": { "xbrltype": "monetaryItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "IssuanceOfSubsidiarySharesToCompany", "crdr": "credit", "presentation": [ "http://www.evogene.com/role/ShareholdersEquityNarrativeDetails", "http://www.evogene.com/role/ShareholdersEquityScheduleOfCompositionNon-controllingInterestsDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the effect of issuance of subsidiary ordinary shares to the company.", "label": "Issuance Of Subsidiary Shares To Company", "terseLabel": "Issuance of a subsidiary ordinary shares to the company" } } }, "auth_ref": [] }, "ifrs-full_IssueOfEquity": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "IssueOfEquity", "crdr": "credit", "presentation": [ "http://www.evogene.com/role/ShareholdersEquityNarrativeDetails", "http://www.evogene.com/role/ShareholdersEquityScheduleOfCompositionNon-controllingInterestsDetails" ], "lang": { "en-us": { "role": { "label": "Issuance of subsidiary's ordinary shares to non-controlling interests", "terseLabel": "Shares issuance by a subsidiary to a non-controlling interest", "verboseLabel": "Increase in equity" } }, "en": { "role": { "documentation": "The increase in equity through the issue of equity instruments." } } }, "auth_ref": [ "r3" ] }, "ifrs-full_IssuedCapital": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "IssuedCapital", "crdr": "credit", "calculation": { "http://www.evogene.com/role/ConsolidatedStatementsOfFinancialPosition": { "parentTag": "ifrs-full_EquityAttributableToOwnersOfParent", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.evogene.com/role/ConsolidatedStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Issued Capital", "verboseLabel": "Ordinary shares of NIS 0.2 par value: Authorized - 15,000,000 ordinary shares; Issued and outstanding - 6,795,589 ordinary shares on December\u00a031, 2024 and 5,079,313 ordinary shares on December\u00a031, 2023" } }, "en": { "role": { "documentation": "The nominal value of capital issued." } } }, "auth_ref": [ "r219" ] }, "ifrs-full_IssuedCapitalMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "IssuedCapitalMember", "presentation": [ "http://www.evogene.com/role/ConsolidatedStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "label": "Share Capital" } }, "en": { "role": { "documentation": "This member stands for a component of equity representing issued capital." } } }, "auth_ref": [ "r4" ] }, "ifrs-full_KeyManagementPersonnelCompensation": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "KeyManagementPersonnelCompensation", "crdr": "debit", "calculation": { "http://www.evogene.com/role/BalancesAndTransactionsWithExecutiveOfficersAndCertainShareholdersScheduleOfBenefitsToKeyOfficersDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.evogene.com/role/BalancesAndTransactionsWithExecutiveOfficersAndCertainShareholdersScheduleOfBenefitsToKeyOfficersDetails" ], "lang": { "en-us": { "role": { "label": "Key management personnel compensation", "totalLabel": "Total" } }, "en": { "role": { "documentation": "The amount of compensation to key management personnel. [Refer: Key management personnel of entity or parent [member]]" } } }, "auth_ref": [ "r67" ] }, "ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "KeyManagementPersonnelCompensationSharebasedPayment", "crdr": "debit", "calculation": { "http://www.evogene.com/role/BalancesAndTransactionsWithExecutiveOfficersAndCertainShareholdersScheduleOfBenefitsToKeyOfficersDetails": { "parentTag": "ifrs-full_KeyManagementPersonnelCompensation", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://www.evogene.com/role/BalancesAndTransactionsWithExecutiveOfficersAndCertainShareholdersScheduleOfBenefitsToKeyOfficersDetails" ], "lang": { "en-us": { "role": { "label": "Key management personnel compensation, share-based payment", "verboseLabel": "Share-based compensation" } }, "en": { "role": { "documentation": "The amount of compensation to key management personnel in the form of share-based payments. [Refer: Key management personnel of entity or parent [member]]" } } }, "auth_ref": [ "r66" ] }, "ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "KeyManagementPersonnelCompensationShorttermEmployeeBenefits", "crdr": "debit", "calculation": { "http://www.evogene.com/role/BalancesAndTransactionsWithExecutiveOfficersAndCertainShareholdersScheduleOfBenefitsToKeyOfficersDetails": { "parentTag": "ifrs-full_KeyManagementPersonnelCompensation", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.evogene.com/role/BalancesAndTransactionsWithExecutiveOfficersAndCertainShareholdersScheduleOfBenefitsToKeyOfficersDetails" ], "lang": { "en-us": { "role": { "label": "Salary and related benefits" } }, "en": { "role": { "documentation": "The amount of compensation to key management personnel in the form of short-term employee benefits. [Refer: Key management personnel of entity or parent [member]]" } } }, "auth_ref": [ "r65" ] }, "evgn_KeyOfficersMember": { "xbrltype": "domainItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "KeyOfficersMember", "presentation": [ "http://www.evogene.com/role/BalancesAndTransactionsWithExecutiveOfficersAndCertainShareholdersScheduleOfBenefitsToKeyOfficersDetails" ], "lang": { "en-us": { "role": { "documentation": "Key officers [Member]", "label": "Key officers [Member]", "terseLabel": "Executive officers [Member]" } } }, "auth_ref": [] }, "evgn_LaboratoryEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "LaboratoryEquipmentMember", "presentation": [ "http://www.evogene.com/role/PropertyPlantAndEquipmentNetScheduleOfPropertyPlantEquipmentToAccumulatedDepreciationDetails", "http://www.evogene.com/role/SignificantAccountingPoliciesScheduleOfDepreciationCalculatedUsingStraight-lineMethodDetails" ], "lang": { "en-us": { "role": { "documentation": "Laboratory equipment [Member]", "label": "Laboratory equipment [Member]" } } }, "auth_ref": [] }, "ifrs-full_LaterThanFiveYearsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "LaterThanFiveYearsMember", "presentation": [ "http://www.evogene.com/role/FinancialInstrumentsScheduleOfCompanysFinancialLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Over 5 Years [Member]" } }, "en": { "role": { "documentation": "This member stands for a time band of later than five years." } } }, "auth_ref": [ "r153", "r154", "r161", "r243", "r245", "r247" ] }, "ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "LaterThanFourYearsAndNotLaterThanFiveYearsMember", "presentation": [ "http://www.evogene.com/role/FinancialInstrumentsScheduleOfCompanysFinancialLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "4 Year To 5 Years [Member]" } }, "en": { "role": { "documentation": "This member stands for a time band of later than four years and not later than five years." } } }, "auth_ref": [ "r153", "r154", "r161", "r243", "r247", "r365" ] }, "ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "LaterThanOneYearAndNotLaterThanTwoYearsMember", "presentation": [ "http://www.evogene.com/role/FinancialInstrumentsScheduleOfCompanysFinancialLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "1 Year To 2 Years [Member]" } }, "en": { "role": { "documentation": "This member stands for a time band of later than one year and not later than two years." } } }, "auth_ref": [ "r153", "r154", "r161", "r243", "r247", "r365" ] }, "ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "LaterThanThreeYearsAndNotLaterThanFourYearsMember", "presentation": [ "http://www.evogene.com/role/FinancialInstrumentsScheduleOfCompanysFinancialLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "3 Year To 4 Years [Member]" } }, "en": { "role": { "documentation": "This member stands for a time band of later than three years and not later than four years." } } }, "auth_ref": [ "r153", "r154", "r161", "r243", "r247", "r365" ] }, "ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "LaterThanTwoYearsAndNotLaterThanThreeYearsMember", "presentation": [ "http://www.evogene.com/role/FinancialInstrumentsScheduleOfCompanysFinancialLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "2 Year To 3 Years [Member]" } }, "en": { "role": { "documentation": "This member stands for a time band of later than two years and not later than three years." } } }, "auth_ref": [ "r153", "r154", "r161", "r243", "r247", "r365" ] }, "evgn_LavieBioLtdMember": { "xbrltype": "domainItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "LavieBioLtdMember", "presentation": [ "http://www.evogene.com/role/CollaborationAndResearchAgreementsNarrativeDetails", "http://www.evogene.com/role/ConvertibleSAFENarrativeDetails", "http://www.evogene.com/role/GeneralNarrativeDetails", "http://www.evogene.com/role/IntangibleAssetsNetNarrativeDetails", "http://www.evogene.com/role/LiabilitiesInRespectOfGovernmentGrantsNarrativeDetails", "http://www.evogene.com/role/ShareholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Lavie Bio Ltd [Member]", "label": "Lavie Bio Ltd [Member]", "verboseLabel": "Lavie Bio Ltd" } } }, "auth_ref": [] }, "evgn_LeaseDeposits": { "xbrltype": "monetaryItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "LeaseDeposits", "crdr": "credit", "presentation": [ "http://www.evogene.com/role/LeasesScheduleOfLeaseLiabilityDetails" ], "lang": { "en-us": { "role": { "documentation": "Lease deposits.", "label": "Lease deposits", "verboseLabel": "Lease deposits" } } }, "auth_ref": [] }, "ifrs-full_LeaseLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "LeaseLiabilities", "crdr": "credit", "presentation": [ "http://www.evogene.com/role/LeasesScheduleOfLeaseLiabilityDetails" ], "lang": { "en-us": { "role": { "periodEndLabel": "Balance at end of year", "periodStartLabel": "Balance at beginning year", "label": "Lease liabilities" } }, "en": { "role": { "documentation": "The amount of liabilities related to the entity's leases. Lease is a contract, or part of a contract, that conveys the right to use an underlying asset for a period of time in exchange for consideration." } } }, "auth_ref": [ "r146" ] }, "evgn_LeaseLiabilitiesLess": { "xbrltype": "monetaryItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "LeaseLiabilitiesLess", "crdr": "credit", "presentation": [ "http://www.evogene.com/role/LeasesScheduleOfFutureMinimumLeasePaymentsUnderNon-cancelableLeasesDetails" ], "lang": { "en-us": { "role": { "documentation": "Less: imputed interest.", "label": "Lease Liabilities Less", "verboseLabel": "Less: imputed interest" } } }, "auth_ref": [] }, "evgn_LeaseLiabilityNominalValue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "LeaseLiabilityNominalValue", "crdr": "credit", "calculation": { "http://www.evogene.com/role/FinancialInstrumentsScheduleOfCompanysFinancialLiabilitiesDetails": { "parentTag": "ifrs-full_FinancialLiabilities", "weight": 1.0, "order": 40.0 } }, "presentation": [ "http://www.evogene.com/role/FinancialInstrumentsScheduleOfCompanysFinancialLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Lease liability, nominal value.", "label": "Lease Liability Nominal Value", "verboseLabel": "Leases liability" } } }, "auth_ref": [] }, "evgn_LeasePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "LeasePayments", "crdr": "credit", "presentation": [ "http://www.evogene.com/role/LeasesScheduleOfLeaseLiabilityDetails" ], "lang": { "en-us": { "role": { "documentation": "Lease payments.", "label": "Lease Payments", "verboseLabel": "Lease payments" } } }, "auth_ref": [] }, "evgn_LeasePeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "LeasePeriod", "presentation": [ "http://www.evogene.com/role/LeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Lease Period.", "label": "Lease period" } } }, "auth_ref": [] }, "evgn_LeaseTermExcludingExtensionPeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "LeaseTermExcludingExtensionPeriod", "presentation": [ "http://www.evogene.com/role/LeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Lease term excluding extension period.", "label": "Lease term excluding extension period" } } }, "auth_ref": [] }, "ifrs-full_LeaseholdImprovementsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "LeaseholdImprovementsMember", "presentation": [ "http://www.evogene.com/role/PropertyPlantAndEquipmentNetScheduleOfPropertyPlantEquipmentToAccumulatedDepreciationDetails", "http://www.evogene.com/role/SignificantAccountingPoliciesScheduleOfDepreciationCalculatedUsingStraight-lineMethodDetails" ], "lang": { "en-us": { "role": { "label": "Leasehold improvements [Member]" } }, "en": { "role": { "documentation": "This member stands for a class of property, plant and equipment representing improvements to assets held under a lease agreement." } } }, "auth_ref": [ "r370" ] }, "evgn_LeaseholdMember": { "xbrltype": "domainItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "LeaseholdMember", "presentation": [ "http://www.evogene.com/role/LeasesNarrativeDetails", "http://www.evogene.com/role/LeasesScheduleOfFutureMinimumLeasePaymentsUnderNon-cancelableLeasesDetails", "http://www.evogene.com/role/LeasesScheduleOfLeaseLiabilityDetails", "http://www.evogene.com/role/LeasesScheduleOfRight-of-useAssetsDetails" ], "lang": { "en-us": { "role": { "documentation": "Leasehold [Member]", "label": "Leasehold [Member]" } } }, "auth_ref": [] }, "evgn_LeaseholdSpaceMember": { "xbrltype": "domainItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "LeaseholdSpaceMember", "presentation": [ "http://www.evogene.com/role/SignificantAccountingPoliciesScheduleOfUsefulLifeOfRightOfUseAssetsDetails" ], "lang": { "en-us": { "role": { "documentation": "Laboratory space [Member]", "label": "Leasehold Space Member", "terseLabel": "Laboratory space [Member]" } } }, "auth_ref": [] }, "evgn_LegalOfSalesAndMarketing": { "xbrltype": "monetaryItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "LegalOfSalesAndMarketing", "crdr": "debit", "calculation": { "http://www.evogene.com/role/StatementsOfComprehensiveLoss-AdditionalInformationScheduleOfIncomeAndExpensesDetails": { "parentTag": "ifrs-full_SalesAndMarketingExpense", "weight": 1.0, "order": 30.0 } }, "presentation": [ "http://www.evogene.com/role/StatementsOfComprehensiveLoss-AdditionalInformationScheduleOfIncomeAndExpensesDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of legal for sales and marketing.", "label": "Legal Of Sales And Marketing", "verboseLabel": "Legal" } } }, "auth_ref": [] }, "ifrs-full_LegalProceedingsContingentLiabilityMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "LegalProceedingsContingentLiabilityMember", "presentation": [ "http://www.evogene.com/role/COMMITMENTSANDCONTINGENTLIABILITIESNarrativeDetails", "http://www.evogene.com/role/SUBSEQUENTEVENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Legal proceedings contingent liability [member]", "verboseLabel": "Legal proceedings by Casterra Ag Ltd [member]" } }, "en": { "role": { "documentation": "This member stands for a contingent liability for legal proceedings. [Refer: Classes of contingent liabilities [domain]]" } } }, "auth_ref": [ "r229" ] }, "ifrs-full_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "Liabilities", "crdr": "credit", "calculation": { "http://www.evogene.com/role/ConsolidatedStatementsOfFinancialPosition": { "parentTag": "ifrs-full_EquityAndLiabilities", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.evogene.com/role/ConsolidatedStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Liabilities", "totalLabel": "TOTAL LIABILITIES" } }, "en": { "role": { "documentation": "The amount of a present obligation of the entity to transfer an economic resource as a result of past events. Economic resource is a right that has the potential to produce economic benefits." } } }, "auth_ref": [ "r16", "r137", "r138", "r139", "r200", "r205" ] }, "evgn_LiabilitiesInRespectOfGovernmentGrants": { "xbrltype": "monetaryItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "LiabilitiesInRespectOfGovernmentGrants", "crdr": "credit", "calculation": { "http://www.evogene.com/role/FinancialInstrumentsScheduleOfCompanysFinancialLiabilitiesDetails": { "parentTag": "ifrs-full_FinancialLiabilities", "weight": 1.0, "order": 30.0 } }, "presentation": [ "http://www.evogene.com/role/FinancialInstrumentsScheduleOfCompanysFinancialLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Liabilities In Respect Of Government Grants.", "label": "Liabilities In Respect Of Government Grants", "verboseLabel": "Liabilities in respect of government grants" } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": [ "http://www.evogene.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "evgn_LongTermDepositsAndOtherReceivables": { "xbrltype": "monetaryItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "LongTermDepositsAndOtherReceivables", "crdr": "debit", "calculation": { "http://www.evogene.com/role/ConsolidatedStatementsOfFinancialPosition": { "parentTag": "ifrs-full_NoncurrentAssets", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.evogene.com/role/ConsolidatedStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "documentation": "Represents about long-term deposits and other receivables.", "label": "Long Term Deposits And Other Receivables", "terseLabel": "Long-term deposits and other receivables", "verboseLabel": "Long-term deposits and other receivables" } } }, "auth_ref": [] }, "evgn_LossesOnExchangeDifferencesOnTranslationNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "LossesOnExchangeDifferencesOnTranslationNetOfTax", "crdr": "debit", "calculation": { "http://www.evogene.com/role/StatementsOfComprehensiveLoss-AdditionalInformationScheduleOfIncomeAndExpensesDetails": { "parentTag": "ifrs-full_FinanceCosts", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://www.evogene.com/role/StatementsOfComprehensiveLoss-AdditionalInformationScheduleOfIncomeAndExpensesDetails" ], "lang": { "en-us": { "role": { "documentation": "Losses recognized in Financing expenses on exchange differences on the translation of foreign currency monetary amounts.", "label": "Losses On Exchange Differences On Translation Net Of Tax", "verboseLabel": "Exchange differences" } } }, "auth_ref": [] }, "evgn_MainlyUsefulLivesOrDepreciationRatesLeases": { "xbrltype": "stringItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "MainlyUsefulLivesOrDepreciationRatesLeases", "presentation": [ "http://www.evogene.com/role/SignificantAccountingPoliciesScheduleOfUsefulLifeOfRightOfUseAssetsDetails" ], "lang": { "en-us": { "role": { "documentation": "The main useful lives or depreciation rates used for leases.", "label": "Mainly Useful Lives Or Depreciation Rates Leases", "verboseLabel": "Mainly %" } } }, "auth_ref": [] }, "evgn_MainlyUsefulLivesOrDepreciationRatesPropertyPlantAndEquipment": { "xbrltype": "stringItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "MainlyUsefulLivesOrDepreciationRatesPropertyPlantAndEquipment", "presentation": [ "http://www.evogene.com/role/SignificantAccountingPoliciesScheduleOfDepreciationCalculatedUsingStraight-lineMethodDetails" ], "lang": { "en-us": { "role": { "documentation": "The main useful lives or depreciation rates used for property, plant and equipment.", "label": "Mainly Useful Lives Or Depreciation Rates Property Plant And Equipment", "terseLabel": "Mainly %" } } }, "auth_ref": [] }, "srt_MajorCustomersAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MajorCustomersAxis", "presentation": [ "http://www.evogene.com/role/BalancesAndTransactionsWithExecutiveOfficersAndCertainShareholdersNarrativeDetails", "http://www.evogene.com/role/CollaborationAndResearchAgreementsNarrativeDetails", "http://www.evogene.com/role/OperatingSegmentsScheduleOfRevenuesFromMajorCustomersDetails" ], "lang": { "en-us": { "role": { "label": "Customer [Axis]" } } }, "auth_ref": [] }, "evgn_MarketingExpensesReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "MarketingExpensesReceivable", "crdr": "debit", "presentation": [ "http://www.evogene.com/role/LiabilitiesInRespectOfGovernmentGrantsNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the amount of grant to be received for marketing expenses.", "label": "Marketing Expenses Receivable", "verboseLabel": "Marketing expenses receivable" } } }, "auth_ref": [] }, "evgn_MaterialsAndSubcontractorsExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "MaterialsAndSubcontractorsExpenses", "crdr": "debit", "calculation": { "http://www.evogene.com/role/StatementsOfComprehensiveLoss-AdditionalInformationScheduleOfIncomeAndExpensesDetails": { "parentTag": "ifrs-full_ResearchAndDevelopmentExpense", "weight": 1.0, "order": 20.0 } }, "presentation": [ "http://www.evogene.com/role/StatementsOfComprehensiveLoss-AdditionalInformationScheduleOfIncomeAndExpensesDetails" ], "lang": { "en-us": { "role": { "documentation": "Materials and sub-contractors from research and development expenses.", "label": "Materials And Subcontractors Expenses", "verboseLabel": "Materials and sub-contractors" } } }, "auth_ref": [] }, "ifrs-full_MaturityAnalysisForNonderivativeFinancialLiabilities": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "MaturityAnalysisForNonderivativeFinancialLiabilities", "presentation": [ "http://www.evogene.com/role/FinancialInstrumentsTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Financial Liabilities" } }, "en": { "role": { "documentation": "The disclosure of a maturity analysis for non-derivative financial liabilities (including issued financial guarantee contracts) that shows the remaining contractual maturities. [Refer: Derivative financial liabilities]" } } }, "auth_ref": [ "r192" ] }, "ifrs-full_MaturityAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "MaturityAxis", "presentation": [ "http://www.evogene.com/role/FinancialInstrumentsScheduleOfCompanysFinancialLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Maturity [Axis]", "verboseLabel": "Maturity [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r19", "r144", "r153", "r154", "r158", "r159", "r160", "r161", "r184", "r194", "r226", "r243" ] }, "ifrs-full_MaturityDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "MaturityDomain", "presentation": [ "http://www.evogene.com/role/FinancialInstrumentsScheduleOfCompanysFinancialLiabilitiesDetails" ], "lang": { "en": { "role": { "documentation": "This member stands for aggregated time bands. It also represents the standard value for the 'Maturity' axis if no other member is used." } } }, "auth_ref": [ "r19", "r144", "r153", "r154", "r158", "r159", "r160", "r161", "r184", "r226", "r243", "r246" ] }, "evgn_MaximumAmountOfValuationForConversion": { "xbrltype": "monetaryItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "MaximumAmountOfValuationForConversion", "crdr": "credit", "presentation": [ "http://www.evogene.com/role/ConvertibleSAFENarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Represent the maximum amount of valuation for conversion.", "label": "Maximum Amount Of Valuation For Conversion", "terseLabel": "Maximum amount of valuation for conversion" } } }, "auth_ref": [] }, "evgn_MaximumGrantsAmountFromSmartMoneyProgram": { "xbrltype": "monetaryItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "MaximumGrantsAmountFromSmartMoneyProgram", "crdr": "credit", "presentation": [ "http://www.evogene.com/role/LiabilitiesInRespectOfGovernmentGrantsNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "The maximum grants amount from Smart money program.", "label": "Maximum Grants Amount From Smart Money Program", "terseLabel": "Maximum grants amount from Smart money program" } } }, "auth_ref": [] }, "evgn_MaximumPercentageOfInterestAcquireThroughAdditionalInvestmentOnFullyDilutedShareCapitalBasis": { "xbrltype": "percentItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "MaximumPercentageOfInterestAcquireThroughAdditionalInvestmentOnFullyDilutedShareCapitalBasis", "presentation": [ "http://www.evogene.com/role/ConvertibleSAFENarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Represent the maximum percentage of interest acquire through additional Investment on fully diluted share capital basis.", "label": "Maximum Percentage Of Interest Acquire Through Additional Investment On Fully Diluted Share Capital Basis", "terseLabel": "Maximum percentage of interest acquire through additional Investment on fully diluted share capital basis" } } }, "auth_ref": [] }, "ecd_MeasureAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Measure [Axis]", "terseLabel": "Measure:" } } }, "auth_ref": [ "r312" ] }, "ecd_MeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Measure Name", "terseLabel": "Name" } } }, "auth_ref": [ "r312" ] }, "evgn_MicroorganismsCollectionMember": { "xbrltype": "domainItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "MicroorganismsCollectionMember", "presentation": [ "http://www.evogene.com/role/IntangibleAssetsNetScheduleOfIntangibleAssetsDetails", "http://www.evogene.com/role/SignificantAccountingPoliciesScheduleOfIntangibleAssetsPurchasedDetails" ], "lang": { "en-us": { "role": { "documentation": "Microorganisms Collection [Member]", "label": "Microorganisms Collection [Member]" } } }, "auth_ref": [] }, "ecd_MnpiDiscTimedForCompValFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MnpiDiscTimedForCompValFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "MNPI Disclosure Timed for Compensation Value [Flag]", "terseLabel": "MNPI Disclosure Timed for Compensation Value" } } }, "auth_ref": [ "r332" ] }, "ifrs-full_MotorVehiclesMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "MotorVehiclesMember", "presentation": [ "http://www.evogene.com/role/LeasesScheduleOfFutureMinimumLeasePaymentsUnderNon-cancelableLeasesDetails", "http://www.evogene.com/role/LeasesScheduleOfLeaseLiabilityDetails", "http://www.evogene.com/role/LeasesScheduleOfRight-of-useAssetsDetails", "http://www.evogene.com/role/SignificantAccountingPoliciesScheduleOfUsefulLifeOfRightOfUseAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Motor vehicles [Member]" } }, "en": { "role": { "documentation": "This member stands for a class of property, plant and equipment representing self-propelled ground vehicles used in the entity's operations. [Refer: Property, plant and equipment]" } } }, "auth_ref": [ "r221" ] }, "ecd_MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Material Terms of Trading Arrangement [Text Block]", "terseLabel": "Material Terms of Trading Arrangement" } } }, "auth_ref": [ "r340" ] }, "evgn_MultiYearCollaborationAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "MultiYearCollaborationAgreementMember", "presentation": [ "http://www.evogene.com/role/ConvertibleSAFENarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "This member is stand for multi year collaboration agreement.", "label": "Multi Year Collaboration Agreement [Member]", "verboseLabel": "Multi Year Collaboration Agreement" } } }, "auth_ref": [] }, "srt_NameOfMajorCustomerDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "NameOfMajorCustomerDomain", "presentation": [ "http://www.evogene.com/role/BalancesAndTransactionsWithExecutiveOfficersAndCertainShareholdersNarrativeDetails", "http://www.evogene.com/role/CollaborationAndResearchAgreementsNarrativeDetails", "http://www.evogene.com/role/OperatingSegmentsScheduleOfRevenuesFromMajorCustomersDetails" ], "lang": { "en-us": { "role": { "label": "Customer [Domain]" } } }, "auth_ref": [] }, "ecd_NamedExecutiveOfficersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NamedExecutiveOfficersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Named Executive Officers, Footnote [Text Block]", "terseLabel": "Named Executive Officers, Footnote" } } }, "auth_ref": [ "r313" ] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLoss", "crdr": "credit", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Net Income (Loss)", "terseLabel": "Net Income (Loss)" } } }, "auth_ref": [] }, "evgn_NonCurrentDeferredExpensesRelatedToIssuanceOfWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "NonCurrentDeferredExpensesRelatedToIssuanceOfWarrants", "crdr": "debit", "calculation": { "http://www.evogene.com/role/ConsolidatedStatementsOfFinancialPosition": { "parentTag": "ifrs-full_NoncurrentAssets", "weight": 1.0, "order": 50.0 } }, "presentation": [ "http://www.evogene.com/role/ConsolidatedStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "documentation": "Represents the amount of non current deferred expenses related to issuance of warrants.", "label": "Non Current Deferred Expenses Related To Issuance Of Warrants", "terseLabel": "Deferred expenses related to issuance of warrants" } } }, "auth_ref": [] }, "ecd_NonGaapMeasureDescriptionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonGaapMeasureDescriptionTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-GAAP Measure Description [Text Block]", "terseLabel": "Non-GAAP Measure Description" } } }, "auth_ref": [ "r312" ] }, "ecd_NonNeosMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonNeosMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-NEOs [Member]", "terseLabel": "Non-NEOs" } } }, "auth_ref": [ "r275", "r286", "r296", "r320", "r329" ] }, "ecd_NonPeoNeoAvgCompActuallyPaidAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgCompActuallyPaidAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Compensation Actually Paid Amount", "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount" } } }, "auth_ref": [ "r303" ] }, "ecd_NonPeoNeoAvgTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Total Compensation Amount", "terseLabel": "Non-PEO NEO Average Total Compensation Amount" } } }, "auth_ref": [ "r302" ] }, "ecd_NonPeoNeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-PEO NEO [Member]", "terseLabel": "Non-PEO NEO" } } }, "auth_ref": [ "r320" ] }, "ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]", "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted" } } }, "auth_ref": [ "r340" ] }, "ecd_NonRule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]", "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": [ "r340" ] }, "ifrs-full_NonadjustingEventsAfterReportingPeriodAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "NonadjustingEventsAfterReportingPeriodAxis", "presentation": [ "http://www.evogene.com/role/LiabilitiesInRespectOfGovernmentGrantsNarrativeDetails", "http://www.evogene.com/role/SUBSEQUENTEVENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Non-adjusting events after reporting period [axis]", "verboseLabel": "Non-adjusting events after reporting period [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r39" ] }, "ifrs-full_NonadjustingEventsAfterReportingPeriodDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "NonadjustingEventsAfterReportingPeriodDomain", "presentation": [ "http://www.evogene.com/role/LiabilitiesInRespectOfGovernmentGrantsNarrativeDetails", "http://www.evogene.com/role/SUBSEQUENTEVENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Non-adjusting events after reporting period [domain]" } }, "en": { "role": { "documentation": "This member stands for events that occur between the end of the reporting period and the date when the financial statements are authorised for issue and are indicative of conditions that arose after the reporting period. It also represents the standard value for the 'Non-adjusting events after reporting period' axis if no other member is used." } } }, "auth_ref": [ "r39" ] }, "evgn_NoncontrollingInterestAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "NoncontrollingInterestAxis", "presentation": [ "http://www.evogene.com/role/ShareholdersEquityScheduleOfCompositionNon-controllingInterestsDetails" ], "lang": { "en-us": { "role": { "documentation": "Noncontrolling Interest [Axis]", "label": "Noncontrolling Interest [Axis]", "verboseLabel": "NoncontrollingInterestAxis [Axis]" } } }, "auth_ref": [] }, "evgn_NoncontrollingInterestDomain": { "xbrltype": "domainItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "NoncontrollingInterestDomain", "presentation": [ "http://www.evogene.com/role/ShareholdersEquityScheduleOfCompositionNon-controllingInterestsDetails" ], "lang": { "en-us": { "role": { "label": "Noncontrolling Interest [Domain]" } } }, "auth_ref": [] }, "ifrs-full_NoncontrollingInterests": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "NoncontrollingInterests", "crdr": "credit", "calculation": { "http://www.evogene.com/role/ConsolidatedStatementsOfFinancialPosition": { "parentTag": "ifrs-full_Equity", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://www.evogene.com/role/ConsolidatedStatementsOfFinancialPosition", "http://www.evogene.com/role/ShareholdersEquityScheduleOfCompositionNon-controllingInterestsDetails" ], "lang": { "en-us": { "role": { "periodEndLabel": "Balance", "periodStartLabel": "Balance", "label": "Non-controlling interests", "totalLabel": "Total equity attributable to owners of parent" } }, "en": { "role": { "documentation": "The amount of equity in a subsidiary not attributable, directly or indirectly, to a parent. [Refer: Total for all subsidiaries [member]]" } } }, "auth_ref": [ "r14", "r121", "r124" ] }, "ifrs-full_NoncontrollingInterestsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "NoncontrollingInterestsMember", "presentation": [ "http://www.evogene.com/role/ConsolidatedStatementsOfChangesInEquity", "http://www.evogene.com/role/ShareholdersEquityNarrativeDetails", "http://www.evogene.com/role/ShareholdersEquityScheduleOfCompositionNon-controllingInterestsDetails" ], "lang": { "en-us": { "role": { "label": "Non-controlling Interests", "verboseLabel": "Non-controlling interests [member]" } }, "en": { "role": { "documentation": "This member stands for equity in a subsidiary not attributable, directly or indirectly, to the parent." } } }, "auth_ref": [ "r4" ] }, "ifrs-full_NoncurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "NoncurrentAssets", "crdr": "debit", "calculation": { "http://www.evogene.com/role/ConsolidatedStatementsOfFinancialPosition": { "parentTag": "ifrs-full_Assets", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://www.evogene.com/role/ConsolidatedStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Total long term assets", "totalLabel": "Total long term assets" } }, "en": { "role": { "documentation": "The amount of assets that do not meet the definition of current assets. [Refer: Current assets]" } } }, "auth_ref": [ "r20", "r127", "r234" ] }, "ifrs-full_NoncurrentAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "NoncurrentAssetsAbstract", "presentation": [ "http://www.evogene.com/role/ConsolidatedStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "LONG-TERM ASSETS:", "verboseLabel": "Non-current assets [abstract]" } } }, "auth_ref": [] }, "ifrs-full_NoncurrentGovernmentGrants": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "NoncurrentGovernmentGrants", "crdr": "credit", "calculation": { "http://www.evogene.com/role/ConsolidatedStatementsOfFinancialPosition": { "parentTag": "ifrs-full_NoncurrentLiabilities", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://www.evogene.com/role/ConsolidatedStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Non-current government grants", "terseLabel": "Liabilities in respect of government grants", "verboseLabel": "Liabilities in respect of government grants" } }, "en": { "role": { "documentation": "The amount of non-current government grants recognised on the statement of financial position as deferred income. [Refer: Government [member]; Government grants]" } } }, "auth_ref": [ "r367" ] }, "ifrs-full_NoncurrentLeaseLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "NoncurrentLeaseLiabilities", "crdr": "credit", "calculation": { "http://www.evogene.com/role/ConsolidatedStatementsOfFinancialPosition": { "parentTag": "ifrs-full_NoncurrentLiabilities", "weight": 1.0, "order": 30.0 } }, "presentation": [ "http://www.evogene.com/role/ConsolidatedStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Lease liability", "terseLabel": "Lease liabilities" } }, "en": { "role": { "documentation": "The amount of non-current lease liabilities. [Refer: Lease liabilities]" } } }, "auth_ref": [ "r146" ] }, "ifrs-full_NoncurrentLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "NoncurrentLiabilities", "crdr": "credit", "calculation": { "http://www.evogene.com/role/ConsolidatedStatementsOfFinancialPosition": { "parentTag": "ifrs-full_Liabilities", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://www.evogene.com/role/ConsolidatedStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Non-current liabilities", "totalLabel": "Total non-current liabilities" } }, "en": { "role": { "documentation": "The amount of liabilities that do not meet the definition of current liabilities. [Refer: Current liabilities]" } } }, "auth_ref": [ "r21", "r129", "r234" ] }, "ifrs-full_NoncurrentLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "NoncurrentLiabilitiesAbstract", "presentation": [ "http://www.evogene.com/role/ConsolidatedStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "LONG-TERM LIABILITIES:" } } }, "auth_ref": [] }, "ifrs-full_NotLaterThanOneYearMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "NotLaterThanOneYearMember", "presentation": [ "http://www.evogene.com/role/FinancialInstrumentsScheduleOfCompanysFinancialLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Up to 1 year [Member]" } }, "en": { "role": { "documentation": "This member stands for a time band of not later than one year." } } }, "auth_ref": [ "r18", "r153", "r154", "r161", "r243", "r247" ] }, "ifrs-full_NotionalAmount": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "NotionalAmount", "presentation": [ "http://www.evogene.com/role/ConvertibleSAFENarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Notional amount", "terseLabel": "Face amount" } }, "en": { "role": { "documentation": "The nominal or face amount of a financial instrument, used to calculate payments made on that instrument." } } }, "auth_ref": [ "r365" ] }, "evgn_NumberAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "NumberAbstract", "presentation": [ "http://www.evogene.com/role/Share-BasedCompensationScheduleOfSummarizedNumberOfShareOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Number Abstract" } } }, "auth_ref": [] }, "evgn_NumberOfDirectorsCompensatedByEntityDuringYear": { "xbrltype": "integerItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "NumberOfDirectorsCompensatedByEntityDuringYear", "presentation": [ "http://www.evogene.com/role/BalancesAndTransactionsWithKeyOfficersAndCertainShareholdersScheduleOfBenefitsToDirectorsDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of directors received the above compensation by the Company.", "label": "Number Of Directors Compensated By Entity During Year", "verboseLabel": "Number of directors that received the above compensation by the Company" } } }, "auth_ref": [] }, "ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "NumberOfInstrumentsOtherEquityInstrumentsGranted", "presentation": [ "http://www.evogene.com/role/SHAREBASEDCOMPENSATIONScheduleOfRestrictedStockUnitsActivityDetails", "http://www.evogene.com/role/Share-BasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Number of other equity instruments granted in share-based payment arrangement", "verboseLabel": "Number of RSUs, Granted" } }, "en": { "role": { "documentation": "The number of other equity instruments (ie other than share options) granted in a share-based payment arrangement." } } }, "auth_ref": [ "r175", "r388" ] }, "evgn_NumberOfIssuanceOfOrdinaryShares": { "xbrltype": "sharesItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "NumberOfIssuanceOfOrdinaryShares", "presentation": [ "http://www.evogene.com/role/ShareholdersEquityScheduleOfChangesInShareCapitalDetails" ], "lang": { "en-us": { "role": { "documentation": "Issuance of ordinary shares.", "label": "Number Of Issuance Of Ordinary Shares", "terseLabel": "Issuance of ordinary shares" } } }, "auth_ref": [] }, "evgn_NumberOfKeyOfficersEmployedByEntityDuringYear": { "xbrltype": "integerItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "NumberOfKeyOfficersEmployedByEntityDuringYear", "presentation": [ "http://www.evogene.com/role/BalancesAndTransactionsWithExecutiveOfficersAndCertainShareholdersScheduleOfBenefitsToKeyOfficersDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of people that received salary and benefits.", "label": "Number Of Key Officers Employed By Entity During Year", "terseLabel": "Number of people that received salary and benefits" } } }, "auth_ref": [] }, "evgn_NumberOfOrdinarySharesSold": { "xbrltype": "sharesItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "NumberOfOrdinarySharesSold", "presentation": [ "http://www.evogene.com/role/GeneralNarrativeDetails", "http://www.evogene.com/role/ShareholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the amount of ordinary shares sold.", "label": "Number Of Ordinary Shares Sold", "verboseLabel": "Number of ordinary shares sold" } } }, "auth_ref": [] }, "ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement", "presentation": [ "http://www.evogene.com/role/SHAREBASEDCOMPENSATIONScheduleOfRestrictedStockUnitsActivityDetails", "http://www.evogene.com/role/ShareholdersEquityNarrativeDetails", "http://www.evogene.com/role/ShareholdersEquityScheduleOfChangesInShareCapitalDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Number of RSUs, Vested", "positiveLabel": "Number of RSUs, Vested", "label": "Number of other equity instruments exercised or vested in share-based payment arrangement", "terseLabel": "Exercise/vested other equity instrument", "verboseLabel": "Exercise of pre-funded warrants" } }, "en": { "role": { "documentation": "The number of other equity instruments (ie other than share options) exercised or vested in a share-based payment arrangement." } } }, "auth_ref": [ "r388" ] }, "ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement", "presentation": [ "http://www.evogene.com/role/SHAREBASEDCOMPENSATIONScheduleOfRestrictedStockUnitsActivityDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Number of RSUs, Forfeited", "label": "Number of other equity instruments forfeited in share-based payment arrangement", "verboseLabel": "Number of RSUs, Forfeited" } }, "en": { "role": { "documentation": "The number of other equity instruments (ie other than share options) forfeited in a share-based payment arrangement." } } }, "auth_ref": [ "r388" ] }, "ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement", "presentation": [ "http://www.evogene.com/role/SHAREBASEDCOMPENSATIONScheduleOfRestrictedStockUnitsActivityDetails" ], "lang": { "en-us": { "role": { "periodEndLabel": "Number of RSUs, Outstanding", "periodStartLabel": "Number of RSUs, Outstanding", "label": "Number of other equity instruments outstanding in share-based payment arrangement" } }, "en": { "role": { "documentation": "The number of other equity instruments (ie other than share options) outstanding in a share-based payment arrangement." } } }, "auth_ref": [ "r388" ] }, "ifrs-full_NumberOfOutstandingShareOptions": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "NumberOfOutstandingShareOptions", "presentation": [ "http://www.evogene.com/role/Share-BasedCompensationScheduleOfShareOptionsOutstandingDetails", "http://www.evogene.com/role/Share-BasedCompensationScheduleOfSummarizedNumberOfShareOptionsDetails" ], "lang": { "en-us": { "role": { "periodEndLabel": "Outstanding at end of year", "periodStartLabel": "Outstanding on beginning of year", "label": "Number of options outstanding" } }, "en": { "role": { "documentation": "The number of share options outstanding in a share-based payment arrangement." } } }, "auth_ref": [ "r163", "r167", "r171" ] }, "evgn_NumberOfPrefundedWarrants": { "xbrltype": "sharesItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "NumberOfPrefundedWarrants", "presentation": [ "http://www.evogene.com/role/GeneralNarrativeDetails", "http://www.evogene.com/role/ShareholdersEquityNarrativeDetails", "http://www.evogene.com/role/ShareholdersEquityScheduleOfChangesInShareCapitalDetails" ], "lang": { "en-us": { "role": { "documentation": "Pre-funded warrants.", "label": "Number Of Prefunded Warrants", "verboseLabel": "Pre-funded warrants" } } }, "auth_ref": [] }, "ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "NumberOfShareOptionsExercisableInSharebasedPaymentArrangement", "presentation": [ "http://www.evogene.com/role/Share-BasedCompensationScheduleOfSummarizedNumberOfShareOptionsDetails" ], "lang": { "en-us": { "role": { "periodEndLabel": "Exercisable at end of year", "label": "Number of share options exercisable in share-based payment arrangement" } }, "en": { "role": { "documentation": "The number of share options exercisable in a share-based payment arrangement." } } }, "auth_ref": [ "r168" ] }, "ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "NumberOfShareOptionsExercisedInSharebasedPaymentArrangement", "presentation": [ "http://www.evogene.com/role/Share-BasedCompensationScheduleOfSummarizedNumberOfShareOptionsDetails", "http://www.evogene.com/role/ShareholdersEquityNarrativeDetails", "http://www.evogene.com/role/ShareholdersEquityScheduleOfChangesInShareCapitalDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Exercised", "label": "Number of share options exercised in share-based payment arrangement", "verboseLabel": "Exercise of options and vesting of restricted share units (\u201cRSUs\u201d)" } }, "en": { "role": { "documentation": "The number of share options exercised in a share-based payment arrangement." } } }, "auth_ref": [ "r166" ] }, "ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement", "presentation": [ "http://www.evogene.com/role/Share-BasedCompensationScheduleOfSummarizedNumberOfShareOptionsDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Forfeited", "label": "Number of share options forfeited in share-based payment arrangement" } }, "en": { "role": { "documentation": "The number of share options forfeited in a share-based payment arrangement." } } }, "auth_ref": [ "r165" ] }, "ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "NumberOfShareOptionsGrantedInSharebasedPaymentArrangement", "presentation": [ "http://www.evogene.com/role/Share-BasedCompensationNarrativeDetails", "http://www.evogene.com/role/Share-BasedCompensationScheduleOfSummarizedNumberOfShareOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Options granted", "verboseLabel": "Granted" } }, "en": { "role": { "documentation": "The number of share options granted in a share-based payment arrangement." } } }, "auth_ref": [ "r164" ] }, "evgn_NumberOfSharesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "NumberOfSharesAbstract", "presentation": [ "http://www.evogene.com/role/ShareholdersEquityScheduleOfChangesInShareCapitalDetails" ], "lang": { "en-us": { "role": { "label": "Number Of Shares Abstract", "terseLabel": "Number of shares" } } }, "auth_ref": [] }, "ifrs-full_NumberOfSharesAuthorised": { "xbrltype": "sharesItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "NumberOfSharesAuthorised", "presentation": [ "http://www.evogene.com/role/ConsolidatedStatementsOfFinancialPositionParenthetical", "http://www.evogene.com/role/ShareholdersEquityScheduleOfShareCapitalDetails" ], "lang": { "en-us": { "role": { "label": "Ordinary shares, Authorized", "terseLabel": "Ordinary shares, authorized", "verboseLabel": "Ordinary shares of NIS 0.02 par value, Authorized" } }, "en": { "role": { "documentation": "The number of shares authorised." } } }, "auth_ref": [ "r24" ] }, "ifrs-full_NumberOfSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "NumberOfSharesIssued", "presentation": [ "http://www.evogene.com/role/ConsolidatedStatementsOfFinancialPositionParenthetical", "http://www.evogene.com/role/GeneralNarrativeDetails", "http://www.evogene.com/role/ShareholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Number of shares issued", "verboseLabel": "Ordinary shares issued" } }, "en": { "role": { "documentation": "The number of shares issued by the entity." } } }, "auth_ref": [ "r364" ] }, "ifrs-full_NumberOfSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "NumberOfSharesOutstanding", "presentation": [ "http://www.evogene.com/role/ConsolidatedStatementsOfFinancialPositionParenthetical" ], "lang": { "en-us": { "role": { "label": "Ordinary shares, Outstanding", "terseLabel": "Ordinary shares, outstanding" } }, "en": { "role": { "documentation": "The number of shares that have been authorised and issued, reduced by treasury shares held. [Refer: Treasury shares]" } } }, "auth_ref": [ "r26" ] }, "ifrs-full_OfficeEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "OfficeEquipmentMember", "presentation": [ "http://www.evogene.com/role/PropertyPlantAndEquipmentNetScheduleOfPropertyPlantEquipmentToAccumulatedDepreciationDetails", "http://www.evogene.com/role/SignificantAccountingPoliciesScheduleOfDepreciationCalculatedUsingStraight-lineMethodDetails" ], "lang": { "en-us": { "role": { "label": "Office equipment and furniture [Member]" } }, "en": { "role": { "documentation": "This member stands for a class of property, plant and equipment representing equipment used to support office functions, not specifically used in the production process. [Refer: Property, plant and equipment]" } } }, "auth_ref": [ "r222" ] }, "evgn_OfficeMaintenanceForResearchAndDevelopment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "OfficeMaintenanceForResearchAndDevelopment", "crdr": "debit", "calculation": { "http://www.evogene.com/role/StatementsOfComprehensiveLoss-AdditionalInformationScheduleOfIncomeAndExpensesDetails": { "parentTag": "ifrs-full_ResearchAndDevelopmentExpense", "weight": 1.0, "order": 40.0 } }, "presentation": [ "http://www.evogene.com/role/StatementsOfComprehensiveLoss-AdditionalInformationScheduleOfIncomeAndExpensesDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of office maintenance for research and development.", "label": "Office Maintenance For Research And Development", "terseLabel": "Office maintenance" } } }, "auth_ref": [] }, "evgn_OfficeOfChiefScientistMember": { "xbrltype": "domainItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "OfficeOfChiefScientistMember", "presentation": [ "http://www.evogene.com/role/LiabilitiesInRespectOfGovernmentGrantsNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "OCS [Member]", "label": "Office Of Chief Scientist Member", "verboseLabel": "IIA [Member]" } } }, "auth_ref": [] }, "evgn_OfficeSpaceMember": { "xbrltype": "domainItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "OfficeSpaceMember", "presentation": [ "http://www.evogene.com/role/SignificantAccountingPoliciesScheduleOfUsefulLifeOfRightOfUseAssetsDetails" ], "lang": { "en-us": { "role": { "documentation": "Office space [Member]", "label": "Office space [Member]" } } }, "auth_ref": [] }, "evgn_OfficesAndCarLeasesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "OfficesAndCarLeasesMember", "presentation": [ "http://www.evogene.com/role/LeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Offices and car leases [Member]", "label": "Offices and car leases [Member]" } } }, "auth_ref": [] }, "ifrs-full_OperatingExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "OperatingExpense", "crdr": "debit", "calculation": { "http://www.evogene.com/role/ConsolidatedStatementsOfProfitOrLoss": { "parentTag": "ifrs-full_ProfitLossFromOperatingActivities", "weight": -1.0, "order": 10.0 } }, "presentation": [ "http://www.evogene.com/role/ConsolidatedStatementsOfProfitOrLoss" ], "lang": { "en-us": { "role": { "label": "Total operating expenses", "totalLabel": "Total operating expenses, net" } }, "en": { "role": { "documentation": "The amount of all operating expenses." } } }, "auth_ref": [ "r369" ] }, "evgn_OperatingExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "OperatingExpenseAbstract", "presentation": [ "http://www.evogene.com/role/ConsolidatedStatementsOfProfitOrLoss" ], "lang": { "en-us": { "role": { "label": "Operating Expense Abstract", "terseLabel": "Operating expenses (income):" } } }, "auth_ref": [] }, "evgn_OperatingLeaseLiabilityInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "OperatingLeaseLiabilityInterest", "crdr": "debit", "calculation": { "http://www.evogene.com/role/StatementsOfComprehensiveLoss-AdditionalInformationScheduleOfIncomeAndExpensesDetails": { "parentTag": "ifrs-full_FinanceCosts", "weight": 1.0, "order": 60.0 } }, "presentation": [ "http://www.evogene.com/role/StatementsOfComprehensiveLoss-AdditionalInformationScheduleOfIncomeAndExpensesDetails" ], "lang": { "en-us": { "role": { "documentation": "Operating lease liability interest.", "label": "Operating Lease Liability Interest", "verboseLabel": "Lease liability interest" } } }, "auth_ref": [] }, "evgn_OperatingSegmentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "OperatingSegmentsAbstract", "lang": { "en-us": { "role": { "label": "Operating Segments Abstract" } } }, "auth_ref": [] }, "evgn_OperatingTaxLossCarryforwardOfParent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "OperatingTaxLossCarryforwardOfParent", "crdr": "credit", "presentation": [ "http://www.evogene.com/role/TaxesOnIncomeDetails" ], "lang": { "en-us": { "role": { "documentation": "Operating tax loss carryforward of parent.", "label": "Operating Tax Loss Carryforward Of Parent", "verboseLabel": "Operating tax loss carryforward of parent" } } }, "auth_ref": [] }, "evgn_OptionsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "OptionsMember", "presentation": [ "http://www.evogene.com/role/LossPerShareScheduleOfBasicLossPerShareDetails" ], "lang": { "en-us": { "role": { "documentation": "Options [Member]", "label": "Options [Member]" } } }, "auth_ref": [] }, "evgn_OrdinarySharesIssuedAndOutstandingReducedByTreasurySharesHeld": { "xbrltype": "sharesItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "OrdinarySharesIssuedAndOutstandingReducedByTreasurySharesHeld", "presentation": [ "http://www.evogene.com/role/ShareholdersEquityScheduleOfChangesInShareCapitalDetails", "http://www.evogene.com/role/ShareholdersEquityScheduleOfShareCapitalDetails" ], "lang": { "en-us": { "role": { "documentation": "The number of shares that have been issued and outstanding, reduced by treasury shares held. [Refer: Treasury shares]", "periodEndLabel": "Outstanding at end of year", "periodStartLabel": "Outstanding at beginning of year", "label": "Ordinary Shares Issued And Outstanding Reduced By Treasury Shares Held", "terseLabel": "Ordinary shares of NIS 0.02 par value, Issued and Outstanding" } } }, "auth_ref": [] }, "evgn_OriginalLeaseMaturityPeriods": { "xbrltype": "stringItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "OriginalLeaseMaturityPeriods", "presentation": [ "http://www.evogene.com/role/LeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Original lease maturity periods.", "label": "Original lease maturity periods" } } }, "auth_ref": [] }, "ifrs-full_OtherAdjustmentsForNoncashItems": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "OtherAdjustmentsForNoncashItems", "crdr": "debit", "calculation": { "http://www.evogene.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "ifrs-full_AdjustmentsForReconcileProfitLoss", "weight": 1.0, "order": 70.0 } }, "presentation": [ "http://www.evogene.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Pre-funded warrants issuance expenses" } }, "en": { "role": { "documentation": "Adjustments for non-cash items to reconcile profit (loss) to net cash flow from (used in) operating activities that the entity does not separately disclose in the same statement or note. [Refer: Profit (loss)]" } } }, "auth_ref": [ "r384" ] }, "ifrs-full_OtherComprehensiveIncome": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "OtherComprehensiveIncome", "crdr": "credit", "presentation": [ "http://www.evogene.com/role/FinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Other comprehensive income", "verboseLabel": "Other comprehensive income (loss)" } }, "en": { "role": { "documentation": "The amount of income and expense (including reclassification adjustments) that is not recognised in profit or loss as required or permitted by IFRSs. [Refer: IFRSs [member]]" } } }, "auth_ref": [ "r2", "r31", "r37", "r131" ] }, "ifrs-full_OtherCurrentPayables": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "OtherCurrentPayables", "crdr": "credit", "calculation": { "http://www.evogene.com/role/ConsolidatedStatementsOfFinancialPosition": { "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0, "order": 10.0 }, "http://www.evogene.com/role/FinancialInstrumentsScheduleOfCompanysFinancialLiabilitiesDetails": { "parentTag": "ifrs-full_FinancialLiabilities", "weight": 1.0, "order": 20.0 } }, "presentation": [ "http://www.evogene.com/role/ConsolidatedStatementsOfFinancialPosition", "http://www.evogene.com/role/FinancialInstrumentsScheduleOfCompanysFinancialLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Other payables" } }, "en": { "role": { "documentation": "The amount of current payables that the entity does not separately disclose in the same statement or note." } } }, "auth_ref": [ "r367" ] }, "ifrs-full_OtherCurrentReceivables": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "OtherCurrentReceivables", "crdr": "debit", "calculation": { "http://www.evogene.com/role/ConsolidatedStatementsOfFinancialPosition": { "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0, "order": 40.0 }, "http://www.evogene.com/role/OtherReceivablesAndPrepaidExpensesScheduleOfOtherReceivablesAndPrepaidExpensesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.evogene.com/role/ConsolidatedStatementsOfFinancialPosition", "http://www.evogene.com/role/OtherReceivablesAndPrepaidExpensesScheduleOfOtherReceivablesAndPrepaidExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Other receivables and prepaid expenses", "totalLabel": "Other receivables", "verboseLabel": "Other receivables and prepaid expenses" } }, "en": { "role": { "documentation": "The amount of current other receivables. [Refer: Other receivables]" } } }, "auth_ref": [ "r217" ] }, "ifrs-full_OtherExpenseByFunction": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "OtherExpenseByFunction", "crdr": "debit", "calculation": { "http://www.evogene.com/role/StatementsOfComprehensiveLoss-AdditionalInformationScheduleOfIncomeAndExpensesDetails": { "parentTag": "ifrs-full_ResearchAndDevelopmentExpense", "weight": 1.0, "order": 80.0 } }, "presentation": [ "http://www.evogene.com/role/StatementsOfComprehensiveLoss-AdditionalInformationScheduleOfIncomeAndExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Other expense, by function", "verboseLabel": "Other" } }, "en": { "role": { "documentation": "The amount of expenses that the entity does not separately disclose in the same statement or note when the entity uses the 'function of expense' form for its analysis of expenses." } } }, "auth_ref": [ "r38", "r75", "r214" ] }, "evgn_OtherExpensesDueToImpairmentOfFixedAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "OtherExpensesDueToImpairmentOfFixedAssets", "crdr": "debit", "presentation": [ "http://www.evogene.com/role/STATEMENTSOFPROFITORLOSSADDITIONALINFORMATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "other expenses due to impairment of fixed assets.", "negatedTerseLabel": "Other expenses", "label": "Other Expenses Due To Impairment Of Fixed Assets", "terseLabel": "Other expenses due to impairment of fixed assets" } } }, "auth_ref": [] }, "evgn_OtherExpensesOfSalesAndMarketing": { "xbrltype": "monetaryItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "OtherExpensesOfSalesAndMarketing", "crdr": "debit", "calculation": { "http://www.evogene.com/role/StatementsOfComprehensiveLoss-AdditionalInformationScheduleOfIncomeAndExpensesDetails": { "parentTag": "ifrs-full_SalesAndMarketingExpense", "weight": 1.0, "order": 40.0 } }, "presentation": [ "http://www.evogene.com/role/StatementsOfComprehensiveLoss-AdditionalInformationScheduleOfIncomeAndExpensesDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of other expenses for sales and marketing.", "label": "Other Expenses Of Sales And Marketing", "verboseLabel": "Other" } } }, "auth_ref": [] }, "evgn_OtherGeneralAndAdministrativeExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "OtherGeneralAndAdministrativeExpenses", "crdr": "debit", "calculation": { "http://www.evogene.com/role/StatementsOfComprehensiveLoss-AdditionalInformationScheduleOfIncomeAndExpensesDetails": { "parentTag": "ifrs-full_SellingGeneralAndAdministrativeExpense", "weight": 1.0, "order": 30.0 } }, "presentation": [ "http://www.evogene.com/role/StatementsOfComprehensiveLoss-AdditionalInformationScheduleOfIncomeAndExpensesDetails" ], "lang": { "en-us": { "role": { "documentation": "Other general and administrative expenses.", "label": "Other General And Administrative Expenses", "verboseLabel": "Other" } } }, "auth_ref": [] }, "ifrs-full_OtherIncome": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "OtherIncome", "crdr": "credit", "calculation": { "http://www.evogene.com/role/ConsolidatedStatementsOfProfitOrLoss": { "parentTag": "ifrs-full_OperatingExpense", "weight": -1.0, "order": 30.0 } }, "presentation": [ "http://www.evogene.com/role/ConsolidatedStatementsOfProfitOrLoss", "http://www.evogene.com/role/STATEMENTSOFPROFITORLOSSADDITIONALINFORMATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Other expenses (income)", "label": "Other income", "terseLabel": "Other income" } }, "en": { "role": { "documentation": "The amount of operating income that the entity does not separately disclose in the same statement or note." } } }, "auth_ref": [ "r74", "r213", "r214" ] }, "evgn_OtherMember": { "xbrltype": "domainItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "OtherMember", "presentation": [ "http://www.evogene.com/role/OperatingSegmentsScheduleOfRevenuesBasedOnCustomersDetails" ], "lang": { "en-us": { "role": { "documentation": "Othe [Member]", "label": "Other [Member]", "terseLabel": "Other [Member]" } } }, "auth_ref": [] }, "ecd_OtherPerfMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OtherPerfMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Other Performance Measure, Amount", "terseLabel": "Other Performance Measure, Amount" } } }, "auth_ref": [ "r312" ] }, "ifrs-full_OtherReceivables": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "OtherReceivables", "crdr": "debit", "calculation": { "http://www.evogene.com/role/OtherReceivablesAndPrepaidExpensesScheduleOfOtherReceivablesAndPrepaidExpensesDetails": { "parentTag": "ifrs-full_OtherCurrentReceivables", "weight": 1.0, "order": 70.0 } }, "presentation": [ "http://www.evogene.com/role/OtherReceivablesAndPrepaidExpensesScheduleOfOtherReceivablesAndPrepaidExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Other" } }, "en": { "role": { "documentation": "The amount receivable by the entity that it does not separately disclose in the same statement or note." } } }, "auth_ref": [ "r217" ] }, "ecd_OutstandingAggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingAggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Outstanding Aggregate Erroneous Compensation Amount", "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r273", "r284", "r294", "r327" ] }, "ecd_OutstandingRecoveryCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Outstanding Recovery Compensation Amount", "terseLabel": "Compensation Amount" } } }, "auth_ref": [ "r276", "r287", "r297", "r330" ] }, "ecd_OutstandingRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Outstanding Recovery, Individual Name", "terseLabel": "Name" } } }, "auth_ref": [ "r276", "r287", "r297", "r330" ] }, "evgn_OwnershipPercentageHeldByOtherEntityInSubsidiary": { "xbrltype": "percentItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "OwnershipPercentageHeldByOtherEntityInSubsidiary", "presentation": [ "http://www.evogene.com/role/GeneralNarrativeDetails", "http://www.evogene.com/role/ShareholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Ownership percentage held by other entity in subsidiary.", "label": "Ownership Percentage Held By Other Entity In Subsidiary", "verboseLabel": "Ownership percentage held by other entity in subsidiary" } } }, "auth_ref": [] }, "evgn_ParValueAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "ParValueAbstract", "presentation": [ "http://www.evogene.com/role/ShareholdersEquityScheduleOfChangesInShareCapitalDetails" ], "lang": { "en-us": { "role": { "label": "Par Value Abstract", "terseLabel": "NIS par value" } } }, "auth_ref": [] }, "evgn_ParValueOfSharesIssuedAndOutstanding": { "xbrltype": "perShareItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "ParValueOfSharesIssuedAndOutstanding", "presentation": [ "http://www.evogene.com/role/ShareholdersEquityScheduleOfChangesInShareCapitalDetails" ], "lang": { "en-us": { "role": { "documentation": "The number of shares par value that have been issued and outstanding,", "periodEndLabel": "Outstanding at end of year", "periodStartLabel": "Outstanding at beginning of year", "label": "Par Value Of Shares Issued And Outstanding" } } }, "auth_ref": [] }, "ifrs-full_ParValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "ParValuePerShare", "presentation": [ "http://www.evogene.com/role/ConsolidatedStatementsOfFinancialPositionParenthetical", "http://www.evogene.com/role/GeneralNarrativeDetails", "http://www.evogene.com/role/ShareholdersEquityNarrativeDetails", "http://www.evogene.com/role/ShareholdersEquityScheduleOfShareCapitalDetails" ], "lang": { "en-us": { "role": { "label": "Par value per share", "terseLabel": "Ordinary shares par value", "verboseLabel": "Ordinary shares per share" } }, "en": { "role": { "documentation": "The nominal value per share." } } }, "auth_ref": [ "r25" ] }, "evgn_ParticipationInRespectOfGovernmentGrantsForResearchAndDevelopment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "ParticipationInRespectOfGovernmentGrantsForResearchAndDevelopment", "crdr": "debit", "calculation": { "http://www.evogene.com/role/StatementsOfComprehensiveLoss-AdditionalInformationScheduleOfIncomeAndExpensesDetails": { "parentTag": "ifrs-full_ResearchAndDevelopmentExpense", "weight": 1.0, "order": 70.0 } }, "presentation": [ "http://www.evogene.com/role/StatementsOfComprehensiveLoss-AdditionalInformationScheduleOfIncomeAndExpensesDetails" ], "lang": { "en-us": { "role": { "documentation": "Participation in respect of government grants.", "label": "Participation In Respect Of Government Grants For Research And Development", "verboseLabel": "Amounts recorded in respect with government grants" } } }, "auth_ref": [] }, "evgn_PatentCostReimbursementCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "PatentCostReimbursementCurrent", "crdr": "debit", "calculation": { "http://www.evogene.com/role/OtherReceivablesAndPrepaidExpensesScheduleOfOtherReceivablesAndPrepaidExpensesDetails": { "parentTag": "ifrs-full_OtherCurrentReceivables", "weight": 1.0, "order": 20.0 } }, "presentation": [ "http://www.evogene.com/role/OtherReceivablesAndPrepaidExpensesScheduleOfOtherReceivablesAndPrepaidExpensesDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of patent cost reimbursement.", "label": "Patent Cost Reimbursement Current", "verboseLabel": "Patent cost reimbursement" } } }, "auth_ref": [] }, "ecd_PayVsPerformanceDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PayVsPerformanceDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Line Items]", "terseLabel": "Pay vs Performance Disclosure" } } }, "auth_ref": [ "r301" ] }, "evgn_PaymentForFinancialExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "PaymentForFinancialExpenses", "crdr": "debit", "calculation": { "http://www.evogene.com/role/StatementsOfComprehensiveLoss-AdditionalInformationScheduleOfIncomeAndExpensesDetails": { "parentTag": "ifrs-full_FinanceCosts", "weight": 1.0, "order": 80.0 } }, "presentation": [ "http://www.evogene.com/role/StatementsOfComprehensiveLoss-AdditionalInformationScheduleOfIncomeAndExpensesDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the amount of payment for Financial expenses.", "label": "Payment For Financial Expenses", "verboseLabel": "Financial expenses paid" } } }, "auth_ref": [] }, "ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities", "crdr": "credit", "calculation": { "http://www.evogene.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": -1.0, "order": 60.0 } }, "presentation": [ "http://www.evogene.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Repayment of lease liabilities", "label": "Payments of lease liabilities, classified as financing activities" } }, "en": { "role": { "documentation": "The cash outflow for payment of lease liabilities, classified as financing activities. [Refer: Lease liabilities]" } } }, "auth_ref": [ "r232" ] }, "ecd_PeerGroupIssuersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupIssuersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Peer Group Issuers, Footnote [Text Block]", "terseLabel": "Peer Group Issuers, Footnote" } } }, "auth_ref": [ "r311" ] }, "ecd_PeerGroupTotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupTotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Peer Group Total Shareholder Return Amount", "terseLabel": "Peer Group Total Shareholder Return Amount" } } }, "auth_ref": [ "r311" ] }, "ecd_PeoActuallyPaidCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoActuallyPaidCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO Actually Paid Compensation Amount", "terseLabel": "PEO Actually Paid Compensation Amount" } } }, "auth_ref": [ "r303" ] }, "ecd_PeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO [Member]", "terseLabel": "PEO" } } }, "auth_ref": [ "r320" ] }, "ecd_PeoName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO Name", "terseLabel": "PEO Name" } } }, "auth_ref": [ "r313" ] }, "ecd_PeoTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO Total Compensation Amount", "terseLabel": "PEO Total Compensation Amount" } } }, "auth_ref": [ "r302" ] }, "evgn_PercentageOfEntityAccordingToLocation": { "xbrltype": "percentItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "PercentageOfEntityAccordingToLocation", "presentation": [ "http://www.evogene.com/role/OperatingSegmentsScheduleOfPercentageOfNon-currentAssetsDetails" ], "lang": { "en-us": { "role": { "documentation": "Percentage of entity according to location.", "label": "Percentage Of Entity According To Location", "terseLabel": "Percentage of entity according to location" } } }, "auth_ref": [] }, "ifrs-full_PercentageOfEntitysRevenue": { "xbrltype": "percentItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "PercentageOfEntitysRevenue", "presentation": [ "http://www.evogene.com/role/OperatingSegmentsScheduleOfRevenuesBasedOnCustomersDetails", "http://www.evogene.com/role/OperatingSegmentsScheduleOfRevenuesFromMajorCustomersDetails" ], "lang": { "en-us": { "role": { "label": "Additional information about revenues", "verboseLabel": "Revenue" } }, "en": { "role": { "documentation": "The percentage of the entity's revenue. [Refer: Revenue]" } } }, "auth_ref": [ "r390" ] }, "evgn_PercentageOfGrantReceived": { "xbrltype": "percentItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "PercentageOfGrantReceived", "presentation": [ "http://www.evogene.com/role/LiabilitiesInRespectOfGovernmentGrantsNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Percentage of grant received.", "label": "Percentage Of Grant Received", "verboseLabel": "Percentage of grant received" } } }, "auth_ref": [] }, "evgn_PercentageOfRoyaltiesCompanyUndertookToPayDescription": { "xbrltype": "stringItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "PercentageOfRoyaltiesCompanyUndertookToPayDescription", "presentation": [ "http://www.evogene.com/role/LiabilitiesInRespectOfGovernmentGrantsNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Percentage of royalties the company undertook to pay description.", "label": "Percentage Of Royalties Company Undertook To Pay Description", "verboseLabel": "Percentage of royalties the company undertook to pay" } } }, "auth_ref": [] }, "evgn_PercentageOfTaxBenefitsRate": { "xbrltype": "percentItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "PercentageOfTaxBenefitsRate", "presentation": [ "http://www.evogene.com/role/TaxesOnIncomeDetails" ], "lang": { "en-us": { "role": { "documentation": "Percentage of tax benefits rate.", "label": "Percentage Of Tax Benefits Rate", "verboseLabel": "Percentage of tax benefits rate" } } }, "auth_ref": [] }, "ifrs-full_PercentageOfVotingEquityInterestsAcquired": { "xbrltype": "percentItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "PercentageOfVotingEquityInterestsAcquired", "presentation": [ "http://www.evogene.com/role/ShareholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Ownership percentage" } }, "en": { "role": { "documentation": "The percentage of voting equity interests acquired in a business combination. [Refer: Total for all business combinations [member]]" } } }, "auth_ref": [ "r177" ] }, "evgn_PercentageOfWeightedAverageCostOfCapitalMeasurement": { "xbrltype": "percentItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "PercentageOfWeightedAverageCostOfCapitalMeasurement", "presentation": [ "http://www.evogene.com/role/FinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "It represents percentage of weighted average cost of capital measurement.", "label": "Percentage Of Weighted Average Cost Of Capital Measurement", "verboseLabel": "Weighted average cost of capital measurement" } } }, "auth_ref": [] }, "evgn_PipelineProductsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "PipelineProductsMember", "presentation": [ "http://www.evogene.com/role/IntangibleAssetsNetScheduleOfIntangibleAssetsDetails", "http://www.evogene.com/role/SignificantAccountingPoliciesScheduleOfIntangibleAssetsPurchasedDetails" ], "lang": { "en-us": { "role": { "documentation": "Pipeline Products [Member]", "label": "Pipeline Products [Member]" } } }, "auth_ref": [] }, "evgn_PlantGrowthAndGreenhouseMaintenanceExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "PlantGrowthAndGreenhouseMaintenanceExpense", "crdr": "debit", "calculation": { "http://www.evogene.com/role/StatementsOfComprehensiveLoss-AdditionalInformationScheduleOfIncomeAndExpensesDetails": { "parentTag": "ifrs-full_ResearchAndDevelopmentExpense", "weight": 1.0, "order": 30.0 } }, "presentation": [ "http://www.evogene.com/role/StatementsOfComprehensiveLoss-AdditionalInformationScheduleOfIncomeAndExpensesDetails" ], "lang": { "en-us": { "role": { "documentation": "Plant growth and greenhouse maintenance.", "label": "Plant Growth And Greenhouse Maintenance Expense", "verboseLabel": "Plant growth and greenhouse maintenance" } } }, "auth_ref": [] }, "ecd_PnsnAdjsPrrSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsPrrSvcCstMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pension Adjustments Prior Service Cost [Member]", "terseLabel": "Pension Adjustments Prior Service Cost" } } }, "auth_ref": [ "r304" ] }, "ecd_PnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsSvcCstMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pension Adjustments Service Cost [Member]", "terseLabel": "Pension Adjustments Service Cost" } } }, "auth_ref": [ "r360" ] }, "ecd_PnsnBnftsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnBnftsAdjFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pension Benefits Adjustments, Footnote [Text Block]", "terseLabel": "Pension Benefits Adjustments, Footnote" } } }, "auth_ref": [ "r303" ] }, "ifrs-full_PostemploymentBenefitExpenseDefinedContributionPlans": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "PostemploymentBenefitExpenseDefinedContributionPlans", "crdr": "debit", "presentation": [ "http://www.evogene.com/role/SeverancePayLiabilityNetScheduleOfDefinedContributionPlansDetails" ], "lang": { "en-us": { "role": { "label": "Expenses - defined contribution plan", "verboseLabel": "Expenses \u2013 in respect to defined contribution plan" } }, "en": { "role": { "documentation": "The amount of post-employment benefit expense relating to defined contribution plans. Defined contribution plans are post-employment benefit plans under which an entity pays fixed contributions into a separate entity (a fund) and will have no legal or constructive obligation to pay further contributions if the fund does not hold sufficient assets to pay all employee benefits relating to employee service in the current and prior periods." } } }, "auth_ref": [ "r58" ] }, "evgn_PostvestingForfeitureRate": { "xbrltype": "percentItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "PostvestingForfeitureRate", "presentation": [ "http://www.evogene.com/role/Share-BasedCompensationScheduleOfAssumptionsUsedToValueOptionsDetails" ], "lang": { "en-us": { "role": { "documentation": "The percentage of an expected forfeiture rate used to calculate the fair value of share options granted.", "label": "Postvesting Forfeiture Rate", "verboseLabel": "Post-vesting forfeiture rate (%)" } } }, "auth_ref": [] }, "evgn_PotentialProductsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "PotentialProductsMember", "presentation": [ "http://www.evogene.com/role/IntangibleAssetsNetScheduleOfIntangibleAssetsDetails", "http://www.evogene.com/role/SignificantAccountingPoliciesScheduleOfIntangibleAssetsPurchasedDetails" ], "lang": { "en-us": { "role": { "documentation": "Potential Products [Member]", "label": "Potential Products [Member]" } } }, "auth_ref": [] }, "evgn_PreFinancingPayment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "PreFinancingPayment", "crdr": "credit", "presentation": [ "http://www.evogene.com/role/CollaborationAndResearchAgreementsNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of pre-financing payment.", "label": "Pre Financing Payment", "terseLabel": "Pre-financing payment" } } }, "auth_ref": [] }, "evgn_PreFundedWarrantsExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "PreFundedWarrantsExercisePrice", "presentation": [ "http://www.evogene.com/role/GeneralNarrativeDetails", "http://www.evogene.com/role/ShareholdersEquityNarrativeDetails", "http://www.evogene.com/role/ShareholdersEquityScheduleOfChangesInShareCapitalDetails" ], "lang": { "en-us": { "role": { "documentation": "Pre-funded warrants, exercise price.", "label": "Pre Funded Warrants Exercise Price", "terseLabel": "Exercise price per warrant", "verboseLabel": "Pre-funded warrants" } } }, "auth_ref": [] }, "evgn_PrePaymentForServices": { "xbrltype": "monetaryItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "PrePaymentForServices", "crdr": "debit", "presentation": [ "http://www.evogene.com/role/COMMITMENTSANDCONTINGENTLIABILITIESNarrativeDetails", "http://www.evogene.com/role/SUBSEQUENTEVENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the amount of pre payment for services recovery.", "label": "Pre Payment For Services", "verboseLabel": "Pre-payment for services" } } }, "auth_ref": [] }, "evgn_PrefundedWarrantPerShare": { "xbrltype": "perShareItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "PrefundedWarrantPerShare", "presentation": [ "http://www.evogene.com/role/GeneralNarrativeDetails", "http://www.evogene.com/role/ShareholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Pre-funded warrant per share.", "label": "Prefunded Warrant Per Share", "verboseLabel": "Pre-funded warrant per share" } } }, "auth_ref": [] }, "evgn_PrefundedWarrantsIssuanceExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "PrefundedWarrantsIssuanceExpenses", "crdr": "debit", "calculation": { "http://www.evogene.com/role/StatementsOfComprehensiveLoss-AdditionalInformationScheduleOfIncomeAndExpensesDetails": { "parentTag": "ifrs-full_FinanceCosts", "weight": 1.0, "order": 70.0 } }, "presentation": [ "http://www.evogene.com/role/StatementsOfComprehensiveLoss-AdditionalInformationScheduleOfIncomeAndExpensesDetails" ], "lang": { "en-us": { "role": { "documentation": "Pre-funded warrants issuance expenses.", "label": "Prefunded Warrants Issuance Expenses", "verboseLabel": "Pre-funded warrants issuance expenses" } } }, "auth_ref": [] }, "evgn_PresentValueOfLeaseLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "PresentValueOfLeaseLiabilities", "crdr": "debit", "presentation": [ "http://www.evogene.com/role/LeasesScheduleOfFutureMinimumLeasePaymentsUnderNon-cancelableLeasesDetails" ], "lang": { "en-us": { "role": { "documentation": "Present value of lease liabilities.", "label": "Present Value Of Lease Liabilities", "verboseLabel": "Present value of lease liabilities" } } }, "auth_ref": [] }, "ifrs-full_PresentationOfLeasesForLesseeAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "PresentationOfLeasesForLesseeAbstract", "lang": { "en-us": { "role": { "label": "Presentation of leases for lessee [Abstract]" } } }, "auth_ref": [] }, "evgn_ProceedsFromAdvancesForPrefundedWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "ProceedsFromAdvancesForPrefundedWarrants", "crdr": "debit", "calculation": { "http://www.evogene.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": 1.0, "order": 90.0 } }, "lang": { "en-us": { "role": { "documentation": "Proceeds from advances for pre-funded warrants.", "label": "Proceeds From Advances For Prefunded Warrants", "verboseLabel": "Proceeds from advances for pre-funded warrants" } } }, "auth_ref": [] }, "ifrs-full_ProceedsFromExerciseOfOptions": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "ProceedsFromExerciseOfOptions", "crdr": "debit", "calculation": { "http://www.evogene.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": 1.0, "order": 30.0 } }, "presentation": [ "http://www.evogene.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Proceeds from exercise of options" } }, "en": { "role": { "documentation": "The cash inflow from the exercise of options." } } }, "auth_ref": [ "r382" ] }, "ifrs-full_ProceedsFromGovernmentGrantsClassifiedAsFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "ProceedsFromGovernmentGrantsClassifiedAsFinancingActivities", "crdr": "debit", "calculation": { "http://www.evogene.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": 1.0, "order": 40.0 } }, "presentation": [ "http://www.evogene.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Proceeds from government grants" } }, "en": { "role": { "documentation": "The cash inflow from government grants, classified as financing activities. [Refer: Government [member]; Government grants]" } } }, "auth_ref": [ "r375" ] }, "evgn_ProceedsFromIssuanceOfConvertibleSafe": { "xbrltype": "monetaryItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "ProceedsFromIssuanceOfConvertibleSafe", "crdr": "debit", "calculation": { "http://www.evogene.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": 1.0, "order": 20.0 } }, "presentation": [ "http://www.evogene.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Represents the amount of proceeds from issuance of convertible safe.", "label": "Proceeds From Issuance Of Convertible Safe", "terseLabel": "Proceeds from issuance of Convertible SAFE" } } }, "auth_ref": [] }, "evgn_ProceedsFromIssuanceOfOrdinarySharesPrefundedWarrantsAndWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "ProceedsFromIssuanceOfOrdinarySharesPrefundedWarrantsAndWarrants", "crdr": "debit", "calculation": { "http://www.evogene.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://www.evogene.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Represents the amount of proceeds from issuance of ordinary shares, pre-funded warrants and warrants.", "label": "Proceeds From Issuance Of Ordinary Shares, Pre-funded Warrants And Warrants", "terseLabel": "Proceeds from issuance of ordinary shares, pre-funded warrants and warrants" } } }, "auth_ref": [] }, "evgn_ProceedsFromIssuanceOfPrefundedWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "ProceedsFromIssuanceOfPrefundedWarrants", "crdr": "debit", "calculation": { "http://www.evogene.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": 1.0, "order": 80.0 } }, "lang": { "en-us": { "role": { "documentation": "Proceeds from issuance of pre-funded warrants.", "label": "Proceeds From Issuance Of Prefunded Warrants", "verboseLabel": "Proceeds from issuance of pre-funded warrants" } } }, "auth_ref": [] }, "evgn_ProceedsFromIssuanceOfSubsidiaryPreferredSharesToNonControllingInterestsFinancingActivity": { "xbrltype": "monetaryItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "ProceedsFromIssuanceOfSubsidiaryPreferredSharesToNonControllingInterestsFinancingActivity", "crdr": "debit", "calculation": { "http://www.evogene.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": 1.0, "order": 70.0 } }, "presentation": [ "http://www.evogene.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Represent the amount of ProceedsFromIssuanceOfSubsidiaryPreferredSharesToNonControllingInterestsFinancingActivity", "label": "Proceeds From Issuance Of Subsidiary Preferred Shares To Non Controlling Interests Financing Activity", "terseLabel": "Issuance of a subsidiary's preferred shares to non-controlling interests" } } }, "auth_ref": [] }, "ifrs-full_ProceedsFromIssueOfOrdinaryShares": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "ProceedsFromIssueOfOrdinaryShares", "crdr": "debit", "calculation": { "http://www.evogene.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.evogene.com/role/ConsolidatedStatementsOfCashFlows", "http://www.evogene.com/role/GeneralNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Proceeds from issue of ordinary shares", "terseLabel": "Proceeds from issuance of ordinary shares, net of issuance expenses", "verboseLabel": "Gross proceeds from ordinary shares" } }, "en": { "role": { "documentation": "The cash inflow from the issuing of ordinary shares. [Refer: Ordinary shares [member]]" } } }, "auth_ref": [ "r382" ] }, "evgn_ProceedsFromIssueOfOrdinarySharesAndPreFundedWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "ProceedsFromIssueOfOrdinarySharesAndPreFundedWarrants", "crdr": "debit", "presentation": [ "http://www.evogene.com/role/ShareholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "The cash inflow from the issuing of ordinary shares and pre-funded warrants.", "label": "Proceeds From Issue Of Ordinary Shares And Pre Funded Warrants", "verboseLabel": "Gross proceeds from ordinary shares and pre-funded warrants" } } }, "auth_ref": [] }, "ifrs-full_ProceedsFromSalesOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "ProceedsFromSalesOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod", "crdr": "debit", "calculation": { "http://www.evogene.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://www.evogene.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Proceeds from sale of marketable securities" } }, "en": { "role": { "documentation": "The cash inflow from sales of investments other than investments accounted for using the equity method. [Refer: Investments accounted for using equity method; Investments other than investments accounted for using equity method]" } } }, "auth_ref": [ "r381" ] }, "ifrs-full_ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities", "crdr": "debit", "calculation": { "http://www.evogene.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": 1.0, "order": 30.0 } }, "presentation": [ "http://www.evogene.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Proceeds from sales of property, plant and equipment, classified as investing activities", "verboseLabel": "Proceeds from sale of property, plant and equipment" } }, "en": { "role": { "documentation": "The cash inflow from sales of property, plant and equipment, classified as investing activities. [Refer: Property, plant and equipment]" } } }, "auth_ref": [ "r231" ] }, "evgn_ProceedsFromShortTermBankDeposits": { "xbrltype": "monetaryItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "ProceedsFromShortTermBankDeposits", "crdr": "debit", "calculation": { "http://www.evogene.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": 1.0, "order": 40.0 } }, "presentation": [ "http://www.evogene.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Amount represents proceeds from short term bank deposits.", "label": "Proceeds From Short Term Bank Deposits", "terseLabel": "Proceeds from short-term bank deposits", "verboseLabel": "Proceeds from short term bank deposits, net" } } }, "auth_ref": [] }, "ifrs-full_ProfessionalFeesExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "ProfessionalFeesExpense", "crdr": "debit", "calculation": { "http://www.evogene.com/role/StatementsOfComprehensiveLoss-AdditionalInformationScheduleOfIncomeAndExpensesDetails": { "parentTag": "ifrs-full_SellingGeneralAndAdministrativeExpense", "weight": 1.0, "order": 20.0 } }, "presentation": [ "http://www.evogene.com/role/StatementsOfComprehensiveLoss-AdditionalInformationScheduleOfIncomeAndExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Professional fees" } }, "en": { "role": { "documentation": "The amount of fees paid or payable for professional services." } } }, "auth_ref": [ "r365" ] }, "ifrs-full_ProfitLoss": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "ProfitLoss", "crdr": "credit", "calculation": { "http://www.evogene.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0, "order": 40.0 }, "http://www.evogene.com/role/ConsolidatedStatementsOfProfitOrLoss": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://www.evogene.com/role/ConsolidatedStatementsOfProfitOrLoss__1": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.evogene.com/role/ConsolidatedStatementsOfCashFlows", "http://www.evogene.com/role/ConsolidatedStatementsOfChangesInEquity", "http://www.evogene.com/role/ConsolidatedStatementsOfProfitOrLoss" ], "lang": { "en-us": { "role": { "negatedTotalLabel": "Loss", "label": "Loss", "totalLabel": "Loss" } }, "en": { "role": { "documentation": "The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]" } } }, "auth_ref": [ "r1", "r30", "r107", "r118", "r120", "r200", "r203", "r234", "r239" ] }, "ifrs-full_ProfitLossAttributableToAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "ProfitLossAttributableToAbstract", "presentation": [ "http://www.evogene.com/role/ConsolidatedStatementsOfProfitOrLoss" ], "lang": { "en-us": { "role": { "label": "Attributable to:" } } }, "auth_ref": [] }, "ifrs-full_ProfitLossAttributableToNoncontrollingInterests": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "ProfitLossAttributableToNoncontrollingInterests", "crdr": "credit", "calculation": { "http://www.evogene.com/role/ConsolidatedStatementsOfProfitOrLoss__1": { "parentTag": "ifrs-full_ProfitLoss", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://www.evogene.com/role/ConsolidatedStatementsOfProfitOrLoss", "http://www.evogene.com/role/ShareholdersEquityScheduleOfCompositionNon-controllingInterestsDetails" ], "lang": { "en-us": { "role": { "label": "Profit Loss Attributable To Noncontrolling Interests", "terseLabel": "Loss attributed to non-controlling interests", "verboseLabel": "Non-controlling interests" } }, "en": { "role": { "documentation": "The profit (loss) from continuing and discontinued operations attributable to non-controlling interests. [Refer: Profit (loss); Non-controlling interests]" } } }, "auth_ref": [ "r32", "r123" ] }, "ifrs-full_ProfitLossAttributableToOwnersOfParent": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "ProfitLossAttributableToOwnersOfParent", "crdr": "credit", "calculation": { "http://www.evogene.com/role/ConsolidatedStatementsOfProfitOrLoss__1": { "parentTag": "ifrs-full_ProfitLoss", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.evogene.com/role/ConsolidatedStatementsOfProfitOrLoss" ], "lang": { "en-us": { "role": { "label": "Equity holders of the Company" } }, "en": { "role": { "documentation": "The profit (loss) from continuing and discontinued operations attributable to owners of the parent. [Refer: Profit (loss)]" } } }, "auth_ref": [ "r33" ] }, "ifrs-full_ProfitLossBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "ProfitLossBeforeTax", "crdr": "credit", "calculation": { "http://www.evogene.com/role/ConsolidatedStatementsOfProfitOrLoss": { "parentTag": "ifrs-full_ProfitLoss", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.evogene.com/role/ConsolidatedStatementsOfProfitOrLoss", "http://www.evogene.com/role/OperatingSegmentsScheduleOfRevenuesAndOperatingLossBySegmentsDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Loss before taxes on income", "label": "Loss before taxes on income", "totalLabel": "Loss before taxes on income", "verboseLabel": "Loss before taxes on income" } }, "en": { "role": { "documentation": "The profit (loss) before tax expense or income. [Refer: Profit (loss)]" } } }, "auth_ref": [ "r182", "r213", "r214", "r248", "r249" ] }, "ifrs-full_ProfitLossFromContinuingOperationsAttributableToOrdinaryEquityHoldersOfParentEntity": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "ProfitLossFromContinuingOperationsAttributableToOrdinaryEquityHoldersOfParentEntity", "crdr": "credit", "presentation": [ "http://www.evogene.com/role/LossPerShareScheduleOfBasicLossPerShareDetails" ], "lang": { "en-us": { "role": { "label": "Number of shares and loss, Loss attributable to equity holders of the Company", "terseLabel": "Loss attributable to equity holders of the Company" } }, "en": { "role": { "documentation": "The profit (loss) from continuing operations attributable to ordinary equity holders of the parent entity. [Refer: Continuing operations, unless line item indicates otherwise [member]; Profit (loss) from continuing operations]" } } }, "auth_ref": [ "r84" ] }, "ifrs-full_ProfitLossFromOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "ProfitLossFromOperatingActivities", "crdr": "credit", "calculation": { "http://www.evogene.com/role/ConsolidatedStatementsOfProfitOrLoss": { "parentTag": "ifrs-full_ProfitLossBeforeTax", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.evogene.com/role/ConsolidatedStatementsOfProfitOrLoss", "http://www.evogene.com/role/GeneralNarrativeDetails", "http://www.evogene.com/role/OperatingSegmentsScheduleOfRevenuesAndOperatingLossBySegmentsDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Operating loss", "label": "Operating loss", "totalLabel": "Operating loss" } }, "en": { "role": { "documentation": "The profit (loss) from operating activities of the entity. [Refer: Profit (loss)]" } } }, "auth_ref": [ "r227", "r369" ] }, "ifrs-full_PropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "PropertyPlantAndEquipment", "crdr": "debit", "calculation": { "http://www.evogene.com/role/ConsolidatedStatementsOfFinancialPosition": { "parentTag": "ifrs-full_NoncurrentAssets", "weight": 1.0, "order": 20.0 } }, "presentation": [ "http://www.evogene.com/role/ConsolidatedStatementsOfFinancialPosition", "http://www.evogene.com/role/PropertyPlantAndEquipmentNetScheduleOfPropertyPlantEquipmentToAccumulatedDepreciationDetails" ], "lang": { "en-us": { "role": { "periodEndLabel": "Balance on end of year", "periodStartLabel": "Balance on beginning year", "label": "Property, plant and equipment, net", "verboseLabel": "Property, plant and equipment, net" } }, "en": { "role": { "documentation": "The amount of tangible assets that: (a) are held for use in the production or supply of goods or services, for rental to others, or for administrative purposes; and (b) are expected to be used during more than one period. Note that right-of-use assets are not included. [Contrast: Property, plant and equipment including right-of-use assets]" } } }, "auth_ref": [ "r6", "r51" ] }, "ifrs-full_PropertyPlantAndEquipmentGrossCarryingAmountFullyDepreciated": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "PropertyPlantAndEquipmentGrossCarryingAmountFullyDepreciated", "crdr": "debit", "presentation": [ "http://www.evogene.com/role/PropertyPlantAndEquipmentNetScheduleOfPropertyPlantEquipmentToAccumulatedDepreciationDetails" ], "lang": { "en-us": { "role": { "periodEndLabel": "Depreciated cost on end of year", "label": "Property, plant and equipment, gross carrying amount of fully depreciated assets still in use" } }, "en": { "role": { "documentation": "The gross carrying amount of fully depreciated property, plant and equipment that is still in use. [Refer: Gross carrying amount [member]; Property, plant and equipment]" } } }, "auth_ref": [ "r223" ] }, "ifrs-full_PropertyPlantAndEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "PropertyPlantAndEquipmentMember", "presentation": [ "http://www.evogene.com/role/LeasesNarrativeDetails", "http://www.evogene.com/role/LeasesScheduleOfFutureMinimumLeasePaymentsUnderNon-cancelableLeasesDetails", "http://www.evogene.com/role/LeasesScheduleOfLeaseLiabilityDetails", "http://www.evogene.com/role/LeasesScheduleOfRight-of-useAssetsDetails", "http://www.evogene.com/role/PropertyPlantAndEquipmentNetScheduleOfPropertyPlantEquipmentToAccumulatedDepreciationDetails", "http://www.evogene.com/role/SignificantAccountingPoliciesScheduleOfDepreciationCalculatedUsingStraight-lineMethodDetails", "http://www.evogene.com/role/SignificantAccountingPoliciesScheduleOfIntangibleAssetsPurchasedDetails", "http://www.evogene.com/role/SignificantAccountingPoliciesScheduleOfUsefulLifeOfRightOfUseAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Property, plant and equipment [member]" } }, "en": { "role": { "documentation": "This member stands for property, plant and equipment. [Refer: Property, plant and equipment]" } } }, "auth_ref": [ "r52", "r228", "r238" ] }, "ifrs-full_ProportionOfOwnershipInterestInSubsidiary": { "xbrltype": "percentItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "ProportionOfOwnershipInterestInSubsidiary", "presentation": [ "http://www.evogene.com/role/BalancesAndTransactionsWithExecutiveOfficersAndCertainShareholdersNarrativeDetails", "http://www.evogene.com/role/GeneralNarrativeDetails", "http://www.evogene.com/role/ShareholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Proportion of ownership interest in subsidiary", "terseLabel": "Proportion of ownership interest in subsidiary", "verboseLabel": "Proportion of ownership interest" } }, "en": { "role": { "documentation": "The proportion of ownership interest in a subsidiary attributable to the entity. [Refer: Total for all subsidiaries [member]]" } } }, "auth_ref": [ "r78", "r80", "r125" ] }, "ifrs-full_ProportionOfOwnershipInterestsHeldByNoncontrollingInterests": { "xbrltype": "percentItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "ProportionOfOwnershipInterestsHeldByNoncontrollingInterests", "presentation": [ "http://www.evogene.com/role/ShareholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Non-controlling interest" } }, "en": { "role": { "documentation": "The proportion of ownership interests in a subsidiary held by non-controlling interests. [Refer: Total for all subsidiaries [member]; Non-controlling interests]" } } }, "auth_ref": [ "r122" ] }, "evgn_ProvisionForDoubtfulAccountsOnAdvances": { "xbrltype": "monetaryItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "ProvisionForDoubtfulAccountsOnAdvances", "crdr": "credit", "presentation": [ "http://www.evogene.com/role/FinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Provision For Doubtful Accounts On Advances", "verboseLabel": "Provision for doubtful accounts" } } }, "auth_ref": [] }, "evgn_PurchaseOfMarketableSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "PurchaseOfMarketableSecurities", "crdr": "credit", "calculation": { "http://www.evogene.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": -1.0, "order": 0.0 } }, "presentation": [ "http://www.evogene.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "The cash outflow for the purchase of marketable securities.", "negatedLabel": "Purchase of marketable securities", "label": "Purchase Of Marketable Securities" } } }, "auth_ref": [] }, "ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities", "crdr": "credit", "calculation": { "http://www.evogene.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": -1.0, "order": 20.0 } }, "presentation": [ "http://www.evogene.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Purchase of property, plant and equipment", "label": "Purchase of property, plant and equipment, classified as investing activities" } }, "en": { "role": { "documentation": "The cash outflow for the purchases of property, plant and equipment, classified as investing activities. [Refer: Property, plant and equipment]" } } }, "auth_ref": [ "r230" ] }, "evgn_PurchasePricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "PurchasePricePerShare", "presentation": [ "http://www.evogene.com/role/GeneralNarrativeDetails", "http://www.evogene.com/role/ShareholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the purchase price per share.", "label": "Purchase Price Per Share", "verboseLabel": "Purchase price per share" } } }, "auth_ref": [] }, "ecd_PvpTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Table]", "terseLabel": "Pay vs Performance Disclosure" } } }, "auth_ref": [ "r301" ] }, "ecd_PvpTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pay vs Performance [Table Text Block]", "terseLabel": "Pay vs Performance Disclosure, Table" } } }, "auth_ref": [ "r301" ] }, "ifrs-full_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "RangeAxis", "presentation": [ "http://www.evogene.com/role/LeasesNarrativeDetails", "http://www.evogene.com/role/SIGNIFICANTACCOUNTINGJUDGMENTSESTIMATESANDASSUMPTIONSUSEDINTHEPREPARATIONOFTHEFINANCIALSTATEMENTSNarrativeDetails", "http://www.evogene.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails", "http://www.evogene.com/role/Share-BasedCompensationScheduleOfAssumptionsUsedToValueOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Range [axis]", "verboseLabel": "Range [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r113", "r141", "r160", "r171", "r235", "r236", "r389" ] }, "ifrs-full_RangeDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "RangeDomain", "presentation": [ "http://www.evogene.com/role/LeasesNarrativeDetails", "http://www.evogene.com/role/SIGNIFICANTACCOUNTINGJUDGMENTSESTIMATESANDASSUMPTIONSUSEDINTHEPREPARATIONOFTHEFINANCIALSTATEMENTSNarrativeDetails", "http://www.evogene.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails", "http://www.evogene.com/role/Share-BasedCompensationScheduleOfAssumptionsUsedToValueOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Range [domain]" } }, "en": { "role": { "documentation": "This member stands for aggregate ranges. It also represents the standard value for the 'Range' axis if no other member is used." } } }, "auth_ref": [ "r113", "r141", "r160", "r171", "r235", "r236", "r389" ] }, "ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "RangesOfExercisePricesForOutstandingShareOptionsAxis", "presentation": [ "http://www.evogene.com/role/Share-BasedCompensationScheduleOfShareOptionsOutstandingDetails" ], "lang": { "en-us": { "role": { "label": "Ranges of exercise prices for outstanding share options [Axis]", "verboseLabel": "Ranges of exercise prices for outstanding share options [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r171" ] }, "ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "RangesOfExercisePricesForOutstandingShareOptionsDomain", "presentation": [ "http://www.evogene.com/role/Share-BasedCompensationScheduleOfShareOptionsOutstandingDetails" ], "lang": { "en-us": { "role": { "label": "Ranges of exercise prices for outstanding share options [domain]" } }, "en": { "role": { "documentation": "This member stands for aggregated ranges of exercise prices for outstanding share options that are meaningful for assessing the number and timing of additional shares that may be issued and the cash that may be received upon exercise of those options. It also represents the standard value for the 'Ranges of exercise prices for outstanding share options' axis if no other member is used. [Refer: Range [domain]]" } } }, "auth_ref": [ "r171" ] }, "ifrs-full_RawMaterials": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "RawMaterials", "crdr": "debit", "calculation": { "http://www.evogene.com/role/SIGNIFICANTACCOUNTINGPOLICIESScheduleOfSummarizesInformationAboutTheInventoryDetails": { "parentTag": "ifrs-full_Inventories", "weight": 1.0, "order": 20.0 } }, "presentation": [ "http://www.evogene.com/role/SIGNIFICANTACCOUNTINGPOLICIESScheduleOfSummarizesInformationAboutTheInventoryDetails" ], "lang": { "en-us": { "role": { "label": "Current raw materials", "terseLabel": "Raw materials" } }, "en": { "role": { "documentation": "A classification of current inventory representing the amount of assets to be consumed in the production process or in the rendering of services. [Refer: Inventories]" } } }, "auth_ref": [ "r218", "r374" ] }, "ifrs-full_RawMaterialsAndConsumablesUsed": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "RawMaterialsAndConsumablesUsed", "crdr": "debit", "calculation": { "http://www.evogene.com/role/StatementsOfComprehensiveLoss-AdditionalInformationScheduleOfIncomeAndExpensesDetails": { "parentTag": "ifrs-full_CostOfSales", "weight": 1.0, "order": 20.0 } }, "presentation": [ "http://www.evogene.com/role/StatementsOfComprehensiveLoss-AdditionalInformationScheduleOfIncomeAndExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Materials" } }, "en": { "role": { "documentation": "The amount of raw materials and consumables used in the production process or in the rendering of services. [Refer: Current raw materials]" } } }, "auth_ref": [ "r38", "r213" ] }, "evgn_ReceivedResearchAndDevelopmentGrantsOfBirdAmounting": { "xbrltype": "monetaryItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "ReceivedResearchAndDevelopmentGrantsOfBirdAmounting", "crdr": "debit", "presentation": [ "http://www.evogene.com/role/LiabilitiesInRespectOfGovernmentGrantsNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Received research and development grants of BIRD amounting.", "label": "Received Research And Development Grants Of Bird Amounting", "verboseLabel": "Research and development grants" } } }, "auth_ref": [] }, "ecd_RecoveryOfErrCompDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RecoveryOfErrCompDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]", "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure" } } }, "auth_ref": [ "r268", "r279", "r289", "r322" ] }, "evgn_ReductionOfLeaseLiabilityForLeasesTerminatedInPeriod": { "xbrltype": "monetaryItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "ReductionOfLeaseLiabilityForLeasesTerminatedInPeriod", "crdr": "credit", "presentation": [ "http://www.evogene.com/role/LeasesScheduleOfLeaseLiabilityDetails" ], "lang": { "en-us": { "role": { "documentation": "Reduction of lease liability for leases terminated in the period.", "label": "Reduction Of Lease Liability For Leases Terminated In Period", "verboseLabel": "Reduction of lease liability for leases terminated in the period" } } }, "auth_ref": [] }, "evgn_RemeasurementOfPrefundedWarrantsOfFinancingExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "RemeasurementOfPrefundedWarrantsOfFinancingExpenses", "crdr": "credit", "calculation": { "http://www.evogene.com/role/StatementsOfComprehensiveLoss-AdditionalInformationScheduleOfIncomeAndExpensesDetails": { "parentTag": "ifrs-full_FinanceIncome", "weight": 1.0, "order": 0.0 } }, "lang": { "en-us": { "role": { "documentation": "Revaluation of pre-funded warrants.", "label": "Remeasurement Of Prefunded Warrants Of Financing Expenses", "verboseLabel": "Revaluation of warrants and pre-funded warrants" } } }, "auth_ref": [] }, "evgn_RemeasurementOfWarrantsAndPreFundedWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "RemeasurementOfWarrantsAndPreFundedWarrants", "crdr": "credit", "calculation": { "http://www.evogene.com/role/StatementsOfComprehensiveLoss-AdditionalInformationScheduleOfIncomeAndExpensesDetails": { "parentTag": "ifrs-full_FinanceIncome", "weight": 1.0, "order": 50.0 } }, "presentation": [ "http://www.evogene.com/role/StatementsOfComprehensiveLoss-AdditionalInformationScheduleOfIncomeAndExpensesDetails" ], "lang": { "en-us": { "role": { "documentation": "Remeasurement of warrants and pre-funded warrants.", "label": "Remeasurement Of Warrants And Pre Funded Warrants", "terseLabel": "Remeasurement of warrants and pre-funded warrants" } } }, "auth_ref": [] }, "ifrs-full_RentDeferredIncomeClassifiedAsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "RentDeferredIncomeClassifiedAsCurrent", "crdr": "credit", "calculation": { "http://www.evogene.com/role/ConsolidatedStatementsOfFinancialPosition": { "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0, "order": 30.0 } }, "presentation": [ "http://www.evogene.com/role/ConsolidatedStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Deferred revenues and other advances" } }, "en": { "role": { "documentation": "The amount of rent deferred income classified as current. [Refer: Rent deferred income]" } } }, "auth_ref": [ "r368" ] }, "ifrs-full_RepairsAndMaintenanceExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "RepairsAndMaintenanceExpense", "crdr": "debit", "calculation": { "http://www.evogene.com/role/StatementsOfComprehensiveLoss-AdditionalInformationScheduleOfIncomeAndExpensesDetails": { "parentTag": "ifrs-full_CostOfSales", "weight": 1.0, "order": 40.0 } }, "presentation": [ "http://www.evogene.com/role/StatementsOfComprehensiveLoss-AdditionalInformationScheduleOfIncomeAndExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Rentals and maintenance", "terseLabel": "Office maintenance" } }, "en": { "role": { "documentation": "The amount of expenses incurred for the day-to-day servicing of assets, which may include the cost of labour, consumables or small parts." } } }, "auth_ref": [ "r369" ] }, "evgn_RepaymentOfGovernmentGrantsClassifiedAsFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "RepaymentOfGovernmentGrantsClassifiedAsFinancingActivities", "crdr": "credit", "calculation": { "http://www.evogene.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": -1.0, "order": 50.0 } }, "presentation": [ "http://www.evogene.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "THe cash outflow of repayment of government grants.", "negatedLabel": "Repayment of government grants", "label": "Repayment Of Government Grants Classified As Financing Activities" } } }, "auth_ref": [] }, "evgn_RepaymentOfShorttermBankDeposits": { "xbrltype": "monetaryItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "RepaymentOfShorttermBankDeposits", "crdr": "credit", "calculation": { "http://www.evogene.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": -1.0, "order": 50.0 } }, "presentation": [ "http://www.evogene.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "The amount represents for proceed from short term bank deposit.", "negatedLabel": "Investment in short-term bank deposits", "label": "Repayment Of Short-term Bank Deposits" } } }, "auth_ref": [] }, "ifrs-full_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "calculation": { "http://www.evogene.com/role/ConsolidatedStatementsOfProfitOrLoss": { "parentTag": "ifrs-full_OperatingExpense", "weight": 1.0, "order": 0.0 }, "http://www.evogene.com/role/StatementsOfComprehensiveLoss-AdditionalInformationScheduleOfIncomeAndExpensesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.evogene.com/role/ConsolidatedStatementsOfProfitOrLoss", "http://www.evogene.com/role/StatementsOfComprehensiveLoss-AdditionalInformationScheduleOfIncomeAndExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Research and development, net", "totalLabel": "Research and development expenses" } }, "en": { "role": { "documentation": "The amount of expenditure directly attributable to research or development activities, recognised in profit or loss." } } }, "auth_ref": [ "r98" ] }, "evgn_ResearchAndDevelopmentExpensesOfTransaction": { "xbrltype": "monetaryItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "ResearchAndDevelopmentExpensesOfTransaction", "presentation": [ "http://www.evogene.com/role/BalancesAndTransactionsWithKeyOfficersAndCertainShareholdersScheduleOfTransactionsWithRelatedPartiesDetails" ], "lang": { "en-us": { "role": { "documentation": "It represents as a research and development expenses of transaction.", "label": "Research And Development Expenses Of Transaction", "terseLabel": "Research and development expenses" } } }, "auth_ref": [] }, "evgn_ResearchAndDevelopmentNetAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "ResearchAndDevelopmentNetAbstract", "presentation": [ "http://www.evogene.com/role/StatementsOfComprehensiveLoss-AdditionalInformationScheduleOfIncomeAndExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Research And Development Net Abstract", "verboseLabel": "Research and development, net:" } } }, "auth_ref": [] }, "ifrs-full_ReserveOfEquityComponentOfConvertibleInstruments": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "ReserveOfEquityComponentOfConvertibleInstruments", "crdr": "credit", "presentation": [ "http://www.evogene.com/role/ConvertibleSAFENarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Reserve of equity component of convertible instruments" } }, "en": { "role": { "documentation": "A component of equity representing components of convertible instruments classified as equity." } } }, "auth_ref": [ "r367" ] }, "ecd_RestatementDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDateAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Restatement Determination Date [Axis]", "terseLabel": "Restatement Determination Date:" } } }, "auth_ref": [ "r269", "r280", "r290", "r323" ] }, "ecd_RestatementDeterminationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDeterminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Restatement Determination Date", "terseLabel": "Restatement Determination Date" } } }, "auth_ref": [ "r270", "r281", "r291", "r324" ] }, "ecd_RestatementDoesNotRequireRecoveryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDoesNotRequireRecoveryTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Restatement Does Not Require Recovery [Text Block]", "terseLabel": "Restatement does not require Recovery" } } }, "auth_ref": [ "r277", "r288", "r298", "r331" ] }, "ifrs-full_RestrictedCashAndCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "RestrictedCashAndCashEquivalents", "crdr": "debit", "calculation": { "http://www.evogene.com/role/OtherReceivablesAndPrepaidExpensesScheduleOfOtherReceivablesAndPrepaidExpensesDetails": { "parentTag": "ifrs-full_OtherCurrentReceivables", "weight": 1.0, "order": 50.0 } }, "presentation": [ "http://www.evogene.com/role/OtherReceivablesAndPrepaidExpensesScheduleOfOtherReceivablesAndPrepaidExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Restricted cash" } }, "en": { "role": { "documentation": "The amount of cash and cash equivalents whose use or withdrawal is restricted. [Refer: Cash and cash equivalents]" } } }, "auth_ref": [ "r367" ] }, "evgn_RestrictedStockUnitVested": { "xbrltype": "monetaryItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "RestrictedStockUnitVested", "crdr": "credit", "presentation": [ "http://www.evogene.com/role/ConsolidatedStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "documentation": "Represents restricted stock unit vested.", "label": "Restricted Stock Unit Vested", "terseLabel": "RSUs vested" } } }, "auth_ref": [] }, "evgn_RestrictedStockUnitsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "RestrictedStockUnitsMember", "presentation": [ "http://www.evogene.com/role/SHAREBASEDCOMPENSATIONScheduleOfRestrictedStockUnitsActivityDetails", "http://www.evogene.com/role/Share-BasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for restricted stock units.", "label": "Restricted Stock Units [Member]", "verboseLabel": "Restricted Share Units (RSUs) [Member]" } } }, "auth_ref": [] }, "ifrs-full_RetainedEarnings": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "RetainedEarnings", "crdr": "credit", "calculation": { "http://www.evogene.com/role/ConsolidatedStatementsOfFinancialPosition": { "parentTag": "ifrs-full_EquityAttributableToOwnersOfParent", "weight": 1.0, "order": 20.0 } }, "presentation": [ "http://www.evogene.com/role/ConsolidatedStatementsOfFinancialPosition", "http://www.evogene.com/role/GeneralNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Retained earnings", "verboseLabel": "Accumulated deficit" } }, "en": { "role": { "documentation": "A component of equity representing the entity's cumulative undistributed earnings or deficit." } } }, "auth_ref": [ "r219", "r220" ] }, "ifrs-full_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "RetainedEarningsMember", "presentation": [ "http://www.evogene.com/role/ConsolidatedStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "label": "Accumulated deficit" } }, "en": { "role": { "documentation": "This member stands for a component of equity representing an entity's cumulative undistributed earnings or deficit." } } }, "auth_ref": [ "r4", "r215" ] }, "evgn_RevaluationOfConvertibleSafe": { "xbrltype": "monetaryItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "RevaluationOfConvertibleSafe", "crdr": "debit", "calculation": { "http://www.evogene.com/role/StatementsOfComprehensiveLoss-AdditionalInformationScheduleOfIncomeAndExpensesDetails": { "parentTag": "ifrs-full_FinanceCosts", "weight": 1.0, "order": 90.0 } }, "presentation": [ "http://www.evogene.com/role/StatementsOfComprehensiveLoss-AdditionalInformationScheduleOfIncomeAndExpensesDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the amount of revaluation of convertible safe.", "label": "Revaluation Of Convertible Safe", "verboseLabel": "Revaluation of convertible SAFE" } } }, "auth_ref": [] }, "evgn_RevaluationOfLiabilitiesInRespectOfGovernmentGrants": { "xbrltype": "monetaryItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "RevaluationOfLiabilitiesInRespectOfGovernmentGrants", "crdr": "credit", "calculation": { "http://www.evogene.com/role/StatementsOfComprehensiveLoss-AdditionalInformationScheduleOfIncomeAndExpensesDetails": { "parentTag": "ifrs-full_FinanceIncome", "weight": 1.0, "order": 30.0 } }, "presentation": [ "http://www.evogene.com/role/StatementsOfComprehensiveLoss-AdditionalInformationScheduleOfIncomeAndExpensesDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the amount of revaluation of liabilities in respect of government grants.", "label": "Revaluation Of Liabilities In Respect Of Government Grants", "verboseLabel": "Financial income in respect of government grants" } } }, "auth_ref": [] }, "evgn_RevaluationOfLiabilitiesOfGovernmentGrantsOfFinancingExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "RevaluationOfLiabilitiesOfGovernmentGrantsOfFinancingExpenses", "crdr": "debit", "calculation": { "http://www.evogene.com/role/StatementsOfComprehensiveLoss-AdditionalInformationScheduleOfIncomeAndExpensesDetails": { "parentTag": "ifrs-full_FinanceCosts", "weight": 1.0, "order": 50.0 } }, "presentation": [ "http://www.evogene.com/role/StatementsOfComprehensiveLoss-AdditionalInformationScheduleOfIncomeAndExpensesDetails" ], "lang": { "en-us": { "role": { "documentation": "Revaluation of liabilities in respect of government grants.", "label": "Revaluation Of Liabilities Of Government Grants Of Financing Expenses", "verboseLabel": "Financial expenses in respect of government grants" } } }, "auth_ref": [] }, "evgn_RevaluationRecognizedInCPI": { "xbrltype": "monetaryItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "RevaluationRecognizedInCPI", "crdr": "credit", "presentation": [ "http://www.evogene.com/role/LeasesScheduleOfRight-of-useAssetsDetails" ], "lang": { "en-us": { "role": { "documentation": "Revaluation recognized in CPI.", "label": "Revaluation Recognized In C P I", "verboseLabel": "Revaluation recognized in CPI" } } }, "auth_ref": [] }, "evgn_RevaluationsRecognizedInCPI": { "xbrltype": "monetaryItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "RevaluationsRecognizedInCPI", "crdr": "debit", "presentation": [ "http://www.evogene.com/role/LeasesScheduleOfLeaseLiabilityDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of revaluations recognized in CPI.", "label": "Revaluations Recognized In C P I", "verboseLabel": "Revaluation recognized in CPI" } } }, "auth_ref": [] }, "ifrs-full_Revenue": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "Revenue", "crdr": "credit", "calculation": { "http://www.evogene.com/role/ConsolidatedStatementsOfProfitOrLoss": { "parentTag": "ifrs-full_GrossProfit", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.evogene.com/role/ConsolidatedStatementsOfProfitOrLoss", "http://www.evogene.com/role/LiabilitiesInRespectOfGovernmentGrantsNarrativeDetails", "http://www.evogene.com/role/OperatingSegmentsScheduleOfRevenuesAndOperatingLossBySegmentsDetails", "http://www.evogene.com/role/ScheduleOfTimingOfRevenuesByTimingOfRevenueRecognition" ], "lang": { "en-us": { "role": { "label": "Revenue", "terseLabel": "Revenues", "verboseLabel": "Order amount" } }, "en": { "role": { "documentation": "The income arising in the course of an entity's ordinary activities. Income is increases in assets, or decreases in liabilities, that result in increases in equity, other than those relating to contributions from holders of equity claims." } } }, "auth_ref": [ "r34", "r130", "r182", "r197", "r202", "r208", "r209", "r211", "r213", "r214", "r234" ] }, "ifrs-full_RevenueAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "RevenueAbstract", "presentation": [ "http://www.evogene.com/role/StatementsOfComprehensiveLoss-AdditionalInformationScheduleOfIncomeAndExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Revenues:" } } }, "auth_ref": [] }, "ifrs-full_RevenueFromInterest": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "RevenueFromInterest", "crdr": "credit", "calculation": { "http://www.evogene.com/role/StatementsOfComprehensiveLoss-AdditionalInformationScheduleOfIncomeAndExpensesDetails": { "parentTag": "ifrs-full_FinanceIncome", "weight": 1.0, "order": 20.0 } }, "presentation": [ "http://www.evogene.com/role/StatementsOfComprehensiveLoss-AdditionalInformationScheduleOfIncomeAndExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Interest income" } }, "en": { "role": { "documentation": "The amount of income arising from interest." } } }, "auth_ref": [ "r133", "r198", "r206", "r365" ] }, "evgn_RevenueRecognisedOverTheNext12Months": { "xbrltype": "monetaryItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "RevenueRecognisedOverTheNext12Months", "crdr": "credit", "presentation": [ "http://www.evogene.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents amount of revenue recognized over the next 12 months.", "label": "Revenue Recognised Over The Next 12 Months", "terseLabel": "Revenue recognised over the next 12 months" } } }, "auth_ref": [] }, "evgn_RevenueRecognizedAtAPointInTimeMember": { "xbrltype": "domainItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "RevenueRecognizedAtAPointInTimeMember", "presentation": [ "http://www.evogene.com/role/ScheduleOfTimingOfRevenuesByTimingOfRevenueRecognition" ], "lang": { "en-us": { "role": { "documentation": "Revenue recognized at a point in time [Member].", "label": "Revenue Recognized At A Point In Time [Member]" } } }, "auth_ref": [] }, "evgn_RevenueRecognizedOverTimeMember": { "xbrltype": "domainItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "RevenueRecognizedOverTimeMember", "presentation": [ "http://www.evogene.com/role/ScheduleOfTimingOfRevenuesByTimingOfRevenueRecognition" ], "lang": { "en-us": { "role": { "documentation": "Revenue recognized over time [Member].", "label": "Revenue Recognized Over Time [Member]" } } }, "auth_ref": [] }, "evgn_RevenuesForTransactionsWithKeyOfficersAndCertainShareholders": { "xbrltype": "monetaryItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "RevenuesForTransactionsWithKeyOfficersAndCertainShareholders", "crdr": "credit", "presentation": [ "http://www.evogene.com/role/BalancesAndTransactionsWithKeyOfficersAndCertainShareholdersScheduleOfTransactionsWithRelatedPartiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of revenue (cost) for transactions with key officers and shareholders.", "label": "Revenues For Transactions With Key Officers And Certain Shareholders", "verboseLabel": "Revenues" } } }, "auth_ref": [] }, "ifrs-full_RightofuseAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "RightofuseAssets", "crdr": "debit", "calculation": { "http://www.evogene.com/role/ConsolidatedStatementsOfFinancialPosition": { "parentTag": "ifrs-full_NoncurrentAssets", "weight": 1.0, "order": 40.0 } }, "presentation": [ "http://www.evogene.com/role/ConsolidatedStatementsOfFinancialPosition", "http://www.evogene.com/role/LeasesScheduleOfRight-of-useAssetsDetails" ], "lang": { "en-us": { "role": { "periodEndLabel": "Balance at end of year", "periodStartLabel": "Balance at beginning year", "label": "Right-of-use-assets", "verboseLabel": "Right-of-use-assets" } }, "en": { "role": { "documentation": "The amount of assets that represent a lessee's right to use an underlying asset for the lease term that do not meet the definition of investment property. Underlying asset is an asset that is the subject of a lease, for which the right to use that asset has been provided by a lessor to a lessee." } } }, "auth_ref": [ "r145", "r151" ] }, "evgn_RightofuseAssetsGrossCarryingAmountFullyDepreciated": { "xbrltype": "monetaryItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "RightofuseAssetsGrossCarryingAmountFullyDepreciated", "crdr": "debit", "presentation": [ "http://www.evogene.com/role/LeasesScheduleOfRight-of-useAssetsDetails" ], "lang": { "en-us": { "role": { "documentation": "The gross carrying amount of fully depreciated right-of-use assets that is still in use.", "periodEndLabel": "Depreciated cost at end of year", "label": "Rightofuse Assets Gross Carrying Amount Fully Depreciated" } } }, "auth_ref": [] }, "evgn_RoyaltiesPaid": { "xbrltype": "monetaryItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "RoyaltiesPaid", "crdr": "debit", "presentation": [ "http://www.evogene.com/role/LiabilitiesInRespectOfGovernmentGrantsScheduleOfLiabilitiesInRespectOfGovernmentGrantsDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of royalty paid.", "label": "Royalties Paid", "verboseLabel": "Royalties paid" } } }, "auth_ref": [] }, "ifrs-full_RoyaltyExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "RoyaltyExpense", "crdr": "debit", "presentation": [ "http://www.evogene.com/role/LiabilitiesInRespectOfGovernmentGrantsNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Royalty expense", "verboseLabel": "Payment for pay royalties" } }, "en": { "role": { "documentation": "The amount of expense arising from royalties." } } }, "auth_ref": [ "r369" ] }, "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Adopted [Flag]", "terseLabel": "Rule 10b5-1 Arrangement Adopted" } } }, "auth_ref": [ "r340" ] }, "ecd_Rule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Terminated [Flag]", "terseLabel": "Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": [ "r340" ] }, "evgn_SalariesAndBenefitsOfSalesAndMarketing": { "xbrltype": "monetaryItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "SalariesAndBenefitsOfSalesAndMarketing", "crdr": "debit", "calculation": { "http://www.evogene.com/role/StatementsOfComprehensiveLoss-AdditionalInformationScheduleOfIncomeAndExpensesDetails": { "parentTag": "ifrs-full_SalesAndMarketingExpense", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.evogene.com/role/StatementsOfComprehensiveLoss-AdditionalInformationScheduleOfIncomeAndExpensesDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of salaries and benefits for sales and marketing.", "label": "Salaries And Benefits Of Sales And Marketing", "verboseLabel": "Salaries and benefits" } } }, "auth_ref": [] }, "evgn_SalaryAndRelatedExpensesForResearchAndDevelopment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "SalaryAndRelatedExpensesForResearchAndDevelopment", "crdr": "debit", "calculation": { "http://www.evogene.com/role/StatementsOfComprehensiveLoss-AdditionalInformationScheduleOfIncomeAndExpensesDetails": { "parentTag": "ifrs-full_ResearchAndDevelopmentExpense", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.evogene.com/role/StatementsOfComprehensiveLoss-AdditionalInformationScheduleOfIncomeAndExpensesDetails" ], "lang": { "en-us": { "role": { "documentation": "Salary and benefits from research and development expenses.", "label": "Salary And Related Expenses For Research And Development", "verboseLabel": "Salaries and benefits" } } }, "auth_ref": [] }, "evgn_SalesAndMarketaingExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "SalesAndMarketaingExpensesAbstract", "presentation": [ "http://www.evogene.com/role/StatementsOfComprehensiveLoss-AdditionalInformationScheduleOfIncomeAndExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Sales And Marketaing Expenses Abstract", "verboseLabel": "Sales and marketing" } } }, "auth_ref": [] }, "ifrs-full_SalesAndMarketingExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "SalesAndMarketingExpense", "crdr": "debit", "calculation": { "http://www.evogene.com/role/ConsolidatedStatementsOfProfitOrLoss": { "parentTag": "ifrs-full_OperatingExpense", "weight": 1.0, "order": 10.0 }, "http://www.evogene.com/role/StatementsOfComprehensiveLoss-AdditionalInformationScheduleOfIncomeAndExpensesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.evogene.com/role/ConsolidatedStatementsOfProfitOrLoss", "http://www.evogene.com/role/StatementsOfComprehensiveLoss-AdditionalInformationScheduleOfIncomeAndExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Sales and marketing expense", "terseLabel": "Sales and marketing", "totalLabel": "Total sales and marketing" } }, "en": { "role": { "documentation": "The amount of expense relating to the marketing and selling of goods or services." } } }, "auth_ref": [ "r369" ] }, "evgn_SalesAndMarketingExpensesOfTransaction": { "xbrltype": "monetaryItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "SalesAndMarketingExpensesOfTransaction", "crdr": "debit", "presentation": [ "http://www.evogene.com/role/BalancesAndTransactionsWithKeyOfficersAndCertainShareholdersScheduleOfTransactionsWithRelatedPartiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Sales and marketing expenses.", "label": "Sales And Marketing Expenses Of Transaction", "terseLabel": "Sales and marketing expenses" } } }, "auth_ref": [] }, "evgn_SecondPaymentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "SecondPaymentMember", "presentation": [ "http://www.evogene.com/role/CollaborationAndResearchAgreementsNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Second payment [Member]", "label": "Second Payment [Member]" } } }, "auth_ref": [] }, "evgn_SecuritiesPurchaseAgreementsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "SecuritiesPurchaseAgreementsMember", "presentation": [ "http://www.evogene.com/role/GeneralNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for securities purchase agreements.", "label": "Securities Purchase Agreements [Member]", "verboseLabel": "Securities purchase agreements [Member]" } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": [ "http://www.evogene.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r251" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": [ "http://www.evogene.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r253" ] }, "ifrs-full_SegmentsAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "SegmentsAxis", "presentation": [ "http://www.evogene.com/role/OperatingSegmentsScheduleOfRevenuesAndOperatingLossBySegmentsDetails" ], "lang": { "en-us": { "role": { "label": "Segments [Axis]", "verboseLabel": "Segments [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r87", "r143", "r200", "r225", "r241" ] }, "ifrs-full_SegmentsDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "SegmentsDomain", "presentation": [ "http://www.evogene.com/role/OperatingSegmentsScheduleOfRevenuesAndOperatingLossBySegmentsDetails" ], "lang": { "en": { "role": { "documentation": "This member stands for all segments of an entity. It also represents the standard value for the 'Segments' axis if no other member is used." } } }, "auth_ref": [ "r87", "r143", "r207", "r225", "r241" ] }, "evgn_SellPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "SellPricePerShare", "presentation": [ "http://www.evogene.com/role/GeneralNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents about sell price per share.", "label": "Sell Price Per Share", "terseLabel": "Sell price per share" } } }, "auth_ref": [] }, "ifrs-full_SellingGeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "SellingGeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://www.evogene.com/role/ConsolidatedStatementsOfProfitOrLoss": { "parentTag": "ifrs-full_OperatingExpense", "weight": 1.0, "order": 20.0 }, "http://www.evogene.com/role/StatementsOfComprehensiveLoss-AdditionalInformationScheduleOfIncomeAndExpensesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.evogene.com/role/ConsolidatedStatementsOfProfitOrLoss", "http://www.evogene.com/role/StatementsOfComprehensiveLoss-AdditionalInformationScheduleOfIncomeAndExpensesDetails" ], "lang": { "en-us": { "role": { "label": "General and administrative", "totalLabel": "General and administrative expenses" } }, "en": { "role": { "documentation": "The amount of expense relating to selling, general and administrative activities of the entity." } } }, "auth_ref": [ "r369" ] }, "evgn_SensitivityAnalysisAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "SensitivityAnalysisAxis", "presentation": [ "http://www.evogene.com/role/FinancialInstrumentsScheduleOfSensitivityTestsRelatingToChangesInMarketFactorsDetails" ], "lang": { "en-us": { "role": { "documentation": "Sensitivity Analysis [Axis]", "label": "Sensitivity Analysis [Axis]", "verboseLabel": "SensitivityAnalysisAxis [Axis]" } } }, "auth_ref": [] }, "evgn_SensitivityAnalysisDomain": { "xbrltype": "domainItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "SensitivityAnalysisDomain", "presentation": [ "http://www.evogene.com/role/FinancialInstrumentsScheduleOfSensitivityTestsRelatingToChangesInMarketFactorsDetails" ], "auth_ref": [] }, "ifrs-full_SensitivityAnalysisForEachTypeOfMarketRisk": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "SensitivityAnalysisForEachTypeOfMarketRisk", "presentation": [ "http://www.evogene.com/role/FinancialInstrumentsTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Sensitivity Tests Relating to Changes in Market Factors" } }, "en": { "role": { "documentation": "The disclosure of the sensitivity analysis for types of market risk to which the entity is exposed, showing how profit or loss and equity would have been affected by changes in the relevant risk variable that were reasonably possible at that date. [Refer: Market risk [member]]" } } }, "auth_ref": [ "r193" ] }, "evgn_SensitivityTestToChangesInMarketPriceOfListedSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "SensitivityTestToChangesInMarketPriceOfListedSecurities", "crdr": "credit", "presentation": [ "http://www.evogene.com/role/FinancialInstrumentsScheduleOfSensitivityTestsRelatingToChangesInMarketFactorsDetails" ], "lang": { "en-us": { "role": { "documentation": "Sensitivity test to changes in the market price of listed securities.", "label": "Sensitivity Test To Changes In Market Price Of Listed Securities", "verboseLabel": "Gain (loss) from change:" } } }, "auth_ref": [] }, "evgn_SensitivityTestToChangesInMarketPriceOfListedSecuritiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "SensitivityTestToChangesInMarketPriceOfListedSecuritiesAbstract", "presentation": [ "http://www.evogene.com/role/FinancialInstrumentsScheduleOfSensitivityTestsRelatingToChangesInMarketFactorsDetails" ], "lang": { "en-us": { "role": { "label": "Sensitivity Test To Changes In Market Price Of Listed Securities Abstract", "verboseLabel": "Sensitivity test to changes in market price of listed securities:" } } }, "auth_ref": [] }, "evgn_SensitivityTestToChangesInNisExchangeRateGainLossFromChange": { "xbrltype": "monetaryItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "SensitivityTestToChangesInNisExchangeRateGainLossFromChange", "crdr": "credit", "presentation": [ "http://www.evogene.com/role/FinancialInstrumentsScheduleOfSensitivityTestsRelatingToChangesInMarketFactorsDetails" ], "lang": { "en-us": { "role": { "documentation": "Sensitivity test to changes in NIS exchange rate, gain (loss) from change.", "label": "Sensitivity Test To Changes In Nis Exchange Rate Gain Loss From Change", "verboseLabel": "Gain (loss) from change:" } } }, "auth_ref": [] }, "evgn_SensitivityTestToChangesInUsdNisExchangeRateAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "SensitivityTestToChangesInUsdNisExchangeRateAbstract", "presentation": [ "http://www.evogene.com/role/FinancialInstrumentsScheduleOfSensitivityTestsRelatingToChangesInMarketFactorsDetails" ], "lang": { "en-us": { "role": { "label": "Sensitivity Test To Changes In Usd Nis Exchange Rate Abstract", "verboseLabel": "Sensitivity test to changes in the USD/NIS exchange rate:" } } }, "auth_ref": [] }, "evgn_SeriesAAndBOrdinaryWarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "SeriesAAndBOrdinaryWarrantMember", "presentation": [ "http://www.evogene.com/role/GeneralNarrativeDetails", "http://www.evogene.com/role/ShareholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Series A and B ordinary warrant [Member].", "label": "Series A And B Ordinary Warrant [Member]" } } }, "auth_ref": [] }, "evgn_SeriesAOrdinaryWarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "SeriesAOrdinaryWarrantMember", "presentation": [ "http://www.evogene.com/role/GeneralNarrativeDetails", "http://www.evogene.com/role/ShareholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Series A Ordinary Warrant [Member].", "label": "Series A Ordinary Warrant [Member]" } } }, "auth_ref": [] }, "evgn_SeriesAOrdinaryWarrantsExercisePrice": { "xbrltype": "sharesItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "SeriesAOrdinaryWarrantsExercisePrice", "presentation": [ "http://www.evogene.com/role/ShareholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Series A ordinary warrants exercise price.", "label": "Series A Ordinary Warrants Exercise Price", "terseLabel": "Series A ordinary warrants exercise price" } } }, "auth_ref": [] }, "evgn_SeriesBOrdinaryWarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "SeriesBOrdinaryWarrantMember", "presentation": [ "http://www.evogene.com/role/GeneralNarrativeDetails", "http://www.evogene.com/role/ShareholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Series B Ordinary Warrant [Member].", "label": "Series B Ordinary Warrant [Member]" } } }, "auth_ref": [] }, "evgn_ShanghaiHealthcareCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "ShanghaiHealthcareCapitalMember", "presentation": [ "http://www.evogene.com/role/GeneralNarrativeDetails", "http://www.evogene.com/role/ShareholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stand for Shanghai Healthcare Capital [Member].", "label": "Shanghai Healthcare Capital [Member]", "verboseLabel": "Shanghai Healthcare Capital [Member]" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "All Award Types", "terseLabel": "All Award Types" } } }, "auth_ref": [] }, "evgn_ShareBasedCompensationToDirectors": { "xbrltype": "monetaryItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "ShareBasedCompensationToDirectors", "crdr": "debit", "calculation": { "http://www.evogene.com/role/BalancesAndTransactionsWithKeyOfficersAndCertainShareholdersScheduleOfBenefitsToDirectorsDetails": { "parentTag": "evgn_AmountOfBenefitsToDirectors", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.evogene.com/role/BalancesAndTransactionsWithKeyOfficersAndCertainShareholdersScheduleOfBenefitsToDirectorsDetails" ], "lang": { "en-us": { "role": { "documentation": "Information about Share-based compensation to directors.", "label": "Share Based Compensation To Directors", "terseLabel": "Share-based compensation to directors not employed by the Company or on its behalf" } } }, "auth_ref": [] }, "evgn_ShareOfLossOfAnAssociate": { "xbrltype": "monetaryItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "ShareOfLossOfAnAssociate", "crdr": "credit", "calculation": { "http://www.evogene.com/role/ConsolidatedStatementsOfProfitOrLoss": { "parentTag": "ifrs-full_ProfitLossBeforeTax", "weight": 1.0, "order": 20.0 }, "http://www.evogene.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "ifrs-full_AdjustmentsForReconcileProfitLoss", "weight": -1.0, "order": 120.0 } }, "presentation": [ "http://www.evogene.com/role/ConsolidatedStatementsOfCashFlows", "http://www.evogene.com/role/ConsolidatedStatementsOfProfitOrLoss" ], "lang": { "en-us": { "role": { "documentation": "Represents the amount of associated Company loss share.", "negatedLabel": "Share of loss of an associate", "negatedTerseLabel": "Share of loss of an associate", "label": "Share Of Loss Of An Associate", "terseLabel": "Associated Company loss share", "verboseLabel": "Share of loss of an associate" } } }, "auth_ref": [] }, "evgn_ShareOptionAndIncentivePlansDescription": { "xbrltype": "stringItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "ShareOptionAndIncentivePlansDescription", "presentation": [ "http://www.evogene.com/role/Share-BasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "The description of the share option and incentive plans the entity maintains.", "label": "Share Option And Incentive Plans Description", "verboseLabel": "Share option and incentive plans description" } } }, "auth_ref": [] }, "ifrs-full_SharePremiumMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "SharePremiumMember", "presentation": [ "http://www.evogene.com/role/ConsolidatedStatementsOfChangesInEquity", "http://www.evogene.com/role/ShareholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Share premium and other capital reserve" } }, "en": { "role": { "documentation": "This member stands for the amount received or receivable from issuance of the entity's shares in excess of nominal value." } } }, "auth_ref": [ "r4" ] }, "evgn_SharebasedCompensationCost": { "xbrltype": "monetaryItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "SharebasedCompensationCost", "crdr": "debit", "calculation": { "http://www.evogene.com/role/StatementsOfComprehensiveLoss-AdditionalInformationScheduleOfIncomeAndExpensesDetails": { "parentTag": "ifrs-full_CostOfSales", "weight": 1.0, "order": 50.0 } }, "presentation": [ "http://www.evogene.com/role/StatementsOfComprehensiveLoss-AdditionalInformationScheduleOfIncomeAndExpensesDetails" ], "lang": { "en-us": { "role": { "documentation": "Cost of revenues share-based compensation.", "label": "Sharebased Compensation Cost", "verboseLabel": "Share-based compensation" } } }, "auth_ref": [] }, "evgn_SharebasedCompensationForResearchAndDevelopment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "SharebasedCompensationForResearchAndDevelopment", "crdr": "debit", "calculation": { "http://www.evogene.com/role/StatementsOfComprehensiveLoss-AdditionalInformationScheduleOfIncomeAndExpensesDetails": { "parentTag": "ifrs-full_ResearchAndDevelopmentExpense", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://www.evogene.com/role/StatementsOfComprehensiveLoss-AdditionalInformationScheduleOfIncomeAndExpensesDetails" ], "lang": { "en-us": { "role": { "documentation": "Share-based compensation from research and development expenses.", "label": "Sharebased Compensation For Research And Development", "verboseLabel": "Share-based compensation" } } }, "auth_ref": [] }, "evgn_SharebasedCompensationOfSalesAndMarketing": { "xbrltype": "monetaryItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "SharebasedCompensationOfSalesAndMarketing", "crdr": "debit", "calculation": { "http://www.evogene.com/role/StatementsOfComprehensiveLoss-AdditionalInformationScheduleOfIncomeAndExpensesDetails": { "parentTag": "ifrs-full_SalesAndMarketingExpense", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://www.evogene.com/role/StatementsOfComprehensiveLoss-AdditionalInformationScheduleOfIncomeAndExpensesDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of share-based compensation for sales and marketing.", "label": "Sharebased Compensation Of Sales And Marketing", "verboseLabel": "Share-based compensation" } } }, "auth_ref": [] }, "ifrs-full_SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares": { "xbrltype": "sharesItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares", "presentation": [ "http://www.evogene.com/role/Share-BasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Number of shares reserved for issue under options and contracts for sale of shares", "verboseLabel": "Number of options approved to grant" } }, "en": { "role": { "documentation": "The number of shares reserved for issue under options and contracts for the sale of shares." } } }, "auth_ref": [ "r27" ] }, "evgn_ShortTermDepositsYieldAnnualInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "ShortTermDepositsYieldAnnualInterestRate", "presentation": [ "http://www.evogene.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents short-term deposits yielded an annual interest rate.", "label": "Short Term Deposits Yield, Annual Interest Rate", "terseLabel": "Short-term deposits yield, annual interest rate" } } }, "auth_ref": [] }, "ifrs-full_ShorttermDepositsNotClassifiedAsCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "ShorttermDepositsNotClassifiedAsCashEquivalents", "crdr": "debit", "calculation": { "http://www.evogene.com/role/ConsolidatedStatementsOfFinancialPosition": { "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://www.evogene.com/role/ConsolidatedStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Short-term bank deposits" } }, "en": { "role": { "documentation": "The amount of short-term deposits held by the entity that are not classified as cash equivalents. [Refer: Cash equivalents]" } } }, "auth_ref": [ "r367" ] }, "ifrs-full_ShorttermEmployeeBenefitsAccruals": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "ShorttermEmployeeBenefitsAccruals", "crdr": "credit", "calculation": { "http://www.evogene.com/role/FinancialInstrumentsScheduleOfCompanysFinancialLiabilitiesDetails": { "parentTag": "ifrs-full_FinancialLiabilities", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://www.evogene.com/role/FinancialInstrumentsScheduleOfCompanysFinancialLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Short-term employee benefits accruals", "verboseLabel": "Employees and payroll accruals" } }, "en": { "role": { "documentation": "The amount of accruals for employee benefits (other than termination benefits) that are expected to be settled wholly within twelve months after the end of the annual reporting period in which the employees render the related services. [Refer: Accruals classified as current]" } } }, "auth_ref": [ "r368" ] }, "evgn_SignificantAccountingPoliciesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "SignificantAccountingPoliciesLineItems", "presentation": [ "http://www.evogene.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Significant Accounting Policies [Line Items]" } } }, "auth_ref": [] }, "evgn_SignificantAccountingPoliciesTable": { "xbrltype": "stringItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "SignificantAccountingPoliciesTable", "presentation": [ "http://www.evogene.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Significant Accounting Policies [Table]" } } }, "auth_ref": [] }, "ifrs-full_SignificantInvestmentsInSubsidiariesAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "SignificantInvestmentsInSubsidiariesAxis", "presentation": [ "http://www.evogene.com/role/GeneralNarrativeDetails", "http://www.evogene.com/role/ShareholdersEquityNarrativeDetails", "http://www.evogene.com/role/TaxesOnIncomeDetails" ], "lang": { "en-us": { "role": { "label": "Subsidiaries [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r79", "r81", "r136" ] }, "ifrs-full_SignificantInvestmentsInSubsidiariesDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "SignificantInvestmentsInSubsidiariesDomain", "presentation": [ "http://www.evogene.com/role/GeneralNarrativeDetails", "http://www.evogene.com/role/ShareholdersEquityNarrativeDetails", "http://www.evogene.com/role/TaxesOnIncomeDetails" ], "lang": { "en-us": { "role": { "label": "Subsidiaries [domain]" } }, "en": { "role": { "documentation": "This member stands for the standard value for the 'Subsidiaries' axis if no other member is used." } } }, "auth_ref": [ "r79", "r81", "r136" ] }, "evgn_SignificantNoncashInvestingTransactionsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "SignificantNoncashInvestingTransactionsAbstract", "presentation": [ "http://www.evogene.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Significant Noncash Investing Transactions Abstract", "verboseLabel": "Significant non-cash activities:" } } }, "auth_ref": [] }, "evgn_StateTaxAuthorityMember": { "xbrltype": "domainItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "StateTaxAuthorityMember", "presentation": [ "http://www.evogene.com/role/TaxesOnIncomeDetails" ], "lang": { "en-us": { "role": { "documentation": "State tax authority", "label": "State Tax Authority [Member]", "terseLabel": "State tax [Member]" } } }, "auth_ref": [] }, "ifrs-full_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "Statement of cash flows [abstract]" } } }, "auth_ref": [] }, "ifrs-full_StatementOfChangesInEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "StatementOfChangesInEquityAbstract", "auth_ref": [] }, "ifrs-full_StatementOfChangesInEquityLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "StatementOfChangesInEquityLineItems", "presentation": [ "http://www.evogene.com/role/ConsolidatedStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "label": "Statement of changes in equity [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_StatementOfChangesInEquityTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "StatementOfChangesInEquityTable", "presentation": [ "http://www.evogene.com/role/ConsolidatedStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "label": "Statement of changes in equity [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to changes in equity." } } }, "auth_ref": [ "r4" ] }, "ifrs-full_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "Statement of financial position [abstract]" } } }, "auth_ref": [] }, "evgn_StatementsOfComprehensiveLossAdditionalInformationExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "StatementsOfComprehensiveLossAdditionalInformationExplanatory", "presentation": [ "http://www.evogene.com/role/StatementsOfComprehensiveLoss-AdditionalInformation" ], "lang": { "en-us": { "role": { "documentation": "This disclosure describes addition information and provides more detailed breakdown of the profit or loss items.", "label": "Statements Of Comprehensive Loss Additional Information Explanatory", "terseLabel": "STATEMENTS OF PROFIT OR LOSS \u2013 ADDITIONAL INFORMATION", "verboseLabel": "STATEMENTS OF COMPREHENSIVE LOSS \u2013 ADDITIONAL INFORMATION" } } }, "auth_ref": [] }, "ecd_StkPrcOrTsrEstimationMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "StkPrcOrTsrEstimationMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Stock Price or TSR Estimation Method [Text Block]", "terseLabel": "Stock Price or TSR Estimation Method" } } }, "auth_ref": [ "r272", "r283", "r293", "r326" ] }, "us-gaap_StockAppreciationRightsSARSMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockAppreciationRightsSARSMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Stock Appreciation Rights (SARs) [Member]", "terseLabel": "Stock Appreciation Rights (SARs)" } } }, "auth_ref": [] }, "evgn_StockOptionsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "StockOptionsMember", "presentation": [ "http://www.evogene.com/role/ShareholdersEquityScheduleOfChangesInShareCapitalDetails" ], "lang": { "en-us": { "role": { "documentation": "Stock option [Member]", "label": "Stock Options Member", "verboseLabel": "Stock option [Member]" } } }, "auth_ref": [] }, "evgn_StockholdersEquityReverseShareSplit": { "xbrltype": "stringItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "StockholdersEquityReverseShareSplit", "presentation": [ "http://www.evogene.com/role/GeneralNarrativeDetails", "http://www.evogene.com/role/ShareholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.", "label": "Stockholders Equity, Reverse Share Split", "verboseLabel": "Reverse share split ratio" } } }, "auth_ref": [] }, "evgn_SubcontractorsAndMaterials": { "xbrltype": "monetaryItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "SubcontractorsAndMaterials", "crdr": "debit", "calculation": { "http://www.evogene.com/role/StatementsOfComprehensiveLoss-AdditionalInformationScheduleOfIncomeAndExpensesDetails": { "parentTag": "ifrs-full_CostOfSales", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://www.evogene.com/role/StatementsOfComprehensiveLoss-AdditionalInformationScheduleOfIncomeAndExpensesDetails" ], "lang": { "en-us": { "role": { "documentation": "Sub-contractors, Materials.", "label": "Subcontractors And Materials", "verboseLabel": "Materials and sub-contractors" } } }, "auth_ref": [] }, "evgn_SubcontractorsAndProfessionalFees": { "xbrltype": "monetaryItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "SubcontractorsAndProfessionalFees", "crdr": "debit", "calculation": { "http://www.evogene.com/role/StatementsOfComprehensiveLoss-AdditionalInformationScheduleOfIncomeAndExpensesDetails": { "parentTag": "ifrs-full_SalesAndMarketingExpense", "weight": 1.0, "order": 20.0 } }, "presentation": [ "http://www.evogene.com/role/StatementsOfComprehensiveLoss-AdditionalInformationScheduleOfIncomeAndExpensesDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the amount of Subcontractors and professional fees.", "label": "Subcontractors And Professional Fees", "verboseLabel": "Subcontractors and professional fees" } } }, "auth_ref": [] }, "evgn_SuboptimalFactor": { "xbrltype": "decimalItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "SuboptimalFactor", "presentation": [ "http://www.evogene.com/role/Share-BasedCompensationScheduleOfAssumptionsUsedToValueOptionsDetails" ], "lang": { "en-us": { "role": { "documentation": "Suboptimal factor", "label": "Suboptimal Factor", "verboseLabel": "Suboptimal factor" } } }, "auth_ref": [] }, "evgn_SubsequentEventsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "SubsequentEventsMember", "presentation": [ "http://www.evogene.com/role/SUBSEQUENTEVENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Subsequent Events [Member].", "label": "Subsequent Events [Member]", "verboseLabel": "Subsequent Events [Member]" } } }, "auth_ref": [] }, "evgn_SubsidiariesEmployeesConsultantsDirectorsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "SubsidiariesEmployeesConsultantsDirectorsMember", "presentation": [ "http://www.evogene.com/role/Share-BasedCompensationScheduleOfAssumptionsUsedToValueOptionsDetails", "http://www.evogene.com/role/Share-BasedCompensationScheduleOfSummarizedNumberOfShareOptionsDetails", "http://www.evogene.com/role/Share-BasedCompensationTables" ], "lang": { "en-us": { "role": { "documentation": "Subsidiaries Employees Consultants and Directors [Member]", "label": "Subsidiaries Employees Consultants Directors Member", "verboseLabel": "Subsidiaries\u2019 options granted to employees, directors and consultants [Member]" } } }, "auth_ref": [] }, "ecd_TabularListTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TabularListTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Tabular List [Table Text Block]", "terseLabel": "Tabular List, Table" } } }, "auth_ref": [ "r319" ] }, "evgn_TaxAuthorityAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "TaxAuthorityAxis", "presentation": [ "http://www.evogene.com/role/TaxesOnIncomeDetails" ], "lang": { "en-us": { "role": { "documentation": "Tax authority.", "label": "Tax Authority [Axis]" } } }, "auth_ref": [] }, "evgn_TaxAuthorityDomain": { "xbrltype": "domainItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "TaxAuthorityDomain", "presentation": [ "http://www.evogene.com/role/TaxesOnIncomeDetails" ], "lang": { "en-us": { "role": { "documentation": "Tax authority.", "label": "Tax Authority [Domain]" } } }, "auth_ref": [] }, "evgn_TaxExemptPeriodUnderTaxBenefits": { "xbrltype": "stringItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "TaxExemptPeriodUnderTaxBenefits", "presentation": [ "http://www.evogene.com/role/TaxesOnIncomeDetails" ], "lang": { "en-us": { "role": { "documentation": "Tax exempt period.", "label": "Tax Exempt Period Under Tax Benefits", "verboseLabel": "Tax exempt period" } } }, "auth_ref": [] }, "evgn_TermForTaxBenefitsRate": { "xbrltype": "decimalItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "TermForTaxBenefitsRate", "presentation": [ "http://www.evogene.com/role/TaxesOnIncomeDetails" ], "lang": { "en-us": { "role": { "documentation": "Term for tax benefits rate.", "label": "Term For Tax Benefits Rate", "verboseLabel": "Term for tax benefits rate" } } }, "auth_ref": [] }, "evgn_TermOfAgreement": { "xbrltype": "stringItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "TermOfAgreement", "presentation": [ "http://www.evogene.com/role/CollaborationAndResearchAgreementsNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Information about the term of the agreement.", "label": "Term Of Agreement", "terseLabel": "Term of agreement" } } }, "auth_ref": [] }, "evgn_TimingOfRevenueRecognitionAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "TimingOfRevenueRecognitionAxis", "presentation": [ "http://www.evogene.com/role/ScheduleOfTimingOfRevenuesByTimingOfRevenueRecognition" ], "lang": { "en-us": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table.", "label": "Timing Of Revenue Recognition [Axis]" } } }, "auth_ref": [] }, "evgn_TimingOfRevenueRecognitionDomain": { "xbrltype": "domainItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "TimingOfRevenueRecognitionDomain", "presentation": [ "http://www.evogene.com/role/ScheduleOfTimingOfRevenuesByTimingOfRevenueRecognition" ], "lang": { "en-us": { "role": { "documentation": "This member stands for all timings of revenue recognition in contracts with customers. It also represents the standard value for the 'Timing of revenue recognition' axis if no other member is used.", "label": "Timing Of Revenue Recognition [Domain]" } } }, "auth_ref": [] }, "ifrs-full_TopOfRangeMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "TopOfRangeMember", "presentation": [ "http://www.evogene.com/role/LeasesNarrativeDetails", "http://www.evogene.com/role/SIGNIFICANTACCOUNTINGJUDGMENTSESTIMATESANDASSUMPTIONSUSEDINTHEPREPARATIONOFTHEFINANCIALSTATEMENTSNarrativeDetails", "http://www.evogene.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails", "http://www.evogene.com/role/Share-BasedCompensationScheduleOfAssumptionsUsedToValueOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Top of range [member]" } }, "en": { "role": { "documentation": "This member stands for top of a range." } } }, "auth_ref": [ "r113", "r141", "r160", "r171", "r235", "r236", "r389" ] }, "evgn_TotalLeasePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "TotalLeasePayments", "crdr": "credit", "calculation": { "http://www.evogene.com/role/LeasesScheduleOfFutureMinimumLeasePaymentsUnderNon-cancelableLeasesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.evogene.com/role/LeasesScheduleOfFutureMinimumLeasePaymentsUnderNon-cancelableLeasesDetails" ], "lang": { "en-us": { "role": { "documentation": "Total lease payments.", "label": "Total Lease Payments", "totalLabel": "Total lease payments" } } }, "auth_ref": [] }, "ecd_TotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Total Shareholder Return Amount", "terseLabel": "Total Shareholder Return Amount" } } }, "auth_ref": [ "r311" ] }, "ecd_TotalShareholderRtnVsPeerGroupTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnVsPeerGroupTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Total Shareholder Return Vs Peer Group [Text Block]", "terseLabel": "Total Shareholder Return Vs Peer Group" } } }, "auth_ref": [ "r318" ] }, "ifrs-full_TradeAndOtherCurrentPayables": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "TradeAndOtherCurrentPayables", "crdr": "credit", "calculation": { "http://www.evogene.com/role/ConsolidatedStatementsOfFinancialPosition": { "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0, "order": 0.0 }, "http://www.evogene.com/role/FinancialInstrumentsScheduleOfCompanysFinancialLiabilitiesDetails": { "parentTag": "ifrs-full_FinancialLiabilities", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.evogene.com/role/ConsolidatedStatementsOfFinancialPosition", "http://www.evogene.com/role/FinancialInstrumentsScheduleOfCompanysFinancialLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Trade payables", "verboseLabel": "Trade Payables" } }, "en": { "role": { "documentation": "The amount of current trade payables and current other payables. [Refer: Current trade payables; Other current payables]" } } }, "auth_ref": [ "r11" ] }, "ecd_TradingArrAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement [Axis]", "terseLabel": "Trading Arrangement:" } } }, "auth_ref": [ "r339" ] }, "ecd_TradingArrByIndTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrByIndTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangements, by Individual [Table]", "terseLabel": "Trading Arrangements, by Individual" } } }, "auth_ref": [ "r341" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": [ "http://www.evogene.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "evgn_TransactionsOfOtherIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "TransactionsOfOtherIncome", "crdr": "debit", "presentation": [ "http://www.evogene.com/role/BalancesAndTransactionsWithKeyOfficersAndCertainShareholdersScheduleOfTransactionsWithRelatedPartiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Information about transactions of other income.", "label": "Transactions Of Other Income", "terseLabel": "Other income" } } }, "auth_ref": [] }, "evgn_TransferOfResearchAndDevelopmentFromEntityRelatedPartyTransactions": { "xbrltype": "monetaryItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "TransferOfResearchAndDevelopmentFromEntityRelatedPartyTransactions", "crdr": "debit", "presentation": [ "http://www.evogene.com/role/BalancesAndTransactionsWithKeyOfficersAndCertainShareholdersScheduleOfTransactionsWithRelatedPartiesDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of transfers of research and development from the entity in related party transactions. [Refer: Related parties [member]]", "label": "Transfer Of Research And Development From Entity Related Party Transactions", "verboseLabel": "Participation in research and development expenses" } } }, "auth_ref": [] }, "ifrs-full_TravelExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "TravelExpense", "crdr": "debit", "calculation": { "http://www.evogene.com/role/StatementsOfComprehensiveLoss-AdditionalInformationScheduleOfIncomeAndExpensesDetails": { "parentTag": "ifrs-full_SalesAndMarketingExpense", "weight": 1.0, "order": 50.0 } }, "presentation": [ "http://www.evogene.com/role/StatementsOfComprehensiveLoss-AdditionalInformationScheduleOfIncomeAndExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Travel" } }, "en": { "role": { "documentation": "The amount of expense arising from travel." } } }, "auth_ref": [ "r365" ] }, "ecd_TrdArrAdoptionDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrAdoptionDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement Adoption Date", "terseLabel": "Adoption Date" } } }, "auth_ref": [ "r342" ] }, "ecd_TrdArrDuration": { "xbrltype": "durationItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrDuration", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement Duration", "terseLabel": "Arrangement Duration" } } }, "auth_ref": [ "r343" ] }, "ecd_TrdArrExpirationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrExpirationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement Expiration Date", "terseLabel": "Expiration Date" } } }, "auth_ref": [ "r343" ] }, "ecd_TrdArrIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Individual Name", "terseLabel": "Name" } } }, "auth_ref": [ "r341" ] }, "ecd_TrdArrIndTitle": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndTitle", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Individual Title", "terseLabel": "Title" } } }, "auth_ref": [ "r341" ] }, "ecd_TrdArrSecuritiesAggAvailAmt": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrSecuritiesAggAvailAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Securities Aggregate Available Amount", "terseLabel": "Aggregate Available" } } }, "auth_ref": [ "r344" ] }, "ecd_TrdArrTerminationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrTerminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement Termination Date", "terseLabel": "Termination Date" } } }, "auth_ref": [ "r342" ] }, "ifrs-full_TypesOfSharebasedPaymentArrangementsAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "TypesOfSharebasedPaymentArrangementsAxis", "presentation": [ "http://www.evogene.com/role/SHAREBASEDCOMPENSATIONScheduleOfRestrictedStockUnitsActivityDetails", "http://www.evogene.com/role/SIGNIFICANTACCOUNTINGJUDGMENTSESTIMATESANDASSUMPTIONSUSEDINTHEPREPARATIONOFTHEFINANCIALSTATEMENTSNarrativeDetails", "http://www.evogene.com/role/Share-BasedCompensationNarrativeDetails", "http://www.evogene.com/role/Share-BasedCompensationScheduleOfAssumptionsUsedToValueOptionsDetails", "http://www.evogene.com/role/Share-BasedCompensationScheduleOfSummarizedNumberOfShareOptionsDetails", "http://www.evogene.com/role/Share-BasedCompensationTables" ], "lang": { "en-us": { "role": { "label": "Types of share-based payment arrangements [axis]", "verboseLabel": "Types of share-based payment arrangements [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r172" ] }, "ifrs-full_TypesOfSharebasedPaymentArrangementsDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "TypesOfSharebasedPaymentArrangementsDomain", "presentation": [ "http://www.evogene.com/role/SHAREBASEDCOMPENSATIONScheduleOfRestrictedStockUnitsActivityDetails", "http://www.evogene.com/role/SIGNIFICANTACCOUNTINGJUDGMENTSESTIMATESANDASSUMPTIONSUSEDINTHEPREPARATIONOFTHEFINANCIALSTATEMENTSNarrativeDetails", "http://www.evogene.com/role/Share-BasedCompensationNarrativeDetails", "http://www.evogene.com/role/Share-BasedCompensationScheduleOfAssumptionsUsedToValueOptionsDetails", "http://www.evogene.com/role/Share-BasedCompensationScheduleOfSummarizedNumberOfShareOptionsDetails", "http://www.evogene.com/role/Share-BasedCompensationTables" ], "lang": { "en-us": { "role": { "label": "Types of share-based payment arrangements [domain]" } }, "en": { "role": { "documentation": "This member stands for an agreement between the entity or another group entity or any shareholder of the group entity and another party (including an employee) that entitles the other party to receive (a) cash or other assets of the entity for amounts that are based on the price (or value) of equity instruments (including shares or share options) of the entity or another group entity; or (b) equity instruments (including shares or share options) of the entity or another group entity, provided that the specified vesting conditions, if any, are met. It also represents the standard value for the 'Types of share-based payment arrangements' axis if no other member is used." } } }, "auth_ref": [ "r172" ] }, "country_US": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2024", "localname": "US", "presentation": [ "http://www.evogene.com/role/OperatingSegmentsScheduleOfPercentageOfNon-currentAssetsDetails", "http://www.evogene.com/role/OperatingSegmentsScheduleOfRevenuesBasedOnCustomersDetails" ], "lang": { "en-us": { "role": { "label": "UNITED STATES", "verboseLabel": "United States [Member]" } } }, "auth_ref": [] }, "evgn_UnallocatedMember": { "xbrltype": "domainItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "UnallocatedMember", "presentation": [ "http://www.evogene.com/role/OperatingSegmentsScheduleOfRevenuesAndOperatingLossBySegmentsDetails" ], "lang": { "en-us": { "role": { "documentation": "Unallocated [Member]", "label": "Unallocated [Member]" } } }, "auth_ref": [] }, "evgn_UndiscountedOperatingLeasePaymentsToBeReceivedAfterFiveYear": { "xbrltype": "monetaryItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "UndiscountedOperatingLeasePaymentsToBeReceivedAfterFiveYear", "crdr": "credit", "calculation": { "http://www.evogene.com/role/LeasesScheduleOfFutureMinimumLeasePaymentsUnderNon-cancelableLeasesDetails": { "parentTag": "evgn_TotalLeasePayments", "weight": 1.0, "order": 40.0 } }, "presentation": [ "http://www.evogene.com/role/LeasesScheduleOfFutureMinimumLeasePaymentsUnderNon-cancelableLeasesDetails" ], "lang": { "en-us": { "role": { "documentation": "Undiscounted Operating Lease Payments To Be Received After Four Year", "label": "Undiscounted Operating Lease Payments To Be Received After Five Year", "verboseLabel": "2030" } } }, "auth_ref": [] }, "evgn_UndiscountedOperatingLeasePaymentsToBeReceivedFiveYear": { "xbrltype": "monetaryItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "UndiscountedOperatingLeasePaymentsToBeReceivedFiveYear", "crdr": "credit", "calculation": { "http://www.evogene.com/role/LeasesScheduleOfFutureMinimumLeasePaymentsUnderNon-cancelableLeasesDetails": { "parentTag": "evgn_TotalLeasePayments", "weight": 1.0, "order": 50.0 } }, "presentation": [ "http://www.evogene.com/role/LeasesScheduleOfFutureMinimumLeasePaymentsUnderNon-cancelableLeasesDetails" ], "lang": { "en-us": { "role": { "documentation": "Undiscounted Operating Lease Payments To Be Received Five Year", "label": "Undiscounted Operating Lease Payments To Be Received Five Year", "terseLabel": "2029" } } }, "auth_ref": [] }, "evgn_UndiscountedOperatingLeasePaymentsToBeReceivedFourYear": { "xbrltype": "monetaryItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "UndiscountedOperatingLeasePaymentsToBeReceivedFourYear", "crdr": "credit", "calculation": { "http://www.evogene.com/role/LeasesScheduleOfFutureMinimumLeasePaymentsUnderNon-cancelableLeasesDetails": { "parentTag": "evgn_TotalLeasePayments", "weight": 1.0, "order": 30.0 } }, "presentation": [ "http://www.evogene.com/role/LeasesScheduleOfFutureMinimumLeasePaymentsUnderNon-cancelableLeasesDetails" ], "lang": { "en-us": { "role": { "documentation": "2026.", "label": "Undiscounted Operating Lease Payments To Be Received Four Year", "verboseLabel": "2028" } } }, "auth_ref": [] }, "evgn_UndiscountedOperatingLeasePaymentsToBeReceivedOneYear": { "xbrltype": "monetaryItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "UndiscountedOperatingLeasePaymentsToBeReceivedOneYear", "crdr": "credit", "calculation": { "http://www.evogene.com/role/LeasesScheduleOfFutureMinimumLeasePaymentsUnderNon-cancelableLeasesDetails": { "parentTag": "evgn_TotalLeasePayments", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.evogene.com/role/LeasesScheduleOfFutureMinimumLeasePaymentsUnderNon-cancelableLeasesDetails" ], "lang": { "en-us": { "role": { "documentation": "2023.", "label": "Undiscounted Operating Lease Payments To Be Received One Year", "verboseLabel": "2025" } } }, "auth_ref": [] }, "evgn_UndiscountedOperatingLeasePaymentsToBeReceivedThreeYear": { "xbrltype": "monetaryItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "UndiscountedOperatingLeasePaymentsToBeReceivedThreeYear", "crdr": "credit", "calculation": { "http://www.evogene.com/role/LeasesScheduleOfFutureMinimumLeasePaymentsUnderNon-cancelableLeasesDetails": { "parentTag": "evgn_TotalLeasePayments", "weight": 1.0, "order": 20.0 } }, "presentation": [ "http://www.evogene.com/role/LeasesScheduleOfFutureMinimumLeasePaymentsUnderNon-cancelableLeasesDetails" ], "lang": { "en-us": { "role": { "documentation": "2025.", "label": "Undiscounted Operating Lease Payments To Be Received Three Year", "verboseLabel": "2027" } } }, "auth_ref": [] }, "evgn_UndiscountedOperatingLeasePaymentsToBeReceivedTwoYear": { "xbrltype": "monetaryItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "UndiscountedOperatingLeasePaymentsToBeReceivedTwoYear", "crdr": "credit", "calculation": { "http://www.evogene.com/role/LeasesScheduleOfFutureMinimumLeasePaymentsUnderNon-cancelableLeasesDetails": { "parentTag": "evgn_TotalLeasePayments", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://www.evogene.com/role/LeasesScheduleOfFutureMinimumLeasePaymentsUnderNon-cancelableLeasesDetails" ], "lang": { "en-us": { "role": { "documentation": "2024.", "label": "Undiscounted Operating Lease Payments To Be Received Two Year", "verboseLabel": "2026" } } }, "auth_ref": [] }, "ecd_UndrlygSecurityMktPriceChngPct": { "xbrltype": "pureItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "UndrlygSecurityMktPriceChngPct", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Underlying Security Market Price Change, Percent", "terseLabel": "Underlying Security Market Price Change" } } }, "auth_ref": [ "r338" ] }, "ifrs-full_VehiclesMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "VehiclesMember", "presentation": [ "http://www.evogene.com/role/LeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Vehicles [member]" } }, "en": { "role": { "documentation": "This member stands for a class of property, plant and equipment representing vehicles used in the entity's operations, specifically to include aircraft, motor vehicles and ships. [Refer: Property, plant and equipment]" } } }, "auth_ref": [ "r370" ] }, "evgn_VestingsAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "VestingsAxis", "presentation": [ "http://www.evogene.com/role/CollaborationAndResearchAgreementsNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Information by vesting schedule of award under share-based payment arrangement.", "label": "Vestings [Axis]" } } }, "auth_ref": [] }, "evgn_VestingsDomain": { "xbrltype": "domainItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "VestingsDomain", "presentation": [ "http://www.evogene.com/role/CollaborationAndResearchAgreementsNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Vesting schedule of award under share-based payment arrangement.", "label": "Vestings [Domain]" } } }, "auth_ref": [] }, "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]", "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year" } } }, "auth_ref": [ "r307" ] }, "ifrs-full_WagesAndSalaries": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "WagesAndSalaries", "crdr": "debit", "calculation": { "http://www.evogene.com/role/StatementsOfComprehensiveLoss-AdditionalInformationScheduleOfIncomeAndExpensesDetails": { "parentTag": "ifrs-full_CostOfSales", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.evogene.com/role/StatementsOfComprehensiveLoss-AdditionalInformationScheduleOfIncomeAndExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Salaries and benefits" } }, "en": { "role": { "documentation": "A class of employee benefits expense that represents wages and salaries. [Refer: Employee benefits expense]" } } }, "auth_ref": [ "r373" ] }, "evgn_WarrantsAndPreFundedWarrantsLiabilitiesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "WarrantsAndPreFundedWarrantsLiabilitiesMember", "presentation": [ "http://www.evogene.com/role/FINANCIALINSTRUMENTSScheduleOfFairValueOfFinancialLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Warrants and pre funded warrants liabilities [Member].", "label": "Warrants And Pre Funded Warrants Liabilities [Member]", "verboseLabel": "Warrants and pre-funded warrants liabilities [Member]" } } }, "auth_ref": [] }, "evgn_WarrantsAndPreFundedWarrantsLiabilityMember": { "xbrltype": "domainItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "WarrantsAndPreFundedWarrantsLiabilityMember", "presentation": [ "http://www.evogene.com/role/SIGNIFICANTACCOUNTINGJUDGMENTSESTIMATESANDASSUMPTIONSUSEDINTHEPREPARATIONOFTHEFINANCIALSTATEMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Warrants And Pre Funded Warrants Liability [Member]", "label": "Warrants And Pre Funded Warrants Liability [Member]" } } }, "auth_ref": [] }, "ifrs-full_WarrantsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "WarrantsMember", "presentation": [ "http://www.evogene.com/role/LossPerShareScheduleOfBasicLossPerShareDetails" ], "lang": { "en-us": { "role": { "label": "Warrants [member]" } }, "en": { "role": { "documentation": "This member stands for warrants." } } }, "auth_ref": [ "r377" ] }, "evgn_WeightedAverageExercisePriceAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "WeightedAverageExercisePriceAbstract", "presentation": [ "http://www.evogene.com/role/Share-BasedCompensationScheduleOfSummarizedNumberOfShareOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Weighted Average Exercise Price Abstract", "verboseLabel": "Weighted Average Exercise Price" } } }, "auth_ref": [] }, "ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019", "presentation": [ "http://www.evogene.com/role/Share-BasedCompensationScheduleOfSummarizedNumberOfShareOptionsDetails" ], "lang": { "en-us": { "role": { "periodEndLabel": "Exercisable at end of year", "label": "Weighted average exercise price of share options exercisable in share-based payment arrangement" } }, "en": { "role": { "documentation": "The weighted average exercise price of share options exercisable in a share-based payment arrangement. [Refer: Weighted average [member]]" } } }, "auth_ref": [ "r168" ] }, "ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019", "presentation": [ "http://www.evogene.com/role/Share-BasedCompensationScheduleOfSummarizedNumberOfShareOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Exercised" } }, "en": { "role": { "documentation": "The weighted average exercise price of share options exercised in a share-based payment arrangement. [Refer: Weighted average [member]]" } } }, "auth_ref": [ "r166" ] }, "ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019", "presentation": [ "http://www.evogene.com/role/Share-BasedCompensationScheduleOfSummarizedNumberOfShareOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Forfeited" } }, "en": { "role": { "documentation": "The weighted average exercise price of share options forfeited in a share-based payment arrangement. [Refer: Weighted average [member]]" } } }, "auth_ref": [ "r165" ] }, "ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019", "presentation": [ "http://www.evogene.com/role/Share-BasedCompensationScheduleOfSummarizedNumberOfShareOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Grants", "terseLabel": "Granted" } }, "en": { "role": { "documentation": "The weighted average exercise price of share options granted in a share-based payment arrangement. [Refer: Weighted average [member]]" } } }, "auth_ref": [ "r164" ] }, "ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019", "presentation": [ "http://www.evogene.com/role/Share-BasedCompensationScheduleOfShareOptionsOutstandingDetails", "http://www.evogene.com/role/Share-BasedCompensationScheduleOfSummarizedNumberOfShareOptionsDetails" ], "lang": { "en-us": { "role": { "periodEndLabel": "Outstanding at end of year", "periodStartLabel": "Outstanding on beginning of year", "label": "Weighted average exercise price" } }, "en": { "role": { "documentation": "The weighted average exercise price of share options outstanding in a share-based payment arrangement. [Refer: Weighted average [member]]" } } }, "auth_ref": [ "r163", "r167" ] }, "evgn_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsForfeited": { "xbrltype": "monetaryItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsForfeited", "crdr": "credit", "presentation": [ "http://www.evogene.com/role/SHAREBASEDCOMPENSATIONScheduleOfRestrictedStockUnitsActivityDetails" ], "lang": { "en-us": { "role": { "documentation": "Weighted average fair value at measurement date, other equity instruments Forfeited", "label": "Weighted Average Fair Value At Measurement Date, Other Equity Instruments Forfeited", "verboseLabel": "Weighted average grant date fair value Forfeited" } } }, "auth_ref": [] }, "ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted", "crdr": "credit", "presentation": [ "http://www.evogene.com/role/SHAREBASEDCOMPENSATIONScheduleOfRestrictedStockUnitsActivityDetails" ], "lang": { "en-us": { "role": { "label": "Weighted average fair value at measurement date, other equity instruments granted", "verboseLabel": "Weighted average grant date fair value Granted" } }, "en": { "role": { "documentation": "The weighted average fair value at the measurement date of granted equity instruments other than share options. [Refer: Weighted average [member]]" } } }, "auth_ref": [ "r175" ] }, "evgn_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsOutstanding": { "xbrltype": "monetaryItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsOutstanding", "crdr": "credit", "presentation": [ "http://www.evogene.com/role/SHAREBASEDCOMPENSATIONScheduleOfRestrictedStockUnitsActivityDetails" ], "lang": { "en-us": { "role": { "documentation": "Weighted average fair value at measurement date, other equity instruments outstanding", "periodEndLabel": "Weighted average grant date fair value Outstanding", "periodStartLabel": "Weighted average grant date fair value Outstanding", "label": "Weighted Average Fair Value At Measurement Date, Other Equity Instruments Outstanding" } } }, "auth_ref": [] }, "evgn_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsVested": { "xbrltype": "monetaryItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsVested", "crdr": "credit", "presentation": [ "http://www.evogene.com/role/SHAREBASEDCOMPENSATIONScheduleOfRestrictedStockUnitsActivityDetails" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value at the measurement date of vested equity instruments other than share options.", "label": "Weighted Average Fair Value At Measurement Date, Other Equity Instruments Vested", "verboseLabel": "Weighted average grant date fair value Vested" } } }, "auth_ref": [] }, "evgn_WeightedAverageFairValueOfShareOptionsGrantedInSharebasedPaymentArrangement": { "xbrltype": "perShareItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "WeightedAverageFairValueOfShareOptionsGrantedInSharebasedPaymentArrangement", "presentation": [ "http://www.evogene.com/role/Share-BasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Weighted average fair value of options granted.", "label": "Weighted Average Fair Value Of Share Options Granted In Sharebased Payment Arrangement", "verboseLabel": "Weighted average fair value of options granted" } } }, "auth_ref": [] }, "ifrs-full_WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16": { "xbrltype": "percentItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16", "presentation": [ "http://www.evogene.com/role/LeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Weighted average lessee's incremental borrowing rate applied to lease liabilities recognised at date of initial application of IFRS 16", "terseLabel": "Weighted average incremental borrowing rate" } }, "en": { "role": { "documentation": "The weighted average lessee's incremental borrowing rate applied to lease liabilities recognised in the statement of financial position at the date of initial application of IFRS 16. The incremental borrowing rate is the rate of interest that a lessee would have to pay to borrow over a similar term, and with a similar security, the funds necessary to obtain an asset of a similar value to the right-of-use asset in a similar economic environment." } } }, "auth_ref": [ "r155" ] }, "ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019": { "xbrltype": "durationItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019", "presentation": [ "http://www.evogene.com/role/Share-BasedCompensationNarrativeDetails", "http://www.evogene.com/role/Share-BasedCompensationScheduleOfShareOptionsOutstandingDetails", "http://www.evogene.com/role/Share-BasedCompensationScheduleOfSummarizedNumberOfShareOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Weighted average outstanding remaining contractual term of options", "terseLabel": "Weighted average remaining contractual life (in Yrs.)", "verboseLabel": "The weighted average remaining contractual life for the share options" } }, "en": { "role": { "documentation": "The weighted average remaining contractual life of outstanding share options. [Refer: Weighted average [member]]" } } }, "auth_ref": [ "r171" ] }, "ifrs-full_WeightedAverageSharePrice2019": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "WeightedAverageSharePrice2019", "presentation": [ "http://www.evogene.com/role/GeneralNarrativeDetails", "http://www.evogene.com/role/ShareholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Weighted average share price", "terseLabel": "Weighted average share price" } }, "en": { "role": { "documentation": "The weighted average share price. [Refer: Weighted average [member]]" } } }, "auth_ref": [ "r170" ] }, "ifrs-full_WeightedAverageShares": { "xbrltype": "sharesItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "WeightedAverageShares", "presentation": [ "http://www.evogene.com/role/ConsolidatedStatementsOfProfitOrLoss", "http://www.evogene.com/role/LossPerShareScheduleOfBasicLossPerShareDetails" ], "lang": { "en-us": { "role": { "label": "Weighted average number of shares used in computing basic and diluted loss per share", "terseLabel": "Weighted average number of shares used in computing basic loss per share", "verboseLabel": "Weighted number of shares" } }, "en": { "role": { "documentation": "The number of ordinary shares outstanding at the beginning of the period, adjusted by the number of ordinary shares bought back or issued during the period multiplied by a time-weighting factor." } } }, "auth_ref": [ "r85" ] }, "evgn_WeightedTaxRateApplicableToCompany": { "xbrltype": "percentItemType", "nsuri": "http://www.evogene.com/20241231", "localname": "WeightedTaxRateApplicableToCompany", "presentation": [ "http://www.evogene.com/role/TaxesOnIncomeDetails" ], "lang": { "en-us": { "role": { "documentation": "Weighted tax rate applicable to company (federal tax and state tax where the company operates).", "label": "Weighted Tax Rate Applicable To Company", "verboseLabel": "Weighted tax rate applicable to U.S. subsidiaries" } } }, "auth_ref": [] }, "ifrs-full_WorkInProgress": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "WorkInProgress", "crdr": "debit", "calculation": { "http://www.evogene.com/role/SIGNIFICANTACCOUNTINGPOLICIESScheduleOfSummarizesInformationAboutTheInventoryDetails": { "parentTag": "ifrs-full_Inventories", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.evogene.com/role/SIGNIFICANTACCOUNTINGPOLICIESScheduleOfSummarizesInformationAboutTheInventoryDetails" ], "lang": { "en-us": { "role": { "label": "Current work in progress", "terseLabel": "Work in progress" } }, "en": { "role": { "documentation": "A classification of current inventory representing the amount of assets currently in production, which require further processes to be converted into finished goods or services. [Refer: Current finished goods; Inventories]" } } }, "auth_ref": [ "r218", "r374" ] }, "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]", "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested" } } }, "auth_ref": [ "r305" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2024-01-01", "Paragraph": "103", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_103&doctype=Standard", "URIDate": "2024-03-27" }, "r1": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2024-01-01", "Paragraph": "106", "Subparagraph": "d", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_106_d_i&doctype=Standard", "URIDate": "2024-03-27" }, "r2": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2024-01-01", "Paragraph": "106", "Subparagraph": "d", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_106_d_ii&doctype=Standard", "URIDate": "2024-03-27" }, "r3": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2024-01-01", "Paragraph": "106", "Subparagraph": "d", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_106_d_iii&doctype=Standard", "URIDate": "2024-03-27" }, "r4": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2024-01-01", "Paragraph": "106", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_106&doctype=Standard", "URIDate": "2024-03-27" }, "r5": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2024-01-01", "Paragraph": "51", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_51&doctype=Standard", "URIDate": "2024-03-27" }, "r6": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2024-01-01", "Paragraph": "54", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_54_a&doctype=Standard", "URIDate": "2024-03-27" }, "r7": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2024-01-01", "Paragraph": "54", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_54_c&doctype=Standard", "URIDate": "2024-03-27" }, "r8": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2024-01-01", "Paragraph": "54", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_54_e&doctype=Standard", "URIDate": "2024-03-27" }, "r9": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2024-01-01", "Paragraph": "54", "Subparagraph": "g", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_54_g&doctype=Standard", "URIDate": "2024-03-27" }, "r10": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2024-01-01", "Paragraph": "54", "Subparagraph": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_54_i&doctype=Standard", "URIDate": "2024-03-27" }, "r11": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2024-01-01", "Paragraph": "54", "Subparagraph": "k", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_54_k&doctype=Standard", "URIDate": "2024-03-27" }, "r12": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2024-01-01", "Paragraph": "54", "Subparagraph": "n", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_54_n&doctype=Standard", "URIDate": "2024-03-27" }, "r13": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2024-01-01", "Paragraph": "54", "Subparagraph": "o", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_54_o&doctype=Standard", "URIDate": "2024-03-27" }, "r14": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2024-01-01", "Paragraph": "54", "Subparagraph": "q", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_54_q&doctype=Standard", "URIDate": "2024-03-27" }, "r15": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2024-01-01", "Paragraph": "54", "Subparagraph": "r", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_54_r&doctype=Standard", "URIDate": "2024-03-27" }, "r16": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2024-01-01", "Paragraph": "55", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_55&doctype=Standard", "URIDate": "2024-03-27" }, "r17": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2024-01-01", "Paragraph": "56", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_56&doctype=Standard", "URIDate": "2024-03-27" }, "r18": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2024-01-01", "Paragraph": "61", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_61_a&doctype=Standard", "URIDate": "2024-03-27" }, "r19": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2024-01-01", "Paragraph": "61", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_61&doctype=Standard", "URIDate": "2024-03-27" }, "r20": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2024-01-01", "Paragraph": "66", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_66&doctype=Standard", "URIDate": "2024-03-27" }, "r21": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2024-01-01", "Paragraph": "69", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_69&doctype=Standard", "URIDate": "2024-03-27" }, "r22": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2024-01-01", "Paragraph": "78", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_78_d&doctype=Standard", "URIDate": "2024-03-27" }, "r23": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2024-01-01", "Paragraph": "78", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_78_e&doctype=Standard", "URIDate": "2024-03-27" }, "r24": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2024-01-01", "Paragraph": "79", "Subparagraph": "a", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_79_a_i&doctype=Standard", "URIDate": "2024-03-27" }, "r25": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2024-01-01", "Paragraph": "79", "Subparagraph": "a", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_79_a_iii&doctype=Standard", "URIDate": "2024-03-27" }, "r26": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2024-01-01", "Paragraph": "79", "Subparagraph": "a", "Clause": "iv", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_79_a_iv&doctype=Standard", "URIDate": "2024-03-27" }, "r27": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2024-01-01", "Paragraph": "79", "Subparagraph": "a", "Clause": "vii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_79_a_vii&doctype=Standard", "URIDate": "2024-03-27" }, "r28": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2024-01-01", "Paragraph": "79", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_79_a&doctype=Standard", "URIDate": "2024-03-27" }, "r29": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2024-01-01", "Paragraph": "79", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_79&doctype=Standard", "URIDate": "2024-03-27" }, "r30": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2024-01-01", "Paragraph": "81A", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_81A_a&doctype=Standard", "URIDate": "2024-03-27" }, "r31": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2024-01-01", "Paragraph": "81A", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_81A_b&doctype=Standard", "URIDate": "2024-03-27" }, "r32": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2024-01-01", "Paragraph": "81B", "Subparagraph": "a", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_81B_a_i&doctype=Standard", "URIDate": "2024-03-27" }, "r33": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2024-01-01", "Paragraph": "81B", "Subparagraph": "a", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_81B_a_ii&doctype=Standard", "URIDate": "2024-03-27" }, "r34": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2024-01-01", "Paragraph": "82", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_82_a&doctype=Standard", "URIDate": "2024-03-27" }, "r35": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2024-01-01", "Paragraph": "82", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_82_b&doctype=Standard", "URIDate": "2024-03-27" }, "r36": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2024-01-01", "Paragraph": "82", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_82_d&doctype=Standard", "URIDate": "2024-03-27" }, "r37": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2024-01-01", "Paragraph": "91", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_91_a&doctype=Standard", "URIDate": "2024-03-27" }, "r38": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2024-01-01", "Paragraph": "99", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_99&doctype=Standard", "URIDate": "2024-03-27" }, "r39": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "10", "IssueDate": "2024-01-01", "Paragraph": "21", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=10&code=ifrs-tx-2024-en-r&anchor=para_21&doctype=Standard", "URIDate": "2024-03-27" }, "r40": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "10", "IssueDate": "2024-01-01", "Section": "Disclosure", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=10&code=ifrs-tx-2024-en-r&doctype=Standard&dita_xref=IAS10_g17-22_TI", "URIDate": "2024-03-27" }, "r41": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "12", "IssueDate": "2024-01-01", "Paragraph": "79", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2024-en-r&anchor=para_79&doctype=Standard", "URIDate": "2024-03-27" }, "r42": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "12", "IssueDate": "2024-01-01", "Paragraph": "81", "Subparagraph": "c", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2024-en-r&anchor=para_81_c_i&doctype=Standard", "URIDate": "2024-03-27" }, "r43": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "12", "IssueDate": "2024-01-01", "Paragraph": "81", "Subparagraph": "c", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2024-en-r&anchor=para_81_c_ii&doctype=Standard", "URIDate": "2024-03-27" }, "r44": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "12", "IssueDate": "2024-01-01", "Paragraph": "81", "Subparagraph": "g", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2024-en-r&anchor=para_81_g_i&doctype=Standard", "URIDate": "2024-03-27" }, "r45": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "12", "IssueDate": "2024-01-01", "Paragraph": "81", "Subparagraph": "g", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2024-en-r&anchor=para_81_g&doctype=Standard", "URIDate": "2024-03-27" }, "r46": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "12", "IssueDate": "2024-01-01", "Section": "Disclosure", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2024-en-r&doctype=Standard&dita_xref=IAS12_g79-88_TI", "URIDate": "2024-03-27" }, "r47": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "16", "IssueDate": "2024-01-01", "Paragraph": "73", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2024-en-r&anchor=para_73_c&doctype=Standard", "URIDate": "2024-03-27" }, "r48": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "16", "IssueDate": "2024-01-01", "Paragraph": "73", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2024-en-r&anchor=para_73_d&doctype=Standard", "URIDate": "2024-03-27" }, "r49": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "16", "IssueDate": "2024-01-01", "Paragraph": "73", "Subparagraph": "e", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2024-en-r&anchor=para_73_e_i&doctype=Standard", "URIDate": "2024-03-27" }, "r50": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "16", "IssueDate": "2024-01-01", "Paragraph": "73", "Subparagraph": "e", "Clause": "vii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2024-en-r&anchor=para_73_e_vii&doctype=Standard", "URIDate": "2024-03-27" }, "r51": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "16", "IssueDate": "2024-01-01", "Paragraph": "73", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2024-en-r&anchor=para_73_e&doctype=Standard", "URIDate": "2024-03-27" }, "r52": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "16", "IssueDate": "2024-01-01", "Paragraph": "73", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2024-en-r&anchor=para_73&doctype=Standard", "URIDate": "2024-03-27" }, "r53": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "16", "IssueDate": "2024-01-01", "Paragraph": "75", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2024-en-r&anchor=para_75_a&doctype=Standard", "URIDate": "2024-03-27" }, "r54": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "16", "IssueDate": "2024-01-01", "Paragraph": "75", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2024-en-r&anchor=para_75_b&doctype=Standard", "URIDate": "2024-03-27" }, "r55": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "16", "IssueDate": "2024-01-01", "Section": "Disclosure", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2024-en-r&doctype=Standard&dita_xref=IAS16_g73-79_TI", "URIDate": "2024-03-27" }, "r56": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "19", "IssueDate": "2024-01-01", "Paragraph": "138", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2024-en-r&anchor=para_138&doctype=Standard", "URIDate": "2024-03-27" }, "r57": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "19", "IssueDate": "2024-01-01", "Paragraph": "140", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2024-en-r&anchor=para_140_a&doctype=Standard", "URIDate": "2024-03-27" }, "r58": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "19", "IssueDate": "2024-01-01", "Paragraph": "53", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2024-en-r&anchor=para_53&doctype=Standard", "URIDate": "2024-03-27" }, "r59": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "19", "IssueDate": "2024-01-01", "Section": "Scope", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2024-en-r&doctype=Standard&dita_xref=IAS19_g2-7_TI", "URIDate": "2024-03-27" }, "r60": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "2", "IssueDate": "2024-01-01", "Paragraph": "36", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=2&code=ifrs-tx-2024-en-r&anchor=para_36_a&doctype=Standard", "URIDate": "2024-03-27" }, "r61": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "2", "IssueDate": "2024-01-01", "Paragraph": "36", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=2&code=ifrs-tx-2024-en-r&anchor=para_36_b&doctype=Standard", "URIDate": "2024-03-27" }, "r62": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "2", "IssueDate": "2024-01-01", "Section": "Disclosure", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=2&code=ifrs-tx-2024-en-r&doctype=Standard&dita_xref=IAS02_g36-39_TI", "URIDate": "2024-03-27" }, "r63": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "20", "IssueDate": "2024-01-01", "Paragraph": "39", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=20&code=ifrs-tx-2024-en-r&anchor=para_39_a&doctype=Standard", "URIDate": "2024-03-27" }, "r64": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "20", "IssueDate": "2024-01-01", "Section": "Disclosure", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=20&code=ifrs-tx-2024-en-r&doctype=Standard&dita_xref=IAS20_g39-39_TI", "URIDate": "2024-03-27" }, "r65": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "24", "IssueDate": "2024-01-01", "Paragraph": "17", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2024-en-r&anchor=para_17_a&doctype=Standard", "URIDate": "2024-03-27" }, "r66": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "24", "IssueDate": "2024-01-01", "Paragraph": "17", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2024-en-r&anchor=para_17_e&doctype=Standard", "URIDate": "2024-03-27" }, "r67": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "24", "IssueDate": "2024-01-01", "Paragraph": "17", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2024-en-r&anchor=para_17&doctype=Standard", "URIDate": "2024-03-27" }, "r68": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "24", "IssueDate": "2024-01-01", "Paragraph": "18", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2024-en-r&anchor=para_18_b&doctype=Standard", "URIDate": "2024-03-27" }, "r69": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "24", "IssueDate": "2024-01-01", "Paragraph": "18", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2024-en-r&anchor=para_18&doctype=Standard", "URIDate": "2024-03-27" }, "r70": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "24", "IssueDate": "2024-01-01", "Paragraph": "18A", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2024-en-r&anchor=para_18A&doctype=Standard", "URIDate": "2024-03-27" }, "r71": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "24", "IssueDate": "2024-01-01", "Paragraph": "19", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2024-en-r&anchor=para_19&doctype=Standard", "URIDate": "2024-03-27" }, "r72": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "24", "IssueDate": "2024-01-01", "Paragraph": "20", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2024-en-r&anchor=para_20&doctype=Standard", "URIDate": "2024-03-27" }, "r73": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "24", "IssueDate": "2024-01-01", "Section": "Disclosures", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2024-en-r&doctype=Standard&dita_xref=IAS24_g13-24_TI", "URIDate": "2024-03-27" }, "r74": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "26", "IssueDate": "2024-01-01", "Paragraph": "35", "Subparagraph": "b", "Clause": "iv", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=26&code=ifrs-tx-2024-en-r&anchor=para_35_b_iv&doctype=Standard", "URIDate": "2024-03-27" }, "r75": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "26", "IssueDate": "2024-01-01", "Paragraph": "35", "Subparagraph": "b", "Clause": "vii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=26&code=ifrs-tx-2024-en-r&anchor=para_35_b_vii&doctype=Standard", "URIDate": "2024-03-27" }, "r76": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "26", "IssueDate": "2024-01-01", "Paragraph": "35", "Subparagraph": "b", "Clause": "viii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=26&code=ifrs-tx-2024-en-r&anchor=para_35_b_viii&doctype=Standard", "URIDate": "2024-03-27" }, "r77": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "27", "IssueDate": "2024-01-01", "Paragraph": "10", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2024-en-r&anchor=para_10&doctype=Standard", "URIDate": "2024-03-27" }, "r78": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "27", "IssueDate": "2024-01-01", "Paragraph": "16", "Subparagraph": "b", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2024-en-r&anchor=para_16_b_iii&doctype=Standard", "URIDate": "2024-03-27" }, "r79": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "27", "IssueDate": "2024-01-01", "Paragraph": "16", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2024-en-r&anchor=para_16_b&doctype=Standard", "URIDate": "2024-03-27" }, "r80": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "27", "IssueDate": "2024-01-01", "Paragraph": "17", "Subparagraph": "b", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2024-en-r&anchor=para_17_b_iii&doctype=Standard", "URIDate": "2024-03-27" }, "r81": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "27", "IssueDate": "2024-01-01", "Paragraph": "17", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2024-en-r&anchor=para_17_b&doctype=Standard", "URIDate": "2024-03-27" }, "r82": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "33", "IssueDate": "2024-01-01", "Paragraph": "66", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2024-en-r&anchor=para_66&doctype=Standard", "URIDate": "2024-03-27" }, "r83": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "33", "IssueDate": "2024-01-01", "Paragraph": "67", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2024-en-r&anchor=para_67&doctype=Standard", "URIDate": "2024-03-27" }, "r84": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "33", "IssueDate": "2024-01-01", "Paragraph": "70", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2024-en-r&anchor=para_70_a&doctype=Standard", "URIDate": "2024-03-27" }, "r85": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "33", "IssueDate": "2024-01-01", "Paragraph": "70", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2024-en-r&anchor=para_70_b&doctype=Standard", "URIDate": "2024-03-27" }, "r86": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "33", "IssueDate": "2024-01-01", "Section": "Disclosure", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2024-en-r&doctype=Standard&dita_xref=IAS33_g70-73A_TI", "URIDate": "2024-03-27" }, "r87": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "36", "IssueDate": "2024-01-01", "Paragraph": "130", "Subparagraph": "d", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2024-en-r&anchor=para_130_d_ii&doctype=Standard", "URIDate": "2024-03-27" }, "r88": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "36", "IssueDate": "2024-01-01", "Paragraph": "134", "Subparagraph": "d", "Clause": "iv", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2024-en-r&anchor=para_134_d_iv&doctype=Standard", "URIDate": "2024-03-27" }, "r89": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "36", "IssueDate": "2024-01-01", "Paragraph": "134", "Subparagraph": "e", "Clause": "iv", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2024-en-r&anchor=para_134_e_iv&doctype=Standard", "URIDate": "2024-03-27" }, "r90": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "37", "IssueDate": "2024-01-01", "Paragraph": "86", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2024-en-r&anchor=para_86&doctype=Standard", "URIDate": "2024-03-27" }, "r91": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "37", "IssueDate": "2024-01-01", "Paragraph": "88", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2024-en-r&anchor=para_88&doctype=Standard", "URIDate": "2024-03-27" }, "r92": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "38", "IssueDate": "2024-01-01", "Paragraph": "118", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2024-en-r&anchor=para_118_a&doctype=Standard", "URIDate": "2024-03-27" }, "r93": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "38", "IssueDate": "2024-01-01", "Paragraph": "118", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2024-en-r&anchor=para_118_c&doctype=Standard", "URIDate": "2024-03-27" }, "r94": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "38", "IssueDate": "2024-01-01", "Paragraph": "118", "Subparagraph": "e", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2024-en-r&anchor=para_118_e_i&doctype=Standard", "URIDate": "2024-03-27" }, "r95": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "38", "IssueDate": "2024-01-01", "Paragraph": "118", "Subparagraph": "e", "Clause": "vi", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2024-en-r&anchor=para_118_e_vi&doctype=Standard", "URIDate": "2024-03-27" }, "r96": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "38", "IssueDate": "2024-01-01", "Paragraph": "118", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2024-en-r&anchor=para_118_e&doctype=Standard", "URIDate": "2024-03-27" }, "r97": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "38", "IssueDate": "2024-01-01", "Paragraph": "118", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2024-en-r&anchor=para_118&doctype=Standard", "URIDate": "2024-03-27" }, "r98": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "38", "IssueDate": "2024-01-01", "Paragraph": "126", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2024-en-r&anchor=para_126&doctype=Standard", "URIDate": "2024-03-27" }, "r99": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "38", "IssueDate": "2024-01-01", "Section": "Disclosure", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2024-en-r&doctype=Standard&dita_xref=IAS38_g118-128_TI", "URIDate": "2024-03-27" }, "r100": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "40", "IssueDate": "2024-01-01", "Paragraph": "76", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2024-en-r&anchor=para_76&doctype=Standard", "URIDate": "2024-03-27" }, "r101": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "40", "IssueDate": "2024-01-01", "Paragraph": "79", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2024-en-r&anchor=para_79_c&doctype=Standard", "URIDate": "2024-03-27" }, "r102": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "40", "IssueDate": "2024-01-01", "Paragraph": "79", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2024-en-r&anchor=para_79_d&doctype=Standard", "URIDate": "2024-03-27" }, "r103": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "40", "IssueDate": "2024-01-01", "Section": "Disclosure", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2024-en-r&doctype=Standard&dita_xref=IAS40_g74-79_TI", "URIDate": "2024-03-27" }, "r104": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "41", "IssueDate": "2024-01-01", "Paragraph": "50", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=41&code=ifrs-tx-2024-en-r&anchor=para_50&doctype=Standard", "URIDate": "2024-03-27" }, "r105": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "41", "IssueDate": "2024-01-01", "Paragraph": "54", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=41&code=ifrs-tx-2024-en-r&anchor=para_54_f&doctype=Standard", "URIDate": "2024-03-27" }, "r106": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2024-01-01", "Paragraph": "10", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_10&doctype=Standard", "URIDate": "2024-03-27" }, "r107": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2024-01-01", "Paragraph": "18", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_18_b&doctype=Standard", "URIDate": "2024-03-27" }, "r108": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2024-01-01", "Paragraph": "20", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_20&doctype=Standard", "URIDate": "2024-03-27" }, "r109": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2024-01-01", "Paragraph": "25", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_25&doctype=Standard", "URIDate": "2024-03-27" }, "r110": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2024-01-01", "Paragraph": "28", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_28&doctype=Standard", "URIDate": "2024-03-27" }, "r111": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2024-01-01", "Paragraph": "31", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_31&doctype=Standard", "URIDate": "2024-03-27" }, "r112": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2024-01-01", "Paragraph": "35", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_35&doctype=Standard", "URIDate": "2024-03-27" }, "r113": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2024-01-01", "Paragraph": "44H", "Subparagraph": "b", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_44H_b_iii&doctype=Standard", "URIDate": "2024-03-27" }, "r114": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2024-01-01", "Paragraph": "45", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_45&doctype=Standard", "URIDate": "2024-03-27" }, "r115": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2024-01-01", "Paragraph": "46", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_46&doctype=Standard", "URIDate": "2024-03-27" }, "r116": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2024-01-01", "Paragraph": "50", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_50_d&doctype=Standard", "URIDate": "2024-03-27" }, "r117": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "1", "IssueDate": "2024-01-01", "Paragraph": "24", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2024-en-r&anchor=para_24_a&doctype=Standard", "URIDate": "2024-03-27" }, "r118": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "1", "IssueDate": "2024-01-01", "Paragraph": "24", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2024-en-r&anchor=para_24_b&doctype=Standard", "URIDate": "2024-03-27" }, "r119": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "1", "IssueDate": "2024-01-01", "Paragraph": "32", "Subparagraph": "a", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2024-en-r&anchor=para_32_a_i&doctype=Standard", "URIDate": "2024-03-27" }, "r120": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "1", "IssueDate": "2024-01-01", "Paragraph": "32", "Subparagraph": "a", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2024-en-r&anchor=para_32_a_ii&doctype=Standard", "URIDate": "2024-03-27" }, "r121": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "10", "IssueDate": "2024-01-01", "Paragraph": "22", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=10&code=ifrs-tx-2024-en-r&anchor=para_22&doctype=Standard", "URIDate": "2024-03-27" }, "r122": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2024-01-01", "Paragraph": "12", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_12_c&doctype=Standard", "URIDate": "2024-03-27" }, "r123": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2024-01-01", "Paragraph": "12", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_12_e&doctype=Standard", "URIDate": "2024-03-27" }, "r124": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2024-01-01", "Paragraph": "12", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_12_f&doctype=Standard", "URIDate": "2024-03-27" }, "r125": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2024-01-01", "Paragraph": "19B", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_19B_c&doctype=Standard", "URIDate": "2024-03-27" }, "r126": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2024-01-01", "Paragraph": "B12", "Subparagraph": "b", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_B12_b_i&doctype=Appendix&subtype=B", "URIDate": "2024-03-27" }, "r127": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2024-01-01", "Paragraph": "B12", "Subparagraph": "b", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_B12_b_ii&doctype=Appendix&subtype=B", "URIDate": "2024-03-27" }, "r128": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2024-01-01", "Paragraph": "B12", "Subparagraph": "b", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_B12_b_iii&doctype=Appendix&subtype=B", "URIDate": "2024-03-27" }, "r129": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2024-01-01", "Paragraph": "B12", "Subparagraph": "b", "Clause": "iv", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_B12_b_iv&doctype=Appendix&subtype=B", "URIDate": "2024-03-27" }, "r130": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2024-01-01", "Paragraph": "B12", "Subparagraph": "b", "Clause": "v", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_B12_b_v&doctype=Appendix&subtype=B", "URIDate": "2024-03-27" }, "r131": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2024-01-01", "Paragraph": "B12", "Subparagraph": "b", "Clause": "viii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_B12_b_viii&doctype=Appendix&subtype=B", "URIDate": "2024-03-27" }, "r132": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2024-01-01", "Paragraph": "B13", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_B13_a&doctype=Appendix&subtype=B", "URIDate": "2024-03-27" }, "r133": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2024-01-01", "Paragraph": "B13", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_B13_e&doctype=Appendix&subtype=B", "URIDate": "2024-03-27" }, "r134": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2024-01-01", "Paragraph": "B13", "Subparagraph": "g", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_B13_g&doctype=Appendix&subtype=B", "URIDate": "2024-03-27" }, "r135": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2024-01-01", "Paragraph": "B16", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_B16&doctype=Appendix&subtype=B", "URIDate": "2024-03-27" }, "r136": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2024-01-01", "Paragraph": "B4", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_B4_a&doctype=Appendix&subtype=B", "URIDate": "2024-03-27" }, "r137": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "13", "IssueDate": "2024-01-01", "Paragraph": "93", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2024-en-r&anchor=para_93_a&doctype=Standard", "URIDate": "2024-03-27" }, "r138": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "13", "IssueDate": "2024-01-01", "Paragraph": "93", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2024-en-r&anchor=para_93_b&doctype=Standard", "URIDate": "2024-03-27" }, "r139": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "13", "IssueDate": "2024-01-01", "Paragraph": "93", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2024-en-r&anchor=para_93_e&doctype=Standard", "URIDate": "2024-03-27" }, "r140": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "13", "IssueDate": "2024-01-01", "Paragraph": "93", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2024-en-r&anchor=para_93&doctype=Standard", "URIDate": "2024-03-27" }, "r141": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "14", "IssueDate": "2024-01-01", "Paragraph": "33", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=14&code=ifrs-tx-2024-en-r&anchor=para_33_b&doctype=Standard", "URIDate": "2024-03-27" }, "r142": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "15", "IssueDate": "2024-01-01", "Paragraph": "114", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2024-en-r&anchor=para_114&doctype=Standard", "URIDate": "2024-03-27" }, "r143": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "15", "IssueDate": "2024-01-01", "Paragraph": "115", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2024-en-r&anchor=para_115&doctype=Standard", "URIDate": "2024-03-27" }, "r144": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "15", "IssueDate": "2024-01-01", "Paragraph": "120", "Subparagraph": "b", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2024-en-r&anchor=para_120_b_i&doctype=Standard", "URIDate": "2024-03-27" }, "r145": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2024-01-01", "Paragraph": "47", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2024-en-r&anchor=para_47_a&doctype=Standard", "URIDate": "2024-03-27" }, "r146": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2024-01-01", "Paragraph": "47", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2024-en-r&anchor=para_47_b&doctype=Standard", "URIDate": "2024-03-27" }, "r147": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2024-01-01", "Paragraph": "53", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2024-en-r&anchor=para_53_a&doctype=Standard", "URIDate": "2024-03-27" }, "r148": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2024-01-01", "Paragraph": "53", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2024-en-r&anchor=para_53_b&doctype=Standard", "URIDate": "2024-03-27" }, "r149": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2024-01-01", "Paragraph": "53", "Subparagraph": "g", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2024-en-r&anchor=para_53_g&doctype=Standard", "URIDate": "2024-03-27" }, "r150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2024-01-01", "Paragraph": "53", "Subparagraph": "h", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2024-en-r&anchor=para_53_h&doctype=Standard", "URIDate": "2024-03-27" }, "r151": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2024-01-01", "Paragraph": "53", "Subparagraph": "j", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2024-en-r&anchor=para_53_j&doctype=Standard", "URIDate": "2024-03-27" }, "r152": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2024-01-01", "Paragraph": "53", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2024-en-r&anchor=para_53&doctype=Standard", "URIDate": "2024-03-27" }, "r153": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2024-01-01", "Paragraph": "94", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2024-en-r&anchor=para_94&doctype=Standard", "URIDate": "2024-03-27" }, "r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2024-01-01", "Paragraph": "97", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2024-en-r&anchor=para_97&doctype=Standard", "URIDate": "2024-03-27" }, "r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2024-01-01", "Paragraph": "C12", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2024-en-r&anchor=para_C12_a&doctype=Appendix&subtype=C", "URIDate": "2024-03-27" }, "r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2024-01-01", "Section": "Disclosure", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2024-en-r&doctype=Standard&dita_xref=IFRS16_g51-60_TI", "URIDate": "2024-03-27" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2024-01-01", "Section": "Presentation", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2024-en-r&doctype=Standard&dita_xref=IFRS16_g47-50_TI", "URIDate": "2024-03-27" }, "r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "17", "IssueDate": "2024-01-01", "Paragraph": "109", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2024-en-r&anchor=para_109&doctype=Standard", "URIDate": "2024-03-27" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "17", "IssueDate": "2024-01-01", "Paragraph": "109A", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2024-en-r&anchor=para_109A&doctype=Standard", "URIDate": "2024-03-27" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "17", "IssueDate": "2024-01-01", "Paragraph": "120", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2024-en-r&anchor=para_120&doctype=Standard", "URIDate": "2024-03-27" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "17", "IssueDate": "2024-01-01", "Paragraph": "132", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2024-en-r&anchor=para_132_b&doctype=Standard", "URIDate": "2024-03-27" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2024-01-01", "Paragraph": "44", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2024-en-r&anchor=para_44&doctype=Standard", "URIDate": "2024-03-27" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2024-01-01", "Paragraph": "45", "Subparagraph": "b", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2024-en-r&anchor=para_45_b_i&doctype=Standard", "URIDate": "2024-03-27" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2024-01-01", "Paragraph": "45", "Subparagraph": "b", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2024-en-r&anchor=para_45_b_ii&doctype=Standard", "URIDate": "2024-03-27" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2024-01-01", "Paragraph": "45", "Subparagraph": "b", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2024-en-r&anchor=para_45_b_iii&doctype=Standard", "URIDate": "2024-03-27" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2024-01-01", "Paragraph": "45", "Subparagraph": "b", "Clause": "iv", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2024-en-r&anchor=para_45_b_iv&doctype=Standard", "URIDate": "2024-03-27" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2024-01-01", "Paragraph": "45", "Subparagraph": "b", "Clause": "vi", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2024-en-r&anchor=para_45_b_vi&doctype=Standard", "URIDate": "2024-03-27" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2024-01-01", "Paragraph": "45", "Subparagraph": "b", "Clause": "vii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2024-en-r&anchor=para_45_b_vii&doctype=Standard", "URIDate": "2024-03-27" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2024-01-01", "Paragraph": "45", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2024-en-r&anchor=para_45_b&doctype=Standard", "URIDate": "2024-03-27" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2024-01-01", "Paragraph": "45", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2024-en-r&anchor=para_45_c&doctype=Standard", "URIDate": "2024-03-27" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2024-01-01", "Paragraph": "45", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2024-en-r&anchor=para_45_d&doctype=Standard", "URIDate": "2024-03-27" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2024-01-01", "Paragraph": "45", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2024-en-r&anchor=para_45&doctype=Standard", "URIDate": "2024-03-27" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2024-01-01", "Paragraph": "47", "Subparagraph": "a", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2024-en-r&anchor=para_47_a_i&doctype=Standard", "URIDate": "2024-03-27" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2024-01-01", "Paragraph": "47", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2024-en-r&anchor=para_47_a&doctype=Standard", "URIDate": "2024-03-27" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2024-01-01", "Paragraph": "47", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2024-en-r&anchor=para_47_b&doctype=Standard", "URIDate": "2024-03-27" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2024-01-01", "Paragraph": "50", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2024-en-r&anchor=para_50&doctype=Standard", "URIDate": "2024-03-27" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "3", "IssueDate": "2024-01-01", "Paragraph": "B64", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2024-en-r&anchor=para_B64_c&doctype=Appendix&subtype=B", "URIDate": "2024-03-27" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "3", "IssueDate": "2024-01-01", "Paragraph": "B64", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2024-en-r&anchor=para_B64&doctype=Appendix&subtype=B", "URIDate": "2024-03-27" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "3", "IssueDate": "2024-01-01", "Paragraph": "B67", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2024-en-r&anchor=para_B67_c&doctype=Appendix&subtype=B", "URIDate": "2024-03-27" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "3", "IssueDate": "2024-01-01", "Paragraph": "B67", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2024-en-r&anchor=para_B67_d&doctype=Appendix&subtype=B", "URIDate": "2024-03-27" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "3", "IssueDate": "2024-01-01", "Paragraph": "B67", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2024-en-r&anchor=para_B67&doctype=Appendix&subtype=B", "URIDate": "2024-03-27" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "5", "IssueDate": "2024-01-01", "Paragraph": "33", "Subparagraph": "b", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=5&code=ifrs-tx-2024-en-r&anchor=para_33_b_i&doctype=Standard", "URIDate": "2024-03-27" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "5", "IssueDate": "2024-01-01", "Section": "Presentation and disclosure", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=5&code=ifrs-tx-2024-en-r&doctype=Standard&dita_xref=IFRS05_g30-42_TI", "URIDate": "2024-03-27" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2024-01-01", "Paragraph": "23B", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_23B_a&doctype=Standard", "URIDate": "2024-03-27" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2024-01-01", "Paragraph": "25", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_25&doctype=Standard", "URIDate": "2024-03-27" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2024-01-01", "Paragraph": "31", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_31&doctype=Standard", "URIDate": "2024-03-27" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2024-01-01", "Paragraph": "35H", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_35H&doctype=Standard", "URIDate": "2024-03-27" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2024-01-01", "Paragraph": "35I", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_35I&doctype=Standard", "URIDate": "2024-03-27" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2024-01-01", "Paragraph": "35K", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_35K&doctype=Standard", "URIDate": "2024-03-27" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2024-01-01", "Paragraph": "35M", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_35M&doctype=Standard", "URIDate": "2024-03-27" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2024-01-01", "Paragraph": "36", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_36&doctype=Standard", "URIDate": "2024-03-27" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2024-01-01", "Paragraph": "39", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_39_a&doctype=Standard", "URIDate": "2024-03-27" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2024-01-01", "Paragraph": "40", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_40_a&doctype=Standard", "URIDate": "2024-03-27" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2024-01-01", "Paragraph": "42E", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_42E_e&doctype=Standard", "URIDate": "2024-03-27" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2024-01-01", "Paragraph": "7", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_7&doctype=Standard", "URIDate": "2024-03-27" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2024-01-01", "Section": "Scope", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&doctype=Standard&dita_xref=IFRS07_g3-5A_TI", "URIDate": "2024-03-27" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2024-01-01", "Paragraph": "23", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&anchor=para_23_a&doctype=Standard", "URIDate": "2024-03-27" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2024-01-01", "Paragraph": "23", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&anchor=para_23_c&doctype=Standard", "URIDate": "2024-03-27" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2024-01-01", "Paragraph": "23", "Subparagraph": "h", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&anchor=para_23_h&doctype=Standard", "URIDate": "2024-03-27" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2024-01-01", "Paragraph": "23", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&anchor=para_23&doctype=Standard", "URIDate": "2024-03-27" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2024-01-01", "Paragraph": "24", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&anchor=para_24_a&doctype=Standard", "URIDate": "2024-03-27" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2024-01-01", "Paragraph": "28", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&anchor=para_28_a&doctype=Standard", "URIDate": "2024-03-27" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2024-01-01", "Paragraph": "28", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&anchor=para_28_b&doctype=Standard", "URIDate": "2024-03-27" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2024-01-01", "Paragraph": "28", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&anchor=para_28_c&doctype=Standard", "URIDate": "2024-03-27" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2024-01-01", "Paragraph": "28", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&anchor=para_28_d&doctype=Standard", "URIDate": "2024-03-27" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2024-01-01", "Paragraph": "28", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&anchor=para_28_e&doctype=Standard", "URIDate": "2024-03-27" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2024-01-01", "Paragraph": "28", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&anchor=para_28&doctype=Standard", "URIDate": "2024-03-27" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2024-01-01", "Paragraph": "32", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&anchor=para_32&doctype=Standard", "URIDate": "2024-03-27" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2024-01-01", "Paragraph": "33", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&anchor=para_33_a&doctype=Standard", "URIDate": "2024-03-27" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2024-01-01", "Paragraph": "33", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&anchor=para_33&doctype=Standard", "URIDate": "2024-03-27" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2024-01-01", "Paragraph": "34", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&anchor=para_34&doctype=Standard", "URIDate": "2024-03-27" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2024-01-01", "Section": "Disclosure", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&doctype=Standard&dita_xref=IFRS08_g20-24_TI", "URIDate": "2024-03-27" }, "r213": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "1", "IssueDate": "2024-01-01", "Paragraph": "102", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_102&doctype=Standard", "URIDate": "2024-03-27" }, "r214": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "1", "IssueDate": "2024-01-01", "Paragraph": "103", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_103&doctype=Standard", "URIDate": "2024-03-27" }, "r215": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "1", "IssueDate": "2024-01-01", "Paragraph": "108", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_108&doctype=Standard", "URIDate": "2024-03-27" }, "r216": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "1", "IssueDate": "2024-01-01", "Paragraph": "68", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_68&doctype=Standard", "URIDate": "2024-03-27" }, "r217": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "1", "IssueDate": "2024-01-01", "Paragraph": "78", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_78_b&doctype=Standard", "URIDate": "2024-03-27" }, "r218": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "1", "IssueDate": "2024-01-01", "Paragraph": "78", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_78_c&doctype=Standard", "URIDate": "2024-03-27" }, "r219": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "1", "IssueDate": "2024-01-01", "Paragraph": "78", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_78_e&doctype=Standard", "URIDate": "2024-03-27" }, "r220": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "1", "IssueDate": "2024-01-01", "Paragraph": "IG6", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_IG6&doctype=Implementation%20Guidance", "URIDate": "2024-03-27" }, "r221": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "16", "IssueDate": "2024-01-01", "Paragraph": "37", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2024-en-r&anchor=para_37_f&doctype=Standard", "URIDate": "2024-03-27" }, "r222": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "16", "IssueDate": "2024-01-01", "Paragraph": "37", "Subparagraph": "h", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2024-en-r&anchor=para_37_h&doctype=Standard", "URIDate": "2024-03-27" }, "r223": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "16", "IssueDate": "2024-01-01", "Paragraph": "79", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2024-en-r&anchor=para_79_b&doctype=Standard", "URIDate": "2024-03-27" }, "r224": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "19", "IssueDate": "2024-01-01", "Paragraph": "138", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2024-en-r&anchor=para_138_a&doctype=Standard", "URIDate": "2024-03-27" }, "r225": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "19", "IssueDate": "2024-01-01", "Paragraph": "138", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2024-en-r&anchor=para_138_d&doctype=Standard", "URIDate": "2024-03-27" }, "r226": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "19", "IssueDate": "2024-01-01", "Paragraph": "147", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2024-en-r&anchor=para_147_c&doctype=Standard", "URIDate": "2024-03-27" }, "r227": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "32", "IssueDate": "2024-01-01", "Paragraph": "IE33", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=32&code=ifrs-tx-2024-en-r&anchor=para_IE33&doctype=Illustrative%20Examples", "URIDate": "2024-03-27" }, "r228": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "36", "IssueDate": "2024-01-01", "Paragraph": "127", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2024-en-r&anchor=para_127&doctype=Standard", "URIDate": "2024-03-27" }, "r229": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "37", "IssueDate": "2024-01-01", "Paragraph": "88", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2024-en-r&anchor=para_88&doctype=Standard", "URIDate": "2024-03-27" }, "r230": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2024-01-01", "Paragraph": "16", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_16_a&doctype=Standard", "URIDate": "2024-03-27" }, "r231": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2024-01-01", "Paragraph": "16", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_16_b&doctype=Standard", "URIDate": "2024-03-27" }, "r232": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2024-01-01", "Paragraph": "17", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_17_e&doctype=Standard", "URIDate": "2024-03-27" }, "r233": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2024-01-01", "Paragraph": "44", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_44_c&doctype=Standard", "URIDate": "2024-03-27" }, "r234": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "12", "IssueDate": "2024-01-01", "Paragraph": "B10", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_B10_b&doctype=Appendix&subtype=B", "URIDate": "2024-03-27" }, "r235": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "13", "IssueDate": "2024-01-01", "Paragraph": "B6", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2024-en-r&anchor=para_B6&doctype=Appendix&subtype=B", "URIDate": "2024-03-27" }, "r236": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "13", "IssueDate": "2024-01-01", "Paragraph": "IE63", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2024-en-r&anchor=para_IE63&doctype=Illustrative%20Examples", "URIDate": "2024-03-27" }, "r237": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "15", "IssueDate": "2024-01-01", "Paragraph": "B89", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2024-en-r&anchor=para_B89_b&doctype=Appendix&subtype=B", "URIDate": "2024-03-27" }, "r238": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "16", "IssueDate": "2024-01-01", "Paragraph": "53", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2024-en-r&anchor=para_53&doctype=Standard", "URIDate": "2024-03-27" }, "r239": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "17", "IssueDate": "2024-01-01", "Paragraph": "113", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2024-en-r&anchor=para_113_b&doctype=Standard", "URIDate": "2024-03-27" }, "r240": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "17", "IssueDate": "2024-01-01", "Paragraph": "96", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2024-en-r&anchor=para_96_b&doctype=Standard", "URIDate": "2024-03-27" }, "r241": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "17", "IssueDate": "2024-01-01", "Paragraph": "96", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2024-en-r&anchor=para_96_c&doctype=Standard", "URIDate": "2024-03-27" }, "r242": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2024-01-01", "Paragraph": "35N", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_35N&doctype=Standard", "URIDate": "2024-03-27" }, "r243": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2024-01-01", "Paragraph": "B11", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_B11&doctype=Appendix&subtype=B", "URIDate": "2024-03-27" }, "r244": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2024-01-01", "Paragraph": "B33", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_B33&doctype=Appendix&subtype=B", "URIDate": "2024-03-27" }, "r245": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2024-01-01", "Paragraph": "B35", "Subparagraph": "g", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_B35_g&doctype=Appendix&subtype=B", "URIDate": "2024-03-27" }, "r246": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2024-01-01", "Paragraph": "B35", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_B35&doctype=Appendix&subtype=B", "URIDate": "2024-03-27" }, "r247": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2024-01-01", "Paragraph": "IG31A", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_IG31A&doctype=Implementation%20Guidance", "URIDate": "2024-03-27" }, "r248": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "8", "IssueDate": "2024-01-01", "Paragraph": "23", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&anchor=para_23&doctype=Standard", "URIDate": "2024-03-27" }, "r249": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "8", "IssueDate": "2024-01-01", "Paragraph": "28", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&anchor=para_28_b&doctype=Standard", "URIDate": "2024-03-27" }, "r250": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r251": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r252": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r253": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r254": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r255": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r256": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16", "Subsection": "J", "Paragraph": "a" }, "r257": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K" }, "r258": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "b", "Paragraph": "1" }, "r259": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "b", "Paragraph": "1", "Subparagraph": "i" }, "r260": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "b", "Paragraph": "1", "Subparagraph": "ii" }, "r261": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "b", "Paragraph": "1", "Subparagraph": "iii" }, "r262": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "b", "Paragraph": "2" }, "r263": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "c", "Paragraph": "1" }, "r264": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "c", "Paragraph": "2" }, "r265": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "c", "Paragraph": "2", "Subparagraph": "i" }, "r266": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "c", "Paragraph": "2", "Subparagraph": "ii" }, "r267": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "c", "Paragraph": "2", "Subparagraph": "iii" }, "r268": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1" }, "r269": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i" }, "r270": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r271": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r272": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r273": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r274": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r275": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii" }, "r276": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "iii" }, "r277": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "2" }, "r278": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r279": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a" }, "r280": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1" }, "r281": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r282": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r283": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r284": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r285": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r286": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "2" }, "r287": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "3" }, "r288": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "b" }, "r289": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a" }, "r290": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1" }, "r291": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r292": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r293": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r294": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r295": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r296": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "2" }, "r297": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "3" }, "r298": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "b" }, "r299": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r300": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v" }, "r301": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "1" }, "r302": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "ii" }, "r303": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii" }, "r304": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Subclause": "ii" }, "r305": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "i" }, "r306": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "ii" }, "r307": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "iii" }, "r308": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "iv" }, "r309": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "v" }, "r310": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "vi" }, "r311": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iv" }, "r312": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "vi" }, "r313": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "3" }, "r314": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "4" }, "r315": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "i" }, "r316": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "ii" }, "r317": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iii" }, "r318": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iv" }, "r319": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6" }, "r320": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6", "Subparagraph": "i" }, "r321": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w" }, "r322": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1" }, "r323": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i" }, "r324": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r325": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r326": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r327": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r328": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r329": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "ii" }, "r330": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "iii" }, "r331": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "2" }, "r332": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "1" }, "r333": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2" }, "r334": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "A" }, "r335": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "C" }, "r336": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "D" }, "r337": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "E" }, "r338": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "F" }, "r339": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a" }, "r340": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "1" }, "r341": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "A" }, "r342": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "B" }, "r343": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "C" }, "r344": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "D" }, "r345": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "b", "Paragraph": "1" }, "r346": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106" }, "r347": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "b", "Paragraph": "1" }, "r348": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "b", "Paragraph": "1", "Subparagraph": "i" }, "r349": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "b", "Paragraph": "1", "Subparagraph": "ii" }, "r350": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "b", "Paragraph": "1", "Subparagraph": "iii" }, "r351": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "b", "Paragraph": "2" }, "r352": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "c", "Paragraph": "1" }, "r353": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "c", "Paragraph": "2" }, "r354": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "c", "Paragraph": "2", "Subparagraph": "i" }, "r355": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "c", "Paragraph": "2", "Subparagraph": "ii" }, "r356": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "c", "Paragraph": "2", "Subparagraph": "iii" }, "r357": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Number": "229", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1" }, "r358": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "A", "Number": "229" }, "r359": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Number": "229" }, "r360": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Subclause": "i", "Number": "229" }, "r361": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r362": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r363": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "1", "IssueDate": "2024-01-01", "Paragraph": "10", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_10_e&doctype=Standard", "URIDate": "2024-03-27" }, "r364": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "1", "IssueDate": "2024-01-01", "Paragraph": "106", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_106_d&doctype=Standard", "URIDate": "2024-03-27" }, "r365": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "1", "IssueDate": "2024-01-01", "Paragraph": "112", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_112_c&doctype=Standard", "URIDate": "2024-03-27" }, "r366": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "1", "IssueDate": "2024-01-01", "Paragraph": "117", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_117&doctype=Standard", "URIDate": "2024-03-27" }, "r367": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "1", "IssueDate": "2024-01-01", "Paragraph": "55", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_55&doctype=Standard", "URIDate": "2024-03-27" }, "r368": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "1", "IssueDate": "2024-01-01", "Paragraph": "78", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_78&doctype=Standard", "URIDate": "2024-03-27" }, "r369": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "1", "IssueDate": "2024-01-01", "Paragraph": "85", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_85&doctype=Standard", "URIDate": "2024-03-27" }, "r370": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "16", "IssueDate": "2024-01-01", "Paragraph": "37", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2024-en-r&anchor=para_37&doctype=Standard", "URIDate": "2024-03-27" }, "r371": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "16", "IssueDate": "2024-01-01", "Paragraph": "73", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2024-en-r&anchor=para_73_d&doctype=Standard", "URIDate": "2024-03-27" }, "r372": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "16", "IssueDate": "2024-01-01", "Paragraph": "73", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2024-en-r&anchor=para_73_e&doctype=Standard", "URIDate": "2024-03-27" }, "r373": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "19", "IssueDate": "2024-01-01", "Paragraph": "9", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2024-en-r&anchor=para_9&doctype=Standard", "URIDate": "2024-03-27" }, "r374": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "2", "IssueDate": "2024-01-01", "Paragraph": "37", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=2&code=ifrs-tx-2024-en-r&anchor=para_37&doctype=Standard", "URIDate": "2024-03-27" }, "r375": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "20", "IssueDate": "2024-01-01", "Paragraph": "28", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=20&code=ifrs-tx-2024-en-r&anchor=para_28&doctype=Standard", "URIDate": "2024-03-27" }, "r376": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "33", "IssueDate": "2024-01-01", "Paragraph": "70", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2024-en-r&anchor=para_70_b&doctype=Standard", "URIDate": "2024-03-27" }, "r377": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "33", "IssueDate": "2024-01-01", "Paragraph": "70", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2024-en-r&anchor=para_70_c&doctype=Standard", "URIDate": "2024-03-27" }, "r378": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "38", "IssueDate": "2024-01-01", "Paragraph": "118", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2024-en-r&anchor=para_118_c&doctype=Standard", "URIDate": "2024-03-27" }, "r379": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "40", "IssueDate": "2024-01-01", "Paragraph": "79", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2024-en-r&anchor=para_79_c&doctype=Standard", "URIDate": "2024-03-27" }, "r380": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "41", "IssueDate": "2024-01-01", "Paragraph": "54", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=41&code=ifrs-tx-2024-en-r&anchor=para_54_f&doctype=Standard", "URIDate": "2024-03-27" }, "r381": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "7", "IssueDate": "2024-01-01", "Paragraph": "16", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_16&doctype=Standard", "URIDate": "2024-03-27" }, "r382": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "7", "IssueDate": "2024-01-01", "Paragraph": "17", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_17&doctype=Standard", "URIDate": "2024-03-27" }, "r383": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "7", "IssueDate": "2024-01-01", "Paragraph": "20", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_20_a&doctype=Standard", "URIDate": "2024-03-27" }, "r384": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "7", "IssueDate": "2024-01-01", "Paragraph": "20", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_20_b&doctype=Standard", "URIDate": "2024-03-27" }, "r385": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "7", "IssueDate": "2024-01-01", "Paragraph": "20", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_20&doctype=Standard", "URIDate": "2024-03-27" }, "r386": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "7", "IssueDate": "2024-01-01", "Paragraph": "35", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_35&doctype=Standard", "URIDate": "2024-03-27" }, "r387": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "7", "IssueDate": "2024-01-01", "Paragraph": "45", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_45&doctype=Standard", "URIDate": "2024-03-27" }, "r388": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IFRS", "Number": "2", "IssueDate": "2024-01-01", "Paragraph": "45", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2024-en-r&anchor=para_45&doctype=Standard", "URIDate": "2024-03-27" }, "r389": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IFRS", "Number": "7", "IssueDate": "2024-01-01", "Paragraph": "7", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_7&doctype=Standard", "URIDate": "2024-03-27" }, "r390": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IFRS", "Number": "8", "IssueDate": "2024-01-01", "Paragraph": "34", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&anchor=para_34&doctype=Standard", "URIDate": "2024-03-27" } } }